PUBLI- CATIES - Jeroen Bosch Ziekenhuis...Het werkterrein van de data scientist. En van de...

PUBLI-CATIES

ONDER REDACTIE VAN:WETENSCHAPSCOMMISSIEWETENSCHAPSBUREAU

JEROEN BOSCH ZIEKENHUIS2015-2016’S-HERTOGENBOSCH 2017

Wetenschap heeft een belangrijke plaats in het palet van activiteiten dat in het JBZ plaatsvindt. Het is net als opleiden een essentiële voorwaarde voor het leveren van goede en up-to-date zorg aan onze patiënten. En het is een essentiële voorwaarde voor een goed professioneel klimaat. Want actieve participatie in wetenschap bevordert het doorvoeren van nieuwe kennis in de praktijk door professionals. Gelukkig zijn er ook wetenschappers die zich met dit soort onderzoek bezighouden en zij hebben dit weer aangetoond.

Voor u ligt het overzicht van die actieve participatie in wetenschap door JBZers in 2015/16. Een lijvig document met publicaties en wetenschappelijke voordrachten dat goed de breedte en diepte van de wetenschap in het JBZ weergeeft. Het past bij het brede scala zorg dat het JBZ levert. Waarin een aantal duidelijke zwaartepunten zitten, zoals Oncologie en Klinische Farmacologie, die weer passen bij de STZ-status van het ziekenhuis.

In de wetenschap gaan de ontwikkelingen snel. Daarom is er in het JBZ een beleidsgroep Wetenschap die voor de komende jaren de lijnen heeft uitgezet waarlangs de wetenschap zich in het JBZ zal gaan ontwikkelen. De nadruk op de vakinhoudelijke gebieden zal blijven, maar daarbij komt een gerichte focus op een drietal thema’s. Deze kunnen de vakinhoudelijke gebieden enerzijds overstijgen en anderzijds ondersteunen. Allereerst is dat Patient-Centered Outcomes Research, passend bij de strategie van het ziekenhuis om gezondheidswelzijn bij inwoners van onze regio zo veel mogelijk te bevorderen en direct gericht op de vraag wat de zorg verbetert in het dagelijks leven van patiënten. Ten tweede leggen we de nadruk op datascience en de ontwikkelingen die daar plaatsvinden. Een onderwerp dat nu nog in de kinderschoenen staat, maar zich snel ontwikkelt. We doen dat in afstemming met de Jheronimus Bosch Academy of Data Science, en in samenwerkingsverband van de Technische Universiteit Eindhoven en Tilburg University. Ten slotte het thema organiseren van zorg, met name in netwerken. Dat doen we in samenwerking met Tranzo, het instituut van Tilburg University dat zich helemaal richt op deze vorm van onderzoek.

Sommige ontwikkelingen ziet u in dit boekje nog niet, omdat ze nog te kort aanwezig zijn om tot resultaten te zijn gekomen in 2015/2016. Dat gaat om de ondersteuning van onderzoek in verpleegkundig en paramedisch domein. Daar is in het kader van het programma Verpleegkundig Leiderschap een aparte module Evidence Based Practice gestart. In de komende tijd wordt dat doorgetrokken naar het bevorderen van eigen verpleegkundig wetenschappelijk onderzoek. En er komt een verbreding van dit programma naar de andere professionals in de organisatie.

Ten slotte is ook de samenwerking op het terrein van wetenschappelijk onderzoek met het Radboudumc in een versnelling aan het komen. Was er aanvankelijk vooral samenwerking op vakgroepsniveau, zoals bij de Geriatrie en de Urologie, waarvan een aantal resultaten in dit boekje al zichtbaar zijn, in 2017 heeft deze samenwerking een breder karakter gekregen en zal bijvoorbeeld door het Promovendifonds er een gemeenschappelijk beleid komen om wetenschap in breedte te stimuleren. Later dit jaar wordt bezien hoe we het kunnen richten naar de thema’s van het academisch netwerk.

Kortom, wetenschap is diep geworteld in het JBZ en ontwikkelt zich op die wortels snel verder. De resultaten daarvan presenteren we graag in de volgende versie van het overzicht.

Piet-Hein Buiting, voorzitter Raad van Bestuur van het Jeroen Bosch Ziekenhuis

VOORWOORD

3VOORWOORD

Voorwoord 3

Interview: Bert Meijboom 6 Esther de Vries 8 Jeroen Derijks / Rob van Marum 10 Carolien Burghout / Bert van Rixtel 12

1. ANESTHESIOLOGIE 15

2. CARDIOLOGIE 17

3. CHIRURGIE 21

4. DERMATOLOGIE 27

5. GERIATRIE 29

6. GYNAECOLOGIE 35

7. INTENSIVE CARE GENEESKUNDE 41

8. INTERNE GENEESKUNDE 45

9. KINDERGENEESKUNDE 53

10. KLINISCHE CHEMIE & HEMATOLOGIE 59

11. KLINISCHE FYSICA 63

12. LONGZIEKTEN 65

13. MAAG, DARM, LEVERZIEKTEN 69

14. MEDISCHE MICROBIOLOGIE 75

15. MOLECULAIRE DIAGNOSTIEK 81

16. NEUROLOGIE 85

Inhoudsopgave

4 PUBLICATIES 2015-2016 JEROEN BOSCH ZIEKENHUISINHOUDSOPGAVE

17. NUCLEAIRE GENEESKUNDE 89

18. ORTHOPEDIE 92

19. PATHOLOGIE 97

20. PLASTISCHE CHIRURGIE 99

21. PSYCHOLOGIE 101

22. RADIOLOGIE 103

23. REUMATOLOGIE 109

24. REVALIDATIE-GENEESKUNDE 111

25. SPOEDEISENDE GENEESKUNDE 113

26. UROLOGIE 115

27. ZIEKENHUISFARMACIE 117

28. OVERIGE STAFDIENSTEN 120

Wetenschapsmiddag 2015 124

Wetenschapsmiddag 2016 126

Bijlage I Wetenschappelijke publicaties 2015-2016 opgenomen in PubMed 128

5 INHOUDSOPGAVE

BIJZONDER HOOGLERAAR BERT MEIJBOOM

“OVERSTAPPEN IS HET SPANNENDSTE MOMENT VAN DE REIS”

“Wanneer er fouten worden gemaakt in de zorg, zit het probleem vaak tussen de verschillende schakels die betrokken zijn bij de patiënt”, aldus prof. dr. ir. Bert Meijboom, bijzonder hoogleraar ‘Organisatie van ketenzorg’. Zijn leerstoel aan de School of Economics and Management van Tilburg University is mogelijk gemaakt door het Jeroen Bosch Ziekenhuis.

De bijzondere leerstoel heeft als doel om bij te dragen aan een betere organisatie van dienstverlening in zorgketens. “Verbetering is noodzakelijk”, zegt Meijboom. “Jaarlijks komt er wetenschappelijk onderzoek beschikbaar waarin letterlijk staat dat ‘de chronisch zieke patiënt gevaar loopt’. Dat heeft te maken met het spanningsveld tussen specialisatie en een integraal zorgaanbod”, legt hij uit. De gezondheidszorg kent vele medisch specialismen die zich richten op veel verschillende doelgroepen.

6 PUBLICATIES 2015-2016 JEROEN BOSCH ZIEKENHUIS

Als gevolg hiervan ontmoet een patiënt met een chronische of complexe aandoening op zijn ‘reis’ door de zorgketen meerdere zorgdisciplines en -aanbieders uit de eerste, tweede en derde lijn. “Als ziekenhuis ben je een halte in de reis van de patiënt en – we weten het allemaal – juist ‘het overstappen’ is altijd een spannend moment. Daar ligt het pijnpunt.”

Samenwerking en communicatie“Neem een oudere patiënt met diabetes”, vervolgt Meijboom. “Hierbij kan zowel huisarts, diabetesverpleegkundige, internist als oogarts betrokken zijn. En de patiënt kan tegelijkertijd te maken hebben met een eerstelijns zorgcentrum, ziekenhuis en thuiszorg. Als de stappen in het behandeltraject organisatorisch naadloos op elkaar aansluiten, schep je de juiste voorwaarden voor de beste zorg. Het probleem is dat het nog te vaak ontbreekt aan een goede samenwerking tussen zorgaanbieders en duidelijke communicatie tussen de verschillende schakels onderling en met de patiënt. Met soms vervelende gevolgen voor de patiënt, bijvoorbeeld doordat fouten ontstaan op het gebied van medicatietoediening. Of doordat het vervolg na ontslag uit het ziekenhuis niet goed geregeld is en de patiënt tussen de wal en het schip raakt.”

Leren van bedrijfslevenBinnen de leerstoel is er ten behoeve van downsyndroompatiënten een promotieonderzoek gestart onder gezamenlijke begeleiding van Bert Meijboom en Esther de Vries (Coordinator Data Science in het JBZ). De promovendus zoekt naar mogelijkheden om vanuit individueel patiëntoogpunt de juiste combinatie van zorgcomponenten samen te stellen voor mensen met Down. In een breder perspectief is de hoogleraar daarnaast betrokken bij het JBZ-project ‘Organisatie van werkprocessen’. “Daarbij kijken we ziekenhuisbreed naar de mogelijkheden om de zorg modulair te ontrafelen met de bedoeling om voor de individuele patiënt vervolgens een maatoplossing samen te stellen.” Meijboom stelt dat de zorg op dit gebied kan leren van het bedrijfsleven. “Daar weten ze doorgaans heel goed hoe ze op efficiënte wijze een klant specifiek aanbod kunnen creëren.” In zijn onderzoek maakt hij dan ook gebruik van ideeën uit Supply Chain Management. “Ik probeer antwoord te geven op de vraag hoe zorgorganisaties zich logistiek en organisatorisch patiëntgeoriënteerd kunnen opstellen. Om in de beeldspraak te blijven: hoe ze zich beter kunnen aanpassen aan ‘de reis van de patiënt’. Voor het JBZ is dit een speerpunt.”

7 INTERVIEW BERT MEIJBOOM

JBZ IS PARTNER VAN DE JHERONIMUS ACADEMY OF DATA SCIENCE

VAN BIG DATA NAAR BIG VALUE

In de zomer van 2016 is de masteropleiding Data Science Entrepreneurship gestart in het voormalig klooster Mariënburg in ‘s-Hertogenbosch. De studie maakt deel uit van een samenwerking tussen de Technische Universiteit Eindhoven TU/e en Tilburg University. Onder de naam JADS, Jheronimus Academy of Data Science, combineren de universiteiten onderzoek, onderwijs en entrepreneurship op het gebied van data science. Het Jeroen Bosch Ziekenhuis is partner van JADS. Coördinator Data Science in het JBZ, Esther de Vries legt uit waarom.


Big Data is hot. Mensen en apparaten produceren elke dag opnieuw triljoenen bytes aan data en wisselen deze uit. Data vertegenwoordigen waarde. “Daar kun je wat mee”, zegt De Vries. “Tenminste, als je data behapbaar kunt maken en weet hoe je ze moet analyseren en benutten.” Het werkterrein van de data scientist. En van de Technische Universiteit Eindhoven en Tilburg University. Zij bieden al twee jaar gezamenlijk bachelors en masters Data Science aan in Tilburg en Eindhoven en sinds de zomer van 2016 ook een master in ’s-Hertogenbosch.

Health analyticsHet samenwerkingsverband JADS werkt met een viertal thema’s, waarvan Health Analytics belangrijk is voor het JBZ. De Vries: “Binnen Health Analytics ga je data science toepassen bij vraagstukken in de gezondheidszorg. Met behulp van data zou je bijvoorbeeld patronen kunnen ontdekken die duiden op een zeldzame ziekte. Of neem imaging. Een getraind systeem kan in een paar minuten tijd foto’s van ‘gewone moedervlekken’ en melanomen doorlopen en vergelijken met die ene foto van de patiënt. Je zou systemen ook kunnen ‘loslaten’ op de meer standaard röntgenfoto’s, als voorwerk voor de radioloog. Er is zoveel mogelijk. Wij doen in het ziekenhuis alles in het Elektronisch Patiëntendossier. Dit EPD omvat een waanzinnige hoeveelheid informatie. Veel data laten we onbenut en bij de data die we wel gebruiken, realiseren we ons niet dat we er ook andere nuttige dingen mee kunnen doen. Zaken waarmee we onze zorg beter kunnen maken. Die mindset, die manier van denken, dat is de kern van toegepaste data science.”

Werelden verbindenIn de functie Coördinator Data Science is De Vries - ze is ook bijzonder hoogleraar bij Tilburg University - naar eigen zeggen de linking pin tussen ziekenhuis, universiteit en de data scientist. “Tussen de wereld van het ziekenhuis en de data science gaapt nog een gat. We spreken elkaars taal niet en in het ziekenhuis herkennen we de kansen nog onvoldoende. Daar ligt in de beginfase een belangrijke opdracht voor mij. Binnen het deelproject RETROSPECT ben ik nu bezig met het afdekken van de medisch-ethische en juridische aspecten. Daarna wil ik met masterstudenten Data Science het huis in en gaat er een pilot van start, waarin we ook dwarsverbanden zoeken met onderzoeksinstituten en het bedrijfsleven. Zo kunnen we samen werken aan gepersonaliseerde zorg, geheel in lijn met onze strategie – de patiënt, als mens, in de regie!”

9 INTERVIEW ESTHER DE VRIES

KLINISCH FARMACOLOGEN JBZ

“OPLEIDING, ONDERZOEK EN PATIËNTENZORG MOE-TEN ELKAAR VERSTERKEN”


Het begon met een ontmoeting tussen ziekenhuisapotheker-klinisch farmacoloog Jeroen Derijks en geriater-klinisch farmacoloog Rob van Marum. Nu zeven jaar later is de vakgroep klinische farmacologie van het Jeroen Bosch Ziekenhuis uitgegroeid tot een brede expertgroep waarin de expertise van verschillende doelgroepen is gebundeld. “Wij zijn een voorbeeld van STZ-onderzoek.”

‘Hoe kunnen we elkaar versterken in onderzoek?’ Kort gezegd, was dat de insteek van de ontmoeting tussen de twee klinisch farmacologen in 2010. Van Marum: “Ik zocht Jeroen op, omdat ik wist dat we elkaar zouden kunnen versterken. Ik met mijn klinische insteek, Jeroen vanuit zijn farmaceutische expertise. Derijks: “Van begin af aan hadden we een duidelijke focus. We wilden de klinische farmacologie op de kaart zetten en ons daarbij met name richten op farmacotherapie bij ouderen.” Van Marum: “Met de afspraak om samen op te trekken. En dat doen we tot op de dag van vandaag.

Aanname- en opleidingsbeleid De samenwerking is in de loop der jaren flink uitgebreid. Binnen de vakgroep geriatrie zijn drie specialisten aangetrokken. “Allemaal geriater- klinisch farmacologen”, aldus Van Marum. “Dat was een eis.” Derijks: “Ook bij ons zijn er drie klinisch farmacologen bijgekomen; intern opgeleid.” Het benadrukt het belang dat zowel apotheek als geriatrie toekennen aan de klinische farmacologie. Derijks: “Het aantal ouderen neemt toe. Veel oudere patiënten kampen met meerdere problemen tegelijk en gebruiken diverse medicijnen naast elkaar. Dat is complex en soms risicovol. We zijn voortdurend op zoek naar manieren om de zorg voor deze patiënten beter en veiliger te maken. Daar is kennis voor nodig en innovatie. Dat vind ik juist ook zo sterk: al onze onderzoeksvragen komen voort uit praktijkobservaties. Methodieken die we ontwikkelen kunnen we vaak direct implementeren.”

Sterke groepDoor de groei van de vakgroep klinische farmacologie zijn de mogelijkheden toegenomen. “We kunnen taken verdelen op het gebied van onderwijs en onderzoek”, bevestigt Van Marum. “Zo maken we optimaal gebruik van ieders kracht.” Derijks: “Het is een sterke groep, die zeer onderzoeksminded is. Ziekenhuisapotheker Walter Hermens, geriater Karen Keijsers, Rob en ik zijn gepromoveerd. Rob is bijzonder hoogleraar farmacotherapie bij ouderen aan het VUmc en zit in veel landelijke richtlijnencommissies. Sinds 2010 hebben we als groep meerdere promoties begeleid en ruim 50 Pubmed publicaties gerealiseerd.” Van Marum: “JBZ geriater-klinisch farmacoloog, Astrid van Strien, promoveert dit jaar op het proefschrift ‘bijwerkingen van antipsychotica’. Karen Keijsers en Jeroen zijn copromotor en ik ben promotor. Alles in eigen huis. We leiden elkaar op!”

HorizontaalVan Marum: “Farmacotherapie is een van de belangrijkste instrumenten voor dokters. De laatste tien jaar is er toenemende aandacht voor problemen rondom medicatie; medicatiefouten, bijwerkingen, de balans tussen effectiviteit en veiligheid. Niet alleen binnen geriatrie en de apotheek, natuurlijk. Daarom streven we altijd naar verbreding. Zo hebben we al een psychiater opgeleid als klinisch farmacoloog en leiden we nu een SEH-arts op.” Derijks: “Als expertgroep willen we ons horizontaal organiseren, dwars door de hele organisatie heen. Uitbreiding naar de keten, richting huisartsen, apothekers in de regio en de verpleeghuiszorg is dan een volgende stap. Van Marum: “Zo kunnen we nog meer betekenen voor patiënten in het ziekenhuis en daarbuiten.”

11 INTERVIEW JEROEN DERIJKS / ROB VAN MARUM

VERPLEEGKUNDIG SPECIALISTEN

“KENNIS EN WETENSCHAP ZIJN ONDERDEEL VAN ONS VAK”

Klinisch handelen, patiëntenzorg is de corebusiness voor verpleegkundig specialisten Carolien Burghout en Bert van Rixtel. “Maar kennis en wetenschap behoren óók tot ons profiel”, weten ze. “Het is een onderdeel van ons vak.”

“Als verpleegkundig specialisten moeten we de ruimte nemen voor wetenschappelijk onderzoek”, zegt Burghout. “Vanuit die gedachte hebben we binnen de vakgroep ook de Journal Club opgericht. Een keer in de drie maanden komen we met alle (30) verpleegkundig specialisten bij elkaar. Een van de deelnemers is de


reviewer. Hij of zij komt met een vraagstelling uit de praktijk, zoekt daar het best passende artikel bij en stuurt dit – inclusief een verantwoording – naar de andere deelnemers. Ter voorbereiding heeft iedereen dus het artikel gelezen. Daarnaast heb je een soort van waarderingslijst gekregen, waarop je aangeeft hoe goed het artikel volgens jou scoort op methodologie, validiteit en betrouwbaarheid.” Van Rixtel: “Leren beoordelen, dat is wat we doen. Belangrijk, vinden wij, want onderzoeksvaardigheden moet je onderhouden, anders raak je op een gegeven moment je affiniteit met wetenschap kwijt.”

Mijlpaal en stimulansDe Journal Club is een eerste stap. Een tweede stap is: zelf wetenschappelijk onderbouwd onderzoek doen. Wat dat betreft is de praktijk nog weerbarstig. De praktijk van de verpleegkundig specialist in een groot algemeen ziekenhuis is vooral gericht op de directe patiëntenzorg. De rest komt later. “Maar het één kan niet zonder het ander”, zegt Van Rixtel. “Het is essentieel dat wij óók tijd investeren in onderzoek, want daardoor komt ons klinisch handelen op een hoger niveau en daarmee de zorg voor de patiënt.” Burghout: “In september gaat het eerste onderzoek van een verpleegkundig specialist in het JBZ van start. Ilona Koenen onderzoekt het valideren van een meetinstrument om dysfagie bij longkankerpatiënten te objectiveren. Een mijlpaal. En een stimulans, want als ik dat hoor, denk ik: ‘ik wil ook’. Omdat ik me wil ontwikkelen, beter wil worden, meer kwaliteit wil leveren.” Artsen én verpleegkundigen“Natuurlijk heeft niet iedere verpleegkundig specialist de drang om zich met onderzoek bezig te houden”, zegt Burghout. “Dat hoeft niet en dat kan ook niet. Binnen onze vakgroep heeft naast het klinische werk ieder zijn eigen taken en aandachtsgebieden. Bert en ik zijn onderzoeksminded, dit past bij ons.” Van Rixtel: “Om die reden zijn we bijvoorbeeld ook uitgenodigd door Procesbegeleider verpleegkundig leiderschap, Sharon van de Ven, om een rol te vervullen in het programma Verpleegkundig Leiderschap van het JBZ. In de afgelopen drie jaar hebben we binnen de module ‘evidence based practice (EBP)’ als zogenoemde EBP-experts deelnemers aan het programma begeleid.” Van Rixtel: “De toegenomen complexiteit van de zorg en de ambities van het ziekenhuis stellen andere (hogere) eisen aan de verpleegkundige. Door het aanbieden van dit programma laat het Jeroen Bosch Ziekenhuis zien dat het belang hecht aan een wetenschappelijke onderbouwing van het handelen. Voor artsen én verpleegkundigen. Daar geven wij heel graag mede invulling aan.”

13 INTERVIEW CAROLIEN BURGHOUT / BERT VAN RIXTEL

Lechner TJ, van Wijk MG. Confirming Loss of Resistance for Epidural Analgesia: A New Role for Technology. Reg Anesth Pain Med. 2015 Jul-Aug;40(4):389-90. doi: 10.1097/AAP.0000000000000256. PMID: 26079355

Vogelaar FJ, Abegg R, van der Linden JC, Cornelisse HG, van Dorsten FR, Lemmens VE, Bosscha K. Epidural analgesia associated with better survival in colon cancer. Int J Colorectal Dis. 2015 Aug;30(8):1103-7. doi: 10.1007/s00384-015-2224-8. PMID: 25916606

ANESTHESIOLOGIE

Wetenschappelijke publicaties

1

15 ANESTHESIOLOGIE

Jacobs LH, van Borren M, Gemen E, van Eck M, van Son B, Glatz JF, Daniels M, Kusters R. Rapidly rule out acute myocardial infarction by combining copep-tin and heart-type fatty acid-binding protein with cardiac troponin. Ann Clin Biochem. 2015 Sep;52(Pt 5):550-61. doi: 10.1177/0004563215578189. Epub 2015 Mar 2.PMID: 25732130

Joustra R, Boulaksil M, Meijburg HW, Daniëls MC. Left bundle branch block in serious hyper-kalaemia: rate-dependency? Neth Heart J. 2016 Sep;24(9):559-60. doi: 10.1007/s12471-016-0865-z. PMID:27457690

Takanari H, Bourgonje VJ, Fontes MS, Raaijmakers AJ, Driessen H, Jansen JA, van der Nagel R, Kok B, van Stuijvenberg L, Boulaksil M, Takemoto Y, Yamazaki M, Tsuji Y, Honjo H, Kamiya K, Kodama I, Anderson ME, van der Heyden MA, van Rijen HV, van Veen TA, Vos MA. Calmodulin/CaMKII inhibition improves intercellular communication and impulse propagation in the heart and is antiarrhythmic under conditions when fibrosis is absent. Cardiovasc Res. 2016 Sep;111(4):410-21. doi: 10.1093/cvr/cvw173. PMID:27357638

Boulaksil M, Bierhuizen MF, Engelen MA, Stein M, Kok BJ, van Amersfoorth SC, Vos MA, van Rijen HV, de Bakker JM, van Veen TA. Spatial Heterogeneity of Cx43 is an Arrhythmogenic Substrate of Polymorphic Ventricular Tachycardias during Compensated Cardiac Hypertrophy in Rats. Front Cardiovasc Med. 2016 Mar 2;3:5. doi: 10.3389/fcvm.2016.00005. eCol-lection 2016. PMID:26973841

Meuwese CL, Meijburg H, Kort E, van Dijk J. Are superior outcomes of early coronary angiography versus a conservative approach in survivors after out-of-hospital cardiac arrest driven by subsets of patients with ST-elevations? Resuscitation. 2016 Jun;103:e11-2. doi: 10.1016/j.resuscita-tion.2016.02.016. Epub 2016 Feb 27. No abstract available. PMID: 26926110

CARDIOLOGIE


2

17 CARDIOLOGIE

Abstracts, voordrachten en posters

Arts I, Boulaksil M, Westra S, Smeets JLRM. Co-existence of A572D mutation and H558R Polymor-phism of SCN5a sodium channel may result in qt prolongation and enhance susceptibility to torsades de pointes arrhythmias. Abstract at 37th Annual Scientific Sessions of the HRS Heart Rhythm Society, San Francisco, CA, 4-7 May, 2016.

Boulaksil M, Bierhuizen M, Engelen M, Stein M, Kok B, van Amersfoorth S, Vos M, van Rijen H, de Bakker J, van Veen T. Spatial heterogeneity of Cx43 and its non-phosphorylated form is an arrhythmogenic substrate of polymorphic ventricular tachycardias in compensated cardiac hypertrophy in rats. Abstract at CARDIOSTIM - EHRA Europace, Nice, France, 8-11 June, 2016.

Maat J, Bouter KP, Bleeker-Rovers CP, van Apeldoorn M, Boulaksil M. Value of FDG-PET/CT in commu-nity-acquired Staphylococcus aureus bacteremia. Abstract at 27e Internistendagen Anual Meeting of the Netherlands Association of Internal Medicine, 22-24 April 2015, Maastricht, the Netherlands.

J. Polad. First real life clinical experiences with the latest generation of DES with abluminally coated biodegradable polymer. Trans radial PCI, experien-ces from the Netherlands.Trans Radial Intervention Course, Moscow, 2015.

Publicaties (niet pubmed)Jawed Polad, Jochen Wöhrle, Balbir Singh, Milan Chag, Seung-Woon Rha, Fazila-Tun-Nesa Malik, Martijn van Eck, Wolfgang Rottbauer. Deliverability of the Resolute Integrity stent and a post hoc com-parison of radial and femoral access: The DELIVER study. Cardiovascular Revascularization Medicine, Vol. 15, Issue 5, p289–294

Jawed Polad, Ben Gho, Huub Meijburg, Peter Els-man. TCT-498 Impact of duration of dual antiplatelet therapy on clinical outcomes 1 year after implan-tation of abluminally coated drug eluting stent with bioresorbable polymer. Oct 2015 • Journal of the American College of Cardiology

Polad J., Gho B., Elsman P., Meijburg H.: Com-parative evaluation of outcomes in high-risk acute coronary syndrome and stable patient treated with bioresorbable polymer drug eluting stent. JACC 2015; 66(15):B163-B164

Polad J, Gho B., Meijburg H., Elsman P.: Impact of duration of dual antiplatelet therapy on clinical outcomes 1 year after implantation of abluminally coated drug eluting stent with bioresorbable polymer. JACC 2015; 66(15):B204


19 CARDIOLOGIE

Van der Linden YT, Boersma D, van Poll D, Lips DJ, Prins HA. Single-port laparoscopic appendectomy in children: single center experience in 50 patients. Acta Chir Belg 2015;115:118-122PMID:26021944

Govaert JA, Fiocco M, van Dijk WA, Kolfschoten NE, Prins HA, Dekker JT, Tollenaar RA, Tanis PJ, Wouters MW; Dutch Value Based Healthcare Study Group. Multicenter Stratified Comparison of Hospital Costs Between Laparoscopic and Open Colorectal Cancer Resections: Influence of Tumor Location and Operative Risk. Ann Surg. 2016 Sep 8. [Epub ahead of print]PMID:27611610

Vogelaar FJ, Lips DJ, van Dorsten FR, Lemmens VE, Bosscha K. Impact of anaesthetic technique on survival in colon cancer: a review of the literature. Gastroenterol Rep (Oxf). 2016 Feb;4(1):30-4. doi: 10.1093/gastro/gov001. Epub 2015 Feb 16. Review. PMID: 25688100

de Rooij T, van Hilst J, Boersma D, Bonsing BA, Daams F, van Dam RM, Dijkgraaf MG, van Eijck CH, Festen S, Gerhards MF, Koerkamp BG, van der Harst E, de Hingh IH, Kazemier G, Klaase J, de Kleine RH, van Laarhoven CJ, Lips DJ, Luyer MD, Molenaar IQ, Patijn GA, Roos D, Scheepers JJ, van der Schelling GP, Steenvoorde P, Vriens MR, Wijsman JH, Gouma DJ, Busch OR, Abu Hilal

M, Besselink MG; Dutch Pancreatic Cancer Group. Impact of a Nationwide Training Program in Minimally Invasive Distal Pancreatectomy (LAELAPS). Ann Surg. 2016 Aug 1. [Epub ahead of print]PMID: 27429027

de Rooij T, Lu MZ, Steen MW, Gerhards MF, Dijkgraaf MG, Busch OR, Lips DJ, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. Minimally Invasive Versus Open Pancreatoduodenectomy: Systematic Review and Meta-analysis of Comparative Cohort and Registry Studies. Ann Surg. 2016 Aug;264(2):257-67. doi: 10.1097/SLA.0000000000001660.PMID: 26863398

Vogelaar FJ, Abegg R, van der Linden JC, Cornelisse HG, van Dorsten FR, Lemmens VE, Bosscha K. Epidural analgesia associated with better survival in colon cancer. Int J Colorectal Dis. 2015 Aug;30(8):1103-7. doi: 10.1007/s00384-015-2224-8. PMID: 25916606

Vogelaar F, Van Erning F, Reimers M, Van Der Linden J, Pruijt J, Van Den Brule A, Bosscha K. The prognostic value of Microsatellite instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients. Mol Med. 2015 Dec 17:1-26. Doi. 10.2119/molmed.2015.00220 PMID 26716438

CHIRURGIE


3

21 CHIRURGIE

De Rooij T, Tol JA, van Eijck CH, Boerma D, Bonsing BA, Bosscha K, van Dam RM, Dijkgraaf MG, Gerhards MF, van Goor H, van der Harst E, de Hingh IH, Kazemier G, Klaase JM, Molenaar IQ, Patijn GA, van Santvoort HC, Scheepers JJ, van der Schelling GP, Sieders E, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis. Ann Surg Oncol. 2016 Feb;23(2):585-91. doi: 10.1245/s10434-015-4930-4. PMID: 26508153

Goos JA, de Cuba EM, Coupé VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JA, Menke-Van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET Group. Collaborators: van Grieken NC, Perk LR, van den Tol MP, te Velde EA, Windhorst AD, Baas J, Rijken AM, van Beek MW, Pijpers HJ, Bril H, Stockmann HB, Zwijnenburg A, Bosscha K, van den Brule AJ, Hoekstra CJ, van der Linden JC, Rinkes IH, van Diest PJ, van Hillegersberg R, Kranenburg O, Lam MG, Snoeren N, Liem IH, Roumen RM, Vening W. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA)Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Ann Surg. 2016 Jan;263(1):138-45. PMID: 25563886

Hagenaars JC, Wever PC, Vlake AW, Renders NH, van Petersen AS, Hilbink M, de Jager-Leclercq MG, Moll FL, Koning OH, Hoekstra CJ. Value of 18F-FDG PET/CT in diagnosing chronic Q fever in patients with central vascular disease. Neth J Med. 2016 Aug;74(7):301-8.PMID: 27571945

Nieuwland AJ, Kokje VB, Koning OH, Hamming JF, Szuhai K, Claas FH, Lindeman JH. Activation of the vitamin D receptor selectively interferes with calcineurin-mediated inflammation: a clinical evaluation in the abdominal aortic aneurysm. Lab Invest. 2016 Jul;96(7):784-90. doi: 10.1038/labinvest.2016.55. Epub 2016 May 30.PMID: 27239732

Broos PP, Hagenaars JC, Kampschreur LM, Wever PC, Bleeker-Rovers CP, Koning OH, Teijink JA, Wegdam-Blans MC. Vascular complications and surgical interventions after world’s largest Q fever outbreak. J Vasc Surg. 2015 Nov;62(5):1273-80. doi: 10.1016/j.jvs.2015.06.217. Epub 2015 Sep 10.PMID: 26365665

Van den Haak RF, Hamans BC, Zuurmond K, Verhoeven BA, Koning OH. Significant Radiation Dose Reduction in the Hybrid Operating Room Using a Novel X-ray Imaging Technology. Eur J Vasc Endovasc Surg. 2015 Oct;50(4):480-6. doi: 10.1016/j.ejvs.2015.06.025. Epub 2015 Aug 15.PMID: 26286386

Boersma D, Smulders DL, Bakker OJ, van den Haak RF, Verhoeven BA, Koning OH. Endovenous laser ablation of insufficient perforating veins: Energy is key to success. Vascular. 2016 Apr;24(2):144-9. doi: 10.1177/1708538115587214. Epub 2015 May 12.PMID: 25972028

Pennings JL, Kremers MN, Hodemaekers HM, Hagenaars JC, Koning OH, Renders NH, Hermans MH, de Klerk A, Notermans DW, Wever PC, Janssen R. Dysregulation of serum gamma interferon levels in vascular chronic Q Fever patients provides insights into disease pathogenesis. Clin Vaccine Immunol. 2015 Jun;22(6):664-71. doi: 10.1128/CVI.00078-15. Epub 2015 Apr 29.PMID: 25924761

Hagenaars JC, Wever PC, Shamelian SO, Van Petersen AS, Hilbink M, Renders NH, De Jager-Leclercq GL, Moll FL, Koning OH. Vascular chronic Q fever: quality of life. Epidemiol Infect. 2015 Oct;143(13):2903-9. doi: 10.1017/S0950268814003951. Epub 2015 Jan 22.PMID: 25608699

Hinnen JW, Konickx MA, Meerwaldt R, Kolkert JL, van der Palen J, Huisman AB, Geelkerken RH. Long Term Results of Kissing Stents in the Aortic Bifurcation. Acta Chir Belg. 2015 May-Jun;115(3):191-7. PMID: 26158249Trefwoorden: Stent iliaca


van la Parra RF, de Wilt JH, Mol SJ, Mulder AH, de Roos WK, Bosscha K. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients? Breast J. 2015 Nov-Dec;21(6):621-6. doi: 10.1111/tbj.12496. Epub 2015 Sep 22.PMID: 26391102

Lodewijkx PJ, Besselink MG, Witteman BJ, Schepers NJ, Gooszen HG, van Santvoort HC, Bakker OJ; Dutch Pancreatitis Study Group. Nutrition in acute pancreatitis: a critical review. Expert Rev Gastroenterol Hepatol. 2016;10(5):571-80. doi: 10.1586/17474124.2016.1141048. Epub 2016 Mar 15. PMID: 26823272

Boersma D, de Borst GJ, Moll FL. A proof-of-concept study of the VeinScrew: A new percutaneous venous closure device. Vascular. 2016 Apr 11. pii: 1708538116644117. [Epub ahead of print] PMID: 27189850

Van Rossem et al and de Appendicitis Collaborative Study Group (B van de Wall). Prospective nationwide outcome audit of surgery for suspected acute appendicitis. Br J Surg. 2016 Jan;103(1):144-51. doi: 10.1002/bjs.9964. Epub 2015 Oct 28.PMID:26509648

Van Rossem CC et al and the Snapshot Appendicitis Collaborative Study Group (B van de Wall). Antibiotic Duration After Laparoscopic Appendectomy for Acute Complicated Appendicitis. JAMA Surg. 2016 Apr;151(4):323-9. doi: 10.1001/jamasurg.2015.4236PMID:26580850

Borstlap WA, Tanis PJ, Koedam TW, Marijnen CA, Cunningham C, Dekker E, van Leerdam ME, Meijer G, van Grieken N, Nagtegaal ID, Punt CJ, Dijkgraaf MG, De Wilt JH, Beets G, de Graaf EJ, van Geloven AA, Gerhards MF, van Westreenen HL, van de Ven AW, van Duijvendijk P, de Hingh IH, Leijtens JW, Sietses C, Spillenaar-Bilgen EJ, Vuylsteke RJ, Hoff C, Burger JW, van Grevenstein WM, Pronk A, Bosker RJ, Prins H, Smits AB, Bruin S, Zimmerman DD, Stassen LP, Dunker MS, Westerterp M,

Coene PP, Stoot J, Bemelman WA, Tuynman JB. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. BMC Cancer. 2016 Jul 21;16:513. doi: 10.1186/s12885-016-2557-x.PMID: 27439975

Van der Linden YT, Boersma D, Prins HA, Bosscha K, Lips DJ. Use of a multi-instrument access device in abdominoperineal resections. J Min Access Surg 2016;12:248-53PMID:27279397

Boersma D, Kornmann VN, van Eekeren RR, Tromp E, Ünlü Ç, Reijnen MM, de Vries JP. Treatment Modalities for Small Saphenous Vein Insufficiency: Systematic Review and Meta-analysis. J Endovasc Ther. 2016;23:199-211PMID:26564912

Prinsen JH, Boersma D, van Loenhout R, van Schaik PM, Verhoeven BA. Persistent endoleak after endovascular aneurysm repair for acute Q-fever-infected aortocaval fistula. Vascular. 2015;23:645-7PMID:25430660

Boezeman RP, Boersma D, Wille J, Kelder JC, Visscher MI, Waanders FG, Moll FL, De Vries JP. The significance of regional hemoglobin oxygen saturation values and limb-to-arm ratios of near-infrared spectroscopy tp detect critical limb ischemia. Vascular. 2016 Oct;24(5):492-500. doi: 10.1177/1708538115613936. Epub 2015 Oct 25.PMID: 26503733

Johannesma PC, van de Beek I, van der Wel JW, Paul MA, Houweling AC, Jonker MA, van Waesberghe JH, Reinhard R, Starink TM, van Moorselaar RJ, Menko FH, Postmus PE. Risk of spontaneous pneumothorax due to air travel and diving in patients with Birt-Hogg-Dubé syndrome.Springerplus. 2016 Sep 7;5(1):1506. PMID: 27652079

23CHIRURGIE

Balan TA, Jonker MA, Johannesma PC, Putter H. Ascertainment correction in frailty models for recurrent events data. Stat Med. 2016 Oct 15;35(23):4183-201. PMID: 27087571

Johannesma PC, Houweling AC, Menko FH, van de Beek I, Reinhard R, Gille JJ, van Waesberghe JT, Thunnissen E, Starink TM, Postmus PE, van Moorselaar RJ. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis? Fam Cancer. 2016 Apr;15(2):297-300. PMID: 26603437

Merten H, Johannesma PC, Lubberding S, Zegers M, Langelaan M, Jukema GN, Heetveld MJ, Wagner C. High risk of adverse events in hospitalised hip fracture patients of 65 years and older: results of a retrospective record review study. BMJ Open. 2015 Sep 7;5(9). PMID: 26346870

Johannesma PC, Reinhard R, Kon Y, Sriram JD, Smit HJ, van Moorselaar RJ, Menko FH, Postmus PE; Amsterdam BHD working group. Prevalence of Birt-Hogg-Dubé syndrome in patients with apparently primary spontaneous pneumothorax. Eur Respir J. 2015 Apr;45(4):1191-4. PMID: 25537564

Paul C. Johannesma. Renal and Pulmonary aspects of Birt-Hogg-Dubé syndrome. Vrije Universiteit (VUmc), 30 september 2016, Amsterdam Promotores: Prof. P.E. Postmus (University of Liverpool), Prof. dr. R.J.A. van Moorselaar (VU medisch centrum)Co-promotores: dr. F.H. Menko (NKI-AvL Amsterdam), dr. J.H.T.M. van Waesberghe (VU medisch centrum)

Sandra Vennix.Minimally invasive strategies for the surgical treatment of colonic peritonitis. 2016.Begeleiders bij het onderzoek, Dr. D.J. Lips, prof.dr. W.A. Bemelman, prof.dr. J. Lange

ProefschriftenKoning OH, van Herwaarden JA. Operatieve benadering van het vaatstelsel. Hoofdstuk: Arteriele toegang voor endovasculaire procedures. Uitgave van de NVVV, ISBN 978-94-6233-261-4

Boeken


Abstracts, voordrachten en postersStrijbos RM, Hinnen JW, van den Haak RF, Ver-hoeven BA, Koning OH. Inadequate health literacy in patients with arterial disease. Voordracht Associ-ation of International Vascular Surgeons (AIVS), Big Sky, MT, VS, mrt 2015.

Koning OH. De hybride OK nut en noodzaak. Voor-dracht Gore Chivo Meeting, Oisterwijk, jun 2015.

Koning OH. Radiation protection in the hybride OR. Voordracht, European Society of Vascular Surgery, Porto, Portugal, sept 2015.

Koning OH. PTA below the knee, it’s not just a blow job! Voordracht Najaarsvergadering NVVV, Den Haag, okt 2015.

Strijbos RM, Hinnen JW, van den Haak RF, Verhoeven BA, Koning OH. High dose Rosuva-statin (Crestor) leads to decreased renal damage after contrast arteriography. Should it be used more widely as a renal protective agent? Voordracht VEITH symposium, New York, USA, nov 2015.

Strijbos RM, Hinnen JW, van den Haak RF, Ver-hoeven BA, Koning OH. Health care literacy in vas-cular patients is inadequate: do we need better ways to inform patients? Voordracht VEITH symposium, New York, USA, nov 2015.

Strijbos RM, Hinnen JW, van den Haak RF, Verhoeven BA, Koning OH. The Role Of Short-Term High-Dose Pre-procedural Statin Treatment In Prevention Of Contrast-Induced Nephropathy. Voor-dracht Association of International Vascular Surgeons (AIVS), Madonna di Campiglio, Italie, mrt 2016.

Koning OH. PTA below the knee, it’s not just a blow job! Voordracht Association of International Vascular Surgeons (AIVS), Madonna di Campiglio, Italie, mrt 2016.

Strijbos RM, Hinnen JW, van den Haak RF, Verhoeven BA, Koning OH. The Role Of Short-Term High-Dose Pre-procedural Statin Treatment In Prevention Of Contrast-Induced Nephropathy. poster, European Society of Vascular and Endovascular Sur-gery, Kopenhagen, Denemarken, sept 2016.

Strijbos RM, Hinnen JW, van den Haak RF, Ver-hoeven BA, Koning OH. Inadequate Health Literacy In Patients With Arterial Vascular Disease. poster, European Society of Vascular and Endovascular Sur-gery, Kopenhagen, Denemarken, sept 2016.

Boersma D. Macroscopic and histological scoring of mechanochemical endovenous ablation using the Clarivein device in an animal model. Annual Meeting European Society of Vascular Surgery 2016, Copen-hagen, Denmark.

Boersma D. The vein is screwed. A proof of concept study of the VeinScrew. Annual Meeting Society of Vascular Surgery 2016, Washington DC, USA.

Boersma D. The vein is screwed. The Veinscrew: a proof of concept study. Charing Cross Meeting / In-novation Showcase, London 2015

Johannesma PC. Regionale Refereeravond Heel-kunde, Utrecht, Nederland, 2016

Johannesma PC. 6th World Congress on Birt-Hogg-Dubé, Syracuse, NY, Verenigde Staten, 2015

Publicaties (niet pubmed)Van Wegen M, van Leijsen SAL, Lips DJ, Hamilton CJ. Verdraaid een appendix; case report. NTOG 2015 April; 128: 139-141.

25 CHIRURGIE

DERMATOLOGIE

Wetenschappelijke publicatiesParren LJ, Munte K, Winnepenninckx V, van Geel M, Steijlen PM, Frank J, van Steensel MA. Clustered unilateral trichoepitheliomas indicate Type 1 segmental manifestation of multiple familial trichoepithelioma. Clin Exp Dermatol. 2016 Aug;41(6):682-4. doi: 10.1111/ced.12856. Epub 2016 Jun 24. PMID:27339671

Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, Arnold WP, Berends MA, Weppner-Parren L, Ossenkoppele PM, Njoo MD, Mommers JM, van Lümig PP, Driessen RJ, Kievit W, de Jong EM. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016 Aug;175(2):340-7. doi: 10.1111/bjd.14552. Epub 2016 Jun 25.PMID:26989852

Moyakine AV, Hermans DJ, Fuijkschot J, van der Vleuten CJ. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development. J Am Acad Dermatol. 2015 Aug;73(2):341-2PMID:26183988

Brouwer MW, Tebbe-Gholami M, Starink MV, van Os TA. [Hereditary leiomyomatosis: a woman with red-brown nodules]. Ned Tijdschr Geneeskd. 2015;159: A8867. Dutch. PMID:25990335

4

Sezgi P, Weppner-Parren LJMT, Greebe RJ, Mol SJJ, Mutsaers ER, van Geest AJ. Kaposi-sarcoom bij 3 hiv-negatieve patienten. Een zeldzaam fenomeen. NTvDV 2015;25:321-4.

Linden vd M, Hendriks IM, Meeuwis KAP, Bulten J, Bosse T, Poelgeest v MIE, Hullu d JA, Hees v CLM; Vulvaire morbus Paget; Ned Tijdschr Derm Venereol; 2015; 25; 609-12

Publicaties (niet pubmed)

27 DERMATOLOGIE

5GERIATRIE

Wetenschappelijke publicatiesKerkenaar ME, van Marum RJ, Sprong T, Bootsma JE. Spondylodiscitis bij de oudere patiënt. Ned Tijdschr Geneeskd. 2016;160:A9375PMID: 27165453

Kröger E, Van Marum R, Souverein P, Carmichael PH, Egberts T. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):276-85. doi: 10.1002/pds.3741. Epub 2015 Feb 4.PMID: 25652526

Kröger E, Mouls M, Wilchesky M, Berkers M, Carmichael PH, van Marum R, Souverein P, Egberts T, Laroche ML. Adverse Drug Reactions Reported with Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase. Ann Pharmacother. 2015 Aug 31. pii: 1060028015602274. PMID: 26324356.

Berm EJ, Hak E, Postma M, Boshuisen M, Breuning L, Brouwers JR, Dhondt T, Jansen PA, Kok RM, Maring JG, van Marum R, Mulder H, Voshaar RC, Risselada AJ, Venema H, Vleugel L, Wilffert B. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with

nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Trials. 2015 Jan 31;16(1):37. doi:10.1186/s13063-015-0561-0. PMID: 25636328; PMCID: PMC4328880.

Drenth-van Maanen AC, van Marum RJ, Jansen PA, Zwart JE, van Solinge WW, Egberts TC. Adherence with Dosing Guideline in Patients with Impaired Renal Function at Hospital Discharge. PLoS One. 2015 Jun 8;10(6):e0128237. doi:10.1371/journal.pone.0128237. eCollection 2015. PMID: 26053481

Eppenga WL, Wester WN, Derijks HJ, Hoedemakers RM, Wensing M, De Smet PA, Van Marum RJ. Fluctuation of the renal function after discharge from hospital and its effects on drug dosing in elderly patients--study protocol. BMC Nephrol. 2015 Jul 7;16:95. doi: 10.1186/s12882-015-0095-4. PMID: 26149449

Reintjes W, Romijn MD, Hollander D, Ter Bruggen JP, van Marum RJ. Reversible Dementia: Two Nursing Home Patients With Voltage-Gated Potassium Channel Antibody-Associated Limbic Encephalitis. J Am Med Dir Assoc. 2015 Sep 1;16(9):790-4. doi: 10.1016/j.jamda.2015.06.008. Epub 2015 Jul 10. PMID: 26170033

29 GERIATRIE

van Marum RJ. Treatment of patients with Alzheimer’s disease: a breakthrough or not? Ned Tijdschr Geneeskd. 2015;159(0):A9494. Dutch. PMID: 26271177

van Marum RJ, Koopmans RT, Bouvy M. Does it still make sense? Deprescribing in the frail elderly. Ned Tijdschr Geneeskd. 2015;159:A8947. Review. Dutch. PMID: 25970678

Knol W, Verduijn MM, Lelie-van der Zande AC, van Marum RJ, Brouwers JR, van der Cammen TJ, Petrovic M, Jansen PA. Detecting inappropriate medication in older people: the revised STOPP/START criteria. Ned Tijdschr Geneeskd. 2015;159:A8904. Review. Dutch. PMID: 25923503

Van der Stelt CA, Vermeulen Windsant-van den Tweel AM, Egberts AC, van den Bemt PM, Leendertse AJ, Hermens WA, van Marum RJ, Derijks HJ. The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study. Drug Saf. 2016 Jan;39(1):79-87. doi: 10.1007/s40264-015-0361-1. PMID: 26553305

Stam H, Harting T, Sluijs Mv, Marum Rv, Horst Hv, Wouden JC, Maarsingh OR. Usual care and management of fall risk increasing drugs in older dizzy patients in Dutch general practice. Scand J Prim Health Care. 2016 Jun;34(2):165-71. doi: 10.3109/02813432.2016.1160634. Epub 2016 Apr 6. PMID: 27049170

Jessurun N, van Marum R, Hermens W, van Puijenbroek E. Advanced Age and Female Sex As Risk Factors for High Anion Gap Metabolic Acidosis After a Drug Interaction Between Paracetamol and Flucloxacillin: A Case Series. J Am Geriatr Soc. 2016 Sep 2. doi: 10.1111/jgs.14332. [Epub ahead of print] No abstract available. PMID:27590524

Stein CE, Keijsers CJ, Bootsma JE, Schouten HJ. Missed diagnosis of pulmonary embolism with age-adjusted d-dimer cut-off value; Age Ageing. 2016 Nov;45(6):910-911. PMID: 27496940 Trefwoorden: d-dimer; age-adjusted cut-off; older people; pulmonary embolism

Vermeij A. Claassen JA, Dautzenberg PL, Kessels RP. Transfer and maintenance effects of online working-memory training in normal ageing and mild cognitive impairment. Neuropsychol Rehabil. 2015 May 26:1-27. [Epub ahead of print] DOI: 10.1080/09602011.2015.1048694. PMID: 26010573

Vermeij A, Kessels RP, Heskamp L, Simons EM, Dautzenberg PL, Claassen JA. Prefrontal activation may predict working-memory training gain in normal aging and mild cognitive impairment. Brain Imaging Behav. 2016 Feb 3. [Epub ahead of print] PMID: 26843001

Van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ. Rating scales to measure side effects of antipsychotic medication: A systematic review. J Psychopharmacol. 2015 Aug;29(8):857-66. doi: 10.1177/0269881115593893. Epub 2015 Jul 8. Review.PMID:26156860

Brinkman DJ, Keijsers CJ, Tichelaar J, Richir MC, van Agtmael MA. Evaluating pharmacotherapy education: urgent need for hard outcomes. Br J Clin Pharmacol. 2016 May;81(5):1000-1. doi: 10.1111/bcp.12862. Epub 2016 Feb 17. No abstract available. PMID: 26663464

Keijsers CJ, Ross S. A pharmacological approach to education.Br J Clin Pharmacol. 2015 Sep;80(3):329-30. doi: 10.1111/bcp.12700. Epub 2015 Jul 22. No abstract available.PMID:26095016


Carolina JPW (Karen) Keijsers. PhD Thesis, Education in Appropriate Pharmacotherapy in Older Patients, Universiteit Utrecht, 15 jan 2015

Keijsers CJ, Leendertse AJ, Faber A, Brouwers JR, de Wildt DJ, Jansen PA. Pharmacists’ and General Practitioners’ Pharmacology Knowledge and Pharmacotherapy Skills. J Clin Pharmacol. 2015 Aug;55(8):936-43. doi: 10.1002/jcph.500. Epub 2015 Apr 30.PMID:25810359

Keijsers CJ, Segers WS, de Wildt DJ, Brouwers JR, Keijsers L, Jansen PA. Implementation of the WHO-6-step method in the medical curriculum to improve pharmacology knowledge and pharmacotherapy skills.Br J Clin Pharmacol. 2015 Jun;79(6):896-906. doi: 10.1111/bcp.12575.PMID: 25556708

Dautzenberg L, Jessurum N, Dautzenberg PL, Keijsers CJ. Reversible Methotrexate-Induced Dementia: A Case Report. J Am Geriatr Soc. 2015 Jun;63(6):1273-4. doi: 10.1111/jgs.13517. No abstract available. PMID:26096416

Keijsers CJ, de Wit JE, Tichelaar J, Brouwers JR, de Wildt DJ, de Vries PG, Jansen PA. Education on prescribing for older patients in the Netherlands: a curriculum mapping. Eur J Clin Pharmacol. 2015 May;71(5):603-9. doi: 10.1007/s00228-015-1830-2. Epub 2015 Mar 11.PMID:25753290

Keijsers CJ, Jansen PA, Brouwers JR, de Wildt DJ. Need for improvement in education on appropriate prescribing in elderly patients. Ned Tijdschr Geneeskd. 2015;159:A9609. PMID:26732217

Graveland PE, Beex-Oosterhuis MM, Gosker-Venis A, van Marum RJ, van Gool AR. Medication review in the mental health care service: experiences on long-stay units. Tijdschr Psychiatr. 2016;58(4):262-71. Dutch. PMID: 27075218

Proefschriften

S. Van Maurik-Brandon, V.H. ten Dam en P.L.J. Dautzenberg (onder redactie van). Protocolaire ouderenzorg Editie 2015. NHG. ISBN 978-90-5793-261-8.

Carolina Keijsers, Marike de Ruiter. Farmacotherapie voor de zorgprofessional, Hoofdstuk 20 Een ziekenhuisopname door dehydratie en elektrolytstoornissen. Jan 2016.

Marike de Ruiter, Carolina Keijsers. Farmacotherapie voor de zorgprofessional, Hoofdstuk 21 Een ziekenhuisopname vanwege een gastro-intestinale bloeding. Jan 2016.

Boeken

31 GERIATRIE

Smit R, Van Marum R, Péquériaux NC, Hollander D, Bleeker M, Hermens WAJJ, Derijks HJ. Prevalentie van correcte anti-Xa bloedspiegels in patiënten met verminderde nierfunctie op basis van een dosisadvies conform de richtlijn van de Nederlandse Federatie voor Nefrologie. Voordracht. Wetenschapsmiddag Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, Nederland, 11-11-2015. Smit R, Van Marum R, Péquériaux NC, Hollander D, Bleeker M, Hermens WAJJ, Derijks HJ. Prevalentie van correcte anti-Xa bloedspiegels in patiënten met verminderde nierfunctie op basis van een dosisadvies conform de richtlijn van de Nederlandse Federatie voor Nefrologie. Poster. Wetenschapsmiddag Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, Nederland, 11-11-2015.

Blenke AA, van Marum RJ, Vermeulen Windsant AM, Hermens WA, Derijks HJ. Success rate of advices and effectuated changes based on a structured medication review in psychogeriatric patients admitted to a nursing home: a prospective cohort study. Ziekenhuisfarmaciedagen 2016, Amersfoort, 10-11 November 2016

Blenke AA, van Marum RJ, Vermeulen Windsant AM, Hermens WA, Derijks HJ. Success rate of advices and effectuated changes based on a structured medication review in psychogeriatric patients admitted to a nursing home: a prospective cohort study. Voorjaarsdag NVKF&B 2016, ’s-Hertogenbosch, 01 April 2016

Jessurun N, van Puijenbroek EP, Otten LS, Mikes O, Vermeulen Windsant AM, van Marum RJ, Grootens K, Derijks HJ. Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high

10-hydroxynortriptyline serum levels. FIGON Dutch Medicines Days 2015, Ede, 05-07 October 2015

Smit R, Van Marum RJ, Péquériaux NC, Hollander AA, Bleeker MW, Hermens WA, Derijks HJ. Prevalence of correct anti-Xa bloodlevels in renally impaired patients in two Dutch Hospitals who are installed on therapeutic use of nadroparin after pharmacy driven dose advice according to a Dutch nephrology guideline. FIGON Dutch Medicines Days 2015, Ede, 05-07 October 2015

Eppenga WL, Wester WN, Derijks HJ, Hoedemakers RM, Wensing M, De Smet PA, Van Marum RJ. Fluctuation of the renal function after discharge from hospital and its effects on drug dosing in elderly patients - study protocol. Prisma Symposium, Amersfoort, 19 May 2015

Van der Stelt CA, Vermeulen Windsant-van den Tweel AM, Egberts AC, van den Bemt PM, Leendertse AJ, Hermens WA, van Marum RJ, Derijks HJ. Medicatiescreening met Beers-criteria en stopp/start-criteria bij de oudere patiënt: associatie tussenpotentieel ongewenst geneesmiddelengebruik en geneesmiddelgerelateerde ziekenhuisopnamen. PW Wetenschappelijk Platform 2015; 9:a1525

Smit R, Van Marum RJ, Péquériaux NC, Hollander AA, Bleeker MW, Hermens WA, Derijks HJ. Prevalentie van correcte anti-Xa-bloedspiegels bij patiënten met verminderde nierfunctie op basis van dosisadvies conform richtlijn Nederlandse Federatie voor Nefrologie. Nederlands Platform voor Farmaceutisch Onderzoek 2016; 1:a1610



J. Bootsma. Polyfarmacie in het Verpleeghuis. Verenso congres 24-11-16

J. Bootsma. Somatiek update voor de (ouderen)psychiater: Vallen. Congres ouderen psychiatrie. 4-11-2016

J. Bootsma. Farmacologie. Landelijke onderwijsdag Farmacologie voor Ziekenhuisartsen in opleiding. 10-6-16

J. Bootsma, W. Knol, namens de SIG Farmacotherapie bij ouderen. Standpunt cardiovasculaire veiligheid van calciumsuppletie bij osteoporose bij kwetsbare ouderen. Ins&Ouds - Tijdschrift voor Geriatrie 2016; 4, pagina 18 tm 25.

Kessels VSW, Dautzenberg PLJ, Vries de J, Schouten L. Global Positioning System (GPS) bij dementie: verwachtingen, wensen en bezwaren van mantelzorgers. In & Ouds 2015; 3:36-38.

Leenders A. Dautzenberg PLJ. Patiënt met delier hoort niet in separeer. Medisch Contact 2015: 1564-66.

Dautzenberg PLJ, Koster-v Ree M, Keijsers CJPW. Eerste lijn kan veel dementiezorg opvangen. MC 2016; 14 april: 18-21.


33 GERIATRIE

6GYNAECOLOGIE

Wetenschappelijke publicatiesMengerink BB, Van Leijsen SA, Vierhout ME, Inthout J, Mol BW, Milani AL, Roovers JP, Van Eijndhoven HW, Van Der Vaart CH, Van Gestel I, Hartog FE, Heesakkers JF, Kluivers KB. The Impact of Midurethral Sling Surgery on Sexual Activity and Function in Women With Stress Urinary Incontinence. J Sex Med. 2016 Oct;13(10):1498-507. doi: 10.1016/j.jsxm.2016.08.005.PMID: 27641921

Van Oostwaard MF, Langenveld J, Schuit E, Papatsonis DN, Brown MA, Byaruhanga RN, Bhattacharya S, Campbell DM, Chappell LC, Chiaffarino F, Crippa I, Facchinetti F, Ferrazzani S, Ferrazzi E, Figueiró-Filho EA, Gaugler-Senden IP, Haavaldsen C, Lykke JA, Mbah AK, Oliveira VM, Poston L, Redman CW, Salim R, Thilaganathan B, Vergani P, Zhang J, Steegers EA, Mol BW, Ganzevoort W. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol. 2015 May;212(5):624.e1-17. doi: 10.1016/j.ajog.2015.01.009. Epub 2015 Jan 9. Erratum in: Am J Obstet Gynecol. 2015 Sep;213(3):400. PMID: 25582098Trefwoorden: Hypertensieve zwangerschapsaandoeningen, herhalingsrisico

Franik S, Hoeijmakers Y, D’Hauwers K, Braat DD, Nelen WL, Smeets D, Claahsen-van der Grinten HL, Ramos L, Fleischer K. Klinefelter syndrome and fertility: sperm preservation should not be offered to children with Klinefelter syndrome. Hum Reprod. 2016 Sep;31(9):1952-9. doi: 10.1093/humrep/dew179. Epub 2016 Jul 13. PMID:27412247

Bensdorp AJ, Tjon-Kon-Fat RI, Bossuyt PM, Koks CA, Oosterhuis GJ, Hoek A, Hompes PG, Broekmans FJ, Verhoeve HR, de Bruin JP, van Golde R, Repping S, Cohlen BJ, Lambers MD, van Bommel PF, Slappendel E, Perquin D, Smeenk JM, Pelinck MJ, Gianotten J, Hoozemans DA, Maas JW, Eijkemans MJ, van der Veen F, Mol BW, van Wely M. Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterine insemination with controlled ovarian hyperstimulation.BMJ. 2015 Jan 9;350:g7771. doi: 10.1136/bmj.g7771. PMID: 25576320.

35 GYNAECOLOGIE

Moolenaar LM, Cissen M, de Bruin JP, Hompes PG, Repping S, van der Veen F, Mol BW. Cost-effectiveness of assisted conception for male subfertility. Reprod Biomed Online. 2015 Feb 24. pii: S1472-6483(15)00093-0. doi: 10.1016/j.rbmo.2015.02.006. [Epub ahead of print] PMID: 25900905

Tjon-Kon-Fat RI, Bensdorp AJ, Bossuyt PM, Koks C, Oosterhuis GJ, Hoek A, Hompes P, Broekmans FJ, Verhoeve HR, de Bruin JP, van Golde R, Repping S, Cohlen BJ, Lambers MD, van Bommel PF, Slappendel E, Perquin D, Smeenk J, Pelinck MJ, Gianotten J, Hoozemans DA, Maas JW, Groen H, Eijkemans MJ, van der Veen F, Mol BW, van Wely M. Is IVF-served two different ways-more cost-effective than IUI with controlled ovarian hyperstimulation? Hum Reprod. 2015 Oct;30(10):2331-9. doi: 10.1093/humrep/dev193. Epub 2015 Aug 12 PMID:26269539

Bensdorp AJ, Tjon-Kon-Fat R, Verhoeve H, Koks C, Hompes P, Hoek A, de Bruin JP, Cohlen B, Hoozemans D, Broekmans F, van Bomme P, Smeenk J, Mol BW, van der Veen F, van Wely M; INeS group. Dropout rates in couples undergoing in vitro fertilization and intrauterine insemination. Eur J Obstet Gynecol Reprod Biol. 2016 Aug 10;205:66-71. doi: 10.1016/j.ejogrb.2016.08.018. [Epub ahead of print]PMID:27567361

de Jong PG, Quenby S, Bloemenkamp KW, Braams-Lisman BA, de Bruin JP, Coomarasamy A, David M, DeSancho MT, van der Heijden OW, Hoek A, Hutten BA, Jochmans K, Koks CA, Kuchenbecker WK, Mol BW, Torrance HL, Scheepers HC, Stephenson MD, Verhoeve HR, Visser J, de Vries JI, Goddijn M, Middeldorp S.ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial. Trials. 2015 May 7;16(1):208. PMID: 25947329

Hamilton JA, Cissen M, Brandes M, Smeenk JM, de Bruin JP, Kremer JA, Nelen WL, Hamilton CJ. Total motile sperm count: a better indicator for the severity of male factor infertility than the WHO sperm classification system. Hum Reprod. 2015 May;30(5):1110-21. doi: 10.1093/humrep/dev058. Epub 2015 Mar 18. PMID: 25788568

Ebisch R, Rovers MM, Bosgraaf RP, van der Pluijm-Schouten HW, Melchers W, van den Akker P, Massuger L, Bekkers R. Evidence supporting see-and-treat management of cervical intraepithelial neoplasia: a systematic review and meta-analysis. BJOG. 2016 Jan;123(1):59-66. doi: 10.1111/1471-0528.13530. Epub 2015 Jul 14. PMID:26177672

Nicolaije KA, Ezendam NP, Vos MC, Pijnenborg JM, Boll D, Boss EA, Hermans RH, Engelhart KC, Haartsen JE, Pijlman BM, van Loon-Baelemans IE, Mertens HJ, Nolting WE, van Beek JJ, Roukema JA, Zijlstra WP, Kruitwagen RF, van de Poll-Franse LV. Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial. J Clin Oncol. 2015 Aug 24. pii: JCO.2014.60.3399. J Clin Oncol. 2015 Nov 1;33(31):3550-9. doi: 10.1200/JCO.2014.60.3399. Epub 2015 Aug 24.PMID:26304900

Vos MC, Hollemans E, Ezendam N, Feijen H, Boll D, Pijlman B, van der Putten H, Klinkhamer P, van Kuppevelt TH, van der Wurff AA, Massuger LF. MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer. J Ovarian Res. 2016 Sep 2;9(1):53. doi: 10.1186/s13048-016-0262-7.PMID:27590006

Kersten FA, Hermens RP, Braat DD, Hoek A, Mol BW, Goddijn M, Nelen WL; Improvement Study Group. Collaborators (23) (de Bruin JP). Overtreatment in couples with unexplained infertility. Hum Reprod. 2015 Sep 4. pii: dev185. PMID:26342018


Cissen M, Bensdorp A, Cohlen BJ, Repping S, de Bruin JP, van Wely M. Assisted reproductive technologies for male subfertility. Cochrane Database Syst Rev. 2016 Feb 26;2:CD000360. doi: 10.1002/14651858.CD000360.pub5. Review. PMID: 26915339

Cissen M, Meijerink AM, D’Hauwers KW, Meissner A, van der Weide N, Mochtar MH, de Melker AA, Ramos L, Repping S, Braat DD, Fleischer K, van Wely M. Prediction model for obtaining spermatozoa with testicular sperm extraction in men with non-obstructive azoospermia. Hum Reprod. 2016 Sep;31(9):1934-41. doi: 10.1093/humrep/dew147. Epub 2016 Jul 12.PMID: 27406950

Meijerink AM, Cissen M, Mochtar MH, Fleischer K, Thoonen I, de Melker AA, Meissner A, Repping S, Braat DD, van Wely M, Ramos L. Prediction model for live birth in ICSI using testicular extracted sperm. Hum Reprod. 2016 Sep;31(9):1942-51. doi: 10.1093/humrep/dew146. Epub 2016 Jul 12.PMID: 27406949

Groenewoud ER, Cohlen BJ, Al-Oraiby A, Brinkhuis EA, Broekmans FJ, de Bruin JP, van den Dool G, Fleisher K, Friederich J, Goddijn M, Hoek A, Hoozemans DA, Kaaijk EM, Koks CA, Laven JS, van der Linden PJ, Manger AP, Slappendel E, Spinder T, Kollen BJ, Macklon NS. A randomized controlled, non-inferiority trial of modified natural versus artificial cycle for cryo-thawed embryo transfer. Hum Reprod. 2016 Jul;31(7):1483-92. doi: 10.1093/humrep/dew120. Epub 2016 May 13.PMID: 27179265

Melman S, Schoorel EC, de Boer K, Burggraaf H, Derks JB, van Dijk D, van Dillen J, Dirksen CD, Duvekot JJ, Franx A, Hasaart TH, Huisjes AJ, Kolkman D, van Kuijk S, Kwee A, Mol BW, van Pampus MG, de Roon-Immerzeel A, van Roosmalen JJ, Roumen FJ, Smid-Koopman E, Smits L, Spaans WA, Visser H, van Wijngaarden WJ, Willekes C, Wouters MG, Nijhuis JG, Hermens RP, Scheepers HC. Development and Measurement of Guidelines-Based Quality Indicators

of Caesarean Section Care in the Netherlands: A RAND-Modified Delphi Procedure and Retrospective Medical Chart Review. PLoS One. 2016 Jan 19;11(1):e0145771. doi: 10.1371/journal.pone.0145771. eCollection 2016. PMID: 26783742

Ten Eikelder ML, Oude Rengerink K, Jozwiak M, de Leeuw JW, de Graaf IM, van Pampus MG, Holswilder M, Oudijk MA, van Baaren GJ, Pernet PJ, Bax C, van Unnik GA, Martens G, Porath M, van Vliet H, Rijnders RJ, Feitsma AH, Roumen FJ, van Loon AJ, Versendaal H, Weinans MJ, Woiski M, van Beek E, Hermsen B, Mol BW, Bloemenkamp KW. Induction of labour at term with oral misoprostol versus a Foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trial. Lancet. 2016 Apr 16;387(10028):1619-28. doi: 10.1016/S0140-6736(16)00084-2. Epub 2016 Feb 3. PMID: 26850983

van Baaren GJ, Broekhuijsen K, van Pampus MG, Ganzevoort W, Sikkema JM, Woiski MD, Oudijk MA, Bloemenkamp K, Scheepers H, Bremer HA, Rijnders R, van Loon AJ, Perquin D, Sporken J, Papatsonis D, van Huizen ME, Vredevoogd CB, Brons J, Kaplan M, van Kaam AH, Groen H, Porath M, van den Berg PP, Mol B, Franssen M, Langenveld J; HYPITAT-II Study Group. An economic analysis of immediate delivery and expectant monitoring in women with hypertensive disorders of pregnancy, between 34 and 37 weeks of gestation (HYPITAT-II). BJOG. 2016 Mar 10. doi: 10.1111/1471-0528.13957. [Epub ahead of print] PMID: 26969198

Ten Eikelder ML, van de Meent MM, Mast K, Rengerink KO, Jozwiak M, de Graaf IM, Scholtenhuis MA, Roumen FJ, Porath MM, van Loon AJ, van den Akker ES, Rijnders RJ, Feitsma AH, Adriaanse AH, Muller MA, de Leeuw JW, Visser H, Woiski MD, Weerd SR, van Unnik GA, Pernet PJ, Versendaal H, Mol BW, Bloemenkamp KW. Women’s Experiences with and Preference for Induction of Labor with Oral Misoprostol or Foley Catheter at Term. Am J Perinatol. 2016 Jun 24. [Epub ahead of print]PMID:27341122

37 GYNAECOLOGIE

Ebisch RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, IntHout J, Verhoef VM, Heideman DA, Snijders PJ, Meijer CJ, van Kemenade FJ, Bulten J, Siebers AG, Bekkers RL, Melchers WJ. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. Int J Cancer. 2016 Aug 1;139(3):691-9. doi: 10.1002/ijc.30090. Epub 2016 Apr 7. PMID: 26991464

Mijke Lambregtse- van den Berg et al (Dullemond RC). Handboek Psychiatrie en Zwangerschap, hoofdstuk 41 medeauteur, ISBN 9789058982698

Boeken

Van Wegen M, van Leijsen SAL, Lips DJ, Hamilton CJ. Verdraaid een appendix; case report. NTOG 2015 April; 128: 139-141.

De Vaan MD. Prostaglandin E2 vs. Foley catheter for induction of labor in pregnancies complicated by FGR or oligohydramnios at term (PROFICIAT trial): A quasi-experimental study”. Kennispoort Verloskunde, Utrecht, 2015



PUBLICATIES 2015-2016 JEROEN BOSCH ZIEKENHUIS 39

PUBLICATIES 2015-2016 JEROEN BOSCH ZIEKENHUIS40

7INTENSIVE CARE GENEESKUNDE

Wetenschappelijke publicatiesSimons KS, Laheij RJ, van den Boogaard M, Moviat MA, Paling AJ, Polderman FN, Rozendaal FW, Salet GA, van der Hoeven JG, Pickkers P, de Jager CP. Dynamic light application therapy to reduce the incidence and duration of delirium in intensive-care patients: a randomised controlled trial. Lancet Respir Med. 2016 Mar;4(3):194-202. doi: 10.1016/S2213-2600(16)00025-4. Epub 2016 Feb 16. PMID:26895652Trefwoorden: lichttherapie, delier

Wassenaar A, van den Boogaard M, van Achterberg T, Slooter AJ, Kuiper MA, Hoogendoorn ME, Simons KS, Maseda E, Pinto N, Jones C, Luetz A, Schandl A, Verbrugghe W, Aitken LM, van Haren FM, Donders AR, Schoonhoven L, Pickkers P. Multinational development and validation of an early prediction model for delirium in ICU patients. Intensive Care Med. 2015 Jun;41(6):1048-56 PMID: 25894620 Trefwoorden: delirium, voorspelling

41 INTENSIVE CARE GENEESKUNDE

KS Simons. Licht en geluidsoverlast op de IC: hoe erg is het nu eigenlijk en wat kunnen we eraan doen? Topics in IC, Lunteren 2 december 2015. KS Simons. de IC omgeving is belangrijk voor het herstel of Hoe kunnen we het voor onze patienten zo min mogelijk vervelend maken Venticare, Utrecht juni 2015. KS Simons. Licht en geluidsoverlast op de IC: hoe erg is het nu eigenlijk en wat kunnen we eraan doen? Refereeravond IC regio ZuidWest, 02-02-2016.

KS Simons. Licht en geluidsoverlast in de IC-box: hoe erg is het eigenlijk en wat kunnen we eraan doen? Regionale refereeravond LUMC 24 mei 2016. KS Simons. Licht en geluid op de IC. Venticare juni 2016

KS Simons. Licht werkt niet bij IC patienten? Topic in IC. Lunteren 08 december 2016


Publicaties (niet pubmed)Kohlrausch A, Park M, de Bruijn W, de Jager CPC, Simons K. Neue ergebnisse zur messung und analyse der schallfelder in intensivstationen, Larmbekampfung Bd 10 (2015).

M. de Gier, M. Garssen, K. Simons, W. Rozendaal. Respiratory insufficiency due to acute bulbar palsy. Neth J Crit Care November 2015;23(5): 18 – 20

Marbus SD, Oost JA, van der Hoek, W, Polderman, FN, de Jager CPC, Groeneveld GH, Schneeberger PM, van Gageldonk-Lafeber AB. Ernstige acute luchtweginfecties: de ontbrekende bouwsteen in de surveillancepiramide. Ned Tijdschr Med Microbiol 2016; 24: nr 1, 52-55.


43 INTENSIVE CARE GENEESKUNDE

8INTERNE GENEESKUNDE

Wetenschappelijke publicatiesManders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: apragmatic multi-centre randomised trial. Arthritis Res Ther. 2015 May 22;17(1):134.PMID: 25997746

Van de Meeberg MM, Derikx LA, Sinnige HA, Nooijen P, Schipper DL, Nissen LH. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient on thiopurine monotherapy. World J Gastroenterol. 2016 Dec 21;22(47):10465-10470. doi: 10.3748/wjg.v22.i47.10465.PMID:28058028

Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016 Mar 3;127(9):1109-16. doi: 10.1182/blood-2015-11-679415. Epub

2016 Jan 22. PMID: 26802176

De Wit HM, Vervoort GM, Jansen HJ, de Galan BE, Tack CJ. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes’ (ELEGANT) randomized controlled trial. J Intern Med. 2016 Mar;279(3):283-92. doi: 10.1111/joim.12447. Epub 2015 Nov 9.PMID:26553486

Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, Leenders F, Bufler P, Boekschoten MV, Müller M, Kersten S, Li S, Kim S, Eini H, Lewis EC, Joosten LA, Tilg H, Netea MG, Tack CJ, Dinarello CA, Stienstra R. Corrigendum: IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2015 Jan 12;6:6039. doi: 10.1038/ncomms7039.PMID:25580956

Ballak D, van Asseldonk EJP, van Diepen JA, Jansen HJ, Hijmans A, Joosten A, Tack CJ, Netea MG, Stienstra R. TLR-3 is present in human adipocytes, but its signalling is not required for obesity-induced inflammation in adipose tissue in vivo. Plos One. E0123152, 2015.PMID:25867514

45 INTERNE GENEESKUNDE

Hagenaars JC, Wever PC, Shamelian SO, Van Petersen AS, Hilbink M, Renders NH, De Jager-Leclercq GL, Moll FL, Koning OH. Vascular chronic Q fever: quality of life. Epidemiol Infect. 2015 Oct;143(13):2903-9. doi: 10.1017/S0950268814003951. Epub 2015 Jan 22.PMID:25608699

Hoogeveen EK, Geleijnse JM, Kromhout D, van’t Sant P, Gemen EF, Kusters R, Giltay EJ. No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: The Alpha Omega Trial. Eur J Prev Cardiol. 2015 May;22(5):648-55. doi: 10.1177/2047487314536694. PMID: 24879357

Hill CJ, Courtney AE, Cardwell CR, Maxwell AP, Lucarelli G, Veroux M, Furriel F, Cannon RM, Hoogeveen EK, Doshi M, McCaughan JA. Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015 Aug;30(8):1403-11. doi: 10.1093/ndt/gfv214. Epub 2015 Jun 4. PMID: 26044837

Van Erning FN, Janssen-Heijnen ML, Creemers GJ, Pruijt HF, Maas HA, Lemmens VE. Deciding on adjuvant chemotherapy for elderly patients with stage III colon cancer: A qualitative insight into the perspectives of surgeons and medical oncologists. J Geriatr Oncol. 2015 May;6(3):219-24. doi: 10.1016/j.jgo.2015.02.001. Epub 2015 Feb 20. PMID: 25703856

Verhoeff SR, van Erning FN, Lemmens VE, de Wilt JH, Pruijt JF. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 2016 Jul 1;139(1):187-93. doi: 10.1002/ijc.30053. Epub 2016 Mar 12. PMID: 26914273

Van Erning FN, Razenberg LG, Lemmens VE, Creemers GJ, Pruijt JF, Maas HA, Janssen-Heijnen ML. Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients. Eur J Cancer. 2016 Jul;61:1-10. doi: 10.1016/j.ejca.2016.03.074. Epub 2016 Apr 27. PMID: 27128782

Van Erning FN, Janssen-Heijnen ML, Creemers GJ, Pruijt JF, Maas HA, Lemmens VE. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy. Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30423. [Epub ahead of print]PMID:27615021


Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, Koene HR; Dutch HOVON 64 study group. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica. 2015 Mar;100(3):e90-2. doi: 10.3324/haematol.2014.110213. No abstract available. PMID: 25425692Trefwoorden: ITP, rituximab

Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7. PMID: 25862517


Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016 Jun;21(6):962-76. doi: 10.1016/j.drudis.2016.03.002. Epub 2016 Mar 17. Review. PMID: 26995271

Ploos van Amstel FK, Tol J, Sessink KH, van der Graaf WT, Prins JB, Ottevanger PB. A Specific Distress Cutoff Score Shortly After Breast Cancer Diagnosis. Cancer Nurs. 2016 Apr 29. [Epub ahead of print] PMID: 27135753

Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. Int J Cancer. 2016 May 15;138(10):2312-21. doi: 10.1002/ijc.29887. PMID: 26452336

De Rooij T, Tol JA, van Eijck CH, Boerma D, Bonsing BA, Bosscha K, van Dam RM, Dijkgraaf MG, Gerhards MF, van Goor H, van der Harst E, de Hingh IH, Kazemier G, Klaase JM, Molenaar IQ, Patijn GA, van Santvoort HC, Scheepers JJ, van der Schelling GP, Sieders E, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis. Ann Surg Oncol. 2016 Feb;23(2):585-91. doi: 10.1245/s10434-015-4930-4. PMID: 26508153

Lobbezoo D, Truin W, Voogd A, Roumen R, Vreugdenhil G, Dercksen MW, van den Berkmortel F, Smilde T, van de Wouw A, van Kampen R, van Riel J, Peters N, Peer P, Tjan-Heijnen VC. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. Oncotarget. 2016 May 17;7(20):29412-9. doi: 10.18632/oncotarget.8838.PMID: 27121067

Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.PMID:27557300

Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016 Aug 1;2(8):1030-7. doi: 10.1001/jamaoncol.2016.1726.PMID:27348762

Hamilton DW, Bins JE, McMeekin P, Pedersen A, Steen N, De Soyza A, Thomson R, Paleri V, Wilson JA. Quality compared to quantity of life in laryngeal cancer: A time trade-off study. Head Neck. 2016 Apr;38 Suppl 1:E631-7. doi: 10.1002/hed.24061. PMID: 25832305



Herbers A.H.E. The role of citrulline in patients following hematopoietic stem cell transplantation.Radboud Universiteit Nijmegen,21 augustus 2015, Nijmegen.

Proefschriften BoekenWedding, Ulrich, Audisio, Riccardo A. (Eds.) Management of Hematological Cancer in Older People. Hoofdstuk 14: Nurses issues: Corien M Eeltink, Angelina Beumer-Grootenhuis & Carolien Burghout. Springer 2015 ISBN 978-1-4471-6971-0

Valckx WJ, Lutgens SP, Haerkens-Arends HE, Barneveld PC, Beutler JJ, Hoogeveen EK. Listeria infection: a diagnostic challenge. C166, p78, (abstract book internistendag, 2015).

Esmeijer K, Geleijnse JM, Giltay EJ, Stijnen T, Dekker FW, de Fijter JW, Kromhout D, Hoogeveen EK. Obesity and kidney function decline in 60-80 years old state-of-the-art drug-treated post-myocardial infarction patients. NDT 2016; (supl 1) i444-i444.

Voskamp PWM, Dekker FW, van Diepen M, Hoogeveen EK, for the PREPARE-2 Study Group. Dual compared to single renin–angiotensin system inhibition and risk of renal replacement therapy or death in predialysis patients: prepare-2 study. NDT 2016; (supl 1) i186-i187.

Maat J, Bouter KP, Bleeker-Rovers CP, van Apeldoorn M, Boulaksil M. Value of FDG-PET/CT in community-acquired Staphylococcus aureus bacteremia. Abstract at 27e Internistendagen Anual Meeting of the Netherlands Association of Internal Medicine, 22-24 April 2015, Maastricht, the Netherlands.

Smit R, Van Marum R, Péquériaux NC, Hollander D, Bleeker M, Hermens WAJJ, Derijks HJ. Prevalentie van correcte anti-Xa bloedspiegels in patiënten met verminderde nierfunctie op basis van een dosisadvies conform de richtlijn van de Nederlandse Federatie voor Nefrologie. Voordracht. Wetenschapsmiddag Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, Nederland, 11-11-2015.

Smit R, Van Marum R, Péquériaux NC, Hollander D, Bleeker M, Hermens WAJJ, Derijks HJ. Prevalentie van correcte anti-Xa bloedspiegels in patiënten met verminderde nierfunctie op basis van een dosisadvies conform de richtlijn van de Nederlandse Federatie voor Nefrologie. Poster. Wetenschapsmiddag Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, Nederland, 11-11-2015.

Van Apeldoorn MJ, van den Akker K, van Esch J, Macken T, Pruijt JFM, de Vries E. Unclassified antibody deficiency: a high rate of bronchiectasis despite milder immunoglobulin abnormalities. European Society for Immunodeficiencies, Barcelona, Spanje, 21-24 September 2016. (project unPAD)





Pieternella Lugtenburg, Peter de Nully Brown, Bronno van der Holt, Francesco d’Amore, Harry Koene, Henriette Berenschot, Rob Fijnheer, Olaf Loosveld, Lara Bohmer, Johannes Pruijt, Gregor Verhoef, Mels Hoogendoorn, Romko de Kan, Gustaaf van Imhoff, Christel van Hooije, King Lam, Bart de Keizer, Daphne de Jong, OttoHoekstra, Josee Zijlstra. Randomized phase iii study of early rituximab intensification in combination with chop14 Followed by rituximab or no maintenance in diffuse large b-cell lymphoma: a hovonnordicLymphoma group study. Kopenhagen 9-12 juni 2016

J. Dierks, M.P. Gaspersz, A. Belkouz, J.L.A. van Vugt, R.J.S. Coelen, J.W.B. de Groot, A. ten Tije, W.G. Meijer, H. Pruijt, T. van Voorthuizen, D.J. van Spronsen, M. Rentinck, D. ten Oever, J.M. Smit, H.M. Otten, T.M. van Gulik, J.W. Wilmink, B. Groot Koerkamp, H. Klümpen. Translating the ABC-02 trial into daily practice: Outcome of palliative treatment in patients with advanced biliary tract cancer treated with gemcitabine and cisplatin. (ID # 2550484), to be presented at the 2016 AASLD Annual Meeting Boston

MMA Brouwer, IPT van Bebber, T Meijs. Beïnvloedende factoren voor het ontstaan van seroom na borstoperatie bij vrouwen met een mammacarcinoom. Ede, 17-18 november 2015.

Netten PM. Diabetische voet. Diabetes Education Study Group. Hoevelaken 15 januari 2015.

Netten PM. Workshop: De aios als teacher. Opleidersdag NIV: De internist van de toekomst. Zeist, 22 januari 2015

Netten PM. Ziekenhuisarts: de stand van zaken. Concilium Medicinae Internae. Utrecht, 28 januari 2015

Netten PM. Waarom een ziekenhuisarts? Profesionals in the lead. AMC, Amsterdam,5 februari 2015

Netten PM. Beroepenstructuur 2030. Federatie medisch specialisten. Utrecht, 12 februari 2015

Netten PM. Waarom een ziekenhuisarts? Gelderse Vallei, Ede – Wageningen, 26 mei 2015

Netten PM. Waarom een Ziekenhuisarts? Deventer Ziekenhuis, 2 juni 2015

Netten PM. De zorg in 2030. Health to Business Community en Health Valley Nederland. ’s-Hertogenbosch, 17 juni 2015

Netten PM. Pareltraject JBZ. Medisch leiderschap in de Vervolgopleidingen. Zeist, 2 juli 2015

Netten PM. De ontwikkeling van de ziekenhuisgeneeskunde. Eerst landelijk congres ziekenhuisgeneeskunde: De ziekenhuisarts komt eraan. ’s-Hertogenbosch 11 september 2015.

Netten PM. Invitational: positionering Ziekenhuisgeneeskunde. VU Amsterdam 1 oktober2015

Netten PM. Workshop: Work as usual. Congres Patiëntveiligheid, 7 oktober, Amersfoort 2015

Netten PM. Naar nieuwe zorg en zorgberoepen: de gezondheidszorg in 2030. ID innovation congres 2015, 8 oktober, Veenendaal 2015

Netten PM. JNIV Smeerolie voor de poli. Workshop diabetes mellitus, 9 oktober, Amersfoort 2015

Netten PM. De opleiding tot ziekenhuisarts. Twee Steden Ziekenhuis, 23 oktober, Tilburg 2015

Netten PM. Ziekenhuisarts: ja of nee. LUMC, 3 november 2016, Leiden 2015

Netten PM. ‘Wie, wat, waar: beginnen met opleiden van aios’. NVMO-congres 13 november, Utrecht 2015


Netten PM. De opleiding tot ziekenhuisarts. Amphia ziekenhuis, 23 november, Breda 2015

Netten PM. Generalist vs specialist, symposium tijdens MMV-congres, 9 december Nieuwegein 2015

Netten PM. Ziekenhuisarts iets voor het Maastrichts Universitair Centrum? 21 januari 2016.

Netten PM. Generalistische zorg in het Ziekenhuis. BOLS-symposium Utrecht. 27 januari 2016.

Netten PM. Ziekenhuisgeneeskunde. Canisius Wilhelmina ZKH, Nijmegen, 3 februari 2016.

Netten PM. De toekomst van de internist. Landelijk Opleidingssymposium Interne Geneeskunde. Zeist 18 februari 2016.

Netten PM. Samenwerking in het ziekenhuis, de ziekenhuisarts, nieuwe zorg en zorgberoepen. Reuniesymposium alumni Geneeskunde 1055 – 1980. Radboudumc, Nijmegen, 8 april 2016.

Netten PM. Wat is generalistische zorg? Buitengewone vergadering Concilium Medicinae Internae. Utrecht 18 mei 2016.

Netten PM. Ontwikkelingen in de ziekenhuisgeneeskunde. Ziekenhuisarts: nieuwe kaste of antwoord op toekomstige ziekenhuiszorg. Elisabeth/Tweesteden ziekenhuis, Tilburg 2 juni 2016.

Netten PM. Ziekenhuisgeneeskunde, de stand van zaken. College Geneeskundig Specialismen, Utrecht, 15 september 2016.

Netten PM. De ziekenhuisartsen komen eraan. Raad Opleidingen, Federatie Medisch Specialismen. Utrecht, 22 september 2016.

Netten PM. Toekomst van de zorg. Anders denken, anders leren, anders doen. Nederlandse Vereniging voor Medisch onderwijs Congres. Egmond aan Zee, 18 november 2016.

Netten PM. Arts van de toekomst. Landelijke themabijeenkomst DeGeneeskundestudent. VU Medisch Centrum, Amsterdam, 26 november 2016

Netten PM. Patiëntveiligheid &Just culture. MMV congres, Opleiden is vooruitzien, Nieuwegein, 9 december 2016

Netten PM. ‘Algemeen’ interne geneeskunde. Workshop. Strategiedag NIV, Amersfoort, 12 december.

S.R. Verhoeff, A.H.E Herbers. Nutritional deficiencies after gastric bypass surgery. NIV abstract boek, C086, 2015

J. van Heek, M.J. van Apeldoorn, A.H.E. Herbers. Hemolytic anemia after visiting Nigeria: delayed onset of malaria without fever in a patient with sickle cell trait. NIV abstract boek, C086, 2015

R.S. Dekker, A. H.E. Herbers. A patient with severe hemolysis due to a ‘walking pneumonia’. NIV abstract boek, C070, 2016

J.E. Bins, A. H.E. Herbers. Filet Americain, a Dutch delight. Or will this spoil your appetite? NIV abstract boek, C071, 2016

K. Pavlov, A. H.E. Herbers. Lytic bone lesions due to presumed coeliac disease. NIV abstract boek, C086, 2016

C.C.M. Schaap, A. H.E. Herbers. Invasive bone marrow examination not always indicated for severe pancytopenia. NIV abstract boek, C107, 2016

F.E.R. Vuik, A. H.E. Herbers, J. Terhaar Sive Droste. Be aware of the life threatening side effect of Metamizole. NIV abstract boek, C218, 2016

Burghout C. en Herbers AHE. Module symptomen en bijwerkingen - nascholing CML. CML E-learning voor verpleegkundig specialisten 2016.


Herbers AHE. De rol van citrulline bij hematologische stamceltransplantatie patiënten Nederlandse Internisten dagen, Laureaat voor D.C. Roosprijs. 22 april 2016, Maastricht.

Herbers AHE. Chronische Myeloide Leukemie. 1e Midden Brabants Casuistiek symposium 1 juni 2016, Vught.

Publicaties (niet pubmed)Jansen HJ, Vervoort GMM, Rutten G, Tack CJ. Insuline-gerelateerde gewichtstoename bij DM2. Huisarts en Wetenschap (NHG).(59): 58-61, 2016.

Jansen HJ, Vervoort GMM, Rutten G, Tack CJ. Insuline-gerelateerde gewichtstoename bij DM2. Tijdschrift voor Praktijkondersteuner.11(2):52-55, 2016.

dr. J.F.M. Pruijt en dr. T. Netelenbos. ITP: de stap durven nemen naar splenectomie. Editorial bij de bijdrage van A. Sobels, C.S.J. Duchateau en M.R. Schipperus, getiteld ‘De ITP-lever/miltscan: een mogelijke voorspeller van de kans op remissie na splenectomie bij ITP-patiënten’. 27128782


9KINDERGENEESKUNDE

Wetenschappelijke publicatiesRoeters van Lennep JE, Visseren FL, Jira PE. Familial hypercholesterolemia: why screening, counselling and treatment should be integrated. Ned. Tijdschr. Geneeskd. 2015;159: PMID: 26013253.Trefwoorden: Familiare Hypercholesterolemie, Screening

Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Van Alfen AA, Van Leeuwen M, Van Wieringen H, Wegdam-den Boer ME, Zwaveling-Soonawala N, Hokken-Koelega AC. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment. J. Clin. Endocrinol. Metab. 2015;100: 1609-1618. PMID: 25668198Trefwoorden: Prader Willi syndroom, Groeihormoon-behandeling

Schatorjé E, van der Flier M, Seppänen M, Browning M, Morsheimer M, Henriet S, Neves JF, Vinh DC, Alsina L, Grumach A, Soler-Palacin P, Boyce T, Celmeli F, Goudouris E, Hayman G, Herriot R, Förster-Waldl E, Seidel M, Simons A, de Vries E. Primary immunodeficiency associated with chromosomal

aberration - an ESID survey. Orphanet J Rare Dis. 2016 Aug 2;11(1):110. PMID: 27484815Trefwoord: chromosoomafwijking afweerstoornis

Schatorjé EJ, de Jong E, van Hout RW, García Vivas Y, de Vries E. The Challenge of Immunoglobulin-G Subclass Deficiency and Specific Polysaccharide Antibody Deficiency--a Dutch Pediatric Cohort Study. J Clin Immunol. 2016 Feb;36(2):141-8. doi: 10.1007/s10875-016-0236-y. Epub 2016 Feb 4PMID: 26846287Trefwoord: specifiek antistoftekort kinderen

Van der Feen C, van der Doef HP, van der Ent CK, Houwen RH. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros. 2016 Nov;15(6):834-838. doi: 10.1016/j.jcf.2016.07.009.PMID:27481229

Wouters E, Wojciechowski M, de Vries E. Two cases of rickets presenting with poor growth, hypotonia, and respiratory problems. Acta Clin Belg. 2015 Jun;70(3):211-4. doi: 10.1179/2295333714Y.0000000103. PubMed PMID: 25443772.

53 KINDERGENEESKUNDE

Fliegauf M, L Bryant V, Frede N, Slade C, Woon ST, Lehnert K, Winzer S, Bulashevska A, Scerri T, Leung E, Jordan A, Keller B, de Vries E, Cao H, Yang F, Schäffer AA, Warnatz K, Browett P, Douglass J, Ameratunga RV, van der Meer JW, Grimbacher B. Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency. Am J Hum Genet. 2015 Sep 3;97(3):389-403. doi: 10.1016/j.ajhg.2015.07.008. Epub 2015 Aug 13. PMID: 26279205; PMCID: PMC4564940

Slok EN, Dijkstra F, de Vries E, Rietveld A, Wong A, Notermans DW, van Steenbergen JE. Estimation of acute and chronic Q fever incidence in children during a three-year outbreak in the Netherlands and a comparison with international literature. BMC Res Notes. 2015 Sep 18;8(1):456. doi: 10.1186/s13104-015-1389-0. PMID: 26384483

Kuipers BC, Jansen EJ, van Mil EG. Een neonaat met een interlabiale cyste. [A neonate with an interlabial cyst]. [Article in Dutch]. Ned Tijdschr Geneeskd. 2015;159:A8355. PMID:25563786

Nieuwesteeg AM, Hartman EE, Aanstoot HJ, van Bakel HJ, Emons WH, van Mil E, Pouwer F. The relationship between parenting stress and parent-child interaction with health outcomes in the youngest patients with type 1 diabetes (0-7 years). Eur J Pediatr. 2016 Mar;175(3):329-38. doi: 10.1007/s00431-015-2631-4. PMID: 26438336

Bart IY, Mourits M, van Gent R, van Leuken MH, Hilbink M, Warris A, Wever PC, de Vries E. Sputum Induction in Children Is Feasible and Useful in a Bustling General Hospital Practice. Glob Pediatr Health. 2016 Mar 4;3:2333794X16636504. doi: 10.1177/2333794X16636504. eCollection 2016. PMID: 27336008

Korterink JJ, Ockeloen LE, Hilbink M, Benninga MA, Deckers-Kocken JM. Yoga Therapy for Abdominal Pain Related-Functional Gastrointestinal Disorders in Children. A Randomized Controlled Trial. J Pediatr Gastroenterol Nutr. 2016 Apr 4. [Epub ahead of print] PMID: 27050045

Van der Aa MP, Elst MA, van de Garde EM, van Mil EG, Knibbe CA, van der Vorst MM. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes. 2016 Aug 29;6(8):e228. doi: 10.1038/nutd.2016.37.PMID:27571249

Nieuwesteeg, E. Hartman, H-J. Aanstoot, H. van Bakel, W. Emons, E. van Mil, F. Pouwer. The relationship between parenting stress and parent-child interaction with health outcomes in youngest patients (0-7 years) with type 1 diabetes (0 – 7 years). Eur J Pediatr. 2016 Mar;175(3):329-38. doi: 10.1007/s00431-015-2631-4. Epub 2015 Oct 5.PMID:26438336

ProefschriftenEllen SchatorjéHypogammaglobulinemia in children – what can we learn from disease classifications and patient registries?Tilburg University, 14 december 2016Promotoren: Prof. Dr. E. de Vries, Prof. Dr. N. WulffraatCo-promotor: Dr. M. van der FlierTrefwoorden: antistoftekort kinderen


BoekenEdgar van Mil and Arianne Struik. ‘Overgewicht en Obesitas bij Kinderen. Verder Kijken dan de Kilo’s. Boom Uitgeverij. 1e druk 2015. ISBN 9789089534262.

Kuijpers TW, Prakken ABJ, de Vries E. Het immuunsysteem, afweerstoornissen en allergie. In: Leerboek Kindergeneeskunde. Heymans HSA, Derksen-Lubsen G, Draaisma JMTh, Nieuwenhuis EES, van Goudoever JB (eds). 2e druk, Uitgeverij de Tijdstroom, 2015. ISBN 978-90-5898-271-1. [Leerboek]

Schatorjé E, van der Flier M, Seppänen M, Browning M, Morsheimer M, Henriet S, Farela Neves J, Cuong Vinh D, Alsina L, Grumach A, Soler-Palacin P, Boyce T, Celmeli F, Goudouris E, Hayman G, Herriot R, Förster-Waldl E, Seidel M, Simons A, de Vries E. Primary immunodeficiency associated with chromo-somal aberration –an ESID Survey. ESID Biennual meeting, Barcelon, Spain, 21-24 september 2016Trefwoorden: chromosoomafwijking afweerstoornis

Van Apeldoorn MJ, van den Akker K, van Esch J, Macken T, Pruijt JFM, de Vries E. Unclassified anti-body deficiency: a high rate of bronchiectasis despite milder immunoglobulin abnormalities. European Society for Immunodeficiencies, Barcelona, Spanje, 21-24 September 2016. (project unPAD)

L.M. Breij Y. Vandenplas, S.N.J. Jespers, A.C. de Mol, P.C. Khoo, M. Kalenga, S. Peeters, R.H.T van Beek, O.F. Norbruis, S. Schoen, M. Abrahamse-Berkeveld, D. Acton, E. van Mil en A.C.S. Hokken-Koelega, and the Mercurius Study Group. An innovative infant formula with large, phospholipid coated lipid droplets supports an adequate growth and is well-tolerated in healthy, term infants. Abstractbook. 3rd International Conference on Nutrition & Growth. Vienna, Austria, March 17-19, 2016.

E. van Mil. Niet morgen maar nu: cardiovasculair risico management. Periodieke Regionale Conferen-tie Kindergeneeskunde RadboudUMC Nijmegen 23 maart 2015.

E van Mil. Regionale Nascholing Kindergenees-kunde. Obesitas bij Kinderen. Geen Kinderachtig probleem. LUMC Leiden 16 april 2015 E. van Mil. OLIC symposium: Overgewicht bij Kinde-ren: de weg naar een integrale aanpak. JBZ 12 Mei 2015 E van Mil. College Pediatrie: overgewicht bij kinde-ren. Universiteit Tilburg, 8 augustus 2015 E. van Mil. “Overgewicht en obesitas bij kinderen; verder kijken naar de kilo’s”. Refereeravond Kinderge-neeskunde Zuid-Oost Brabant. Catharina Ziekenhuis te Eindhoven op: 22 september 2015

A Kruisdijk en E. van Mil. Effect of metformin on energy expenditure in obese adolescents. Jaarijkse congres Nederlandse Vereniging van Kindergenees-kunde 5 november 2015. E. van Mil. Lezing Gezonde Jeugd in een Gezonde Stad. Almere 16 april 2016 E. van Mil Lezing Inspiratie dag Gezonde Gewicht, 23 september 2016.E. van Mil. Obesitas bij Kinderen. Van behande-ling naar leerweg. Symposium Samen Overgewicht Onder Controle JBZ 14 november 2016


55 KINDERGENEESKUNDE

Publicaties (niet pubmed)M.A.J. Elst, M.P. van der Aa, E.G.A.H. van Mil, M.M.J. van der Vorst. Screening op type 2-diabetes mellitus: de heilige graal? Tijdschr Kindergeneeskd 2015 - 83 - nr 1

E.G.A.H. van Mil en M. Sijben. Obesitas en de kracht van de kinderarts in de keten. Praktische Pediatrie; 3: 187-189, 2016

OverigeE. van Mil en A. Struik. Boekpresentatie: Overgewicht en Obesitas bij Kinderen. Verkade fabriek Den Bosch 5 maart 2015

E. van Mil. Great Achievement Award: Aanpak overgewicht bij kinderen. Jaarijkse congres Nederlandse Vereniging van Kindergeneeskunde 5 november 2015

E. van Mil en A. Struik. Overgewicht en Obesitas bij kinderen. Wat te zien, te denken en te doen. Professionele aanpak bij een veel voorkomende probleem. Verkade fabriek. Workshops 5 maart 2015, 2 juli 2015, 12 december 2015, 23 juni 2016.


KLINISCHE CHEMIE & HEMATOLOGIE


10Jacobs LH, van Borren M, Gemen E, van Eck M, van Son B, Glatz JF, Daniels M, Kusters R. Rapidly rule out acute myocardial infarction by combining copeptin and heart-type fatty acid-binding protein with cardiac troponin. Ann Clin Biochem. 2015 Sep;52(Pt 5):550-61. doi: 10.1177/0004563215578189. Epub 2015 Mar 2.PMID: 25732130

Noordegraaf M, Wolthuis A, Peters F, de Groot M, Hoedemakers R. Performance characteristics of a new automated method for measurement of anti-cyclic citrullinated peptide. Clin Chem Lab Med. 2015 Jan 12. doi: 10.1515/cclm-2014-0961. PMID:25581759

de Vries C, Doggen C, Hilbers E, Verheij R, IJzerman M, Geertsma R, Kusters R. Results of a survey among GP practices on how they manage patient safety aspects related to point-of-care testing in every day practice. BMC Fam Pract. 2015 Feb 5;16(1):9. PMID:25648985

Hoogeveen EK, Geleijnse JM, Kromhout D, van’t Sant P, Gemen EF, Kusters R, Giltay EJ. No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: The Alpha Omega Trial. Eur J Prev Cardiol. 2015 May;22(5):648-55. doi: 10.1177/2047487314536694. PMID: 24879357

Hopstaken RM, van Balen JA, Kusters R. Point-of-care-testing in general practice. Ned Tijdschr Geneeskd. 2015;159:A9475. Dutch. PMID: 26395570

Evers D, Middelburg RA, de Haas M, Zalpuri S, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, Schonewille H, Zwaginga JJ, van der Bom JG. Red-blood-cell alloimmunisation in relation to antigens’ exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016 Jun;3(6):e284-92. doi: 10.1016/S2352-3026(16)30019-9. Epub 2016 May 9. PMID: 27264038

Evers D, Zwaginga JJ, Tijmensen J, Middelburg RA, de Haas M, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, van der Bom JG. Treatments for hematological malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization. Haematologica. 2016 Sep 15. pii: haematol.2016.152074. [Epub ahead of print]PMID:27634204

Evers D, van der Bom JG, Tijmensen J, Middelburg RA, de Haas M, Zalpuri S, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, Zwaginga JJ. Red cell alloimmunisation in patients with different types of infections. Br J Haematol. 2016 Aug 18. doi: 10.1111/bjh.14307. [Epub ahead of print]PMID:27539877

59 KLINISCHE CHEMIE & HEMATOLOGIE

van Balveren JA, Huijskens MJ, Gemen EF, Péquériaux NC, Kusters R. Effects of time and temperature on 48 routine chemistry, haematology and coagulation analytes in whole blood samples. Ann Clin Biochem. 2016 Aug 5. pii: 0004563216665868. [Epub ahead of print]PMID:27497436

Van de Ven AC, Netea-Maier MR, Smit JW, Kusters GC, van der Stappen JW, Pronk-Admiraal CJ, Buijs MM, Schoenmakers CC, Koehorst SG, de Groot MJ, Sweep FC, Hermus AR, den Heijer M. Thyrotropin versus age relation as an indicator of historical iodine intake. Thyroid. 2015 Jun;25(6):629-34. doi: 10.1089/thy.2014.0574. Epub 2015 Apr 20. PMID: 25811973

Kip MM, Kusters R, Ijzerman MJ, Steuten LM. A PCT algorithm for discontinuation of antibiotic therapy is a safe and cost-effective intervention to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ. 2015 Nov;18(11):944-53. doi: 10.3111/13696998.2015.1064934. Epub 2015 Jul 20. PMID: 26105574

Eppenga WL, Wester WN, Derijks HJ, Hoedemakers RM, Wensing M, De Smet PA, Van Marum RJ. Fluctuation of the renal function after discharge from hospital and its effects on drug dosing in elderly patients - study protocol. BMC Nephrol. 2015 Jul 7;16(1):95. PMID: 26149449

Joustra R, Péquériaux NC. Thema van de bijeenkomst is Myeloproliferatieve ziekten. Casus 1. Voordracht. 6e Z.O. Brabants Casuïstiek. Symposium Hematologie Eindhoven, Nederland, 16-3-2015.

Jager MJ, van der Velden J, Paanakker M. Renske. Poster. Congres: International forum on quality & saftety in healthcare. London, Verenigd Koninkrijk, 21-4-2015 - 24-4-2015.

Verbruggen B. Prelimenary validation of the factor VIII low titre inhibitor assay. Voordracht. ISTH congres, SSC and Educational program. Toronto, Canada, 22-6-2015. Noordegraaf M, de Vrije I, van den Brule A, Hoededemakers RM. Typering van HLA-DQ2/8 met GenVinset HLA Celiac test. Poster. NVKC-voorjaarscongres. Veldhoven, Nederland, 15-4-2015 - 17-4-2015.

Noordegraaf M, Gerven ML, Leuvenink J. Nieuwe afkapwaarde absolute lymfocyten voor manuele differentiatie. Poster. NVKC-voorjaarscongres Veldhoven, Nederland, 15-4-2015 - 17-4-2015.




Tel-Karthaus N, Salet GA, Jacobs LH, Hoedemakers RM. Hypernatriëmie op de Intensive care – weet wat je meet. Poster. Wetenschapsmiddag Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, Nederland, 11-11-2015.


Van Balveren JA, Gemen EF, Péquériaux NC, Kusters GC. Accuraat bloedtransport is essentieel voor patiëntveiligheid. Voordracht. Wetenschapsmiddag Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, Nederland, 11-11-2015. Van Balveren JA, Gemen EF, Péquériaux NC, Kusters GC. Accuraat bloedtransport is essentieel voor patiëntveiligheid. Poster. Wetenschapsmiddag Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, Nederland, 11-11-2015.

Kusters GC Labs on the move. Voordracht.Bravis Ziekenhuis, Ossendrecht, Nederland, 2015.

Van Balveren JA, Litsenburg E, Péquériaux NC. Onverwachte HZFP (hemolytische ziekte van foetus en pasgeborene). Sanquin avond: Te verwachten ‘onverwachte’ immunohematologische diagnostiek? Sanquin, Amsterdam, Nederland, 18-11-2015.



Verbruggen B. Diagnostiek van de verlengde APTT. ECAT-cursus. ECAT Foundation, Utrecht, Nederland, 26 november 2015.

Leuvenink J. RBC Correlation and beyond. Siemens gebruikersdag. Marburg, Duitsland, 9 juni 2015.

Bakkeren DL, Vermeer HL, Kusters R. Online consultatie van laboratoriumspecialisten: een gewaardeerde service naar patiënten. Nederlands tijdschrift voor klinische chemie en laboratoriumgeneeskunde. 2015; 40: p. 21-25.

Willemsen RT, Kietselaer BL, Kusters R, Buntinx F, Glatz JF, Dinant GJ. Diagnosing acute coronary syndrome: a challenge for general practitioners and cardiologists. Emerg Med (Los Angel) ISSN:2165-7548 EGM, an open access journal. Volume 5, Issue 2, 1000242

Van ’t Sant P. Reflecterend testen in het JBZ. Voordracht. PAOKC klinische chemie: workshop Reflecterend testen. ’s-Hertogenbosch, Nederland, 12-6-2015.


61 KLINISCHE CHEMIE & HEMATOLOGIE

PUBLICATIES 2015-2016 JEROEN BOSCH ZIEKENHUIS62

KLINISCHE FYSICA

11Wetenschappelijke publicatiesHulsen DJ, Geurts J, van Gestel NA, van Rietbergen B, Arts JJ. Mechanical behaviour of Bioactive Glass granules and morselized cancellous bone allograft in load bearing defects. J Biomech. 2016 May 3;49(7):1121-7. PMID: 26972764Trefwoorden: orthopedische biomechanica, bioactief glas

Van Gestel NA, Geurts J, Hulsen DJ, van Rietbergen B, Hofmann S, Arts JJ. Clinical Applications of S53P4 Bioactive Glass in Bone Healing and Osteomyelitic Treatment: A Literature Review. Biomed Res Int. 2015;2015:684826 PMID: 26504821Trefwoorden: osteomyelitis, bioactief glas

63 KLINISCHE FYSICA

LONGZIEKTEN

12Wetenschappelijke publicatiesVan Veggel BA, Biesma B, Smit EF. Pharmacotherapy for treatment of lung cancer in the elderly. Expert Opin Pharmacother. 2015 May;16(7):1021-34. doi: 10.1517/14656566.2015.1028357. Epub 2015 Mar 22. PMID: 25797389

Aarts MJ, Aerts JG, Van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in patients with small cell lung cancer: trends and prognostic impact. Clin Lung Cancer. 16(4):282-91, 2015. doi: 10.1016/j.cllc.2014.12.003.PMID:25572007

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators (Biesma B.). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371; 2167-77, 2014. doi: 10.1056/NEJMoa1408440. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582. doi: 10.1056/NEJMx150034.PMID:26466011

Dingemans AM, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV

non-squamous-non-small cell lung cancer: NVALT 12 (NCT01171170). Ann Oncol. 2015 Nov;26(11):2286-93. doi: 10.1093/annonc/mdv370. Epub 2015 Sep 7.PMID:26347109

Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators (Biesma B.). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 16(8):897-907, 2015. doi: 10.1016/S1470-2045(15)00006-6.PMID:26156651

Senan S, Brade A, Wang L, Vansteenkiste JF, Dakhil S, Biesma B, Martinez Aguillo M, Aerts JG, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: A Randomized, Phase III Trial of Pemetrexed, Cisplatin or Etoposide, Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small Cell Lung Cancer. J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824.PMID:26811519

65 LONGZIEKTEN

Hendriks LE, Brouns AJ, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JS, De Ruysscher DK, Van den Heuvel MM, Dingemans AC. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: does the type of chemotherapy regimen matter? Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008.PMID:27794410

Hendriks L, Brouns A, Amini M, Uyterlinde W, Wijsman R, Biesma B, Stigt J, Ruysscher DD, Heuvel Mv, Dingemans AM. 115PD: Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter? J Thorac Oncol. 2016 Apr;11(4 Suppl):S106. doi: 10.1016/S1556-0864(16)30228-3. Epub 2016 Apr 15. No abstract available. PMID: 27198257

Levy ML, Dekhuijzen P, Barnes PJ, Broeders M, Corrigan CJ, Chawes BL, Corbetta L, Dubus JC, Hausen T, Lavorini F, Roche N, Sanchis J, Usmani OS, Viejo J, Vincken W, Voshaar T, Crompton GK, Pedersen S. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). NPJ Prim Care Respir Med. 2016 May 26;26:16028. doi: 10.1038/npjpcrm.2016.28. No abstract available. PMID: 27227425

Levy ML, Dekhuijzen PN, Barnes PJ, Broeders M, Corrigan CJ, Chawes BL, Corbetta L, Dubus JC, Hausen T, Lavorini F, Roche N, Sanchis J, Usmani OS, Viejo J, Vincken W, Voshaar T, Crompton GK, Pedersen S. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). NPJ Prim Care Respir Med. 2016 Apr 21;26:16017. doi: 10.1038/npjpcrm.2016.17. Review.PMID: 27098045

Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25. PMID: 26811519


Abstracts, voordrachten en postersSenan S, Brade A, Wang L-h, Vansteenkiste J, Dakhil S, Biesma B, Martinez M, Aerts J, Govindan R. Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, Chouaki N, Vokes E. PROCLAIM: final overall survival results of a phase 3 trial of pemetrexed (Pem) , cisplatin (Cis) and thoracic radiotherapy (XTR) followed by consolidation Pem vs Etoposide, Cis and XRT followed by consolidation cytotoxic chemotherapy (CTX) of choice in patients with locally advanced stage III nonsquamous non-small cell lung cancer. ASCO Annual Meeting Abstracts Vol 33, No 15, suppl (May 20 Supplement), 7506, 2015.

Scheepers PTJ, Masen-Poos L; van Rooy FGBGJ, van Daalen Ea, Cremers R, Lichtenbeld H, Biesma B, Koponen IK, Larsen ST, Wolkoff P, Nørgaard AW. Pulmonary injury associated with spray application of a water-based waterproofing product. Presented at the International Society for Exposure Sciences, 25th Annual Meeting Nevada 18-22 oktober, 2015.

Hendriks LEL, Brouns AJWM, Amini M, Uyterlinde W, Wijsman R, Biesma B, Stigt JA, De Ruysscher DKM, Van den Heuvel MM4, A-M.C. Dingemans A-MC. Brain metastases (BM) development after chemoradiation (CRT) for stage III Non-Small Cell Lung Cancer (NSCLC): does the type of chemotherapy matter? Presented at ELCC Genève 13-16 april, 2016.

Groen HJM, van der Heijden E, Klinkenberg ThJ, Biesma B, Aerts J, Verhagen A, Kloosterziel C, Smit HJM, Schramel F, van der Noort V, van Tinteren H, Smit EF Dingemans A-MC. Randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small-cell lung cancer patients: the NVALT- 8 study. Oral presentation ASCO 2016. J Clin Oncol 34, 2016 (suppl; abstr 8506)

Hendriks L, Brouns A, Amini M, Uyterlinde W, Wijsman R, Biesma B, Stigt J, Ruysscher DD, Heuvel Mv, Dingemans AM. Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter?. J Thorac Oncol. 2016 Apr;11(4 Suppl):S106. doi: 10.1016/S1556-0864(16)30228-3.

Van Apeldoorn MJ, van den Akker K, van Esch J, Macken T, Pruijt JFM, de Vries E. Unclassified antibody deficiency: a high rate of bronchiectasis despite milder immunoglobulin abnormalities. European Society for Immunodeficiencies, Barcelona, Spanje, 21-24 September 2016. (project unPAD)

67 LONGZIEKTEN

MAAG, DARM, LEVER-ZIEKTEN

13Wetenschappelijke publicatiesRömkens TE, Gijsbers K, Kievit W, Hoentjen F, Drenth JP. Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice. J Gastrointestin Liver Dis. 2016 Dec;25(4):465-471. doi: 10.15403/jgld.2014.1121.254.ken.PMID: 27981302.

Schepers NJ, Bakker OJ, Besselink MG, Bollen TL, Dijkgraaf MG, van Eijck CH, Fockens P, van Geenen EJ, van Grinsven J, Hallensleben ND, Hansen BE, van Santvoort HC, Timmer R, Anten MP, Bolwerk CJ, van Delft F, van Dullemen HM, Erkelens GW, van Hooft JE, Laheij R, van der Hulst RW, Jansen JM, Kubben FJ, Kuiken SD, Perk LE, de Ridder RJ, Rijk MC, Römkens TE, Schoon EJ, Schwartz MP, Spanier BW, Tan AC, Thijs WJ, Venneman NG, Vleggaar FP, van de Vrie W, Witteman BJ, Gooszen HG, Bruno MJ; Dutch Pancreatitis Study Group. Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial. Trials. 2016 Jan 5;17:5. doi: 10.1186/s13063-015-1132-0. PMID: 26729193; PMCID: PMC4700728.

Römkens TE, Bulte GJ, Nissen LH, Drenth JP. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol. 2016 Jan 21;22(3):1321-30. doi: 10.3748/wjg.v22.i3.1321. PubMed PMID: 26811669; PMCID: PMC4716042.

da Costa DW, Schepers NJ, Römkens TE, Boerma D, Bruno MJ, Bakker OJ; Dutch Pancreatitis Study Group. Endoscopic sphincterotomy and cholecystectomy in acute biliary pancreatitis. Surgeon. 2016 Apr;14(2):99-108. doi: 10.1016/j.surge.2015.10.002. Epub 2015 Nov 2. Review. PMID: 26542765.

Ahmed Ali U, Issa Y, van Goor H, van Eijck CH, Nieuwenhuijs VB, Keulemans Y, Fockens P, Busch OR, Drenth JP, Dejong CH, van Dullemen HM, van Hooft JE, Siersema PD, Spanier BW, Poley JW, Poen AC, Timmer R, Seerden T, Tan AC, Thijs WJ, Witteman BJ, Romkens TE, Roeterdink AJ, Gooszen HG, van Santvoort HC, Bruno MJ, Boermeester MA; Dutch Pancreatitis Study Group. Dutch Chronic Pancreatitis Registry (CARE): design and rationale of a nationwide prospective evaluation and follow-up. Pancreatology. 2015 Jan-Feb;15(1):46-52. doi: 10.1016/j.pan.2014.11.002. Epub 2014 Nov 29. PMID: 25511908.

Van der Have M, Oldenburg B, Kaptein AA, Jansen JM, Scheffer RC, van Tuyl BA, van der Meulen-de Jong AE, Pierik M, Siersema PD, van Oijen MG, Fidder HH. Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. J Crohns Colitis.

69 MAAG, DARM, LEVERZIEKTEN

2016 May;10(5):549-55. doi: 10.1093/ecco-jcc/jjw002. Epub 2016 Jan 6. PMID: 26738757

Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team. (van Munster IP, Scheffer RC, Römkes TE, Schipper DL) Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002. Epub 2015 Jun 11.PMID:26072396

Walter D, van Boeckel PG, Groenen MJ, Weusten BL, Witteman BJ, Tan G, Brink MA, Nicolai J, Tan AC, Alderliesten J, Venneman NG, Laleman W, Jansen JM, Bodelier A, Wolters FL, van der Waaij LA, Breumelhof R, Peters FT, Scheffer RC, Leenders M, Hirdes MM, Steyerberg EW, Vleggaar FP, Siersema PD. Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial. Gastroenterology. 2015 Jul;149(1):130-8. doi: 10.1053/j.gastro.2015.03.012. Epub 2015 Mar 17.PMID: 25790742

D’Agnolo, HMA, Kievit, W, Takkenberg RB, Riaño I, Bujanda L, Neijenhuis MK, Brunenberg EJL, Beuers U, Banales JM, Drenth JPH. Ursodeoxycholic acid in advanced polycystic liver disease: an international multicenter randomized controlled phase 2 trial: CURSOR: Controlled trial of URSOdeoxycholic acid to Reduce liver volume in polycystic liver disease. J Hepatol. 2016 Sep;65(3):601-7. doi: 10.1016/j.jhep.2016.05.009. Epub 2016 May 17.PMID:27212247Trefwoorden: polycystic liver disease and ursodeoxycholic acid

D’Agnolo HM, Drenth JP. Risk factors for progressive polycystic liver disease: where do we stand? Nephrol Dial Transplant. 2016 Jun;31(6):857-9. doi: 10.1093/ndt/gfv417. Epub 2015 Dec 17. PMID:26681732Trefwoorden: polycystic liver disease and risk factors

D’Agnolo HMA, Kievit W, Andrade RJ, Karlsen TH, Wedemeyer H, Drenth JPH. Creating an effective clinical registry for rare diseases. United European Gastroenterol J. 2016 Jun;4(3):333-8. doi: 10.1177/2050640615618042. Epub 2015 Nov 13 PMID:27403298Trefwoorden: international registry and rare diseases

Nissen LH, Nagtegaal ID, de Jong DJ, Kievit W, Derikx LA, Groenen PJ, van Krieken JH, Hoentjen F. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. J Crohns Colitis. 2015 May;9(5):398-403. doi: 10.1093/ecco-jcc/jjv040. PMID:25740811

Derikx LA, Nissen LH, Drenth JP, van Herpen CM, Kievit W, Verhoeven RH, Mulders PF, Hulsbergen-vande Kaa CA, Boers-Sonderen MJ, van den Heuvel TR, Pierik M, Nagtegaal ID, Hoentjen F. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget 2015;6(35):38336-38347.PMID:26447542

Derikx LA, Nissen LH, Smits LJ, Shen B, Hoentjen F.Neoplasia risk after colectomy in inflammatory bowel disease patients – A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016 Jun;14(6):798-806.e20. doi: 10.1016/j.cgh.2015.08.042. Epub 2015 Sep 25.PMID:26407752

Derikx LA, Nissen LH, Oldenburg B, Hoentjen F. Controversies in pouch surveillance for patients with inflammatory bowel disease. J Crohns Colitis. 2016 Jun;10(6):747-51. doi: 10.1093/ecco-jcc/jjw035. Epub 2016 Jan 28. PMID:26822612

Boers-Sonderen M, Mulder SF, Nagtegaal ID, Derikx LA, Wanten G, Mulders P, van der Graaf WT, Hoentjen F, van Herpen CM. Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: is the cause in the mucosa. Acta Oncol. 2016;55(4):444-8. doi: 10.3109/0284186X.2015.1119883. PMID:26959411


Derikx LA, Vierdag WM, Kievit W, Bosch S, Hoentjen F, Nagtegaal ID. Increased prevalence of colonic neuroendocrine tumors in inflammatory bowel disease. Int J Cancer. 2016 Aug 1;139(3):535-42. doi: 10.1002/ijc.30096. Epub 2016 Apr 4.PMID:26992110

Derikx LA, Dieleman LA, Hoentjen F. Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):55-71. doi: 10.1016/j.bpg.2016.02.005. Epub 2016 Feb 9. PMID:27048897

Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016 Nov;10(11):1287-1293. Epub 2016 Apr 19.PMID:27095751

Nissen LH, Assendorp EL, van der Post RS, Derikx LA, de Jong DJ, Kievit W, Pierik M, van den Heuvel TR, Verhoeven R, Overbeek LI, Hoentjen F, Nagtegaal ID. On behalf of Dutch Initiative on Crohn and Colitis, PALGA group and IBD and gastric cancer group. Impaired gastric cancer survival in inflammatory bowel disease patients. J Gastrointestin Liver Dis. 2016 Dec;25(4):431-440. doi: 10.15403/jgld.2014.1121.254.nis.PMID:27981298

Van de Meeberg MM, Derikx LA, Sinnige HA, Nooijen P, Schipper DL, Nissen LH. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient on thiopurine monotherapy. World J Gastroenterol. 2016 Dec 21;22(47):10465-10470. doi: 10.3748/wjg.v22.i47.10465. PMID:28058028

Derikx LA, Nissen LH, Smits LJ, Shen B, Hoentjen F. Risk of Neoplasia After Colectomy in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016 Jun;14(6):798-806.e20. doi: 10.1016/j.cgh.2015.08.042. Epub 2015 Sep 25.PMID:26407752

Derikx LA, Nissen LH, Drenth JP, van Herpen CM, Kievit W, Verhoeven RH, Mulders PF, Hulsbergen-van de Kaa CA, Boers-Sonderen MJ, van den Heuvel TR, Pierik M, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis; PALGA Group. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget. 2015 Nov 10;6(35):38336-47. doi: 10.18632/oncotarget.5186. PMID:26447542

Nissen LH, Assendorp EL, van der Post RS, Derikx LA, de Jong DJ, Kievit W, Pierik M, van den Heuvel T, Verhoeven R, Overbeek LI, Hoentjen F, Nagtegaal ID. Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease. J Gastrointestin Liver Dis. 2016 Dec;25(4):431-440. doi: 10.15403/jgld.2014.1121.254.nis.PMID:27981298

Van der Velden WJ, Nissen L, van Rijn M, Rijntjes J, de Haan A, Venkatraman L, Catherwood M, Liu H, El-Daly H, van de Laar L, Craenmehr MH, van Krieken JH, Stevens WB, Groenen PJ. Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders. Haematologica. 2015 Apr;100(4):e152-4. doi: 10.3324/haematol.2014.116780. PMID:25527569

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015 Nov;9(11):945-65. doi: 10.1093/ecco-jcc/jjv141. Epub 2015 Aug 20. PMID:26294789

Römkens TE, Bulte GJ, Nissen LH, Drenth JP. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol. 2016 Jan 21;22(3):1321-30. doi: 10.3748/wjg.v22.i3.1321. PMID:26811669

71 MAAG, DARM, LEVERZIEKTEN

Braamse AM, van Turenhout ST, Terhaar Sive Droste JS, de Groot GH, van der Hulst RW, Klemt-Kropp M, Kuiken SD, Loffeld RJ, Uiterwaal MT, Mulder CJ, Dekker J. Factors associated with anxiety and depressive symptoms in colorectal cancer survivors. Eur J Gastroenterol Hepatol. 2016 Jul;28(7):831-5. doi: 10.1097/MEG.0000000000000615. PMID: 26928565

Abstracts, voordrachten en postersDerikx LAAP. Neoplasia risk after colectomy in inflammatory bowel disease patients – A systematic review and meta-analysis. Poster presentatie DDW, 16-19 mei 2015, Washington DC

Derikx LAAP. Colorectal cancer risk in patients with both Lynch syndrome and inflammatory bowel disease. Mondelinge presentatie NVGE, 8-9 oktober 2015, Veldhoven

Derikx LAAP. Colorectal cancer risk in patients with both Lynch syndrome and inflammatory bowel disease. Mondelinge presentatie UEGW, 24-28 oktober 2015, Barcelona

Derikx LAAP. Neoplasia risk after colectomy in inflammatory bowel disease patients – A systematic review and meta-analysis. Poster presentatie UEGW, 24-28 oktober 2015, Barcelona

Derikx LAAP. Casus presentatie: dysplasie bij inflammatoire darmziekten. Mondelinge presentatie NVGE, 6-7 oktober 2016, Veldhoven

Derikx LAAP. Colorectal cancer risk in a nationwide inflammatory bowel disease cohort with low grade dysplasia. Mondelinge presentatie NVGE, 6-7 oktober 2016, Veldhoven

Derikx LAAP. Colorectal cancer risk in a nationwide inflammatory bowel disease cohort with low grade dysplasia. Mondelinge presentatie UEGW, 15-19 oktober 2016, Wenen

HMA D’Agnolo. “The association of combined total kidney liver volume with pain and gastrointestinal symptoms in patients with later stage ADPKD”. Poster presentatie ERA-EDTA congres, Wenen, Oostenrijk, 2016.Trefwoord: ADPKD en symptomen

HMA D’Agnolo. “Ursodeoxycholic acid in advanced polycystic liver disease: a multicenter randomized controlled phase 2 trial (CURSOR)”. EASL recording award + poster + poster tour ILC EASL congres, Barcelona, Spanje 2016.Trefwoord: polycystic liver disease and ursodeoxycholic acid

HMA D’Agnolo. Polycystic liver disease in ADPKD and ADPLD: one and the same? Results of the international PLD registry. Presentatie Europe ADPKD consortium, Barcelona, Spanje 2016. Trefwoord: ADPKD and treatment

HMA D’Agnolo. “ursodeoxyucholic acisd acid as treatment for symptomatic polycystic liver disease: an international, multicenter, randomized, controlled trial”Poster ILC EASL congres, Wenen, Oostenrijk 2015.Trefwoord: polycystic liver disease and ursodeoxycholic acid

Publicaties (niet pubmed)Maartje v.d. Vrugt, Saskia Cornelissen, Thom Timmerhuis en Eric Smits. Slim samenwerken aan een evenwichtige bedbezetting. Stator; 03-12-2016, blz. 34 t/m 38.


MEDISCHE MICROBIOLOGIE

14Wetenschappelijke publicatiesWielders CC, Teunis PF, Hermans MH, van der Hoek W, Schneeberger PM. Kinetics of antibody response to Coxiella burnetii infection (Q fever): Estimation of the seroresponse onset from antibody levels.Epidemics. 2015 Dec;13:37-43. PMID: 26616040

Beernink TM, Wever PC, Hermans MH, Bartholomeus MG. Capnocytophaga canimorsus meningitis diagnosed by 16S rRNA PCR. Pract Neurol. 2016 Apr;16(2):136-8. PMID: 26608220

Hagenaars JC, Wever PC, Vlake AW, Renders NH, van Petersen AS, Hilbink M, de Jager-Leclercq MG, Moll FL, Koning OH, Hoekstra CJ. Value of 18F-FDG PET/CT in diagnosing chronic Q fever in patients with central vascular disease. Neth J Med. 2016 Aug;74(7):301-8. PMID: 27571945

van der Bij AK, Frentz D, Bonten MJ; ISIS-AR Study Group (Renders NH). Gram-positive cocci in Dutch ICUs with and without selective decontamination of the oropharyngeal and digestive tract: a retrospective database analysis. J Antimicrob Chemother. 2016 Mar;71(3):816-20. doi: 10.1093/jac/dkv396. Epub 2015 Dec 11. PMID: 26661393

van der Steen M, Leenstra T, Kluytmans JA, van der Bij AK; ISIS-AR study group (Renders NH). Trends in Expanded-Spectrum Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae among Dutch Clinical Isolates, from 2008 to 2012. PLoS One. 2015 Sep 18;10(9):e0138088. doi: 10.1371/journal.pone.0138088. eCollection 2015. PMID: 26381746

Kampschreur LM, Wegdam-Blans MC, Wever PC, Renders NH, Delsing CE, Sprong T, van Kasteren ME, Bijlmer H, Notermans D, Oosterheert JJ, Stals FS, Nabuurs-Franssen MH, Bleeker-Rovers CP; Dutch Q Fever Consensus Group. Chronic Q fever diagnosis— consensus guideline versus expert opinion. Emerg Infect Dis. 2015 Jul;21(7):1183-8. PMID: 26277798

Wielders CC, van Loenhout JA, Morroy G, Rietveld A, Notermans DW, Wever PC, Renders NH, Leenders AC, van der Hoek W, Schneeberger PM. Long-Term Serological Follow-Up of Acute Q-Fever Patients after a Large Epidemic. PLoS One. 2015 Jul 10;10(7):e0131848. doi: 10.1371/journal.pone.0131848. eCollection 2015. PMID: 26161658

75 MEDISCHE MICROBIOLOGIE

Pennings JL, Kremers MN, Hodemaekers HM, Hagenaars JC, Koning OH, Renders NH, Hermans MH, de Klerk A, Notermans DW, Wever PC, Janssen R. Dysregulation of serum gamma interferon levels in vascular chronic Q Fever patients provides insights into disease pathogenesis. Clin Vaccine Immunol. 2015 Jun;22(6):664-71. doi: 10.1128/CVI.00078-15. Epub 2015 Apr 29. PMID: 25924761

Hagenaars JC, Wever PC, Shamelian SO, Van Petersen AS, Hilbink M, Renders NH, De Jager-Leclercq GL, Moll FL, Koning OH. Vascular chronic Q fever: quality of life. Epidemiol Infect. 2015 Oct;143(13):2903-9. doi: 10.1017/S0950268814003951. Epub 2015 Jan 22. PMID: 25608699

Wielders CC, Hackert VH, Schimmer B, Hodemaekers HM, de Klerk A, Hoebe CJ, Schneeberger PM, van Duynhoven YT, Janssen R. Single nucleotide polymorphisms in immune response genes in acute Q fever cases with differences in self-reported symptoms. Eur J Clin Microbiol Infect Dis. 2015 May;34(5):943-50. doi: 10.1007/s10096-014-2310-9. Epub 2015 Jan 11.PMID:25577174

Wielders CC, Boerman AW, Schimmer B, van den Brom R, Notermans DW, van der Hoek W, Schneeberger PM. Persistent high IgG phase I antibody levels against Coxiella burnetii among veterinarians compared to patients previously diagnosed with acute Q fever after three years of follow-up. PLoS One. 2015 Jan 20;10(1):e0116937. doi: 10.1371/journal.pone.0116937. eCollection 2015. PMID: 25602602

Van de Sande-Bruinsma N, Leverstein van Hall MA, Janssen M, Nagtzaam N, Leenders S, de Greeff SC, Schneeberger PM. Impact of livestock-associated MRSA in a hospital setting. Antimicrob Resist Infect Control. 2015 Apr 17;4:11. doi: 10.1186/s13756-015-0053-8. eCollection 2015. PMID:25908965.

Morroy G, van der Hoek W, Albers J, Coutinho RA, Bleeker-Rovers CP, Schneeberger PM. Population Screening for Chronic Q-Fever Seven Years after a Major Outbreak. PLoS One. 2015 Jul 1;10(7):e0131777. doi: 10.1371/journal.pone.0131777. eCollection 2015. PMID: 26132155

Morroy G, Van Der Hoek W, Nanver ZD, Schneeberger PM, Bleeker-Rovers CP, Van Der Velden J, Coutinho RA. The health status of a village population, 7 years after a major Q fever outbreak. Epidemiol Infect. 2015 Nov 12:1-10. PMID: 26560803

Brandwagt DA, Herremans T, Schneeberger PM, Hackert VH, Hoebe CJ, Paget J, van der Hoek W. Waning population immunity prior to a large Q fever epidemic in the south of The Netherlands. Epidemiol Infect. 2016 Apr 14:1-7. [Epub ahead of print] PMID: 27075042

Van der Wardt J, Olde Dubbelink TB, Visée HF, Schneeberger PM, Lutgens SP, van Eijk JJ. Neurologische symptomen bij hepatitis E-infectie. Ned Tijdschr Geneeskd. 2016;160(0):D107.PMID:27378260

Brooke RJ, Teunis PF, Kretzschmar ME, Wielders CC, Schneeberger PM, Waller LA. Use of a Dose-Response Model to Study Temporal Trends in Spatial Exposure to Coxiella burnetii: Analysis of a Multiyear Outbreak of Q Fever. Zoonoses Public Health. Epub 2016 Aug 23. PMID:27549241

de Lange MM, Hukkelhoven CW, Munster JM, Schneeberger PM, van der Hoek W. Nationwide registry-based ecological analysis of Q fever incidence and pregnancy outcome during an outbreak in the Netherlands.BMJ Open. 2015 Apr 10;5(4):e006821. doi: 10.1136/bmjopen-2014-006821.PMID:25862010


Kampschreur LM, Wegdam-Blans MCA, Wever PC, Renders NHM, Delsing CE, Sprong T, van Kasteren MEE, Bijlmer H, Notermans D, Oosterheert JJ, Stals FS, Nabuurs-Franssen MH, Bleeker-Rovers CP. Chronic Q fever diagnosis-consensus guideline versus expert opinion. Emerg Infect Dis. 2015 Jul;21(7):1183-8. PMID: 26277798

Wever PC. Adrian Stokes en ‘trench jaundice’. Ned Tijdschr Geneeskd. 2015;159:A8648. PMID: 25804113

Schoffelen T, Ammerdorffer A, Hagenaars JC, Bleeker-Rovers CP, Wegdam-Blans MC, Wever PC, Joosten LA, van der Meer JW, Sprong T, Netea MG, van Deuren M, van de Vosse E. Genetic Variation in Pattern Recognition Receptors and Adaptor Proteins Associated With Development of Chronic Q Fever. J Infect Dis. 2015 Feb 26. pii: jiv113. [Epub ahead of print] PMID:25722298.

Broos PP, Hagenaars JC, Kampschreur LM, Wever PC, Bleeker-Rovers CP, Koning OH, Teijink JA, Wegdam-Blans MC. Vascular complications and surgical interventions after world’s largest Q fever outbreak. J Vasc Surg. 2015 Sep 10. pii: S0741-5214(15)01484-6. doi: 10.1016/j.jvs.2015.06.217. PMID:26365665

Ammerdorffer A, Stappers MH, Oosting M, Schoffelen T, Hagenaars JC, Bleeker-Rovers CP, Wegdam-Blans MC, Wever PC, Roest HJ, van de Vosse E, Netea MG, Sprong T, Joosten LA. Genetic variation in TLR10 is not associated with chronic Q fever, despite the inhibitory effect of TLR10 on Coxiella burnetii-induced cytokines in vitro. Cytokine. 2016 Jan;77:196-202. doi: 10.1016/j.cyto.2015.09.005. PMID: 26364993

Bart IY, Mourits M, van Gent R, van Leuken MH, Hilbink M, Warris A, Wever PC, de Vries E. Sputum Induction in Children Is Feasible and Useful in a Bustling General Hospital Practice. Glob Pediatr Health. 2016 Mar 4;3:2333794X16636504. doi:

10.1177/2333794X16636504. eCollection 2016. PMID: 27336008

Wever PC, Hodges AJ. The First World War years of Sydney Domville Rowland: an early case of possible laboratory-acquired meningococcal disease. J R Army Med Corps. 2016 Aug;162(4):310-5. doi: 10.1136/jramc-2016-000634. Epub 2016 Apr 15. PMID: 27084843

Wever PC, Korst MBJM, Otte M. The U.S. Army medical belt for front line first aid: a well-considered design that failed the Medical Department during the First World War. Mil Med 2016;181:1187-1194.PMID:27753550

Wever PC. No 10 Stationary Hospital and the chapel ward at Saint-Omer, France, 1914-18. BMJ 2016;355: i6509 (Christmas issue).PMID:27956438

Roerdink RL, Douw CM, Leenders AC, Dekker RS, Dietvorst M, Oosterbos CJ, Roerdink HT, Kempen RW, Bom LP. Bilateral periprosthetic joint infection with Ureaplasma urealyticum in an immunocompromised patient. Infection. 2016 Dec;44(6):807-810. Epub 2016 May 28.PMID:27236775

Dietvorst M, Roerdink R, Leenders AC, Kiel MA, Bom LP. Acute Mono-Arthritis of the Knee: A Case Report of Infection with Parvimonas Micra and Concomitant Pseudogout. J Bone Jt Infect. 2016 Oct 1;1:65-67.PMID:28529856

Leenders AC. Prevention of Surgical Site Infections: Universal Decontamination Not for All, but for a Selection of Surgical Patients. Clin Infect Dis. 2016 Jun 1;62(11):1469-70. doi: 10.1093/cid/ciw214. Epub 2016 Apr 5. No abstract available. PMID: 27048744


Abstracts, voordrachten en postersIlse J.E. Kouijzer, Linda M. Kampschreur, Peter C. Wever, Corneline Hoekstra, Marjo E.E. van Kasteren, Monique G.L. de Jager-Leclerque, Marrigje H. Nabuurs-Franssen, Marjolijn C.A. Wegdam-Blans, Lioe-Fee de Geus-Oei, Wim J.G. Oyen, Chantal P. Bleeker-Rovers: The value of FDG-PET/CT in diagnosis and during follow-up of 271 patients suspected of chronic Q fever. Oral presentation SNM, Denver USA 2016

Ilse J.E. Kouijzer, Linda M. Kampschreur, Peter C. Wever, Corneline Hoekstra, Marjo E.E. van Kasteren, Monique G.L. de Jager-Leclerque, Marrigje H. Nabuurs-Franssen, Marjolijn C.A. Wegdam-Blans, Lioe-Fee de Geus-Oei, Wim J.G. Oyen, Chantal P. Bleeker-Rovers. The value of FDG-PET/CT in diagnosis and during follow-up of 271 patients suspected of chronic Q fever. Oral presentation: ECCMID, Amsterdam 2016.

Publicaties (niet pubmed)A.C.A.P. Leenders, A.H.P.M. Essink, dr. D.W. Notermans, M.G.J. Koene, B. Schimmer, C.M. Swaan, A. Rietveld. Tularaemia back in The Netherlands after 60 years? The Dutch situation in connection with a patient with tularemia and an infected hare. Tijdschrift voor Infectieziekten. 2015, 10; 194-198.

Marbus SD, Oost JA, van der Hoek, W, Polderman, FN, de Jager CPC, Groeneveld GH, Schneeberger PM, van Gageldonk-Lafeber AB. Ernstige acute luchtweginfecties: de ontbrekende bouwsteen in de surveillancepiramide. Ned Tijdschr Med Microbiol 2016; 24: nr 1, 52-55.


MOLECULAIRE DIAGNOSTIEK

15Wetenschappelijke publicatiesWielders CC, Teunis PF, Hermans MH, van der Hoek W, Schneeberger PM. Kinetics of antibody response to Coxiella burnetii infection (Q fever): Estimation of the seroresponse onset from antibody levels. Epidemics. 2015 Dec;13:37-43. PMID: 26616040

Beernink TM, Wever PC, Hermans MH, Bartholomeus MG. Capnocytophaga canimorsus meningitis diagnosed by 16S rRNA PCR. Pract Neurol. 2016 Apr;16(2):136-8. PMID: 26608220

Huijsmans CJ, van den Brule AJ, Rigter H, Poodt J, van der Linden JC, Savelkoul PH, Hilbink M, Hermans MH. Allelic imbalance at the HER2/TOP2A locus in breast cancer. Diagn Pathol. 2015 May 29;10:56. doi: 10.1186/s13000-015-0289-x.PMID: 26022247

Huijsmans CJ, Geurts-Giele WR, Leeijen C, Hazenberg HL, van Beek J, de Wild C, van der Linden JC, van den Brule AJ. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows. BMC Cancer. 2016 Nov 28;16(1):922.PMID: 27894291


Pennings JL, Kremers MN, Hodemaekers HM, Hagenaars JC, Koning OH, Renders NH, Hermans MH, de Klerk A, Notermans DW, Wever PC, Janssen R. Dysregulation of serum gamma interferon levels in vascular chronic Q Fever patients provides insights into disease pathogenesis. Clin Vaccine Immunol. 2015 Jun;22(6):664-71.PMID: 25924761

Harder E, Thomsen LT, Frederiksen K, Munk C, Iftner T, van den Brule A, Kjaer SK. Risk Factors for Incident and Redetected Chlamydia trachomatis Infection in Women: Results of a Population-Based Cohort Study. Sex Transm Dis. 2016 Feb;43(2):113-9. doi: 10.1097/OLQ.0000000000000394. PMID: 26760181

81 MOLECULAIRE DIAGNOSTIEK

Loonen AJ, Schuurman R, van den Brule AJ. Multidisciplinary molecular diagnostics: the 9th European meeting on molecular diagnostics. Expert Rev Mol Diagn. 2016;16(4):395-7. doi: 10.1586/14737159.2016.1152185. Epub 2016 Feb 26. PMID: 26854825

Santosaningsih D, Santoso S, Budayanti NS, Suata K, Lestari ES, Wahjono H, Djamal A, Kuntaman K, van Belkum A, Laurens M, Snijders SV, Willemse-Erix D, Goessens WH, Verbrugh HA, Severin JA. Characterisation of clinical Staphylococcus aureus isolates harbouring mecA or Panton-Valentine leukocidin genes from four tertiary care hospitals in Indonesia. Trop Med Int Health. 2016 May;21(5):610-8. doi: 10.1111/tmi.12692. Epub 2016 Mar 30. PMID: 26970318


Noordegraaf M, de Vrije I, van den Brule A, Hoededemakers RM. Typering van HLA-DQ2/8 met GenVinset HLA Celiac test. Poster. NVKC-voorjaarscongres. Veldhoven, Nederland, 15-4-2015 - 17-4-2015.



NEUROLOGIE

16Wetenschappelijke publicatiesVan der Wardt J, Olde Dubbelink TB, Visée HF, Schneeberger PM, Lutgens SP, van Eijk JJ. Neurological symptoms with a hepatitis E virus infection]. Ned Tijdschr Geneeskd. 2016;160(0):D107. Dutch. PMID: 27378260

Van Eijk JJ, Groothuis J, van Alfen N. Reply. Muscle Nerve. 2016 Aug;54(2):342-3. doi: 10.1002/mus.25172. Epub 2016. May 27. No abstract available. PMID: 27144614

Wijburg MT, Siepman D, van Eijk JJ, Killestein J, Wattjes MP Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. J Neurol. 2016 Apr;263(4):649-56. doi: 10.1007/s00415-015-8001-3. Epub 2016 Jan 25. PMID:26810721

Dalton HR, Kamar N, van Eijk JJ, Mclean BN, Cintas P, Bendall RP, Jacobs BC. Hepatitis E virus and neurological injury. Nat Rev Neurol. 2016 Feb;12(2):77-85. doi: 10.1038/nrneurol.2015.234. Epub 2015 Dec 29. Review. PMID: 26711839

Van Eijk JJ, Groothuis JT, Van Alfen N. Neuralgic amyotrophy: An update on diagnosis, pathophysiology, and treatment. Muscle Nerve. 2016 Mar;53(3):337-50. doi: 10.1002/mus.25008. Epub 2016 Jan 20. Review. PMID: 26662794

Van Alfen N, van Eijk JJ, Ennik T, Flynn SO, Nobacht IE, Groothuis JT, Pillen S, van de Laar FA. Incidence of neuralgic amyotrophy (Parsonage Turner syndrome) in a primary care setting--a prospective cohort study. PLoS One. 2015 May 27;10(5):e0128361. doi: 10.1371/journal.pone.0128361. eCollection 2015. PMID: 26016482

Groothuis JT, van Eijk JJ, van de Laar FA, van Alfen N [Incidence of neuralgic amyotrophy in a primary care setting: a prospective cohort study]. Ned Tijdschr Geneeskd. 2015;160:A9957. Dutch. PMID: 27027209

Duijghuisen JJ, Greebe P, Nieuwkamp DJ, Algra A, Rinkel GJ. Sex-Related Differences in Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage. J Stroke Cerebrovasc Dis. 2016 Aug;25(8):2067-70. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.018. Epub 2016 Jun 1.PMID: 27263033

85 NEUROLOGIE

Murk JL, Nieuwkamp DJ, van Oosten BW. Dr. Murk and colleagues reply. N Engl J Med. 2016 Jan 21;374(3):296. No abstract available.PMID: 26798868

Nieuwkamp DJ, Murk JL, van Oosten BW. PML in Patients Treated with Dimethyl Fumarate.N Engl J Med. 2015 Aug 6;373(6):584. doi: 10.1056/NEJMc1506151. No abstract available.PMID: 26244324 Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, Van Hecke W, Frijlink DW, Wattjes MP; PML in Dutch MS Patients Consortium. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 2015 Apr 9;372(15):1474-6. doi: 10.1056/NEJMc1413724. PMID: 25853764

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand’Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group. Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler. 2016 Apr 7. pii: 1352458516643392. PMID: 27055805

Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, Sinnige LG, Verhagen WI, Visser LH, van der Kruijk R, Verheul F, Boringa J, Heerings M, Gladdines W, Lönnqvist F, Gaillard P. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. J Neurol. 2016 Aug;263(8):1641-51. doi: 10.1007/s00415-016-8183-3. Epub 2016 Jun 7.PMID:27272956


L.M.E. de Ceuster, Dr. S.F.T.M. de Bruijn en Dr. M.P.J. Garssen. Postinfectieuze cerebellaire syndromen (post infectious cerebellar syndromes). Tijdsch Neurol Neurochir 2016;117(2):67-72.

Publicaties (niet pubmed)M. de Gier, M. Garssen, K. Simons, W. Rozendaal. Respiratory insufficiency due to acute bulbar palsy. Neth J Crit Care, Volume 23, no 5; november 2015.


NUCLEAIRE GENEESKUNDE

17Wetenschappelijke publicaties


Kist JW, de Keizer B, van der Vlies M, Brouwers AH, Huysmans DA, van der Zant FM, Hermsen R, Stok-kel MP, Hoekstra OS, Vogel WV; THYROPET Study Group; other members of the THYROPET Study group are John M.H. de Klerk. Collaborators: van Tinteren H, Paul de Boer J, Morreau H, Huisman MC, Lentjes EG, Links TP, Smit JW, Lavalaye J, de Jager PL, Hoekstra CJ, Gotthardt M, Schelfhout VJ, de Bruin WI, Sivro F, Adam JA, Phan HT, Sloof GW, Wagenaar NR. Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recur-rence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). J Nucl Med. 2016 May;57(5):701-7. doi: 10.2967/jnumed.115.168138. Epub 2015 Nov 25. PMID: 26609180

Goos JA, de Cuba EM, Coupé VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JA, Menke-Van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET Group.

Collaborators: van Grieken NC, Perk LR, van den Tol MP, te Velde EA, Windhorst AD, Baas J, Rijken AM, van Beek MW, Pijpers HJ, Bril H, Stockmann HB, Zwij-nenburg A, Bosscha K, van den Brule AJ, Hoekstra CJ, van der Linden JC, Rinkes IH, van Diest PJ, van Hillegersberg R, Kranenburg O, Lam MG, Snoeren N, Liem IH, Roumen RM, Vening W. Glucose Transpor-ter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA)Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Ann Surg. 2016 Jan;263(1):138-45. PMID: 25563886

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. FDG PET/CT: EANM pro-cedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. PMID: 25452219

Claassen B, Barneveld PC, Jager G, Rutten MJ. Abdominal splenosis. Ned Tijdschr Geneeskd. 2015;159:A8880.PMID: 26104005

89 NUCLEAIRE GENEESKUNDE

BoekenNC Veltman. Procedure guidelines Nuclear Medicine. Dutch Society of Nuclear Medicine. Part 1; Diagnostic methods. Locomotor system. Oktober 2016. ISBN 978-90-78876-09-0

Vainer J, Habets JH, Schalla S, Lousberg AH, de Pont CD, Vöö SA, Brans BT, Hoorntje JC, Waltenberger J. Cardiac shockwave therapy in patients with chronic refractory angina pectoris. Neth Heart J. 2016 May;24(5):343-9. PMID: 26936156


Ilse J.E. Kouijzer, Linda M. Kampschreur, Peter C. Wever, Corneline Hoekstra, Marjo E.E. van Kaste-ren, Monique G.L. de Jager-Leclerque, Marrigje H. Nabuurs-Franssen, Marjolijn C.A. Wegdam-Blans, Lioe-Fee de Geus-Oei, Wim J.G. Oyen, Chantal P. Bleeker-Rovers: The value of FDG-PET/CT in diagno-sis and during follow-up of 271 patients suspected of chronic Q fever. Oral presentation SNM, Denver USA 2016

Ilse J.E. Kouijzer, Linda M. Kampschreur, Peter C. Wever, Corneline Hoekstra, Marjo E.E. van Kaste-ren, Monique G.L. de Jager-Leclerque, Marrigje H. Nabuurs-Franssen, Marjolijn C.A. Wegdam-Blans, Lioe-Fee de Geus-Oei, Wim J.G. Oyen, Chantal P. Bleeker-Rovers. The value of FDG-PET/CT in diagno-sis and during follow-up of 271 patients suspected of chronic Q fever. Oral presentation: ECCMID, Amsterdam 2016.

Valckx WJ, Lutgens SP, Haerkens-Arends HE, Barne-veld PC, Beutler JJ, Hoogeveen EK. Listeria infection: a diagnostic challenge. C166, p78, (abstract book internistendag, 2015).


ORTHOPEDIE

18Wetenschappelijke publicatiesRoerdink RL, Douw CM, Leenders AC, Dekker RS, Dietvorst M, Oosterbos CJ, Roerdink HT, Kempen RW, Bom LP. Bilateral periprosthetic joint infection with Ureaplasma urealyticum in an immunocompromised patient. Infection. 2016 Dec;44(6):807-810. Epub 2016 May 28.PMID:27236775

Dietvorst M, Roerdink R, Leenders AC, Kiel MA, Bom LP. Acute Mono-Arthritis of the Knee: A Case Report of Infection with Parvimonas Micra and Concomitant Pseudogout. J Bone Jt Infect. 2016 Oct 1;1:65-67.PMID:28529856

Delawi D, Jacobs W, van Susante JL, Rillardon L, Prestamburgo D, Specchia N, Gay E, Verschoor N, Garcia-Fernandez C, Guerado E, Quarles van Ufford H, Kruyt MC, Dhert WJ, Oner FC. OP-1 Compared with Iliac Crest Autograft in Instrumented Posterolateral Fusion: A Randomized, Multicenter Non-Inferiority Trial. J Bone Joint Surg Am. 2016 Mar 16;98(6):441-8. doi: 10.2106/JBJS.O.00209.PMID: 26984911

Poolman RW, Verhaar JA, Schreurs BW, Bom LP, Nelissen RG, Koot HW, Goosen JH, Verheyen CC. Finding the right hip implant for patient and surgeon: the Dutch strategy - empowering patients. Hip Int. 2015 Apr 20;25(2):131-7. doi: 10.5301/

hipint.5000209. Epub 2015 Feb 28.PMID: 25633758

Huijbregts HJ, Khan RJ, Fick DP, Jarrett OM, Haebich S. Prosthetic alignment after total knee replacement is not associated with dissatisfaction or change in Oxford Knee Score: A multivariable regression analysis. Knee. 2016 Jun;23(3):535-9. doi: 10.1016/j.knee.2015.12.007. Epub 2016 Jan 27. PMID: 26826945

Huijbregts HJ, Khan RJ, Sorensen E, Fick DP, Haebich S. Patient-specific instrumentation does not improve radiographic alignment or clinical outcomes after total knee arthroplasty. Acta Orthop. 2016 Aug;87(4):386-94. doi: 10.1080/17453674.2016.1193799. Epub 2016 Jun PMID:27249110

Huijbregts HJ, Khan RJ, Fick DP, Hall MJ, Punwar SA, Sorensen E, Reid MJ, Vedove SD, Haebich S. Component alignment and clinical outcome following total knee arthroplasty: a randomised controlled trial comparing an intramedullary alignment system with patient-specific instrumentation. Bone Joint J. 2016 Aug;98-B(8):1043-9. doi: 10.1302/0301-620X.98B8.37240.PMID: 27482015

93 ORTHOPEDIE

Abstracts, voordrachten en postersVan Loon T. Anatomy of the Anterior Cruciate Ligament and Graft Selection for Reconstruction. International Advanced Instructional Course on Arthroscopy of the Knee, University Medical Center, Utrecht. 7 juli 2015

Van Loon T. How to repair the Meniscus. Internati-onal Advanced Instructional Course on Arthroscopy of the Knee, University Medical Center, Utrecht. 7 juli 2015

Van Loon T. Complications in Anterior Cruciate Ligament Surgery. International Advanced Instructi-onal Course on Arthroscopy of the Knee, University Medical Center, Utrecht. 5 juli 2016

Publicaties (niet pubmed)Roerdink RL, Dietvorst M, Bom LP. De invloed van extracorporale shock wave therapie bij tendinitis calcarea, achillespeestendinopathie en fasciitis plan-taris op pijn, beperkingen in dagelijkse activiteiten en beperkingen in sport: een retrospectieve studie. Sport en geneeskunde juni 2016.


PATHOLOGIE

19Wetenschappelijke publicatiesvan la Parra RF, de Wilt JH, Mol SJ, Mulder AH, de Roos WK, Bosscha K. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients. Breast J. 2015 Nov-Dec;21(6):621-6. doi: 10.1111/tbj.12496. Epub 2015 Sep 22. PMID: 26391102

Van de Meeberg MM, Derikx LA, Sinnige HA, Nooijen P, Schipper DL, Nissen LH. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient on thiopurine monotherapy. World J Gastroenterol. 2016 Dec 21;22(47):10465-10470. doi: 10.3748/wjg.v22.i47.10465.PMID:28058028

Visser NC, Bulten J, van der Wurff AA, Boss EA, Bronkhorst CM, Feijen HW, Haartsen JE, van Herk HA, de Kievit IM, Klinkhamer PJ, Pijlman BM, Snijders MP, Vandenput I, Vos MC, de Wit PE, van de Poll-Franse LV, Massuger LF, Pijnenborg JM. PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study. BMC Cancer. 2015 Jun 30;15:487PMID: 26123742

Huijsmans CJ, Geurts-Giele WR, Leeijen C, Hazenberg HL, van Beek J, de Wild C, van der Linden JC, van den Brule AJ. HPV Prevalence in the Dutch cervical cancer

screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows. BMC Cancer. 2016 Nov 28;16(1):922.PMID: 27894291

Huijsmans CJ, van den Brule AJ, Rigter H, Poodt J, van der Linden JC, Savelkoul PH, Hilbink M, Hermans MH. Allelic imbalance at the HER2/TOP2A locus in breast cancer. Diagn Pathol. 2015 May 29;10:56. doi: 10.1186/s13000-015-0289-x. PMID: 26022247


97 PATHOLOGIE

Kubat BB, Buiskool MM, van Suylen RJ. Traumatic vertebral artery injury: proposal for classification of the severity of trauma and likelihood of fatal outcome. Int J Legal Med. 2015 Jan;129(1):141-8. doi: 10.1007/s00414-014-1095-9. PMID: 25311511

Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Smit EF, Groen HJ, Speel EJ, Dingemans AM. A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors. J Thorac Oncol. 2016 Apr;11(4):593-602. doi: 10.1016/j.jtho.2015.12.106. Epub 2016 Jan 9.PMID: 26776865

Derks JL, Speel EJ, Thunnissen E, van Suylen RJ, Buikhuisen WA, van Velthuysen ML, Dingemans AM. Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle. J Thorac Oncol. 2016 Mar;11(3):e35-8. doi: 10.1016/j.jtho.2015.10.013.PMID: 26723240

Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, van Suylen RJ, Houben R, Damhuis RA, Speel EJ, Dingemans AM. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2016 Feb;47(2):615-24. doi: 10.1183/13993003.00618-2015.PMID: 26541538

Vogelaar FJ, Abegg R, van der Linden JC, Cornelisse HG, van Dorsten FR, Lemmens VE, Bosscha K. Epidural analgesia associated with better survival in colon cancer. Int J Colorectal Dis. 2015 Apr 28.PMID: 25916606


ProefschriftenIna Geurts-Giele. Next Generation Diagnostic Molecular Pathology. 29-11-2016.Promotor: Prof.dr. F.J. van Kemenade.

Publicaties (niet pubmed)Sezgi P, Weppner-Parren LJMT, Greebe RJ, Mol SJJ, Mutsaers ER, van Geest AJ. Kaposi-sarcoom bij 3 hiv-negatieve patienten. Een zeldzaam fenomeen. NTvDV 2015;25:321-4.


PLASTISCHE CHIRURIE

20Wetenschappelijke publicatiesDumont EA. Sir Harold Gillies, pionier van plastische chirurgie. Ned Tijdschr Geneeskd. 2016;160:A9547.PMID: 26934436

Abstracts, voordrachten en postersFranken RJPM, Friedeman E: Ziekte van Dupuytren en Handartrose. Regionale bijeenkomst reumaverenigingregio Oost-Brabant, 23 september 2015. Franken RJPM: Stuurgroep Wondzorg JBZ: De WoCom. 1e Wondcongres JBZ, ’s-Hertogenbosch, 8 oktober 2015. Paulus V, Bleijs RLAW, Franken RJPM: Bilateral Anomaly of the Flexor Digitorum superficialis Muscle in the Palm of the Hand; an Anatomical Variation with Clinical Impact. NVvHand, Najaarsvergadering St. Michelsgestel, 14 november 2015.

drs V Paulus, prof.dr. R Bleys, drs R Franken. Bilateral anomaly of the flexor digitorum superficialis muscle in the palm of the hand; an anatomical variation with clinical impact. voordracht int congres Nederlandse Vereniging voor Handchirurgie. nov 2015.

Strijbosch R, Friedeman E, Franken RJPM: De Diabetische Hand. Regionale Internisten bijeenkomst Zuid-Nederland, 4 november 2015.

Publicaties (niet pubmed)Paulus VA, Bleijs RLAW, Franken RJPM: Een patiënt met bilateraal een aberrante flexor digitorum superficialis spierbuik in de handpalm; een anatomische variatie met klinisch impact. Case-Report. Nederlands Tijdschrift voor Plastische Chirurgie februari 2016.

Paulus VA, Franken RJPM, van der Heijden EP. A woman with a chronic wound on her index finger. Ned Tijdschr Geneeskd. 2015; 159:A9075.PMID:26230345

99 PLASTISCH CHIRURGIE

PSYCHOLOGIE

21Wetenschappelijke publicatiesHolleman M, Vink M, Nijland R, Schmand B. Effects of intensive neuropsychological rehabilitation for acquired brain injury. Neuropsychol Rehabil. 2016 Aug 3:1-14. [Epub ahead of print]PMID:27487525

101 PSYCHOLOGIE

RADIOLOGIE

22Wetenschappelijke publicatiesClaassen B, Barneveld PC, Jager GJ, Rutten MJ. Abdominale splenose. Ned Tijdschr Geneeskd. 2015; 159: A8880. PMID: 26104005Trefwoorden: splenose, diagnostiek

Nijhof WH, Baltussen EJ, Kant IM, Jager GJ, Slump CH, Rutten MJ. Low dose CT angiography of the abdominal aorta and reduced contrast medium volume: Assessment of image quality and radiation dose. Clinical Radiology 2016; 71(1):64-73. doi: 10.1016/j.crad.2015.10.007.PMID: 26541440Trefwoorden: CTA, contrastreductie, stralendosis reductie

Nijhof WH, Hilbink M, Jager GJ, Slump CH, Rutten MJ. A non-invasive Cardiac Output measurement as an alternative to the test bolus technique during CT angiography. Clinical Radiology 2016 Sep;71(9):940.e1-5. doi: 10.1016/j.crad.2016.03.007. Epub 2016 Apr 10. PMID: 27076253Trefwoorden: CTA, contrastreductie

Mourits MM, Nijhof WH, van Leuken MH, Jager GJ, Rutten MJ. Reducing contrast medium volume and kilo voltage in CTA of the pulmonary artery. Clinical Radiology 2016 Jun;71(6):615.e7-615.e13. doi: 10.1016/j.crad.2016.03.005.PMID: 27059387Trefwoorden: CTA, contrastreductie, stralendosis reductie

Nijhof WH, Jansen MM, Jager GJ, Slump CH, Rutten MJ. Feasibility of a low concentration test-bolus in CT angiography. Clin Radiol. 2016 Dec;71(12):1313.e1-1313.e4. doi: 10.1016/j.crad.2016.08.008.PMID: 27720180Trefwoorden: CTA, contrastreductie

Araújo T, Abayazid M, Rutten MJ, Misra S. Segmentation and three-dimensional reconstruction of lesions using the automated breast volume scanner (ABVS). Int J Med Robot. 2016 Sep 4. doi: 10.1002/rcs.1767. [Epub ahead of print]PMID:27593688


de Bruin JL, Groenwold RH, Baas AF, Brownrigg JR, Prinssen M, Grobbee DE, Blankensteijn JD; DREAM Study Group. Bak AA, Buth J, Pattynama PM, Verhoeven EL, van Voorthuisen AE, Blankensteijn JD, Balm R, Buth J, Cuypers PW, Grobbee DE, Prinssen M, van Sambeek MR, G Verhoeven EL, Baas AF, Hunink MG, van Engelshoven JM, Jacobs MJ, de Mol BA, van

103 RADIOLOGIE

Bockel JH, Balm R, Reekers J, Tielbeek X, Verhoeven EL, Wisselink W, Boekema N, Heuveling I Sikking LM, Prinssen M, Balm R, Blankensteijn JD, Buth J, Cuypers PW, van Sambeek MR, Verhoeven EL, de Bruin JL, Baas AF, Blankensteijn JD, Prinssen M, Buth J, Tielbeek AV, Blankensteijn JD, Balm R, Reekers JA, van Sambeek MR, Pattynama P, Verhoeven EL, Prins T, van der Ham AC, van der Velden JJ, van Sterkenburg SM, Ten Haken GB, Bruijninckx CM, van Overhagen H, Tutein Nolthenius RP, Hendriksz TR, Teijink JA, Odink HF, de Smet AA, Vroegindeweij D, van Loenhout RM, Rutten MJ, Hamming JF, Lampmann LE, Bender MH, Pasmans H, Vahl AC, de Vries C, Mackaay AJ, van Dortmont LM, van der Vliet AJ, Schultze Kool LJ, Boomsma JH, van Dop HR, de Mol van Otterloo JC, de Rooij TP, Smits TM, Yilmaz EN, Wisselink W, van den Berg Vrije FG, Visser MJ, van der Linden E, Schurink GW, de Haan M, Smeets HJ, Stabel P, van Elst F, Poniewierski J, Vermassen FE. Quality of life from a randomized trial of open and endovascular repair for abdominal aortic aneurysm. Br J Surg. 2016 Jul;103(8):995-1002. doi: 10.1002/bjs.10130.PMID: 27059152Trefwoorden: abdominal aortic aneurysma, EVAR

De Bruin JL, Karthikesalingam A, Holt PJ, Prinssen M, Thompson MM, Blankensteijn JD; Dutch RandomisedEndovascular Aneurysm Management (DREAM) Study Group. Bak AA, Buth J, Pattynama PM, Verhoeven EL, van Voorthuisen AE, Blankensteijn JD, Balm R, Buth J, Cuypers PW, Grobbee DE, Prinssen M, van Sambeek MR,Verhoeven EL, Baas AF, Hunink MG, van Engelshoven JM, Jacobs MJ, de Mol BA, van Bockel JH, Balm R, Reekers J, Tielbeek X, Verhoeven EL, Wisselink W, Boekema N, Heuveling LM, Sikking I, Prinssen M, Balm R, Blankensteijn JD, Buth J, Cuypers PW, van Sambeek MR, Verhoeven EL, de Bruin JL, Baas AF, Blankensteijn JD, Prinssen M, Buth J, Tielbeek AV, Blankensteijn JD, Balm R, Reekers JA, van Sambeek MR, Pattynama P, Verhoeven EL, Prins T, van der Ham AC, van der Velden JJ, van Sterkenburg SM, Ten Haken GB, Bruijninckx CM, van Overhagen H, Tutein Nolthenius RP, Hendriksz TR, Teijink JA, Odink HF, de Smet AA, Vroegindeweij D, van Loenhout RM, Rutten MJ, Hamming JF, Lampmann LE, Bender MH, Pasmans H, Vahl AC, de Vries C, Mackaay AJ, van

Dortmont LM, van der Vliet AJ, Schultze Kool LJ, Boomsma JH, van HR, de Mol van Otterloo JC, de Rooij TP, Smits TM, Yilmaz EN, Wisselink W, van den Berg FG, Visser MJ, van der Linden E, Schurink GW, de Haan M, Smeets HJ, Stabel P, van Elst F, Poniewierski J, Vermassen FE. Predicting reinterventions after open and endovascular aneurysm repair using the St George’s Vascular Institute score. J Vasc Surg. 2016 Jun;63(6):1428-1433. doi: 10.1016/j.jvs.2015.12.028.PMID: 27005591Trefwoorden: abdominal aortic aneurysma, EVAR

van Grinsven J, van Brunschot S, Bakker OJ, Bollen TL, Boermeester MA, Bruno MJ, Dejong CH, Dijkgraaf MG, van Eijck CH, Fockens P, van Goor H, Gooszen HG, Horvath KD, van Lienden KP, van Santvoort HC, Besselink MG; Dutch Pancreatitis Study Group (Cappendijk VC). Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. HPB (Oxford). 2016 Jan;18(1):49-56. doi: 10.1016/j.hpb.2015.07.003. Epub 2015 Dec 20.PMID: 26776851 PMCID:PMC4766363 DOI:10.1016/j.hpb.2015.07.003

van Grinsven J, van Brunschot S, Bakker OJ, Bollen TL, Boermeester MA, Bruno MJ, Dejong CH, Dijkgraaf MG, van Eijck CH, Fockens P, van Goor H, Gooszen HG, Horvath KD, van Lienden KP, van Santvoort HC, Besselink MG; Dutch Pancreatitis Study Group (Cappendijk VC). Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. HPB (Oxford). 2015 Oct 17. doi: 10.1111/hpb.12491. PMID: 26475650

Lahaye MJ, Lambregts DM, Mutsaers E, Essers BA, Breukink S, Cappendijk VC, Beets GL, Beets-Tan RG. Mandatory imaging cuts costs and reduces the rate of unnecessary surgeries in the diagnostic work-up of patients suspected of having appendicitis. Eur Radiol. 2015 May;25(5):1464-70. doi: 10.1007/s00330-014-3531-0. Epub 2015 Jan 16.PMID: 25591748


Ranschaert ER, Boland GW, Duerinckx AJ, Barneveld Binkhuysen FH. Comparison of European (ESR) and American (ACR) white papers on teleradiology: patient primacy is paramount. J Am Coll Radiol. 2015 Feb;12(2):174-82. doi: 10.1016/j.jacr.2014.09.027. PMID: 25652303

ProefschriftenRutten MJCM: Copromotor PhD Thesis Technische Geneeskunde / TU Twente.Wouter Nijhof (TU Twente) Technische Geneeskunde: Reduction of contrast medium volume and radiation dose in CT angiography. 2015-12-11

Rutten MJCM: Copromotor Master Thesis Technische Geneeskunde / TU TwenteDhabia Al Samarrai. M3 Master stage: neurostimulation of the plexus coeliacus as a treatment for overweight and obesity. 2015

Rutten MJCM: Copromotor Master Thesis Technische Geneeskunde / TU TwenteDhabia Al Samarrai. M3 Master stage: Microwave ablation in solitary breast cancer. 2016

Ranschaert ER, van Ooijen PM, Lee S, Ratib O, Parizel PM. Social media for radiologists: an introduction. Insights Imaging. 2015 Dec;6(6):741-752. Epub 2015 Sep 22. PMID:26395089

Abstracts, voordrachten en postersRutten MJCM, Maresch SJ. MSK related clicks, clunks and snaps: role of dynamic US imaging Sandwichcursus Musculoskeletale Radiologie, NVVR Ede, 3 Februari 2015

Rutten MJCM, Maresch SJ. MSK related clicks, clunks and snaps: role of dynamic US imaging Sandwichcursus Musculoskeletale Radiologie, NVVR Ede, 6 Februari 2015

Rutten MJ. Echografie elleboog. Echografie verdieping het Specialistenlokaal / DynamicAmersfoort, 14 March 2015

Nijhof W, Rutten MJ. Low dose CT angiography of the abdominal aorta and reduced contrast medium volume: Assessment of image quality and radiation dose. European Congres of Radiology, Vienna, Austria, March 2015

Rutten MJ. Shoulder Ultrasound. How to do it. 1st International Congress of Musculoskeletal UltrasoundAmsterdam, 28 March 2015

Rutten MJ. Inleiding over bekwaamheidsniveaus in opleiden. Onderwijskundig perspectief: Concretisering van JCI-normeringen t.a.v. bekwaamheidsverklaringen. Bespreking Best Practices Radiologie. ZIN in Opleiden. Vught, 30 Maart 2015

Rutten MJ. Inleiding in de radiologie. College voor postHBO - Master opleiding Fysiotherapie 1e jaar MMR HAN University of Applied Sciences, Institute Health Studies. Nijmegen, 1 april 2015

Rutten MJ, Nijhof W. Reduction of contrast medium volume and radiation dose in CT angiography.Kick off meeting: Join innovation 4M @JBZ. Den Bosch, 13 mei 2015

105 RADIOLOGIE

Rutten MJ. Beeldvorming bij sportblessures en LWK problematiek. PostHBO - Master opleiding Fysiotherapie 2e jaar MMR HAN University of Applied Sciences, Institute Health Studies Nijmegen, 27 mei 2015

Rutten MJ, Maresch SJ. Radiologie/Beeldvormende diagnostiek in de topsport. MSK related clicks, clunks and snaps: role of dynamic US imaging. Curriculum Masterclass Topsportartsen te Papendal. Arnhem, 11 september 2015

Nijhof W, Rutten MJ. (Thoraco)abdominal aortic CT angiography at 80 and 100 kVp with personalized contrast medium volume: Assessment of image quality and radiation dose. Radiologendagen Rotterdam, The Netherlands, september 2015

Rutten MJ. Studiedag beeldvormend onderzoek. Het binnenste in beeld met röntgen en CT. De buik gescand: wat zien we hier? Ede, 15 oktober 2015

Rutten MJ. MSU Schouder | Enkel. Amsterdam, 24 ontober 2015

Van Zelst JCM, Woldringh G, Mus R, Bult P, Rutten MJCM, Hoogerbrugge N, Karssemeijer N, Mann RM. Three-modality screening in BRCA carriers; a prospective evaluation of a multimodal regimen. Chicago, RSNA 2015

W. E. Shiels, DO; C. . Martinoli, MD, Genova, GE ITALY; J. A. Bouffard, MD, Detroit, MI; C. J. Brandon, MD, Ann Arbor, MI; E. . Cardinal, MD, Montreal, QC; M. M. Chiavaras, MD, PhD, Hamilton, ON; J. G. Craig, MD, Detroit, MI; M. A. Dipietro, MD, Ann Arbor, MI; D. P. Fessell, MD, Ann Arbor, MI; G. . Habra, MD, Troy, MI; A. . Klauser, MD, Innsbruck, Tirol AUSTRIA; M. T. Van Holsbeeck, MD, Detroit, MI; R. B. Hulen, MD, Detroit, MI; M. . Kislyakova, MD, Moscow, RUSSIA; J. H. Introcaso, MD, Neenah, WI; J. A. Jacobson, MD, Ann Arbor, MI; K. S. Lee, MD, Madison, WI; H. G. Rosas, MD, Madison, WI; M.J. Rutten, MD, Hertogenbosch, NETHERLANDS; A. S. Tagliafico, MD, Genova, GE Italy; X. L. Wortsman, MD, Santiago, RM CHILE. RSNA

Refresher course: Nerve Ultrasound Based on a Regional Approach: Elbow to Hand (Hands-on Workshop). Course Number: RC452. RSNA 101th Scientific assembly and annual Meeting. Chicago, 1 dec 2015 / 4:30PM - 6:00PM

Rutten MJ. MSK echografie schouder. Almere, 19 en 20 januari 2016

Rutten MJ. MSK echografie elleboog. Almere, 19 en 20 januari 2016

Rutten MJ. Injectables - steroids and Platelet Rich Plasma (PRP): how and when? E3 (European Excellence in Education)– ECR Master Class (E³ 1826) entitled ‘MSK and intervention’. 28th European Congress of Radiology (ECR 2016) Vienna, E³ 1826: Sunday, March 6, 2016/10:30-12:00/Room A

Jan van Zelst, MD; Albert Gubern-Merida, PhD; Daniel Drieling; Tao Tan, PhD: Matthieu Rutten, MD PhD; Nico Karssemeijer PhD; Ritse Mann, MD PhD. Fast and accurate screening of women with dense breasts with a dedicated Computer Aided Detection based reading protocol in automated 3D breast ultrasound. 28th European Congress of Radiology (ECR 2016)

Jager GJ, Rutten MJ. Complaints against radiologist submitted to disciplinary tribunals (DT) in the Netherlands (2007-2014). 28th European Congress of Radiology (ECR 2016) Topic: Breast Session Number: SS 1402a Session Title: Screening. Vienna, Saturday Mar 5 2016 10:30 AM - 12:00 PM

Rutten MJ. Inleiding in de radiologie. PostHBO - Master opleiding Fysiotherapie 1e jaar MMR. HAN University of Applied Sciences, Institute Health Studies Nijmegen, 30 maart 2016

Rutten MJ, Maresch SJ. Musculoskeletal Ultrasound: Basic Course & Hands-on Training Shoulder Ultrasound: Anatomy, How to, sonopathology. Arnhem (Papendal), 14 april 2016


Rutten MJ, Maresch SJ. Musculoskeletal Ultrasound: Basic Course & Hands-on Training Elbow Ultrasound: Anatomy, How to, sonopathology. Arnhem (Papendal), 14 april 2016

Rutten MJ, Maresch SJ. Musculoskeletal Ultrasound: Basic Course & Hands-on Training Hand & Wrist Ultrasound: Anatomy, How to, sonopathology. Arnhem (Papendal), 19 mei 2016

Rutten MJ, Maresch SJ. Musculoskeletal Ultrasound: Basic Course & Hands-on Training Hip Ultrasound: Anatomy, How to, sonopathology. Arnhem (Papendal), 19 mei 2016

Rutten MJ, Maresch SJ. Musculoskeletal Ultrasound Master Class. Arnhem (Papendal), 21-22 mei 2016

Rutten MJ. Beeldvorming bij sportblessures en LWK problematiek. College voor postHBO - Master opleiding Fysiotherapie. 2e jaar MMR. HAN University of Applied Sciences, Institute Health Studies. Nijmegen, 8 juni 2016

Rutten MJ, Maresch SJ. Musculoskeletal Ulatrasound Course: Elbow & Knee. Hitachi. Amsterdam, 14 juni 2016

Rutten MJ, Maresch SJ. Musculoskeletal Ultrasound: Basic Course & Hands-on Training Knee Ultrasound: Anatomy, How to, sonopathology. Arnhem (Papendal), 16 juni 2016

Rutten MJ, Maresch SJ. Musculoskeletal Ultrasound: Basic Course & Hands-on Training Ankle & Foot Ultrasound: Anatomy, How to, sonopathology. Arnhem (Papendal), 16 juni 2016

Van Baardewijk L, Rutten MJ. Arthritiden. Hoe ze radiologisch te onderscheiden. Regionale refereeravond OOR-ON. ‘s-Hertogenbosch, 19 september 2016

Claassen B, Rutten MJ. Shoulder Barbotage clinical outcome study. Regionale refereeravond OOR-ON. ‘s-Hertogenbosch, 19 september 2016

W. E. Shiels, DO; C. . Martinoli, MD, Genova, GE ITALY; J. A. Bouffard, MD, Detroit, MI; C. J. Brandon, MD, Ann Arbor, MI; E. . Cardinal, MD, Montreal, QC; M. M. Chiavaras, MD, PhD, Hamilton, ON; J. G. Craig, MD, Detroit, MI; M. A. Dipietro, MD, Ann Arbor, MI; D. P. Fessell, MD, Ann Arbor, MI; G. . Habra, MD, Troy, MI; A. . Klauser, MD, Innsbruck, Tirol AUSTRIA; M. T. Van Holsbeeck, MD, Detroit, MI; R. B. Hulen, MD, Detroit, MI; M. . Kislyakova, MD, Moscow, RUSSIA; J. H. Introcaso, MD, Neenah, WI; J. A. Jacobson, MD, Ann Arbor, MI; K. S. Lee, MD, Madison, WI; H. G. Rosas, MD, Madison, WI; M.J. Rutten, MD, Hertogenbosch, NETHERLANDS; A. S. Tagliafico, MD, Genova, GE Italy; X. L. Wortsman, MD, Santiago, RM CHILE. RSNA Refresher course: Nerve Ultrasound Based on a Regional Approach: Elbow to Hand (Hands-on Workshop). Course Number: RC452. RSNA 102th Scientific assembly and annual Meeting. Chicago, 29 Nov 2016 / 4:30PM - 6:00PM

Nijhof WH, Baltussen EJM, Kant IMJ, Jager GJ, Slump C, Rutten MJ. Abdominal aorta CT angiography with 80 kV and reduced contrast medium volume: a comparative analysis of image quality and radiation dose. Scientific Exhibit: Poster No: C-0830. Keywords: Vascular, CT-angiography, Efficacy studies, Dosimetry.EPOSTM, ESR’s Electronic Presentation Online System. Doi: 10.1594/ecr2015/C-0830. DOI-Link: http://dx.doi.org/10.1594/ecr2015/C-0830. Vienna, ECR 2015 van Zelst J, Gubern-Merida A, Drieling D, Tan T, Rutten M, Karssemeijer N, Mann R. Fast and accurate screening of women with dense breasts with a dedicated computer-aided detection-base reading protocol in automated 3D breast ultrasound. Scientific Exhibit. Awarded ‘Best Scientific Paper Presentation’. Vienna, ECR 2016

107 RADIOLOGIE


Rutten MJ. Snel betrouwbare patiënteninformatie vinden in een ‘lerend’ systeem. FOCUS JBZ Februari 2015;7: 14-15.Trefwoorden: database, medische data

Rutten MJ. Capita selecta: Waarde van MRI bij vroegdetectie van reumatoide artritis. Imago sept 2015; 1 (1): 51-52.Trefwoorden: reumatoide arthristis, vroegdiagnostiek

Qaderdan KA, Serafino GP, Rutten MJ. Renal artery dissection. Radiological Documents 2014; 32 (3), case 21 (published Nov 2015).Trefwoorden: arteria renalis, dissectie

Hurkmans S, Nijhof W, Rutten MJ. Contrastmiddel- en stralingsreductie bij CT-angio procedure van de abdominale aorta: effect op objectieve en subjectieve beeldkwaliteit. Medisch Beeldvormende en Radiotherapeutische Technieken aan de Fontys Paramedische Hogeschool te Eindhoven 2015.Trefwoorden: CTA, contrastreductie, stralendosis reductie


REUMATOLOGIE23Wetenschappelijke publicatiesMertens JS, Zweers MC, Kievit W, Knaapen HK, Gerritsen M, Radstake TR, van den Hoogen FH, Creemers MC, de Jong EM. High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis. JAMA Dermatol. 2016 Aug 17. doi: 10.1001/jamadermatol.2016.2873. [Epub ahead of print]PMID:27541801

109 REUMATOLOGIE

REVALIDATIE-GENEESKUNDE

24Wetenschappelijke publicatiesOsterthun R, van Asbeck FW, Nijendijk JH, Post MW. In-hospital end-of-life decisions after new traumatic spinal cord injury in the Netherlands. Spinal Cord. 2016 Apr 12. doi: 10.1038/sc.2016.37. [Epub ahead of print] PMID: 27067656

111 REVALIDATIEGENEESKUNDE

SPOEDEISENDE GENEESKUNDE

25Wetenschappelijke publicatiesVan Roosmalen J, van der Linden Y, Bod-Jaspers J. A man with a raised upper arm. Ned Tijdschr Geneeskd. 2015;159(0):A8279. Dutch. PMID: 25563783Trefwoorden: schouderluxatie, Erecta

Jie KE, van Dam LF, Hammacher ER. Isolated fat pad sign in acute elbow injury: is it clinically relevant?Eur J Emerg Med. 2016 Jun;23(3):228-31.PMID 26153882Trefwoorden: elleboogtrauma, geisoleerde fatpad

Gathier PP, Schönberger TJ. A man with an infected finger: a case report. J Med Case Rep. 2015 May 23;9(1):119. [Epub ahead of print] PMID: 26001830

Van Dongen MJ, Falger-Veeken SN. The Risk of a Bicycle Helmet: Hyoid Bone Fracture. Ann Emerg Med. 2016 Jan;67(1):145-6. doi: 10.1016/j.annemergmed.2015.09.012. PMID: 26707528

Van der Toorn M, de Klerk S. A 43-year-old woman with a quadriparesis. Neth J Med. 2016 Aug;74(7):318. No abstract available. PMID:27571950

113 SPOEDEISENDE GENEESKUNDE

UROLOGIE

26Wetenschappelijke publicatiesSylvester R, Gontero P, Oddens J. Reply to Stephen B. Williams and Ashish M. Kamat’s Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9. Eur Urol. 2016 Jun;69(6):e123-4. doi: 10.1016/j.eururo.2016.01.055. Epub 2016 Feb 10. No abstract available. PMID: 26874805

Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. PMID: 26210894

Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N’Dow J, Oddens JR, Babjuk M. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. 2016 Feb;69(2):231-44. doi: 10.1016/j.eururo.2015.05.050. PMID: 26091833

Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Alfred Witjes J, Oosterlinck W. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. BJU Int. 2016 Sep;118(3):423-8. doi: 10.1111/bju.13474. Epub 2016 Apr 2. PMID: 26945890

115 UROLOGIE

Proefschriften

Castermans E, Coenders M, Beerlage HP, De Vries J. Psychosocial Screening for Patients with Prostate Cancer: the Development and Validation of the Psychosocial Distress Questionnaire-Prostate Cancer (PDQ-PC). J Psychosoc Oncol. 2016 Sep 9:0. [Epub ahead of print]PMID:27610695

Gayet M, van der Aa A, Beerlage HP, Schrier BP, Mulders PF, Wijkstra H. The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review. BJU Int. 2016 Mar;117(3):392-400. doi: 10.1111/bju.13247. PMID: 26237632Trefwoorden: Prostaatkanker, MRI

Gayet M, van der Aa A, Schmitz P, Beerlage HP, Schrier, BP, Mulders PF, Mischi M, Wijkstra. 3D Navigo™ versus TRUS-guided prostate biopsy in prostate cancer detection. World J Urol. 2016 Sep;34(9): 1255-60. doi: 10.1007/s00345-016-1775-9. Epub 2016 Feb 4.PMID: 26847183Trefwoorden: Prostaatkanker, biopten

Jorg Oddens. Clinical efficacy and side effects of maintenance bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. 3 juni 2016. Begeleiders bij het onderzoek: Prof dr. A.J. Witjes, Dr. R. Sylvester.


ZIEKENHUISFARMACIE

27Wetenschappelijke publicatiesEppenga WL, Kramers C, Derijks HJ, Wensing M, Wetzels JF, De Smet PA. Drug therapy management in patients with renal impairment: how to use creatinine-based formulas in clinical practice. Eur J Clin Pharmacol 2016; 72(12):1433-39PMID:27568310

Van der Stelt CA, Vermeulen Windsant-van den Tweel AM, Egberts AC, van den Bemt PM, Leendertse AJ, Hermens WA, van Marum RJ, Derijks HJ. The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study. Drug Saf. 2016 Jan;39(1):79-87. doi: 10.1007/s40264-015-0361-1. PMID: 26553305

Jessurun N, van Marum R, Hermens W, van Puijenbroek E. Advanced Age and Female Sex As Risk Factors for High Anion Gap Metabolic Acidosis After a Drug Interaction Between Paracetamol and Flucloxacillin: A Case Series. J Am Geriatr Soc. 2016 Sep 2. doi: 10.1111/jgs.14332. [Epub ahead of print] No abstract available. PMID:27590524

van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ. Rating scales to measure side effects of antipsychotic medication - A systematic review. J Psychopharm 2015; 29(8):857-66. PMID: 26156860

Eppenga WL, Wester WN, Derijks HJ, Hoedemakers RM, Wensing M, De Smet PA, Van Marum RJ. Fluctuation of the renal function after discharge from hospital and its effects on drug dosing in elderly patients - study protocol. BMC Nephrol 2015; 16(1):95PMID: 26149449

de Wit HA, Mestres Gonzalvo C, Cardenas J, Derijks HJ, Janknegt R, van der Kuy PH, Winkens B, Schols JM. Evaluation of clinical rules in a standalone pharmacy based clinical decision support system for hospitalized and nursing home patients. Int J Med Inform 2015 Jun;84(6):396-405. doi: 10.1016/j.ijmedinf.2015.02.004. Epub 2015 Feb 19. PMID: 25746461

Eppenga WL, Kramers C, Derijks HJ, Wensing M, Wetzels JF, De Smet PA. Individualizing Pharmacotherapy in Patients with Renal Impairment: The Validity of the Modification of Diet in Renal Disease Formula in Specific Patient Populations with a Glomerular Filtration Rate below 60 Ml/Min. A Systematic Review. PLoS One 2015 Mar 5;10(3):e0116403. doi: 10.1371/journal.pone.0116403. eCollection 2015. PMID: 25741695

117 ZIEKENHUISFARMACIE

Blenke AA, van Marum RJ, Vermeulen Windsant AM, Hermens WA, Derijks HJ. Success rate of advices and effectuated changes based on a structured medication review in psychogeriatric patients admitted to a nursing home: a prospective cohort study. Ziekenhuisfarmaciedagen 2016, Amersfoort, 10-11 November 2016

Kuiper JG, van Herk-Sukel MP, van der Eijk JE, van Dijk WD, Derijks HJ, Olsman JO. Insight into the use and indication of expensive drugs: linkage of in-patient pharmacy data to a quality registry. Ziekenhuisfarmaciedagen 2016, Amersfoort, 10-11 November 2016

Van Oijk AL, Hemmelder M, Hoogendoorn M, Folkeringa R, Smit R, Derijks HJ, Hofma SH, van Roon EN. Anti-Xa-activity after reduced therapeutic dose of nadroparin in renally impaired patients using a dosage guideline of the Dutch federation of nephrology. European Congress in Thrombosis and Haemostasis, Den Haag, 28-30 September 2016

Blenke AA, van Marum RJ, Vermeulen Windsant AM, Hermens WA, Derijks HJ. Success rate of advices and effectuated changes based on a structured medication review in psychogeriatric patients admitted to a nursing home: a prospective cohort study. Voorjaarsdag NVKF&B 2016, ’s-Hertogenbosch, 01 April 2016

Jessurun N, van Puijenbroek EP, Otten LS, Mikes O, Vermeulen Windsant AM, van Marum RJ, Grootens K, Derijks HJ. Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels. FIGON Dutch Medicines Days 2015, Ede, 05-07 October 2015




Eppenga WL (promovendus), de Smet PA (promotor), Wensing M (promotor), Derijks HJ (co-promotor). Personalized drug therapy management in patients with renal impairment. Nijmegen, 12 januari 2016

Proefschriften


Van Oijk AL, Hemmelder M, Hoogendoorn M, Folkeringa R, Smit R, Derijks HJ, Hofma SH, van Roon EN. Anti-Xa-activiteit van therapeutische nadroparine bij verminderder nierfunctie en behandeling conform richtlijn Nederlandse federatie voor Nefrologie: vergelijking met standaarddosis bij normale nierfunctie. Nederlands Platform voor Farmaceutisch Onderzoek 2016; 1:a1631

van der Stelt CA, Vermeulen Windsant-van den Tweel AM, Egberts AC, van den Bemt PM, Leendertse AJ, Hermens WA, van Marum RJ, Derijks HJ. Medicatiescreening met Beers-criteria en stopp/start-criteria bij de oudere patiënt: associatie tussenpotentieel ongewenst geneesmiddelengebruik en geneesmiddelgerelateerde ziekenhuisopnamen. PW Wetenschappelijk Platform 2015; 9:a1525

Eppenga WL, Derijks HJ, Conemans JM, Hermens WA, Wensing M, de Smet PA. Vergelijking van een eenvoudig en een geavanceerd medicatiebewakingssysteem in een Nederlands ziekenhuis. PW Wetenschappelijk Platform 2015; 9:a1507




119 ZIEKENHUISFARMACIE

OVERIGE STAFDIENSTEN

28Jeroen Bosch AcademieWetenschappelijke publicatiesHagenaars JC, Wever PC, Shamelian SO, van Petersen AS, Hilbink M, Renders NH, DE Jager-Leclercq GL, Moll FL, Koning OH. Vascular chronic Q fever: quality of life. Epidemiol Infect. 2015 Jan 22:1-7. [Epub ahead of print] PMID: 25608699

Huijsmans CJ, van den Brule AJ, Rigter H, Poodt J, van der Linden JC, Savelkoul PH, Hilbink M, Hermans MH. Allelic imbalance at the HER2/TOP2A locus in breast cancer. Diagn Pathol. 2015 May 29;10:56. doi: 10.1186/s13000-015-0289-x.PMID: 26022247


Korterink JJ, Ockeloen LE, Hilbink M, Benninga MA, Deckers-Kocken JM. Yoga Therapy for Abdominal Pain Related-Functional Gastrointestinal Disorders in Children. A Randomized Controlled Trial. J Pediatr Gastroenterol Nutr. 2016 Apr 4. [Epub ahead of print] PMID: 27050045

Nijhof WH, Hilbink M, Jager GJ, Slump CH, Rutten MJ. A non-invasive Cardiac Output measurement as an alternative to the test bolus technique during CT angiography. Clinical Radiology 2016 Sep;71(9):940.e1-5. doi: 10.1016/j.crad.2016.03.007. Epub 2016 Apr 10.PMID: 27076253


121 OVERIGE STAFDIENSTEN

Kwaliteit en veiligheidWetenschappelijke publicatiesM. Hilbink, M. Jager, K. Smulders. Geen komkommertijd in de patiëntenzorg! Kwaliteit in zorg, Nr.3, 2016

M. Hilbink, G. Zeeman, M. Jager, L. Schouten. ‘Was dit het vak waarvoor ik had gekozen?’ Kwaliteit in zorg, Nr. 3, 2016

Medische informatie communicatie technologie Abstracts, voordrachten en postersVan Velzen MHN, van de Ven J. De mogelijkheden met 3D printen binnen het ziekenhuis. Wetenschapsmiddag Jeroen Bosch Ziekenhuis 2016, ’s Hertogenbosch.


123 OVERIGE STAFDIENSTEN

WETENSCHAPSMIDDAG 2015

Programma 10de Wetenschapsmiddag JBZ –

11 november 2015 – auditorium

15.00 uur Ontvangst + presentatie E-posters, Adriaan van den Brule, Namens organisatiecommissie

15.30 uur Ketenzorg = over de muren heen kijken! Prof. Dr. Esther de Vries, Decaan wetenschap en innovatie JBZ

15.55 uur Farmacotherapie bij ouderen: de wankele balans tussen helpen en schaden. Prof. Dr. Rob van Marum

16.20 uur Meerwaarde meetbaar maken. Prof. Dr. Ron Kusters

16.45 uur Pauze + presentatie e-posters

17.05 uur Uitleg Pitch en publieksstemmen Wouter Nijhof en Jasper Broen, Moderator

17.15 uur • Incidentie van neuralgische amyotrofie in de 1e lijn, een prospectieve cohort studie, Jeroen van Eijk, Neurologie • Cervical cancer screening in the Netherlands determination of HPV prevalence using three different systems. Ronald Huijsmans, Moleculaire biologie / Pathologie • Self-administered Gerocognitive Examination (SAGE): Klinische toepasbaarheid, validiteit en betrouwbaarheid van de Nederlandse versie van de SAGE in het diagnostiseren van Mild Cognitive

Impairment (MCI) en dementie. Iris Harmsen, Geriatrie • Prevalentie van correcte anti-Xa bloedspiegels in patienten met verminderde nierfunctie op basis van een dosisadvies conform de richtlijn van de Nederlandse Federatie voor Nefrologie. Reinier Smit, Zanob Apotheek • Adjuvant chemotherapy is associated with improved relative and overall survival for high risk pT4 stage II colon cancer. Sarah Verhoeff, Interne/Oncologie • Een innovatie op de endoscopiekamer: de Poliepmanager. Maartje vd Meeberg, MDL • Accuraat bloedtransport is essentieel voor patiëntveiligheid. Jasmijn van Balveren, Klinische Chemie • Hoog tien-jaarsrisico op een niet-traumatische fractuur bij ouderen zonder osteoporose. Merel Krulder, Geriatrie • Beleidswijziging veegerelateerde MRSA (LA-MRSA) in het Jereoen Bosch Ziekenhuis en Bernhoven, Jamie Meekelenkamp, Med. Microbiologie • IgG-subklasse deficiëntie en specifieke polysacharide antistofdeficiëntie bij kinderen in Nederland. Ellen Schatorjé, Kindergeneeskunde • Kunnen er meer patiënten thuis worden behandeld met hemodialyse? Marloes Aloserij, Interne/Nefrologie

18.30 uur Buffet (+juryberaad)

19.20 uur Prijsuitreiking. voorzitter jury


Winnaar e-posters

Evaluatie beleidswijziging LA-MRSA

Een project over vee

gerelateerde MRSA

(LA-MRSA

) in he

t Jeroe

n Bo

sch Zieken

huis en Be

rnho

ven

Inde

land

elijkerichtlijn

envoor

isolatieverpleging

vanpa

tiënten

isge

enon

derscheidtussen

verschille

ndesoortenvanMRSA

.Echter,on

derzoekheeft

aangetoond

datL

A-MRSA

zich

ande

rsgedraagt

dande

ande

reMRSA

-type

n.Zo

blijkth

etrisicoop

verspreiding

vanLA

-MRSA

ineenziekenhuis,

sign

ificant

kleiner

1 .Met

ditp

rojectisee

nge

differentieerdbeleid

voor

LA-MRSA

geïntro

duceerdwa

arbijdeinfectiepreventiemaatre

gelenbetera

ansluiten

bijh

ettra

nsmissie

risico

vanLA

-MRSA

.Daa

rmee

bieden

wezorg

diepa

tiëntvriendelijker

ismet

minde

risolatiemaa

tregelen,

waa

rbijkosten

worden

bespaa

rden

dewerkdrukw

ordtverla

agd.

Jamie Mee

kelenkam

pDeskund

ige infectiepreventie

j.mee

kelenkam

[email protected]

Strikte isolatie

Con

tactisolatie

Resultaten

Methode

Introductie

Conclusie

Patiënten

met (risico op

) LA-MRSA

:•

Worde

n verpleeg

d in co

ntactisolatie in plaats v

an strikte isolatie

•Worde

n ge

screen

d met een

snelle iden

tificatie va

n LA

-MRSA

do

or een

zelf on

twikkelde DNA-test

2

•Med

ewerkers die zo

rgen

voor de pa

tiënt worde

n ge

controleerd

om overdracht uit te sluiten

•Bij LA-MRSA

is con

tactisolatie in het zieken

huis even effectief als strikte isolatie

•Con

tactisolatie en aa

ngep

aste diagnostiek leiden tot patiëntge

richt, kostenb

espa

rend, w

erkdrukverlagend

beleid

•De ep

idem

iologie van LA

-MRSA

moe

t blijvend

worde

n on

derzocht om de even

tuele on

twikkeling van ge

netische veranderingen tijdig op

te sp

oren

1.

van de S

ande

et al. Im

pact in

hum

ans of high endemic livestock associated

MRSA

. Antim

icrobial resistance &infection

control 2

015

2.

van Meurs et a

l. Realtim

e PC

R to distinguishlivestock

associated

from

non-livestock

associated

methicillinresistantS

taphylococcus

aureus. Infection

2012

Resultaten na een looptijd van 19 maanden

125


Programma 11de Wetenschapsmiddag JBZ –

9 november 2016 – auditorium

15.00 uur Ontvangst + presentatie E-posters, Piet-Hein Buiting, Voorzitter RvB JBZ15.30 uur Visie en strategie wetenschap in het JBZ Piet-Hein Buiting, Voorzitter RvB JBZ15.55 uur Thema presentatie. Prof. dr. ir. Bert Meijboom, Tilburg School of Economics and Management 16.20 uur Thema presentatie. Sharon van de Ven , Procesbegeleider verpleegkundig leiderschap, EBP

16.45 uur Pauze + presentatie e-posters

17.05 uur Uitleg Pitch en publieksstemmen Karen Keijsers, Moderator

• Patroon van symptomen bij patienten met een primaire antistofdeficientie: een kwalitatief onderzoek. Kim van den Akker (co ass), Kindergeneeskunde • Dysfagie, wat nu? Ilona Coenen (vpk spec io), Longgeneeskunde • Objectieve plausibiliteits check van schildklier test uitslagen: een innovatieve verbetering. Nina Tel-Karthaus (klin chem io), Lab. Klinische Chemie • Spierspasmen; een onverwachte bijwerking van pemetrexed? Nikki de Rouw (zh apotheker io), Ziekenhuisapotheek • Verbeteren van het zorgaanbod aan de patiënt met een gemetastaseerd prostaatcarcinoom tijdens de follow-up op de polikliniek Urologie van het JBZ. Anita Op ’t Hoog (vpk spec io), Urologie - oncologie • Kan de kopstuitlengte vroeg in de zwangerschap het geboortegewicht en het ontstaan van pretemrme geboorte na fertiliteitsbehandeling voorspellen? Sarah Simaitis (co ass), Verloskunde-Gynaecologie • Succespercentage van adviezen en geëffectueerde wijzigingen gebaseerd op gestructureerde medicatiereviews bij psychogeriatrische patiënten na opname in verpleeghuis: een prospectieve cohort studie. Audrey Blenke (zh apotheker), Ziekenhuisapotheek • Modulariteit in de ketenzorg voor mensen met het syndroom van Down: een case study over Downteams en de transitie van kindertijd naar volwassenheid. Vincent Peters (PhD student), Tranzo Tilburg • Associatie tussen urineweginfecties en het gebruik van antipsychotica bij oudere vrouwen. Astrid van Strien (geriater), Geriatrie • Extra-corporale geoxygeneerde perfusie van vrije lappen om weefselverval te bepreken tijdens ischemietijd. Nicholas Slater (aios), Chirurgie • Het ‘hanging chin sign’, een nieuw radiologisch kenmerk geassocieerd met sterfte en frailty in ernstig zieke patienten. Marissa Zegers (arts IC), Intensive Care • De mogelijkheden met 3D printen binnen het ziekenhuis. Marit van Velzen (med technoloog), Medische Technologie

18.30 uur Buffet (+juryberaad) 19.20 uur Prijsuitreiking en afsluiting (en aansluitend borrel). voorzitter jury



Winnaar e-posters

1a L

abor

ator

ium

voo

r klin

isch

e ch

emie

en

hem

atol

ogie

en

1b A

fdel

ing

inte

rne

gene

esku

nde,

Rijn

stat

e zi

eken

huis

, Arn

hem

. 2a

Lab

orat

oriu

m v

oor k

linis

che

chem

ie e

n he

mat

olog

ie e

n 2b

Afd

elin

g in

tern

e ge

nees

kund

e, J

eroe

n B

osch

Zi

eken

huis

’s-H

erto

genb

osch

. 3 L

abor

ator

ium

voo

r klin

isch

e ch

emie

en

hem

atol

ogie

, Maa

ssta

d z

ieke

nhui

s, R

otte

rdam

. 4 L

abor

ator

ium

voo

r klin

isch

e ch

emie

en

hem

atol

ogie

, zie

kenh

uis

Trea

nt z

orgg

roep

, loc

atie

Sch

eper

, Em

men

. 5

Labo

rato

rium

voo

r klin

isch

e ch

emie

en

hem

atol

ogie

, zie

kenh

uis

Gel

ders

e V

alle

i, E

de. 6

MIR

AIn

stitu

utvo

or b

iom

edis

che

tech

nolo

gie

en te

chni

sche

gen

eesk

unde

, afd

elin

g ge

zond

heid

tech

nolo

gie

en d

iens

tver

lene

nd o

nder

zoek

, U

nive

rsite

it Tw

ente

, Ens

ched

e. *

Gel

ijke

bijd

rage

eer

ste

aute

ur

Obj

ectie

ve p

laus

ibili

teits

chec

k va

n sc

hild

klie

r tes

t uits

lage

n: e

en in

nova

tieve

ver

bete

ring

M.v

an B

orre

n1a*

, N. T

el-K

arth

aus2

a*, R

.Wul

kan3

, M. v

an d

er H

orst

4 , P

. van

’t S

ant2a

, S.

End

enbu

rg5 ,

R. V

ande

rloo2

a , L.

Kem

ink2

b , H

. de

Boe

r1b ,

R. K

uste

rs2a

,6

Dr.

Nin

a Te

l-Kar

thau

s, a

ssis

tent

LK

CH

n.te

l@jb

z.nl

, sei

n 11

32

Het

ont

wik

kele

n va

n ee

n m

etho

de o

nafh

anke

lijke

reke

nmod

ule

voor

obj

ectie

ve h

erke

nnin

g va

n di

scor

dant

e TS

H/fT

4ui

tsla

gen.

Methode

Resultaten

Doel

Conclusie

•De

obje

ctie

ve p

laus

ibilit

eits

che

ck is

sup

erio

r aan

het

hu

idig

e su

bjec

tieve

oor

deel

van

de

clin

ici e

n la

bora

toriu

msp

ecia

liste

n m

et 1

00%

juis

te c

lass

ifica

tie.

•Dez

e ro

buus

te re

kenm

etho

de te

r her

kenn

ing

van

disc

orda

ntie

kan

in d

e va

lidat

ie s

oftw

are

opge

nom

en w

orde

n.

•Het

redu

ceer

t het

aan

tal m

isin

terp

reta

ties

en is

ona

fhan

kelijk

van

het t

ype

test

.

Fig

1:

TS

H_f

T4 =

TSH

_fT4

max

* TS

HTS

H0,

5 +

TSH

•TSH

- fT4

data

van

1e

en 2

e lijn

spa

tiënt

en.

• Ide

ntifi

catie

dis

cord

ante

mon

ster

s d.

m.v

. het

99s

te p

erce

ntie

l.

Fig

2: 1

00%

pla

tform

spe

cifie

ke d

isco

rdan

teTS

H-fT

4co

mbi

natie

s va

llen

buite

n he

t 99e

per

cent

ielv

an h

etal

gorit

me.

Fig

3: H

et a

lgor

itme

is in

sta

at o

m 1

00%

med

icijn

en

antil

icha

am g

ebas

eerd

e in

terfe

rent

ies

corre

ct te

clas

sific

eren

.C

linic

i en

labo

rato

rium

spe

cial

iste

n sc

oord

en u

it 18

TSH

-fT4

com

bina

ties

conc

orda

nt: 7

8% ju

ist e

n di

scor

dant

slec

hts

56%

ju

ist (

data

nie

t get

oond

).

Fig.

1

Fig.

2

Fig.

3

AB

Fig.

3

AB

127

BIJLAGE I

Wetenschappelijke publicaties 2015-2016 opgenomen in PubMed

Volgorde op PubMed ID nummer.Waar mogelijk is een samenvatting van de publicatie opgenomen. De artikelen worden in het overzicht opgenomen op basis van het jaar van publicatie (dus niet het jaar van Epub).

PMID: 24879357Hoogeveen EK, Geleijnse JM, Kromhout D, van’t Sant P, Gemen EF, Kusters R, Giltay EJ. No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: The Alpha Omega Trial. Eur J Prev Cardiol. 2015 May;22(5):648-55. doi: 10.1177/2047487314536694.

BACKGROUND: heart failure is a major risk factor for cardiovascular mortality, for which n-3 fatty acids may have beneficial

effects. We examined the effect of marine eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and plant-

derived alpha-linolenic acid (ALA) on N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP), a biomarker of heart failure.

METHODS: we randomly assigned 4837 post-myocardial infarction patients, aged 60-80 years (82% men), to margarines

supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for

40 months. In a random selection of 639 patients, NT-proBNP was determined both at baseline and at the end of follow-

up. NT-proBNP was loge-transformed and analysed by type of treatment using analysis of covariance adjusting for baseline

NT-proNBP. RESULTS: patients consumed on average 19.8 g margarine/day, providing an additional amount of 238 mg/

day EPA with 158 mg/day DHA, 1.98 g/day ALA, or both, in the active-treatment groups. In the placebo group, the geometric

mean level NT-proBNP increased from 245 ng/l (95%-confidence interval [CI]: 207-290) to 294 ng/l (95%-CI: 244-352) af-

ter 40 months (p = 0.001). NT-proBNP levels were not affected by ALA (+8% versus placebo; 95%-CI: -8% to +25%; p = 0.34),

EPA-DHA (+2% versus placebo; 95%-CI: -14% to +18%; p = 0.78), nor EPA-DHA plus ALA (+9% versus placebo; 95%-CI: -8%

to +25%; p = 0.31) treatment. CONCLUSIONS: supplementation with modest amounts of EPA-DHA, with or without ALA, did

not have a significant effect on NT-proBNP levels in patients with a history of myocardial infarction. TRIAL REGISTRATION:

ClinicalTrials.gov NCT00127452.

PMID: 25311511Kubat BB, Buiskool MM, van Suylen RJ. Traumatic vertebral artery injury: proposal for classification of the severity of trauma and likelihood of fatal outcome. Int J Legal Med. 2015 Jan;129(1):141-8. doi: 10.1007/s00414-014-1095-9.

Vertebral artery injury (VAI) occurs after (blunt) trauma as well as spontaneously. The risk of incurring VAI from a blunt

trauma probably parallels the severity of trauma, often referred to as major- and minor-trauma. However, the literature

does not provide concrete definitions of these terms. This study aims to define minor- and major-trauma and to analyze the


likelihood of fatal outcome in VAI. For this purpose, classification criteria of major- and minor-trauma were developed and a

PubMed database search was performed for articles on VAI published prior to 2013. The definitions of minor- and major-

trauma, derived mainly from radiological screening criteria in cervical spine injury and based on the mechanism leading to

the injury, were used in the analysis of the literature. The search produced 241 VAI cases with sufficiently detailed data for

the comparison of major-trauma (52 cases, 50 lethal), minor-trauma (8 cases, none lethal), and no-trauma (182 cases, 69

lethal). The numbers of lethal cases in the total study population and subgroups differed significantly between the groups

(Fisher’s exact test) and the likelihood ratios (LRs) of lethal outcome were substantially higher in the major-trauma group

compared to the other groups. The highly significant p values show that the proposed criteria differentiate between trauma

types with regard to fatal outcome. The presented results can assist in the evaluation of forensic cases of VAI.

PMID: 25425692Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, Koene HR; Dutch HOVON 64 study group. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica. 2015 Mar;100(3):e90-2. doi: 10.3324/haematol.2014.110213. No abstract available.

PMID:25430660Prinsen JH, Boersma D, van Loenhout R, van Schaik PM, Verhoeven BA. Persistent endoleak after endovascular aneurysm repair for acute Q-fever-infected aortocaval fistula. Vascular. 2015;23:645-7

We present a case of an endovascular aneurysm repair for a Q-fever-infected acute abdominal aortic aneurysm with aorto-

caval fistula. Type 2 endoleak persisted after successful endovascular repair.

PMID: 25443772Wouters E, Wojciechowski M, de Vries E. Two cases of rickets presenting with poor growth, hypotonia, and respiratory problems. Acta Clin Belg. 2015 Jun;70(3):211-4. doi: 10.1179/2295333714Y.0000000103.

Rickets is a rare disease in developed countries. In children, it is a disease which affects growing bone. Depending on the

severity, it can present with a wide variety of symptoms. Because it is such a rare disease in developed countries, symptoms

suggesting rickets are often not easily recognized. This can cause a delay in diagnosing and treating rickets. Often unneces-

sary and sometimes invasive investigations are performed. First leading clues to rickets on physical examination are poor

growth, especially length, thickening of wrists, bow legs, and craniotabes. At further examination, special attention should

be paid to osteopenia and cupping and fraying at the metaphyses on X-rays. Laboratory results suggestive for rickets are

elevated alkaline phosphatase and disturbances in calcium and phosphate homeostasis. In this report, we present two cases

presenting with poor growth, severe pain, and respiratory problems secondary to calcipenic rickets.

PMID: 25452219 Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54.

129 BIJLAGE WETENSCHAPPELIJKE PUBLICATIES 2013-2014 OPGENOMEN IN PUBMED

The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results

of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique and therefore requires a

common quality control (QC)/quality assurance (QA) procedure to maintain the accuracy and precision of quantitation. Re-

peatability and reproducibility are two essential requirements for any quantitative measurement and/or imaging biomarker.

Repeatability relates to the uncertainty in obtaining the same result in the same patient when he or she is examined more

than once on the same system. However, imaging biomarkers should also have adequate reproducibility, i.e. the ability to

yield the same result in the same patient when that patient is examined on different systems and at different imaging sites.

Adequate repeatability and reproducibility are essential for the clinical management of patients and the use of FDG PET/

CT within multicentre trials. A common standardised imaging procedure will help promote the appropriate use of FDG PET/

CT imaging and increase the value of publications and, therefore, their contribution to evidence-based medicine. Moreover,

consistency in numerical values between platforms and institutes that acquire the data will potentially enhance the role of

semiquantitative and quantitative image interpretation. Precision and accuracy are additionally important as FDG PET/CT

is used to evaluate tumour response as well as for diagnosis, prognosis and staging. Therefore both the previous and these

new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.

PMID: 25511908 Ahmed Ali U, Issa Y, van Goor H, van Eijck CH, Nieuwenhuijs VB, Keulemans Y, Fockens P, Busch OR, Drenth JP, Dejong CH, van Dullemen HM, van Hooft JE, Siersema PD, Spanier BW, Poley JW, Poen AC, Timmer R, Seerden T, Tan AC, Thijs WJ, Witteman BJ, Romkens TE, Roeterdink AJ, Gooszen HG, van Santvoort HC, Bruno MJ, Boermeester MA; Dutch Pancreatitis Study Group. Dutch Chronic Pancreatitis Registry (CARE): design and rationale of a nationwide prospective evaluation and follow-up. Pancreatology. 2015 Jan-Feb;15(1):46-52. doi: 10.1016/j.pan.2014.11.002. Epub 2014 Nov 29.

BACKGROUND: Chronic pancreatitis is a complex disease with many unanswered questions regarding the natural history

and therapy. Prospective longitudinal studies with long-term follow-up are warranted. METHODS: The Dutch Chronic

Pancreatitis Registry (CARE) is a nationwide registry aimed at prospective evaluation and follow-up of patients with chronic

pancreatitis. All patients with (suspected) chronic or recurrent pancreatitis are eligible for CARE. Patients are followed-up

by yearly questionnaires and review of medical records. Study outcomes are pain, disease complications, quality of life, and

pancreatic function. The target sample size was set at 500 for the first year and 1000 patients within 3 years. RESULTS: A

total of 1218 patients were included from February 2010 until June 2013 by 76 participating surgeons and gastroentero-

logist from 33 hospitals. Participation rate was 90% of eligible patients. Eight academic centers included 761 (62%) patients,

while 25 community hospitals included 457 (38%). Patient centered outcomes were assessed by yearly questionnaires,

which had a response rate of 85 and 82% for year 1 and 2, respectively. The median age of patients was 58 years, 814

(67%) were male, and 38% had symptoms for less than 5 years. DISCUSSION: The CARE registry has successfully recruited

over 1200 patients with chronic and recurrent pancreatitis in about 3 years. The defined inclusion criteria ensure patients

are included at an early disease stage. Participation and compliance rates are high. CARE offers a unique opportunity with

sufficient power to investigate many clinical questions regarding natural course, complications, and efficacy and timing of

treatment strategies.

PMID: 25527569Van der Velden WJ, Nissen L, van Rijn M, Rijntjes J, de Haan A, Venkatraman L, Catherwood M, Liu H, El-Daly H, van de Laar L, Craenmehr MH, van Krieken JH, Stevens WB, Groenen PJ. Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders. Haematologica. 2015 Apr;100(4):e152-4. doi: 10.3324/haematol.2014.116780.


PMID: 25537564Johannesma PC, Reinhard R, Kon Y, Sriram JD, Smit HJ, van Moorselaar RJ, Menko FH, Postmus PE; Amsterdam BHD working group. Prevalence of Birt-Hogg-Dubé syndrome in patients with apparently primary spontaneous pneumothorax. Eur Respir J. 2015 Apr;45(4):1191-4.

PMID: 25556708Keijsers CJ, Segers WS, de Wildt DJ, Brouwers JR, Keijsers L, Jansen PA. Implementation of the WHO-6-step method in the medical curriculum to improve pharmacology knowledge and pharmacotherapy skills.Br J Clin Pharmacol. 2015 Jun;79(6):896-906. doi: 10.1111/bcp.12575.

AIM: The only validated tool for pharmacotherapy education for medical students is the 6-step method of the World Health

Organization. It has proven effective in experimental studies with short term interventions. The generalizability of this effect

after implementation in a contextual-rich medical curriculum was investigated. METHODS: The pharmacology knowledge

and pharmacotherapy skills of cohorts of students, from years before, during and after implementation of a WHO-6-step-

based integrated learning programme were tested using a standardized assessment containing 50 items covering know-

ledge of basic (n = 25) and clinical (n = 24) pharmacology, and pharmacotherapy skills (n = 1 open question). All scores are

expressed as a percentage of the maximum score possible per (sub)domain. RESULTS: In total, 1652 students were included

between September 2010 and July 2014 (participation rate 89%). The WHO-6-step-based learning programme improved

students’ knowledge of basic pharmacology (mean score ± SD, 60.6 ± 10.5% vs. 63.4 ± 10.9%, P < 0.01) and clinical or ap-

plied pharmacology (63.7 ± 10.4% vs. 67.4 ± 10.3%, P < 0.01), and improved their pharmacotherapy skills (68.8 ± 26.1% vs.

74.6% ± 22.9%, P 0.02). Moreover, satisfaction with education increased (5.7 ± 1.3 vs. 6.3 ± 1.0 on a 10-point scale, P < 0.01)

and as did students’ confidence in daily practice (from -0.81 ± 0.72 to -0.50 ± 0.79 on a -2 to +2 scale, P < 0.01). CONCLU-

SIONS: The WHO-6-step method was successfully implemented in a medical curriculum. In this observational study, the

integrated learning programme had positive effects on students’ knowledge of basic and applied pharmacology, improved

their pharmacotherapy skills, and increased satisfaction with education and self-confidence in prescribing. Whether this

training method leads to better patient care remains to be established.

PMID: 25563783Van Roosmalen J, van der Linden Y, Bod-Jaspers J. A man with a raised upper arm. Ned Tijdschr Geneeskd. 2015;159(0):A8279. Dutch.

A 43-year-old man presented at our emergency department with a painful shoulder after a fall with his arm in abduction.

Clinical presentation was typical for a luxatio erecta without evidence for neurovasculair damage. It is a rare but important

diagnosis because of the high risk of plexus injury.

PMID:25563786Kuipers BC, Jansen EJ, van Mil EG. Een neonaat met een interlabiale cyste. [A neonate with an interlabial cyst]. [Article in Dutch]. Ned Tijdschr Geneeskd. 2015;159:A8355.

During a routine physical examination of a term, healthy neonate of Somalian origin we observed an anteriorly located

interlabial yellow cyst with visible vascularisation on the outer surface. It caused lateralisation of the urinary meatus without

notable obstruction. A Skene’s duct cyst, or paraurethral cyst, was clinically diagnosed with spontaneous regression. This is a

self-limiting phenomenon of unknown origin that rarely requires surgical drainage in case of urinary obstruction.


PMID: 25563886Goos JA, de Cuba EM, Coupé VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JA, Menke-Van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET Group. Collaborators: van Grieken NC, Perk LR, van den Tol MP, te Velde EA, Windhorst AD, Baas J, Rijken AM, van Beek MW, Pijpers HJ, Bril H, Stockmann HB, Zwijnenburg A, Bosscha K, van den Brule AJ, Hoekstra CJ, van der Linden JC, Rinkes IH, van Diest PJ, van Hillegersberg R, Kranenburg O, Lam MG, Snoeren N, Liem IH, Roumen RM, Vening W. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA)Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Ann Surg. 2016 Jan;263(1):138-45.

OBJECTIVE: To investigate the individual and combined prognostic value of HIF1κ, SLC2A1, and vascular endothelial

growth factor A (VEGFA) in a multi-institutional cohort of patients with resected colorectal cancer liver metastasis (CRCLM).

BACKGROUND: In the majority of patients with CRCLM, resection seems not to be curative, despite its curative intent.

Overexpression of hypoxia-inducible factor 1κ (HIF1κ), glucose transporter 1 (SLC2A1; also known as GLUT1), and VEGFA

has been associated with tumor progression and poor prognosis of patients with colorectal cancer (CRC). METHODS: Tissue

microarrays were generated using CRCLM and patient-matched primary CRC from patients who underwent CRCLM resec-

tion between 1990 and 2010. Prognostic value of HIF1κ, SLC2A1, and VEGFA was determined by immunohistochemistry. A

500-fold cross-validated hazard rate ratio (HRRav) for overall survival was calculated. RESULTS: HIF1κ, SLC2A1, and VEGFA

expression could be evaluated in 328, 350, and 335 patients, respectively. High SLC2A1 expression was associated with

good prognosis (HRRav, 0.67; P (HRR >1) < 0.01) and high VEGFA expression to poor prognosis (HRRav, 1.84; P (HRR < 1) =

0.02), also after multivariate analysis including established clinicopathological prognostic variables (HRRav, 0.67; P (HRR >

1) < 0.01 and HRRav, 1.50; P (HRR < 1) = 0.02, respectively). SLC2A1 showed prognostic value particularly in patients trea-

ted with systemic therapy (P < 0.01), whereas the prognostic value of VEGFA expression was mainly observed in patients not

treated with systemic therapy (P < 0.01). Prognosis was especially poor in patients with both low SLC2A1 and high VEGFA

expression (P < 0.01). HIF1κ expression was not associated with survival. CONCLUSIONS: SLC2A1 and VEGFA expression

are prognostic molecular biomarkers for patients with CRCLM with added value to established clinicopathological variables.

PMID: 25572007Aarts MJ, Aerts JG, Van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in patients with small cell lung cancer: trends and prognostic impact. Clin Lung Cancer. 16(4):282-91, 2015. doi: 10.1016/j.cllc.2014.12.003.

INTRODUCTION: We evaluated the trends in the prevalence of comorbidity and its prognostic impact in a cohort of un-

selected patients with small-cell lung cancer (SCLC). PATIENTS AND METHODS: All patients (n = 4142) diagnosed with

SCLC from 1995 to 2012 were identified from the population-based Netherlands Cancer Registry in the Eindhoven region.

RESULTS: The prevalence of comorbidity increased from 55% in 1995 to 1998 to 76% in 2011 to 2012 and multimorbi-

dity (ie, ≥ 2 concomitant diseases) from 23% to 51%. The prevalence of a comorbidity increased with age. Among the men,

hypertension, cardiac disease, and diabetes, in particular, became more common (increased from 11% to 35%, from 19% to

36%, and from 7% to 18%, respectively). In the women, the rate of pulmonary disease, hypertension, and cardiac disease

increased the most (increased from 18% to 30%, from 12% to 28%, and from 11% to 24%, respectively). Multimorbidity was

associated with a slightly increased hazard of death, independent of treatment in those with limited-stage SCLC (hazard

ratio [HR] for ≥ 2 comorbidities vs. no comorbidities, 1.2; 95% confidence interval [CI], 1.0-1.4). The prognostic effects of

multimorbidity resulted from treatment in those with extensive-stage SCLC (HR for ≥ 2 comorbidities vs. no comorbidities,

final model, 1.2; 95% CI, 1.0-1.2). The prognostic impact of the specific comorbidities varied, with digestive disease reducing

the hazard and cardiac disease increasing the hazard in those with limited-stage SCLC (HR for digestive disease vs. no

digestive disease, 0.7 [95% CI, 0.5-0.9], and HR for cardiac vs. no cardiac disease, 1.2 [95% CI, 1.0-1.3]). Also, cardiac and


cerebrovascular disease increased the hazard in those with extensive-stage SCLC (HR 1.2 [95% CI, 1.0-1.3] and HR 1.3 [95%

CI, 1.1-1.6], respectively). CONCLUSION: Comorbidity among patients with SCLC is very common and has been increasing.

Multimorbidity was associated with a slightly increased hazard of death in those with limited-stage SCLC, independent of

treatment. However, the prognostic effects in those with advanced-stage SCLC resulted from treatment. Digestive disease

favorably affected survival and cardiac disease negatively affected the prognosis for those with limited-stage SCLC, and

cardiac and cerebrovascular diseases had a negative prognostic effect for those with extensive-stage SCLC. With the burden

of comorbidities in patients with SCLC increasing, more attention to individualized treatment approaches is needed.

PMID: 25576320Bensdorp AJ, Tjon-Kon-Fat RI, Bossuyt PM, Koks CA, Oosterhuis GJ, Hoek A, Hompes PG, Broekmans FJ, Verhoeve HR, de Bruin JP, van Golde R, Repping S, Cohlen BJ, Lambers MD, van Bommel PF, Slappendel E, Perquin D, Smeenk JM, Pelinck MJ, Gianotten J, Hoozemans DA, Maas JW, Eijkemans MJ, van der Veen F, Mol BW, van Wely M. Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterine insemination with controlled ovarian hyperstimulation.BMJ. 2015 Jan 9;350:g7771. doi: 10.1136/bmj.g7771.

OBJECTIVES: To compare the effectiveness of in vitro fertilisation with single embryo transfer or in vitro fertilisation in a

modified natural cycle with that of intrauterine insemination with controlled ovarian hyperstimulation in terms of a healthy

child. DESIGN: Multicentre, open label, three arm, parallel group, randomised controlled non-inferiority trial. SETTING:

17 centres in the Netherlands. PARTICIPANTS: Couples seeking fertility treatment after at least 12 months of unprotected

intercourse, with the female partner aged between 18 and 38 years, an unfavourable prognosis for natural conception, and

a diagnosis of unexplained or mild male subfertility. INTERVENTIONS: Three cycles of in vitro fertilisation with single embryo

transfer (plus subsequent cryocycles), six cycles of in vitro fertilisation in a modified natural cycle, or six cycles of intrauterine

insemination with ovarian hyperstimulation within 12 months after randomisation. MAIN OUTCOME MEASURES: The pri-

mary outcome was birth of a healthy child resulting from a singleton pregnancy conceived within 12 months after randomi-

sation. Secondary outcomes were live birth, clinical pregnancy, ongoing pregnancy, multiple pregnancy, time to pregnancy,

complications of pregnancy, and neonatal morbidity and mortality. RESULTS: 602 couples were randomly assigned between

January 2009 and February 2012; 201 were allocated to in vitro fertilisation with single embryo transfer, 194 to in vitro

fertilisation in a modified natural cycle, and 207 to intrauterine insemination with controlled ovarian hyperstimulation. Birth

of a healthy child occurred in 104 (52%) couples in the in vitro fertilisation with single embryo transfer group, 83 (43%) in the

in vitro fertilisation in a modified natural cycle group, and 97 (47%) in the intrauterine insemination with controlled ovarian

hyperstimulation group. This corresponds to a risk, relative to intrauterine insemination with ovarian hyperstimulation, of

1.10 (95% confidence interval 0.91 to 1.34) for in vitro fertilisation with single embryo transfer and 0.91 (0.73 to 1.14) for

in vitro fertilisation in a modified natural cycle. These 95% confidence intervals do not extend below the predefined threshold

of 0.69 for inferiority. Multiple pregnancy rates per ongoing pregnancy were 6% (7/121) after in vitro fertilisation with

single embryo transfer, 5% (5/102) after in vitro fertilisation in a modified natural cycle, and 7% (8/119) after intrauterine

insemination with ovarian hyperstimulation (one sided P=0.52 for in vitro fertilisation with single embryo transfer compared

with intrauterine insemination with ovarian hyperstimulation; one sided P=0.33 for in vitro fertilisation in a modified natural

cycle compared with intrauterine insemination with controlled ovarian hyperstimulation). CONCLUSIONS: In vitro fertilisation

with single embryo transfer and in vitro fertilisation in a modified natural cycle were non-inferior to intrauterine insemina-

tion with controlled ovarian hyperstimulation in terms of the birth of a healthy child and showed comparable, low multiple

pregnancy rates.Trial registration Current Controlled Trials ISRCTN52843371; Nederlands Trial Register NTR939.


PMID: 25577174Wielders CC, Hackert VH, Schimmer B, Hodemaekers HM, de Klerk A, Hoebe CJ, Schneeberger PM, van Duynhoven YT, Janssen R. Single nucleotide polymorphisms in immune response genes in acute Q fever cases with differences in self-reported symptoms. Eur J Clin Microbiol Infect Dis. 2015 May;34(5):943-50. doi: 10.1007/s10096-014-2310-9. Epub 2015 Jan 11.

Genes involved in human immune response are well recognized to influence the clinical course of infection. The association

of host genetics with susceptibility to and severity of clinical symptoms in acute Q fever was investigated. Single nucleotide

polymorphisms (SNPs) in the IFNG (rs2430561/rs1861493), STAT1 (rs1914408), and VDR (rs2228570) genes were deter-

mined in 85 patients from the 2007 Dutch acute Q fever outbreak, and a symptom score was calculated. IFNG rs1861493

showed a significant association with the symptom score; IFNG rs2430561 showed a similar trend. These SNPs were then

used to reproduce results in a 2009 outbreak population (n = 123). The median symptom score differed significantly in both

populations: 2 versus 7. The significant association of IFNG rs1861493 with symptom score in the first population was not

reproduced in the second population. We hypothesize that individuals in the second outbreak were exposed to a higher

Coxiella burnetii dose compared to the first, which overruled the protection conferred by the A-allele of IFNG rs1861493 in

the first population.

PMID: 25580956Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, Leenders F, Bufler P, Boekschoten MV, Müller M, Kersten S, Li S, Kim S, Eini H, Lewis EC, Joosten LA, Tilg H, Netea MG, Tack CJ, Dinarello CA, Stienstra R. Corrigendum: IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2015 Jan 12;6:6039. doi: 10.1038/ncomms7039.

PMID: 25581759Noordegraaf M, Wolthuis A, Peters F, de Groot M, Hoedemakers R. Performance characteristics of a new automated method for measurement of anti-cyclic citrullinated peptide. Clin Chem Lab Med. 2015 Jan 12. doi: 10.1515/cclm-2014-0961.

BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory auto-immune disease affecting approximately 1%-2%

of the population worldwide. RA is a potentially crippling disease since it results in malformation of the joints. RA is mostly

diagnosed based on clinical manifestations but serological tests against autoantibodies, such as rheumatoid factor and anti-

cyclic citrullinated peptides (aCCP), are available. The presence of aCCP antibodies is strongly associated with a more severe,

destructive disease course. Recently, a new test for the measurement of aCCP antibodies on the IMMULITE 2000(XPi)

platform was developed by Siemens Healthcare. In this study we investigated the performance characteristics of this new

aCCP test in four different hospital laboratories and compared the new test with three different commercially available

platforms. METHODS: Samples were collected from patients presented to the hospital for aCCP measurement. Serum

aCCP levels were determined by aCCP (Ig)G assay for IMMULITE 2000(XPi) systems (Siemens Healthcare), ImmunoScan

RA enzyme-linked immunosorbent assay (ELISA) test (Eurodiagnostica), Immunocap 250 (Thermofisher) or aCCP IgG assay

on the Modular system (Roche Diagnostics). The evaluation protocol consisted of within-run imprecision (20 sequential

runs), between-run imprecision (16 workdays), comparison of serum and plasma measurement and method comparison.

RESULTS: The within-run imprecision (n=20) for aCCP IgG assay on three different IMMULITE 2000(XPi) systems ranged

from 3.0% to 6.9% at levels 3.2-171.2 U/mL. Between-run imprecision (n=16 days) ranged from 5.2% to 11% at levels of

3.2-106.9 U/mL. Method comparison showed good correlation when samples were measured on two different Immulite

analyzers in two different hospital laboratories [0.21+0.96x (n=40)]. Method comparison of the IMMULITE 2000(XPi) aCCP


test with aCCP on Immunoscan RA ELISA (n=112), Immunocap 250 (n=105) and the Modular system (n=289) resulted in a

concordance of 90.2%, 93.3% and 94.8%, respectively. Correlation of serum versus heparin samples showed a correlation of

0.12+1.08x for the Immulite 2000(XPi) test. CONCLUSIONS: The aCCP assay on the IMMULITE 2000(XPi) has good perfor-

mance characteristics and shows high level of concordance with the aCCP test on Immunoscan RA ELISA test, Immunocap

250 and the Modular systems.

PMID: 25582098Van Oostwaard MF, Langenveld J, Schuit E, Papatsonis DN, Brown MA, Byaruhanga RN, Bhattacharya S, Campbell DM, Chappell LC, Chiaffarino F, Crippa I, Facchinetti F, Ferrazzani S, Ferrazzi E, Figueiró-Filho EA, Gaugler-Senden IP, Haavaldsen C, Lykke JA, Mbah AK, Oliveira VM, Poston L, Redman CW, Salim R, Thilaganathan B, Vergani P, Zhang J, Steegers EA, Mol BW, Ganzevoort W. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol. 2015 May;212(5):624.e1-17. doi: 10.1016/j.ajog.2015.01.009. Epub 2015 Jan 9. Erratum in: Am J Obstet Gynecol. 2015 Sep;213(3):400.

OBJECTIVE: We performed an individual participant data (IPD) metaanalysis to calculate the recurrence risk of hyperten-

sive disorders of pregnancy (HDP) and recurrence of individual hypertensive syndromes. STUDY DESIGN: We performed

an electronic literature search for cohort studies that reported on women experiencing HDP and who had a subsequent

pregnancy. The principal investigators were contacted and informed of our study; we requested their original study data.

The data were merged to form one combined database. The results will be presented as percentages with 95% confidence

interval (CI) and odds ratios with 95% CI. RESULTS: Of 94 eligible cohort studies, we obtained IPD of 22 studies, including a

total of 99,415 women. Pooled data of 64 studies that used published data (IPD where available) showed a recurrence rate

of 18.1% (n=152,213; 95% CI, 17.9-18.3%). In the 22 studies that are included in our IPD, the recurrence rate of a HDP was

20.7% (95% CI, 20.4-20.9%). Recurrence manifested as preeclampsia in 13.8% of the studies (95% CI,13.6-14.1%), gestatio-

nal hypertension in 8.6% of the studies (95% CI, 8.4-8.8%) and hemolysis, elevated liver enzymes and low platelets (HELLP)

syndrome in 0.2% of the studies (95% CI, 0.16-0.25%). The delivery of a small-for-gestational-age child accompanied the

recurrent HDP in 3.4% of the studies (95% CI, 3.2-3.6%). Concomitant HELLP syndrome or delivery of a small-for-gestati-

onal-age child increased the risk of recurrence of HDP. Recurrence increased with decreasing gestational age at delivery in

the index pregnancy. If the HDP recurred, in general it was milder, regarding maximum diastolic blood pressure, proteinuria,

the use of oral antihypertensive and anticonvulsive medication, the delivery of a small-for-gestational-age child, premature

delivery, and perinatal death. Normotensive women experienced chronic hypertension after pregnancy more often after

experiencing recurrence (odds ratio, 3.7; 95% CI, 2.3-6.1). CONCLUSION: Among women that experience hypertension in

pregnancy, the recurrence rate in a next pregnancy is relatively low, and the course of disease is milder for most women

with recurrent disease. These reassuring data should be used for shared decision-making in women who consider a new

pregnancy after a pregnancy that was complicated by hypertension.

PMID: 25591748Lahaye MJ, Lambregts DM, Mutsaers E, Essers BA, Breukink S, Cappendijk VC, Beets GL, Beets-Tan RG. Mandatory imaging cuts costs and reduces the rate of unnecessary surgeries in the diagnostic work-up of patients suspected of having appendicitis. Eur Radiol. 2015 May;25(5):1464-70. doi: 10.1007/s00330-014-3531-0. Epub 2015 Jan 16.

OBJECTIVE: To evaluate whether mandatory imaging is an effective strategy in suspected appendicitis for reducing un-

necessary surgery and costs. METHODS: In 2010, guidelines were implemented in The Netherlands recommending the

mandatory use of preoperative imaging to confirm/refute clinically suspected appendicitis. This retrospective study included


1,556 consecutive patients with clinically suspected appendicitis in 2008-2009 (756 patients/group I) and 2011-2012 (800

patients/group II). Imaging use (none/US/CT and/or MRI) was recorded. Additional parameters were: complications, medical

costs, surgical and histopathological findings. The primary study endpoint was the number of unnecessary surgeries before

and after guideline implementation. RESULTS: After clinical examination by a surgeon, 509/756 patients in group I and

540/800 patients in group II were still suspected of having appendicitis. In group I, 58.5% received preoperative imaging

(42% US/12.8% CT/3.7% both), compared with 98.7% after the guidelines (61.6% US/4.4% CT/ 32.6% both). The percentage of

unnecessary surgeries before the guidelines was 22.9%. After implementation, it dropped significantly to 6.2% (p<0.001). The

surgical complication rate dropped from 19.9% to 14.2%. The average cost-per-patient decreased by 594 <euro> from 2,482

to 1,888 <euro> (CL:-1081; -143). CONCLUSION: Increased use of imaging in the diagnostic work-up of patients with cli-

nically suspected appendicitis reduced the rate of negative appendectomies, surgical complications and costs. KEY POINTS:

• The 2010 Dutch guidelines recommend mandatory imaging in the work-up of appendicitis. • This led to a considerable

increase in the use of preoperative imaging. • Mandatory imaging led to reduction in unnecessary surgeries and surgical

complications. • Use of mandatory imaging seems to reduce health care costs.

PMID: 25602602Wielders CC, Boerman AW, Schimmer B, van den Brom R, Notermans DW, van der Hoek W, Schneeberger PM. Persistent high IgG phase I antibody levels against Coxiella burnetii among veterinarians compared to patients previously diagnosed with acute Q fever after three years of follow-up. PLoS One. 2015 Jan 20;10(1):e0116937. doi: 10.1371/journal.pone.0116937. eCollection 2015.

BACKGROUND: Little is known about the development of chronic Q fever in occupational risk groups. The aim of this study

was to perform long-term follow-up of Coxiella burnetii seropositive veterinarians and investigate the course of IgG phase

I and phase II antibodies against C. burnetii antigens and to compare this course with that in patients previously diagnosed

with acute Q fever. METHODS: Veterinarians with IgG phase I ≥ 1:256 (immunofluorescence assay) that participated in a

previous seroprevalence study were asked to provide a second blood sample three years later. IgG antibody profiles were

compared to a group of acute Q fever patients who had IgG phase I ≥ 1:256 twelve months after diagnosis. RESULTS: IgG

phase I was detected in all veterinarians (n = 76) and in 85% of Q fever patients (n = 98) after three years (p<0.001). IgG

phase I ≥ 1:1,024, indicating possible chronic Q fever, was found in 36% of veterinarians and 12% of patients (OR 3.95, 95%

CI: 1.84-8.49). CONCLUSIONS: IgG phase I persists among veterinarians presumably because of continuous exposure to C.

burnetii during their work. Serological and clinical follow-up of occupationally exposed risk groups should be considered.

PMID: 25608699 Hagenaars JC, Wever PC, Shamelian SO, Van Petersen AS, Hilbink M, Renders NH, De Jager-Leclercq GL, Moll FL, Koning OH. Vascular chronic Q fever: quality of life. Epidemiol Infect. 2015 Oct;143(13):2903-9. doi: 10.1017/S0950268814003951. Epub 2015 Jan 22.

The aim of this study was to evaluate the quality of life in patients with vascular chronic Q fever at time of diagnosis and

during follow-up. Based upon the SF-36 questionnaire, the mean physical and mental health of each patient were assessed

at 3-month intervals for up to 18 months. A total of 26 patients were included in the study. At time of diagnosis, the mean

physical health and mental health score was 50•6 [95% confidence interval (CI) 46•7-54•4] and 44•6 (95% CI 41•6-47•5),

respectively. During treatment, the mean physical health score declined significantly by 1•7 points each 3 months (P <

0•001) to 40•8 (95% CI 34•4-45•1). The mean mental health score significantly and steadily increased towards 51•2 (95%

CI 46•9-54•3) during follow-up (P = 0•026). A total of 23% of patients were cured after 18 months of follow-up. In con-

clusion, quality of life at time of diagnosis for patients with vascular chronic Q fever is lower compared to a similar group of


patients, matched for age and gender, with an aortic abdominal aneurysmal disease, and physical health decreases further

after starting treatment. Considering the low percentage of cure, the current treatment of vascular chronic Q fever patients

may require a separate strategy from that of endocarditis in order to increase survival.

PMID: 25633758Poolman RW, Verhaar JA, Schreurs BW, Bom LP, Nelissen RG, Koot HW, Goosen JH, Verheyen CC. Finding the right hip implant for patient and surgeon: the Dutch strategy - empowering patients. Hip Int. 2015 Apr 20;25(2):131-7. doi: 10.5301/hipint.5000209. Epub 2015 Feb 28.

We describe the implementation process of hip prostheses selection in the Netherlands. The recent problems with large

head metal-on-metal hip prostheses resulted in substantial damage to the surgeons’ credibility and reputation in the media.

This led to a true sense of urgency among orthopaedic surgeons to increase their activities to secure patient safety. The

board of the Dutch Orthopaedic Association (NOV) in the Netherlands established a Dutch Hip Task Force (DHTF) with the

explicit assignment of formulating criteria to classify the quality of total hip implants on the Dutch market based on survi-

vorship. The aim was to offer unequivocal information enabling a balanced choice of total hip prosthesis. The ultimate goal

of the NOV is that all implanted total hip prostheses implanted in the Netherlands are based on reliable clinical evidence. The

DHTF decided to adapt the principles of the National Institute for Health and Care Excellence (NICE, UK) (www.nice.org.uk).

The taskforce uses data from the registries as well as the Orthopaedic Data Evaluation Panel (ODEP). If the ODEP guidelines

had been chosen as standard alone, one quarter of our listed hip components would not have been included. In our view this

underlines the strength in the Dutch approach where high quality registry data and ODEP ratings are complementary and

result in a list of reliable hip prostheses. Most importantly we offer patients insights into the known quality of the implants

by sharing the results of our implant review. This will facilitate shared decision making by empowering patients in their

knowledge on available hip arthroplasties.

PMID: 25636328Berm EJ, Hak E, Postma M, Boshuisen M, Breuning L, Brouwers JR, Dhondt T, Jansen PA, Kok RM, Maring JG, van Marum R, Mulder H, Voshaar RC, Risselada AJ, Venema H, Vleugel L, Wilffert B. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy withnortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Trials. 2015 Jan 31;16(1):37. doi:10.1186/s13063-015-0561-0.

BACKGROUND: Nortriptyline and venlafaxine are commonly used antidepressants for treatment of depression in older

patients. Both drugs are metabolized by the polymorphic cytochrome P450-2D6 (CYP2D6) enzyme and guidelines for

dose adaptations based on the CYP2D6 genotype have been developed. The CYP2D6 Screening Among Elderly (CYSCE)

trial is designed to address the potential health and economic value of genotyping for CYP2D6 in optimizing dose-finding

of nortriptyline and venlafaxine. METHODS/DESIGN: In a pragmatic randomized controlled trial, patients diagnosed with

a major depressive disorder according to the DSM-IV and aged 60 years or older will be recruited from psychiatric centers

across the Netherlands. After CYP2D6 genotyping determined in peripheral blood obtained by finger-prick, patients will

be grouped into poor, intermediate, extensive, or ultrarapid metabolizers. Patients with deviant genotype (that is poor,

intermediate or ultrarapid genotype) will be randomly allocated to an intervention group in which the genotype and dosing

advice is communicated to the treating physician, or to a control group in which patients receive care as usual. Additionally,

an external reference group of patients with the extensive metabolizer genotype is included. Primary outcome in all groups

is time needed to obtain an adequate blood level of the antidepressant drug. Secondary outcomes include adverse drug

reactions measured by a shortened Antidepressant Side-Effects Checklist (ASEC), and cost-effectiveness of the screening.


DISCUSSION: Results of this trial will guide policy-making with regard to pharmacogenetic screening prior to treatment with

nortriptyline or venlafaxine among older patients with depression. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01778907 ;

registration date: 22 January 2013.

PMID: 25648985de Vries C, Doggen C, Hilbers E, Verheij R, IJzerman M, Geertsma R, Kusters R. Results of a survey among GP practices on how they manage patient safety aspects related to point-of-care testing in every day practice. BMC Fam Pract. 2015 Feb 5;16(1):9.

BACKGROUND: Point-of-care (POC) tests are devices or test strips that can be used near or at the site where care is

delivered to patients, enabling a relatively fast diagnosis. Although many general practitioners (GPs) in the Netherlands are

using POC tests in their practice, little is known on how they manage the corresponding patient safety aspects. METHODS:

To obtain information on this aspect, an invitation to participate in a web-based questionnaire was sent to a random sample

of 750 GP practices. Of this sample 111 GP practices returned a complete questionnaire. Data was analysed by using des-

criptive statistics. RESULTS: Results show that there is not always attention for quality control measures such as checking

storage conditions, executing calibration, and maintenance. In addition, universal hygienic measures, such as washing hands

before taking a blood sample, are not always followed. Refresher courses on the use of POC tests are hardly organized. Only

a few of the GPs contact the manufacturer of the device when a device failure occurs. Well-controlled aspects include patient

identification and actions taken when ambiguous test results are obtained. CONCLUSIONS: We observed a number of risks

for errors with POC tests in GP practices that may be reduced by proper training of personnel, introduction of standard

operating procedures and measures for quality control and improved hygiene. To encourage proper use of POCT in general

practices, a national POCT guideline, dedicated to primary care and in line with ISO standards, should be introduced.

PMID: 25652303Ranschaert ER, Boland GW, Duerinckx AJ, Barneveld Binkhuysen FH. Comparison of European (ESR) and American (ACR) white papers on teleradiology: patient primacy is paramount. J Am Coll Radiol. 2015 Feb;12(2):174-82. doi: 10.1016/j.jacr.2014.09.027.

The ACR and European Society of Radiology white papers on teleradiology propose best practice guidelines for teleradiology,

with each body focusing on its respective local situation, market, and legal regulations. The organizations have com-

mon viewpoints, the most important being patient primacy, maintenance of quality, and the “supplementary” position of

teleradiology to local services. The major differences between the white papers are related mainly to the market situation,

the use of teleradiology, teleradiologist credentialing and certification, the principles of “international” teleradiology, and the

need to obtain “informed consent” from patients. The authors describe these similarities and differences by highlighting the

background and context of teleradiology in Europe and the United States.

PMID: 25652526Kröger E, Van Marum R, Souverein P, Carmichael PH, Egberts T. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):276-85. doi: 10.1002/pds.3741. Epub 2015 Feb 4.

BACKGROUND: Treatment of Alzheimer disease (AD) with cholinesterase inhibitors (ChEIs) may increase the risk of urinary

incontinence (UI). OBJECTIVE: To assess whether ChEI use was associated with the risk of UI among older patients with

AD. METHODS: A crossover cohort study using the PHARMO Record Linkage System included 10 years of data on drug


dispensing histories for over two million Dutch residents. Included patients were aged 50 +, free of UI for the last 6 months,

received a first ChEI prescription during the study period, had at least 12 months prior drug exposure history and one

subsequent prescription of any drug. UI was defined as a first dispensing of a urinary spasmolytic or of incontinence

products for at least 30 days. Cox regression with time-varying covariates and multivariate adjustment allowed assessing

whether UI incidence was associated with ChEI exposure. RESULTS: Among 3154 patients there were 657 UI cases during

a mean follow-up of 5.1 years before a first ChEI dispensing, and 499 cases after ChEI initiation, during a mean follow-up

of 2.0 years. Among the 2700 participants free of UI one year before ChEI initiation, the adjusted hazard ratio (HR) for UI

was 1.13 (95% CI: 0.97-1.32) when periods with ChEI use were compared to periods without ChEI use. Sensitivity analyses

may suggest an increased risk in the 1(st) month after ChEI initiation (HR: 1.72, p = 0.09) CONCLUSION: Worsening AD may

increase incidence of UI, but no firm association between ChEI treatment and risk of UI could be shown from these data.

PMID: 25668198Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Van Alfen AA, Van Leeuwen M, Van Wieringen H, Wegdam-den Boer ME, Zwaveling-Soonawala N, Hokken-Koelega AC. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment. J. Clin. Endocrinol. Metab. 2015;100: 1609-1618.

CONTEXT: Longitudinal data on bone mineral density (BMD) in children and adolescents with Prader-Willi Syndrome (PWS)

during long-term GH treatment are not available. OBJECTIVE: This study aimed to determine effects of long-term GH

treatment and puberty on BMD of total body (BMDTB), lumbar spine (BMDLS), and bone mineral apparent density of the

lumbar spine (BMADLS) in children with PWS. DESIGN AND SETTING: This was a prospective longitudinal study of a Dutch

PWS cohort. PARTICIPANTS: Seventy-seven children with PWS who remained prepubertal during GH treatment for 4 years

and 64 children with PWS who received GH treatment for 9 years participated in the study. INTERVENTION: The children

received GH treatment, 1 mg/m(2)/day (κ 0.035 mg/kg/d). MAIN OUTCOME MEASURES: BMDTB, BMDLS, and BMADLS

was measured by using the same dual-energy x-ray absorptiometry machine for all annual measurements. RESULTS: In

the prepubertal group, BMDTB standard deviation score (SDS) and BMDLSSDS significantly increased during 4 years of GH

treatment whereas BMADLSSDS remained stable. During adolescence, BMDTBSDS and BMADLSSDS decreased signifi-

cantly, in girls from the age of 11 years and in boys from the ages of 14 and 16 years, respectively, but all BMD parameters

remained within the normal range. Higher Tanner stages tended to be associated with lower BMDTBSDS (P = .083) and a

significantly lower BMADLSSDS (P = .016). After 9 years of GH treatment, lean body mass SDS was the most powerful pre-

dictor of BMDTBSDS and BMDLSSDS in adolescents with PWS. CONCLUSIONS: This long-term GH study demonstrates that

BMDTB, BMDLS, and BMADLS remain stable in prepubertal children with PWS but decreases during adolescence, parallel

to incomplete pubertal development. Based on our findings, clinicians should start sex hormone therapy from the age of 11

years in girls and 14 years in boys unless there is a normal progression of puberty.

PMID: 25688100Vogelaar FJ, Lips DJ, van Dorsten FR, Lemmens VE, Bosscha K. Impact of anaesthetic technique on survival in colon cancer: a review of the literature. Gastroenterol Rep (Oxf). 2016 Feb;4(1):30-4. doi: 10.1093/gastro/gov001. Epub 2015 Feb 16. Review.

An oncological surgical resection is the mainstay of treatment for potentially curable colon cancer. At the time of surgery, a

large fraction of patients do harbour-although not visibly-minimal residual disease at the time of surgery. The immunosup-

pression that accompanies surgery may have an effect on disease recurrence and survival. Regional or neuraxial anaesthetic

techniques like epidural anaesthesia may suppress immune function less than opioid analgesia, by reducing stress response


and significantly reducing exposure to opioids. Consistent with this hypothesis, regional anaesthetic techniques have been as-

sociated with lower recurrence rates in breast cancer and prostate cancer. Results for colon cancer, however, are contradictory.

In this review of the literature we describe all studies addressing the association of the use of epidural anaesthesia and survival

in colon cancer surgery.

PMID: 25703856Van Erning FN, Janssen-Heijnen ML, Creemers GJ, Pruijt HF, Maas HA, Lemmens VE. Deciding on adjuvant chemotherapy for elderly patients with stage III colon cancer: A qualitative insight into the perspectives of surgeons and medical oncologists. J Geriatr Oncol. 2015 May;6(3):219-24. doi: 10.1016/j.jgo.2015.02.001. Epub 2015 Feb 20.

OBJECTIVE: The aim of this study is to identify doctor-related factors determining the decision-making for adjuvant chemo-

therapy for patients with stage III colon cancer aged ≥75years. MATERIALS AND METHODS: 21 surgeons and 15 medical

oncologists from 10 community hospitals were asked to complete a short questionnaire including tick-box questions regarding

motives for non-referral/non-treatment, consultation of geriatricians, chemotherapy schemes prescribed and an open ques-

tion regarding tolerability of chemotherapy. RESULTS: 29 medical specialists returned a completed questionnaire (response

81%). The motives for non-referral/non-treatment reported most often were comorbidity/bad general health condition of

the patient; surgical complications; and treatment offered but refused by patient/family. 39% of the surgeons and 55% of the

medical oncologists reported consultation of a geriatrician in 2-30% of their decisions. CAPOX and capecitabine were reported

by medical oncologists as the most frequently prescribed regimens. Factors that influenced the decision for monotherapy or

combination therapy were comorbidity; general health condition of the patient; and toxicity profile of the chemotherapeutics.

In general, medical oncologists defined grade ≤2 toxicities as tolerable, with the exception of neuropathy, for which grade ≤1

toxicity was accepted. CONCLUSIONS: In case medical oncologists prescribe adjuvant chemotherapy to elderly patients with

stage III colon cancer, the chemotherapy schemes used are in line with clinical guidelines and they agree on acceptable levels

of toxicity. However, the variation among surgeons and medical oncologists in motives for non-referral, non-treatment and

consultation of geriatricians when deciding on adjuvant chemotherapy for elderly patients with stage III colon cancer, shows

the complexity and need for specific knowledge.

PMID: 25722298Schoffelen T, Ammerdorffer A, Hagenaars JC, Bleeker-Rovers CP, Wegdam-Blans MC, Wever PC, Joosten LA, van der Meer JW, Sprong T, Netea MG, van Deuren M, van de Vosse E. Genetic Variation in Pattern Recognition Receptors and Adaptor Proteins Associated With Development of Chronic Q Fever. J Infect Dis. 2015 Feb 26. pii: jiv113. [Epub ahead of print]

BACKGROUND: Q fever is an infection caused by Coxiella burnetii. Persistent infection (chronic Q fever) develops in 1%-5% of

patients. We hypothesize that inefficient recognition of C. burnetii and/or activation of host-defense in individuals carrying

genetic variants in pattern recognition receptors or adaptors would result in an increased likelihood to develop chronic Q

fever. METHODS: Twenty-four single-nucleotide polymorphisms in genes encoding Toll-like receptors, nucleotide-binding

oligomerization domain-like receptor-2, κvκ3 integrin, CR3, and adaptors myeloid differentiation primary response protein

88 (MyD88), and Toll interleukin 1 receptor domain-containing adaptor protein (TIRAP) were genotyped in 139 patients with

chronic Q fever and in 220 controls with cardiovascular risk-factors and previous exposure to C. burnetii. Associations between

these single-nucleotide polymorphisms and chronic Q fever were assessed by means of univariate logistic regression models.

Cytokine production in whole-blood stimulation assays was correlated with relevant genotypes. RESULTS: Polymorphisms in

TLR1 (R80T), NOD2 (1007fsX1), and MYD88 (-938C>A) were associated with chronic Q fever. No association was observed


for polymorphisms in TLR2, TLR4, TLR6, TLR8, ITGAV, ITGB3, ITGAM, and TIRAP. No correction for multiple testing was per-

formed because only genes with a known role in initial recognition of C. burnetii were included. In the whole-blood assays,

individuals carrying the TLR1 80R-allele showed increased interleukin 10 production with C. burnetii exposure. CONCLU-

SIONS: Polymorphisms in TLR1 (R80T), NOD2 (L1007fsX1), and MYD88 (-938C>A) are associated with predisposition to

development of chronic Q fever. For TLR1, increased interleukin 10 responses to C. burnetii in individuals carrying the risk

allele may contribute to the increased risk of chronic Q fever.

PMID: 25732130Jacobs LH, van Borren M, Gemen E, van Eck M, van Son B, Glatz JF, Daniels M, Kusters R. Rapidly rule out acute myocardial infarction by combining copeptin and heart-type fatty acid-binding protein with cardiac troponin. Ann Clin Biochem. 2015 Sep;52(Pt 5):550-61. doi: 10.1177/0004563215578189. Epub 2015 Mar 2.

BACKGROUND: The rapid exclusion of acute myocardial infarction in patients with chest pain can reduce the length of hos-

pital admission, prevent unnecessary diagnostic work-up and reduce the burden on our health-care systems. The combined

use of biomarkers that are associated with different pathophysiological aspects of acute myocardial infarction could improve

the early diagnostic assessment of patients presenting with chest pain. METHODS: We measured cardiac troponin I, copep-

tin and heart-type fatty acid-binding protein concentrations in 584 patients who presented to the emergency department

with acute chest pain. The diagnostic performances for the diagnosis of acute myocardial infarction and NSTEMI were

calculated for the individual markers and their combinations. Separate calculations were made for patients presenting to the

emergency department <3 h, 3-6 h and 6-12 h after chest pain onset. RESULTS: For ruling out acute myocardial infarction,

the net predictive values (95% CI) of cardiac troponin I, copeptin and heart-type fatty acid-binding protein were 90.4%

(87.3-92.9), 84% (79.8-87.6) and 87% (83.5-90), respectively. Combining the three biomarkers resulted in a net predictive

value of 95.8% (92.8-97.8). The improvement was most pronounced in the early presenters (<3 h) where the combined net

predictive value was 92.9% (87.3-96.5) compared to 84.6% (79.4-88.9) for cardiac troponin I alone. The area under the

receiver operating characteristic for the triple biomarker combination increased significantly (P < 0.05) compared to that of

cardiac troponin I alone (0.880 [0.833-0.928] vs. 0.840 [0.781-0.898], respectively). CONCLUSIONS: Combining copeptin,

heart-type fatty acid-binding protein and cardiac troponin I measurements improves the diagnostic performance in patients

presenting with chest pain. Importantly, in patients who present early (<3 h) after chest pain onset, the combination impro-

ves the diagnostic performance compared to the standard cardiac troponin I measurement alone.

PMID: 25740811Nissen LH, Nagtegaal ID, de Jong DJ, Kievit W, Derikx LA, Groenen PJ, van Krieken JH, Hoentjen F. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. J Crohns Colitis. 2015 May;9(5):398-403. doi: 10.1093/ecco-jcc/jjv040.

BACKGROUND: Inflammatory bowel disease (IBD) patients on thiopurine therapy are at increased risk of Epstein-Barr virus

(EBV)-associated lymphomas. This virus is frequently detected in the intestinal mucosa of IBD patients and may cause a

wide spectrum of lymphoproliferations similar to post-transplantation lymphoproliferative disorders (PTLDs). We aimed to

assess whether histological aberrations aid in predicting EBV presence and to correlate histological assessment and EBV

load with disease outcome in IBD. METHODS: We included all IBD patients from our centre who underwent EBV testing of

intestinal biopsies between January 2004 and October 2013. All biopsies were classified according to the WHO PTLD clas-

sification and the EBV load was scored per high-power field (HPF). Clinical data were collected from patient charts. Reported

clinical outcomes included colectomy, need for chemotherapy and mortality. RESULTS: Our cohort included 58 patients: 28

were EBV-positive and 30 EBV-negative. An atypical infiltrate was seen more frequently in EBV-positive than in EBV-nega-

tive patients (57.1 versus 3.3%; p < 0.001). A high EBV load occurred more frequently in EBV-positive patients undergoing


colectomy than in EBV-positive patients without colectomy (50.0 versus 10.0%; p = 0.048). Monomorphic lymphoprolifera-

tive disorders, including two overt lymphomas, were present in 10 patients. Reduction of immunosuppression resulted in

histological normalization and loss of EBV expression in seven of eight non-lymphoma patients. CONCLUSION: The presence

of atypical infiltrate in the intestinal mucosa of IBD patients warrants EBV testing. Reduction of immunosuppression is an

effective strategy to achieve morphological normalization and loss of EBV. Lymphoproliferation related to IBD appears to

have less aggressive clinical behaviour than PTLDs.

PMID: 25741695Eppenga WL, Kramers C, Derijks HJ, Wensing M, Wetzels JF, De Smet PA. Individualizing Pharmacotherapy in Patients with Renal Impairment: The Validity of the Modification of Diet in Renal Disease Formula in Specific Patient Populations with a Glomerular Filtration Rate below 60 Ml/Min. A Systematic Review. PLoS One 2015 Mar 5;10(3):e0116403. doi: 10.1371/journal.pone.0116403. eCollection 2015.

BACKGROUND: The Modification of Diet in Renal Disease (MDRD) formula is widely used in clinical practice to assess the

correct drug dose. This formula is based on serum creatinine levels which might be influenced by chronic diseases itself or

the effects of the chronic diseases. We conducted a systematic review to determine the validity of the MDRD formula in spe-

cific patient populations with renal impairment: elderly, hospitalized and obese patients, patients with cardiovascular disease,

cancer, chronic respiratory diseases, diabetes mellitus, liver cirrhosis and human immunodeficiency virus. METHODS AND

FINDINGS: We searched for articles in Pubmed published from January 1999 through January 2014. Selection criteria

were (1) patients with a glomerular filtration rate (GFR) < 60 ml/min (/1.73 m2), (2) MDRD formula compared with a gold

standard and (3) statistical analysis focused on bias, precision and/or accuracy. Data extraction was done by the first author

and checked by a second author. A bias of 20% or less, a precision of 30% or less and an accuracy expressed as P30% of

80% or higher were indicators of the validity of the MDRD formula. In total we included 27 studies. The number of patients

included ranged from 8 to 1831. The gold standard and measurement method used varied across the studies. For none of

the specific patient populations the studies provided sufficient evidence of validity of the MDRD formula regarding the three

parameters. For patients with diabetes mellitus and liver cirrhosis, hospitalized patients and elderly with moderate to severe

renal impairment we concluded that the MDRD formula is not valid. Limitations of the review are the lack of considering the

method of measuring serum creatinine levels and the type of gold standard used. CONCLUSION: In several specific patient

populations with renal impairment the use of the MDRD formula is not valid or has uncertain validity.

PMID: 25746461De Wit HA, Mestres Gonzalvo C, Cardenas J, Derijks HJ, Janknegt R, van der Kuy PH, Winkens B, Schols JM. Evaluation of clinical rules in a standalone pharmacy based clinical decision support system for hospitalized and nursing home patients. Int J Med Inform 2015 Jun;84(6):396-405. doi: 10.1016/j.ijmedinf.2015.02.004. Epub 2015 Feb 19.

OBJECTIVES: To improve the current standalone pharmacy clinical decision support system (CDSS) by identifying and

quantifying the benefits and limitations of the system. METHODS: Alerts and handling of the executed clinical rules were

extracted from the CDSS from the period September 2011 to December 2011. The number of executed clinical rule alerts,

number of actions on alerts, and the reason why alerts were classified as not relevant were analyzed. The alerts where

considered clinically relevant when the pharmacist needed to contact the physician. RESULTS: The 4065 alerts have been

separated into: 1137 (28.0%) new alerts, 2797 (68.8%) repeat alerts and 131 (3.2%) double alerts. When the alerts were

analyzed, only 3.6% were considered clinically relevant. Reasons why alerts were considered as not to be relevant were:

(a) the dosage was correct or already adjusted, (b) the drug was (temporarily) stopped and (c) the monitored laboratory

value or drug dosage had already reverted to be within the reference limits. The reasons for no action were linked to three


categorical limitations of the used system: ‘algorithm alert criteria’, ‘CDSS optimization’, and ‘data delivery’. CONCLUSION: This

study highlighted a number of ways in which the CDSS could be improved. These different aspects have been identified as

important for developing an efficient CDSS.

PMID: 25753290Keijsers CJ, de Wit JE, Tichelaar J, Brouwers JR, de Wildt DJ, de Vries PG, Jansen PA. Education on prescribing for older patients in the Netherlands: a curriculum mapping. Eur J Clin Pharmacol. 2015 May;71(5):603-9. doi: 10.1007/s00228-015-1830-2. Epub 2015 Mar 11.

PURPOSE: Pharmacology and pharmacotherapy education is being increasingly integrated in medical curricula, which might

lead to a specific loss of knowledge in these subjects. This, in turn, could lead to harmful prescribing errors, especially in

vulnerable older patients. METHODS: Teachers who coordinated education in Dutch medical schools completed a structured

interview on (geriatric) pharmacology and pharmacotherapy education. A list of core learning goals was developed. Pharma-

cology and pharmacotherapy education in general was compared to geriatric pharmacology and pharmacotherapy education.

RESULTS: All Dutch medical schools participated. Contact hours for education in pharmacology and pharmacotherapy ranged

from 39 to 107 h; ECTSs (representing 28 study hours) ranged from 0 to 3. The various curricula covered, on average, 79% of

all learning goals for these subjects: knowledge 85%, skills 76%, and attitudes 66%; the curricula also covered specific geriatric

goals: knowledge 87% and skills 65%. All geriatric learning goals were met if a geriatrician was among the coordinators. Half

(4 of 8) of the medical schools lacked appropriate assessment procedures. Evaluation was mostly based on students’ opinions.

Teachers rated students as being moderately well prepared for daily practice. CONCLUSIONS: There are large differences in

the quantity and quality of (geriatric) pharmacology and pharmacotherapy education in Dutch medical schools. In general,

more time should be devoted to skills and attitude, and the assessment procedures should be optimized with high priority.

Other curricula with a problem-based approach might benefit from the points of improvement described in this article.

PMID: 25788568Hamilton JA, Cissen M, Brandes M, Smeenk JM, de Bruin JP, Kremer JA, Nelen WL, Hamilton CJ. Total motile sperm count: a better indicator for the severity of male factor infertility than the WHO sperm classification system. Hum Reprod. 2015 May;30(5):1110-21. doi: 10.1093/humrep/dev058. Epub 2015 Mar 18.

STUDY QUESTION: Does the prewash total motile sperm count (TMSC) have a better predictive value for spontaneous

ongoing pregnancy (SOP) than the World Health Organization (WHO) classification system? SUMMARY ANSWER: The prewash

TMSC shows a better correlation with the spontaneous ongoing pregnancy rate (SOPR) than the WHO 2010 classification

system. WHAT IS KNOWN ALREADY: According to the WHO classification system, an abnormal semen analysis can be diag-

nosed as oligozoospermia, astenozoospermia, teratozoospermia or combinations of these and azoospermia. This classification

is based on the fifth percentile cut-off values of a cohort of 1953 men with proven fertility. Although this classification sug-

gests accuracy, the relevance for the prognosis of an infertile couple and the choice of treatment is questionable. The TMSC

is obtained by multiplying the sample volume by the density and the percentage of A and B motility spermatozoa. STUDY

DESIGN, SIZE, DURATION: We analyzed data from a longitudinal cohort study among unselected infertile couples who were

referred to three Dutch hospitals between January 2002 and December 2006. Of the total cohort of 2476 infertile couples,

only the couples with either male infertility as a single diagnosis or unexplained infertility were included (n = 1177) with a

follow-up period of 3 years. PARTICIPANTS/MATERIALS, SETTING, METHODS: In all couples a semen analysis was perfor-

med. Based on the best semen analysis if more tests were performed, couples were grouped according to the WHO clas-

sification system and the TMSC range, as described in the Dutch national guidelines for male infertility. The primary outcome

measure was the SOPR, which occurred before, during or after treatments, including expectant management, intrauterine

insemination, in vitro fertilization or intracytoplasmic sperm injection. After adjustment for the confounding factors (female


and male age, duration and type of infertility and result of the postcoital test) the odd ratios (ORs) for risk of SOP for each

WHO and TMSC group were calculated. The couples with unexplained infertility were used as reference. MAIN RESULTS

AND THE ROLE OF CHANCE: A total of 514 couples did and 663 couples did not achieve a SOP. All WHO groups have a lower

SOPR compared with the unexplained group (ORs varying from 0.136 to 0.397). Comparing the couples within the abnor-

mal WHO groups, there are no significant differences in SOPR, except when oligoasthenoteratozoospermia is compared

with asthenozoospermia [OR 0.501 (95% CI 0.311-0.809)] and teratozoospermia [OR 0.499 (95% CI: 0.252-0.988)], and

oligoasthenozoospermia is compared with asthenozoospermia [OR 0.572 (95% CI: 0.373-0.877)]. All TMSC groups have a

significantly lower SOPR compared with the unexplained group (ORs varying from 0.171 to 0.461). Couples with a TMSC of

<1 × 10(6) and 1-5 × 10(6) have significantly lower SOPR compared with couples with a TMSC of 5-10 × 10(6) [respectively,

OR 0.371 (95% CI: 0.215-0.64) and OR 0.505 (95% CI: 0.307-0.832)]. LIMITATIONS, REASON FOR CAUTION: To include all

SOPs during the follow-up period of 3 years, couples were not censured at the start of treatment. WIDER IMPLICATIONS OF

THE FINDINGS: Roughly, three prognostic groups can be discerned: couples with a TMSC <5, couples with a TMSC between

5 and 20 and couples with a TMSC of more than 20 × 10(6) spermatozoa. We suggest using TMSC as the method of choice

to express severity of male infertility. STUDY FUNDING/COMPETING INTERESTS: None.

PMID: 25790742Walter D, van Boeckel PG, Groenen MJ, Weusten BL, Witteman BJ, Tan G, Brink MA, Nicolai J, Tan AC, Alderliesten J, Venneman NG, Laleman W, Jansen JM, Bodelier A, Wolters FL, van der Waaij LA, Breumelhof R, Peters FT, Scheffer RC, Leenders M, Hirdes MM, Steyerberg EW, Vleggaar FP, Siersema PD. Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial. Gastroenterology. 2015 Jul;149(1):130-8. doi: 10.1053/j.gastro.2015.03.012. Epub 2015 Mar 17.

BACKGROUND & AIMS: Endoscopic stents are placed for palliation of extrahepatic bile duct obstruction. Although self-

expandable metal stents (SEMS) remain patent longer than plastic stents, they are more expensive. We aimed to evaluate

which type of stent (plastic, uncovered SEMS [uSEMS], or partially covered SEMS [pcSEMS]) is the most effective and we

assessed costs. METHODS: We performed a multicenter randomized trial in 219 patients at 18 hospitals in The Nether-

lands from February 2008 through February 2013. Patients were assigned randomly for placement of a plastic stent (n =

73), uSEMS (n = 75), or pcSEMS (n = 71) during endoscopic retrograde cholangiopancreatography. Patients were followed

up for up to 1 year. Researchers were not blinded to groups. The main study end points included functional stent time and

costs. RESULTS: The mean functional stent times were 172 days for plastic stents, 288 days for uSEMS, and 299 days

for pcSEMS (P < .005 for uSEMS and pcSEMS vs plastic). The initial placement of plastic stents (κ1042 or $1106) cost

significantly less than placement of SEMS (κ1973 or $2094) (P = .001). However, the total cost per patient at the end of

the follow-up period did not differ significantly between plastic stents (κ7320 or $7770) and SEMS (κ6932 or $7356) (P

= .61). Furthermore, in patients with short survival times (≤3 mo) or metastatic disease, the total cost per patient did not

differ between plastic stents and SEMS. No differences in costs were found between pcSEMS and uSEMS. CONCLUSIONS:

Although placement of SEMS (uncovered or partially covered) for palliation of extrahepatic bile duct obstruction initially is

more expensive than placement of plastic stents, SEMS have longer functional time. The total costs after 1 year do not differ

significantly with stent type. Dutch Clinical Trial Registration no: NTR1361.

PMID: 25797389Van Veggel BA, Biesma B, Smit EF. Pharmacotherapy for treatment of lung cancer in the elderly. Expert Opin Pharmacother. 2015 May;16(7):1021-34. doi: 10.1517/14656566.2015.1028357. Epub 2015 Mar 22.

INTRODUCTION: The chance for elderly patients with NSCLC to receive chemotherapy decreases significantly with age. In

addition, older patients are often underrepresented in clinical trials. Consequently, due to the paucity of data, evidence-


based decisions with regard to chemotherapy treatment strategies in the elderly are lacking. AREAS COVERED: We

performed a literature search to identify mainly randomized trials focusing on treatment of NSCLC in older patients with

chemotherapy and targeted therapy, toxicity and quality of life. In conclusion, the efficacy of regular chemotherapy and

targeted therapy seems quite similar in older patients compared to their younger counterparts, with increased toxicity, but

acceptable. However, these data are mostly derived from subgroup analyses and highly selected fit patients, which may not

represent the general older population. EXPERT OPINION: Further research is necessary to investigate the role of a compre-

hensive geriatric assessment in older patients, before the start of a chemotherapeutic treatment. Proteomic tests can have

potential in the future, if these tests turn out to be able to separate patients with advanced NSCLC into groups with better

or worse outcomes. It can be of special interest for the elderly population, to prevent unnecessary side effects of a possible

inferior treatment.

PMID: 25804113Wever PC. Adrian Stokes en ‘trench jaundice’. Ned Tijdschr Geneeskd. 2015;159:A8648.

On the day that Great Britain declared war on Germany in 1914, the Irish physician and bacteriologist Adrian Stokes travel-

led to London to volunteer. One week later he left for France with the first British troops as an officer with the Royal Army

Medical Corps. He spent most of the First World War attached to No. 1 Mobile Bacteriological Laboratory at the Remy Siding

British-Canadian field hospital in Flanders. In April 1916, he was confronted with an outbreak of trench jaundice, also known

as epidemic jaundice (Weil’s disease). Conditions in the trenches contributed to the hundred cases identified by Stokes in

a short period. In 1917, he was the first to publish (in The Lancet) the finding that the bacterium Spirochaeta icterohae-

morrhagiae, the causative agent of epidemic jaundice, could be isolated from the kidneys of rats. A subsequent rat control

campaign in the trenches successfully curbed the disease.

PMID: 25810359Keijsers CJ, Leendertse AJ, Faber A, Brouwers JR, de Wildt DJ, Jansen PA. Pharmacists’ and General Practitioners’ Pharmacology Knowledge and Pharmacotherapy Skills. J Clin Pharmacol. 2015 Aug;55(8):936-43. doi: 10.1002/jcph.500. Epub 2015 Apr 30.

Understanding differences in the pharmacology knowledge and pharmacotherapy skills of pharmacists and physicians is vital

to optimizing interprofessional collaboration and education. This study investigated these differences and the potential in-

fluence of work experience. The pharmacology knowledge and pharmacotherapy skills of pharmacists, general practitioners

(GPs), and trainees were compared, using a written assessment; 294 participants were included. Overall scores (mean ± SD)

ranged from 69.3% ± 6.5% to 76.5% ± 9.5% for basic knowledge, 70.3% ± 10.8% to 79.7% ± 8.4% for applied knowledge, and

66.3% ± 21.1% to 84.7% ± 20.7% for pharmacotherapy skills (analysis of variance all P < .05). The pharmacists had the highest

scores for all domains (P < .05), with the exception of pharmacist trainees, who had comparable scores for basic know-

ledge and pharmacotherapy skills (both P > .05). The GPs scored the lowest for pharmacotherapy skills (P < .05). More work

experience was associated with better knowledge of applied pharmacology among pharmacists (by 2% per 10 work-years),

but with poorer pharmacotherapy skills among pharmacists and GPs (by 3% and 4% per 10 work-years, respectively). In

conclusion, pharmacists and GPs differ in their knowledge and skills, and these differences become more pronounced with

more work experience. In general, pharmacists outperform pharmacist trainees, whereas GP trainees outperform GPs.

These differences could be important for interdisciplinary collaboration and education.


PMID: 25811973 Van de Ven AC, Netea-Maier MR, Smit JW, Kusters GC, van der Stappen JW, Pronk-Admiraal CJ, Buijs MM, Schoenmakers CC, Koehorst SG, de Groot MJ, Sweep FC, Hermus AR, den Heijer M. Thyrotropin versus age relation as an indicator of historical iodine intake. Thyroid. 2015 Jun;25(6):629-34. doi: 10.1089/thy.2014.0574. Epub 2015 Apr 20.

BACKGROUND: In populations with mild iodine deficiency, the serum level of thyrotropin (TSH) is negatively and the serum

free thyroxine (FT4) is positively associated with age. An ongoing decrease of TSH and increase of FT4 can be found after

iodine supplementation. The aim of this study was to investigate whether there are current differences in the relation

between thyroid function and age in relation to differences in iodine intake in the past. METHODS: Eight medical laboratories

in several regions of The Netherlands, which are all iodine sufficient at present but with a difference in iodine status in the

past, provided the results of all TSH and FT4 measurements performed from 2006 until 2011, resulting in 330,802 TSH

and 103,940 FT4 measurements. RESULTS: The negative association between TSH and age in the elderly is only present

in areas with a historical iodine deficiency (regression coefficients [RC] -0.008, 95% confidence interval [CI] -0.009; -0.007).

In the historically iodine-sufficient population, TSH shows no obvious increase or decrease with age. In both the historically

iodine-sufficient and iodine-deficient populations, FT4 levels were positively associated with age in the elderly (RC 0.009,

95% CI 0.008; 0.010 and RC 0.008, 95% CI 0.007; 0.010, respectively). CONCLUSIONS: There are differences in relation

between thyroid function and age between populations with differences in iodine intake in the past, despite an adequate

iodine status at present. This raises the question whether the present but also historical iodine status of a population should

be taken into account when establishing the reference limits of TSH and FT4.

PMID: 25832305Hamilton DW, Bins JE, McMeekin P, Pedersen A, Steen N, De Soyza A, Thomson R, Paleri V, Wilson JA. Quality compared to quantity of life in laryngeal cancer: A time trade-off study. Head Neck. 2016 Apr;38 Suppl 1:E631-7. doi: 10.1002/hed.24061.

BACKGROUND: The purpose of this study was to use time trade-off to assess the factors influencing patients’ decisions

in advanced laryngeal cancer. Time trade-off is a well-established method of assessing how individuals value a particular

health state. METHODS: We developed vignettes depicting life after chemoradiotherapy or laryngectomy. One hundred

fourteen participants ranked them, assigned utility values, and rated the importance of survival on treatment choice. RE-

SULTS: Chemoradiotherapy was preferred by 62% and laryngectomy by 38%. Chemoradiotherapy optimal outcome had the

highest mean utility value (0.64) followed by total laryngectomy optimal outcome (0.56). Total laryngectomy poor outcome

(0.33) was equivalent to chemoradiotherapy poor outcome (0.32).The average survival advantage required for a participant

to change their preferred choice was 2.1 years. CONCLUSION: The functional treatment outcome had a greater effect on

health state utility values than treatment modality. In many individuals, larynx conservation may not be the primary consi-

deration in treatment preference. © 2015 Wiley Periodicals, Inc. Head Neck 38: E631-E637, 2016.

PMID: 25853764Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, Van Hecke W, Frijlink DW, Wattjes MP; PML in Dutch MS Patients Consortium. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 2015 Apr 9;372(15):1474-6. doi: 10.1056/NEJMc1413724.


PMID: 25862010de Lange MM, Hukkelhoven CW, Munster JM, Schneeberger PM, van der Hoek W. Nationwide registry-based ecological analysis of Q fever incidence and pregnancy outcome during an outbreak in the Netherlands.BMJ Open. 2015 Apr 10;5(4):e006821. doi: 10.1136/bmjopen-2014-006821.

OBJECTIVE: Whether areas affected by Q fever during a large outbreak (2008-2010) had higher rates of adverse pregnancy

outcomes than areas not affected by Q fever. DESIGN: Nationwide registry-based ecological study. SETTING: Pregnant wo-

men in areas affected and not affected by Q fever in the Netherlands, 2003-2004 and 2008-2010. PARTICIPANTS: Index

group (N=58,737): pregnant women in 307 areas with more than two Q fever notifications. Reference group (N=310,635):

pregnant women in 921 areas without Q fever notifications. As a baseline, pregnant women in index and reference areas

in the years 2003-2004 were also included in the reference group to estimate the effect of Q fever in 2008-2010, and not

the already existing differences before the outbreak. MAIN OUTCOME MEASURES: Preterm delivery, small for gestational

age, perinatal mortality. RESULTS: In 2008-2010, there was no association between residing in a Q fever-affected area and

both preterm delivery (adjusted OR 1.01 (95% CI 0.94 to 1.08)), and perinatal mortality (adjusted OR 0.87 (95% CI 0.72 to

1.05)). In contrast, we found a weak significant association between residing in a Q fever-affected area in 2008-2010 and

small for gestational age (adjusted OR 1.06 (95% CI 1.01 to 1.12)), with a population-attributable fraction of 0.70% (95% CI

0.07% to 1.34%). We observed no dose-response relation for this outcome with increasing Q fever notifications, and we did

not find a stronger association for women who were in their first trimester of pregnancy during the months of high human

Q fever incidence. CONCLUSIONS: This study found a weak association between residing in a Q fever-affected area and the

pregnancy outcome small for gestational age. Early detection of infection would require mass screening of pregnant women;

this does not seem to be justified considering these results, and the uncertainties about its efficacy and the adverse effects

of antibiotic treatment.

PMID: 25862517Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.

BACKGROUND: The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in

patients with metastatic colorectal cancer is unknown. The CAIRO3 study was designed to determine the efficacy of

maintenance treatment with capecitabine plus bevacizumab versus observation. METHODS: In this open-label, phase 3,

randomised controlled trial, we recruited patients in 64 hospitals in the Netherlands. We included patients older than 18

years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six

3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate

bone marrow, liver, and renal function. Patients were randomly assigned (1:1) to either maintenance treatment with

capecitabine and bevacizumab (maintenance group) or observation (observation group). Randomisation was done centrally

by minimisation, with stratification according to previous adjuvant chemotherapy, response to induction treatment, WHO

performance status, serum lactate dehydrogenase concentration, and treatment centre. Both patients and investigators

were aware of treatment assignment. We assessed disease status every 9 weeks. On first progression (defined as PFS1),

patients in both groups were to receive the induction regimen of CAPOX-B until second progression (PFS2), which was the

study’s primary endpoint. All endpoints were calculated from the time of randomisation. Analyses were done by intention

to treat. This trial is registered with ClinicalTrials.gov, number NCT00442637. FINDINGS: Between May 30, 2007, and Oct

15, 2012, we randomly assigned 558 patients to either the maintenance group (n=279) or the observation group (n=279).


Median follow-up was 48 months (IQR 36-57). The primary endpoint of median PFS2 was significantly improved in patients

on maintenance treatment, and was 8•5 months in the observation group and 11•7 months in the maintenance group (HR

0•67, 95% CI 0•56-0•81, p<0•0001). This difference remained significant when any treatment after PFS1 was conside-

red. Maintenance treatment was well tolerated, although the incidence of hand-foot syndrome was increased (64 [23%]

patients with hand-foot skin reaction during maintenance). The global quality of life did not deteriorate during maintenance

treatment and was clinically not different between treatment groups. INTERPRETATION: Maintenance treatment with

capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does

not compromise quality of life. FUNDING: Dutch Colorectal Cancer Group (DCCG). The DCCG received financial support for the

study from the Commissie Klinische Studies (CKS) of the Dutch Cancer Foundation (KWF), Roche, and Sanofi-Aventis.

PMID: 25867514Ballak D, van Asseldonk EJP, van Diepen JA, Jansen HJ, Hijmans A, Joosten A, Tack CJ, Netea MG, Stienstra R. TLR-3 is present in human adipocytes, but its signalling is not required for obesity-induced inflammation in adipose tissue in vivo. Plos One. E0123152, 2015.

Innate immunity plays a pivotal role in obesity-induced low-grade inflammation originating from adipose tissue. Key recep-

tors of the innate immune system including Toll-like receptors-2 and -4 (TLRs) are triggered by nutrient excess to promote

inflammation. The role of other TLRs in this process is largely unknown. In addition to double-stranded viral mRNA, TLR-3

can also recognize mRNA from dying endogenous cells, a process that is frequently observed within obese adipose tissue.

Here, we identified profound expression of TLR-3 in adipocytes and investigated its role during diet-induced obesity. Human

adipose tissue biopsies (n=80) and an adipocyte cell-line were used to study TLR-3 expression and function. TLR-3-/- and

WT animals were exposed to a high-fat diet (HFD) for 16 weeks to induce obesity. Expression of TLR-3 was significantly

higher in human adipocytes compared to the non-adipocyte cells part of the adipose tissue. In vitro, TLR-3 expression was

induced during differentiation of adipocytes and stimulation of the receptor led to elevated expression of pro-inflammatory

cytokines. In vivo, TLR-3 deficiency did not significantly influence HFD-induced obesity, insulin sensitivity or inflammation.

In humans, TLR-3 expression in adipose tissue did not correlate with BMI or insulin sensitivity (HOMA-IR). Together, our

results demonstrate that TLR-3 is highly expressed in adipocytes and functionally active. However, TLR-3 appears to play a

redundant role in obesity-induced inflammation and insulin resistance.

PMID: 25894620 Wassenaar A, van den Boogaard M, van Achterberg T, Slooter AJ, Kuiper MA, Hoogendoorn ME, Simons KS, Maseda E, Pinto N, Jones C, Luetz A, Schandl A, Verbrugghe W, Aitken LM, van Haren FM, Donders AR, Schoonhoven L, Pickkers P. Multinational development and validation of an early prediction model for delirium in ICU patients. Intensive Care Med. 2015 Jun;41(6):1048-56

RATIONALE: Delirium incidence in intensive care unit (ICU) patients is high and associated with poor outcome. Identification

of high-risk patients may facilitate its prevention. PURPOSE: To develop and validate a model based on data available at ICU

admission to predict delirium development during a patient’s complete ICU stay and to determine the predictive value of this

model in relation to the time of delirium development. METHODS: Prospective cohort study in 13 ICUs from seven coun-

tries. Multiple logistic regression analysis was used to develop the early prediction (E-PRE-DELIRIC) model on data of the

first two-thirds and validated on data of the last one-third of the patients from every participating ICU. RESULTS: In total,

2914 patients were included. Delirium incidence was 23.6%. The E-PRE-DELIRIC model consists of nine predictors assessed

at ICU admission: age, history of cognitive impairment, history of alcohol abuse, blood urea nitrogen, admission category,

urgent admission, mean arterial blood pressure, use of corticosteroids, and respiratory failure. The area under the receiver

operating characteristic curve (AUROC) was 0.76 [95% confidence interval (CI) 0.73-0.77] in the development dataset and


0.75 (95% CI 0.71-0.79) in the validation dataset. The model was well calibrated. AUROC increased from 0.70 (95% CI 0.67-

0.74), for delirium that developed <2 days, to 0.81 (95% CI 0.78-0.84), for delirium that developed >6 days. CONCLUSION:

Patients’ delirium risk for the complete ICU length of stay can be predicted at admission using the E-PRE-DELIRIC model,

allowing early preventive interventions aimed to reduce incidence and severity of ICU delirium.

PMID: 25900905Moolenaar LM, Cissen M, de Bruin JP, Hompes PG, Repping S, van der Veen F, Mol BW. Cost-effectiveness of assisted conception for male subfertility. Reprod Biomed Online. 2015 Feb 24. pii: S1472-6483(15)00093-0. doi: 10.1016/j.rbmo.2015.02.006. [Epub ahead of print]

Intrauterine insemination (IUI), with or without ovarian stimulation, IVF and intracytoplasmatic sperm injection (ICSI) are

frequently used treatments for couples with male subfertility. No consensus has been reached on specific cut-off values for

semen parameters, at which IVF would be advocated over IUI and ICSI over IVF. The aim of this study was to evaluate the

cost-effectiveness of interventions for male subfertility according to total motile sperm count (TMSC). A computer-simulated

cohort of subfertile women aged 30 years with a partner was analysed with a pre-wash TMSC of 0 to 10 million. Three tre-

atments were evaluated: IUI with and without controlled ovarian stimulation; IVF; and ICSI. Main outcome was expected live

birth; secondary outcomes were cost per couple and the incremental cost-effectiveness ratio. The choice of IVF over IUI with

ovarian stimulation and ICSI over IVF depends on the willingness to pay for an extra live birth. If only cost per live birth is

considered for each treatment, above a pre-wash TMSC of 3 million, IUI is less costly than IVF and, below a pre-wash, TMSC

of 3 million ICSI is less costly. Effectiveness needs to be confirmed in a large randomized controlled trial.

PMID: 25908965Van de Sande-Bruinsma N, Leverstein van Hall MA, Janssen M, Nagtzaam N, Leenders S, de Greeff SC, Schneeberger PM. Impact of livestock-associated MRSA in a hospital setting. Antimicrob Resist Infect Control. 2015 Apr 17;4:11. doi: 10.1186/s13756-015-0053-8. eCollection 2015.

OBJECTIVES: The Netherlands is known for a stringent search and destroy policy to prevent spread of MRSA. In the hospital

setting, livestock-associated MRSA (LA-MRSA) is frequently found in patients coming from the high density farming area in

the south of the Netherlands. The aim of the study was to determine the contribution of LA-MRSA in the epidemiology of

MRSA in cases found following the Dutch search and destroy policy. PATIENTS AND METHODS: From two hospitals serving a

population of 550,000 persons all data on MRSA cultures and subsequent control measures from 2008 and 2009 were re-

trospectively collected and analyzed. RESULTS: A total of 3856 potential index patients were screened for MRSA, 373 (9.7%)

were found to be positive, 292 ( 78%) LA-MRSA and 81 (22%) non-LA-MRSA respectively. No secondary cases were found

among contact research in persons exposed to LA-MRSA (0/416), whereas similar contact research for non-LA-MRSA

resulted in 83 (2.5%) secondary cases. LA-MRSA were rarely found to cause infections. CONCLUSIONS: LA-MRSA is more

prevalent than non-LA-MRSA in Dutch Hospitals in the South of the Netherlands. However, retrospectively studied cases

show that the transmission rate for LA-MRSA was much lower than for non-LA-MRSA. This suggest that infection control

practices for LA-MRSA may possibly be less stringent than for non-LA-MRSA.


PMID: 25916606Vogelaar FJ, Abegg R, van der Linden JC, Cornelisse HG, van Dorsten FR, Lemmens VE, Bosscha K. Epidural analgesia associated with better survival in colon cancer. Int J Colorectal Dis. 2015 Aug;30(8):1103-7. doi: 10.1007/s00384-015-2224-8.

PURPOSE: Surgery remains the mainstay of treatment for potentially curable colon cancer. Otherwise, the surgical stress

response might increase the likelihood of cancer dissemination during and after cancer surgery. There is growing evidence

that the type of anaesthesia during cancer surgery plays a role in the metastatic process. Therefore, we assessed if the

method of anaesthesia is associated with long-term survival after colon cancer surgery. METHOD: A retrospective single-

centre study was conducted including 588 patients who underwent colorectal cancer surgery, TNM stage I-IV, in the Jeroen

Bosch Hospital between 1995 and 2003. The Cox proportional hazard model was used for statistical analysis. Adjustments

were made for age, sex, comorbidity, TNM stage, chemotherapy, emergency surgery status and year of incidence. RESULTS:

Of the 588 primary colon cancer patients with a median age of 70 years, 399 (68 %) patients underwent colon surgery

with epidural anaesthesia, whilst 189 (32 %) patients were operated without epidural anaesthesia. Five-year survival for

patients not receiving epidural analgesia was 42 % versus 51 % for patients receiving epidural analgesia (p = 0.03). This

effect remained after adjustment for relevant patient, tumour, and treatment characteristics (hazard ratio (HR) 1.30 (95 %

confidence interval (CI) 1.05-1.59), p = 0.01). Subgroup analysis in patients of 80 years and older (n = 100) showed also a

better overall survival after receiving epidural analgesia (HR 1.74 (95 % CI 1.11-2.72), p = 0.01). CONCLUSION: Epidural

analgesia during colon cancer surgery was associated with a better overall survival. Prospective trials evaluating the effects

of locoregional analgesia on colon cancer recurrence are warranted.

PMID: 25923503Knol W, Verduijn MM, Lelie-van der Zande AC, van Marum RJ, Brouwers JR, van der Cammen TJ, Petrovic M, Jansen PA. Detecting inappropriate medication in older people: the revised STOPP/START criteria. Ned Tijdschr Geneeskd. 2015;159:A8904. Review. Dutch.

The use of potentially inappropriate medications (PIMs) by older people and potential prescribing omissions (PPOs) repre-

sent a serious problem. It increases the risk of adverse drug reactions (ADRs), however it is susceptible to influence in a

substantial number of cases. Use of the STOPP/START criteria developed in Ireland to optimise pharmacotherapy of older

people reduces the number of ADRs and medication errors. Licensing of new drugs, the increased number of potentially

inappropriate drugs, and the availability of new literature were grounds for an update of the first version of the STOPP/

START criteria which was published in 2008. In order to develop a screening tool with a broader application, a consensus

panel of experts in the field of pharmacotherapy of older people was selected from 14 European countries for the second

version of the STOPP/START criteria, including two from the Netherlands. The translation of the second version of the

STOPP/START criteria has been adapted to the situation in the Netherlands, partly by omitting drugs that are not licensed in

the Netherlands.

PMID: 25924761Pennings JL, Kremers MN, Hodemaekers HM, Hagenaars JC, Koning OH, Renders NH, Hermans MH, de Klerk A, Notermans DW, Wever PC, Janssen R. Dysregulation of serum gamma interferon levels in vascular chronic Q Fever patients provides insights into disease pathogenesis. Clin Vaccine Immunol. 2015 Jun;22(6):664-71.

A large community outbreak of Q fever occurred in the Netherlands in the period 2007 to 2010. Some of the infected

patients developed chronic Q fever, which typically includes pathogen dissemination to predisposed cardiovascular sites, with

potentially fatal consequences. To identify the immune mechanisms responsible for ineffective clearance of Coxiella burnetii


in patients who developed chronic Q fever, we compared serum concentrations of 47 inflammation-associated markers

among patients with acute Q fever, vascular chronic Q fever, and past resolved Q fever. Serum levels of gamma interferon

were strongly increased in acute but not in vascular chronic Q fever patients, compared to past resolved Q fever patients. In-

terleukin-18 levels showed a comparable increase in acute as well as vascular chronic Q fever patients. Additionally, vascular

chronic Q fever patients had lower serum levels of gamma interferon-inducible protein 10 (IP-10) and transforming growth

factor κ (TGF-κ) than did acute Q fever patients. Serum responses for these and other markers indicate that type I immune

responses to C. burnetii are affected in chronic Q fever patients. This may be attributed to an affected immune system in

cardiovascular patients, which enables local C. burnetii replication at affected cardiovascular sites.

PMID: 25924761 Pennings JL, Kremers MN, Hodemaekers HM, Hagenaars JC, Koning OH, Renders NH, Hermans MH, de Klerk A, Notermans DW, Wever PC, Janssen R. Dysregulation of serum gamma interferon levels in vascular chronic Q Fever patients provides insights into disease pathogenesis. Clin Vaccine Immunol. 2015 Jun;22(6):664-71. doi: 10.1128/CVI.00078-15. Epub 2015 Apr 29.

A large community outbreak of Q fever occurred in the Netherlands in the period 2007 to 2010. Some of the infected

patients developed chronic Q fever, which typically includes pathogen dissemination to predisposed cardiovascular sites, with

potentially fatal consequences. To identify the immune mechanisms responsible for ineffective clearance of Coxiella burnetii

in patients who developed chronic Q fever, we compared serum concentrations of 47 inflammation-associated markers

among patients with acute Q fever, vascular chronic Q fever, and past resolved Q fever. Serum levels of gamma interferon

were strongly increased in acute but not in vascular chronic Q fever patients, compared to past resolved Q fever patients. In-

terleukin-18 levels showed a comparable increase in acute as well as vascular chronic Q fever patients. Additionally, vascular

chronic Q fever patients had lower serum levels of gamma interferon-inducible protein 10 (IP-10) and transforming growth

factor κ (TGF-κ) than did acute Q fever patients. Serum responses for these and other markers indicate that type I immune

responses to C. burnetii are affected in chronic Q fever patients. This may be attributed to an affected immune system in

cardiovascular patients, which enables local C. burnetii replication at affected cardiovascular sites.

PMID: 25947329de Jong PG, Quenby S, Bloemenkamp KW, Braams-Lisman BA, de Bruin JP, Coomarasamy A, David M, DeSancho MT, van der Heijden OW, Hoek A, Hutten BA, Jochmans K, Koks CA, Kuchenbecker WK, Mol BW, Torrance HL, Scheepers HC, Stephenson MD, Verhoeve HR, Visser J, de Vries JI, Goddijn M, Middeldorp S.ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial. Trials. 2015 May 7;16(1):208.

BACKGROUND: A large number of studies have shown an association between inherited thrombophilia and recurrent

miscarriage. It has been hypothesized that anticoagulant therapy might reduce the number of miscarriages and stillbirth in

these women. In the absence of randomized controlled trials evaluating the efficacy of anticoagulant therapy in women with

inherited thrombophilia and recurrent miscarriage, a randomized trial with adequate power that addresses this question is

needed. The objective of the ALIFE2 study is therefore to evaluate the efficacy of low-molecular-weight heparin (LMWH) in

women with inherited thrombophilia and recurrent miscarriage, with live birth as the primary outcome. METHODS/DESIGN:

Randomized study of LMWH plus standard pregnancy surveillance versus standard pregnancy surveillance alone. STUDY

POPULATION: pregnant women of less than 7 weeks’ gestation, and confirmed inherited thrombophilia with a history of 2

or more miscarriages or intra-uterine fetal deaths, or both. SETTING: multi-center study in centers from the Dutch Con-

sortium of Fertility studies; centers outside the Netherlands are currently preparing to participate. INTERVENTION: LMWH

enoxaparin 40 mg subcutaneously once daily started prior to 7 weeks gestational age plus standard pregnancy surveillance


or standard pregnancy surveillance alone. Main study parameters/endpoints: the primary efficacy outcome is live birth.

Secondary efficacy outcomes include adverse pregnancy outcomes, such as miscarriage, pre-eclampsia, syndrome of

hemolysis, elevated liver enzymes and low platelets (HELLP syndrome), fetal growth restriction, placental abruption,

premature delivery and congenital malformations. Safety outcomes include bleeding episodes, thrombocytopenia and

skin reactions. DISCUSSION: After an initial period of slow recruitment, the recruitment rate for the study has increased.

Improved awareness of the study and acknowledgement of the need for evidence are thought to be contributing to the

improved recruitment rates. We aim to increase the number of recruiting centers in order to increase enrollment into the

ALIFE2 study. The study website can be accessed via www.ALIFE2study.org. TRIAL REGISTRATION: The ALIFE2 study was

registered on 19 March 2012 under registration number NTR3361.

PMID: 25970678van Marum RJ, Koopmans RT, Bouvy M. Does it still make sense? Deprescribing in the frail elderly. Ned Tijdschr Geneeskd. 2015;159:A8947. Review. Dutch.

Elderly patients with multimorbidity often take several chronically used medicines. A large part of this polypharmacy is

preventive in intention. Although one would expect that, at the end of life, the ratio of preventive therapy, would decrease

in proportion to symptomatic treatment, this appears often not to be the case in practice. Although patients seem to be

open to stopping medication, physicians seem to find it difficult to deprescribe preventive medication in particular. One

of the major reasons for this is uncertainty about the potential clinical consequences of deprescribing. Since frail elderly

people seldom participate in clinical drug trials, clear information is not available for this patient group on the balance

between the chance of efficacy and the risk of harm of drug therapy. Discussion with the patient about his or her prefe-

rences and options with respect to drug therapy is the basis for all subsequent steps and must form part of the periodic

reviews of medication.

PMID: 25972028Boersma D, Smulders DL, Bakker OJ, van den Haak RF, Verhoeven BA, Koning OH. Endovenous laser ablation of insufficient perforating veins: Energy is key to success. Vascular. 2016 Apr;24(2):144-9. doi: 10.1177/1708538115587214. Epub 2015 May 12.

OBJECTIVE: To evaluate the feasibility and anatomical success of endovenous laser ablation (EVLA) of incompetent perfo-

rating veins (IPV). METHODS: All 135 consecutive patients with IPV treated with ELVA (intention-to-treat) from January

2008 to December 2013 were included. Up to the end of 2011, an 810-nm laserset (14 W) was used, and afterwards, a

1470-nm laserset (6 W) was introduced. Duplex ultrasound was performed at 6 weeks’ follow-up to assess anatomical

success. RESULTS: Overall anatomical success at 6 weeks’ follow-up was 56%. Anatomical success was 63% after treat-

ment with 810 nm and 45% with 1470 nm (p = 0.035). This difference in the success rate seems associated with the signi-

ficantly higher amount of energy delivered in the 810 nm cohort (560 J) versus 1470 nm (186 J). Regardless of the type

of laser, anatomical success was significantly higher after treatment with more than 400 J (66%) compared with 0-200 J

(40%, p = 0.009) and 200-400 J (43%, p = 0.029). Complications were limited to two cases of transient paresthesia. CON-

CLUSIONS: EVLA of IPVs is safe and feasible. The amount of energy is highly important in achieving anatomical success.

PMID:25990335Brouwer MW, Tebbe-Gholami M, Starink MV, van Os TA. [Hereditary leiomyomatosis: a woman with red-brown nodules]. Ned Tijdschr Geneeskd. 2015;159: A8867. Dutch.


BACKGROUND: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare disorder involving multiple organ

systems. It is caused by a mutation in the fumarate hydratase (FH) gene. Patients show cutaneous abnormalities or

uterine myomas. Approximately 10% of these patients also develop an aggressive type of renal cell carcinoma. CASE

DESCRIPTION: A 35-year-old woman was referred by her general practitioner with a number of progressive red-brown

nodules on her arms and trunk. A biopsy was taken, revealing cutaneous leiomyoma. On further examination, a small,

benign uterine myoma was found. There were no signs of a renal cell carcinoma. Further diagnostic procedures showed

a FH mutation, confirming the diagnosis of HLRCC. CONCLUSION: HRLCC is a rare condition that can be missed easily

as clinical symptoms are often subtle. Considering the risk of developing an aggressive form of renal cell carcinoma, it is

important to screen these patients thoroughly and to follow them up.

PMID: 25997746Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: apragmatic multi-centre randomised trial. Arthritis Res Ther. 2015 May 22;17(1):134.

INTRODUCTION: For patients with rheumatoid arthritis (RA) whose treatment with a tumour necrosis factor inhibitor

(TNFi) is failing, several biological treatment options are available. Often, another TNFi or a biological with another mode

of action is prescribed. The objective of this study was to compare the effectiveness and cost-effectiveness of three biolo-

gic treatments with different modes of action in patients with RA whose TNFi therapy is failing. METHODS: We conducted

a pragmatic, 1-year randomised trial in a multicentre setting. Patients with active RA despite previous TNFi treatment

were randomised to receive abatacept, rituximab or a different TNFi. The primary outcome (Disease Activity Score in 28

joints) and the secondary outcomes (Health Assessment Questionnaire Disability Index and 36-item Short Form Health

Survey scores) were analysed using linear mixed models. Cost-effectiveness was analysed on the basis of incremental

net monetary benefit, which was based on quality-adjusted life-years (calculated using EQ-5D scores), and all medication

expenditures consumed in 1 year. All analyses were also corrected for possible confounders. RESULTS: Of 144 rando-

mised patients, 5 were excluded and 139 started taking abatacept (43 patients), rituximab (46 patients) or a different

TNFi (50 patients). There were no significant differences between the three groups with respect to multiple measures of

RA outcomes. However, our analysis revealed that rituximab therapy is significantly more cost-effective than both aba-

tacept and TNFi over a willingness-to-pay range of 0 to 80,000 euros. CONCLUSIONS: All three treatment options were

similarly effective; however, when costs were factored into the treatment decision, rituximab was the best option available

to patients whose first TNFi treatment failed. However, generalization of these costs to other countries should be under-

taken carefully. TRIAL REGISTRATION: Netherlands Trial Register number NTR1605. Registered 24 December 2008.

PMID: 26001830Gathier PP, Schönberger TJ. A man with an infected finger: a case report. J Med Case Rep. 2015 May 23;9(1):119. [Epub ahead of print]

Whitlow is an infection of a finger or around the fingernails, generally caused by bacterium. However, in rare cases, it

may also be caused by the herpes simplex virus. As herpetic whitlow is not seen often, it may go under-recognised or be

mistaken for a different kind of infection of the finger. Delayed recognition and/or treatment puts patients at risk of com-

plications ranging from superinfection to herpetic encephalitis. CASE PRESENTATION: A 23-year-old Caucasian man with

no medical history was referred by his primary care physician because of erythema and swelling of the little finger of his

left hand. The primary care physician had already treated him with the oral antibiotic Augmentin® (amoxicillin-clavulanic

acid) and incision of the finger, but this had not resolved his complaints. He had multiple vesicles on the finger, which led


to the diagnosis of herpetic whitlow, which we confirmed by polymerase chain reaction testing. All cutaneous abnorma-

lities disappeared after treatment. CONCLUSIONS: Whitlow is rarely caused by the herpes simplex virus, but this disease

requires a swift recognition and treatment to prevent complications. This case serves to emphasise that not all whitlow is

caused by a bacterial infection, and that it is important to differentiate between herpetic and bacterial whitlow, as these

diseases require a different treatment.

PMID: 26010573Vermeij A. Claassen JA, Dautzenberg PL, Kessels RP. Transfer and maintenance effects of online working-memory training in normal ageing and mild cognitive impairment. Neuropsychol Rehabil. 2015 May 26:1-27. [Epub ahead of print] DOI: 10.1080/09602011.2015.1048694.

Working memory (WM) is one of the cognitive functions that is susceptible to ageing-related decline. Interventions that

are able to improve WM functioning at older age are thus highly relevant. In this pilot study, we explored the transfer

effects of core WM training on the WM domain and other cognitive domains in 23 healthy older adults and 18 patients

with amnestic mild cognitive impairment (MCI). Performance on neuropsychological tests was assessed before and after

completion of the online five-week adaptive WM training, and after a three-month follow-up period. After training, both

groups improved on the Digit Span and Spatial Span, gains that were maintained at follow-up. At an individual level, a

limited number of participants showed reliable training gain. Healthy older adults, and to a lesser extent MCI patients,

additionally improved on figural fluency at group level, but not at individual level. Results furthermore showed that global

brain atrophy and hippocampal atrophy, as assessed by MRI, may negatively affect training outcome. Our study examined

core WM training, showing gains on trained and untrained tasks within the WM domain, but no broad generalisation

to other cognitive domains. More research is needed to evaluate the clinical relevance of these findings and to identify

participant characteristics that are predictive of training gain.

PMID: 26013253Roeters van Lennep JE, Visseren FL, Jira PE. Familial hypercholesterolemia: why screening, counselling and treatment should be integrated. Ned. Tijdschr. Geneeskd. 2015;159.

Familial hypercholesterolemia (FH) is a monogenic autosomal dominant disorder. FH is the most common hereditary

cause of raised serum cholesterol levels and is associated with an increased risk of premature cardiovascular disease

(CVD). This disorder is known to have a genetic cause, and effective drug therapies exist for patients with FH. Successful

cascade screening, within the framework of a national screening programme, gave the Netherlands an international role

as model and pioneer as far as FH detection is concerned. With the ending of this screening programme as of 1 January

2014 the care for FH patients, including screening and counselling has had to be incorporated within the basic Dutch

healthcare insurance system. It is essential that detection of FH should continue in as efficient and cost-effective a man-

ner as possible. Our proposal is that this detection should be performed and co-ordinated by those treating patients with

FH so that FH screening, counselling and treatment are integrated.

PMID: 26016482Van Alfen N, van Eijk JJ, Ennik T, Flynn SO, Nobacht IE, Groothuis JT, Pillen S, van de Laar FA. Incidence of neuralgic amyotrophy (Parsonage Turner syndrome) in a primary care setting--a prospective cohort study. PLoS One. 2015 May 27;10(5):e0128361. doi: 10.1371/journal.pone.0128361. eCollection 2015.

OBJECTIVE: Neuralgic amyotrophy is considered a rare peripheral nervous system disorder but in practice seems grossly

under recognized, which negatively affects care for these patients. In this study we prospectively counted the one-year


incidence rate of classic neuralgic amyotrophy in a primary care setting. METHODS: In a prospective cohort study during

the year 2012 we registered all new cases of neck, shoulder or arm complaints from two large primary care centers

serving a population of 14,118. Prior to study, general practitioners received a short training on how to diagnose classic

neuralgic amyotrophy. Neuralgic amyotrophy was defined according to published criteria irrespective of family history.

Only patients with a classic phenotype were counted as definite cases. After inclusion, patients with suspected neuralgic

amyotrophy who had not yet seen a neurologist were offered neurologic evaluation for diagnostic confirmation. RESULTS:

Of the 492 patients identified with new onset neck, shoulder or arm complaints, 34 were suspected of having neural-

gic amyotrophy. After neurologic evaluation the diagnosis was confirmed in 14 patients. This amounts to a one-year

incidence rate for classic neuralgic amyotrophy of 1 per 1000. CONCLUSIONS: Our findings suggest that neuralgic amyo-

trophy is 30-50 times more common than previously thought. Unawareness of the disorder and its clinical presentation

seems the most likely explanation for this difference. An incidence rate of 1 per 1000 and the long-term sequelae many

patients suffer warrant more vigilance in diagnosing the disorder, to pave the way for timely treatment and prevent

complications.

PMID: 26021944Van der Linden YT, Boersma D, van Poll D, Lips DJ, Prins HA. Single-port laparoscopic appendectomy in children: single center experience in 50 patients. Acta Chir Belg 2015;115:118-122

BACKGROUND: Recent years evolution of minimal invasive laparoscopic procedures led to new techniques, like single-

port laparoscopy (SPL), resulting in nearly-scarless procedures. The purpose of this study is to evaluate that SPL ap-

pendectomy is a safe and feasible procedure using a commercially available trocar (LESS: Laparo Endoscopic Single Site

trocar; Olympus TriPort+) in pediatric patients. METHODS: From July 2011 to March 2014 all patients undergoing SPL

appendectomy under 18 years were included in this retrospective study. Per- en postoperative data were collected in a

prospective database. RESULTS: A total of 50 children (mean age 12 years) diagnosed as acute appendicitis underwent

SPL appendectomy. SPL appendectomy was feasible and safe in all cases, both in non-perforated and perforated appen-

dicitis. In one procedure (2%) an extra trocar was placed. Seven patients (14%) were readmitted to the hospital after initial

uncomplicated postoperative course. One patient (2%) needed reoperation due to a wound abscess. Three patients (6%)

were readmitted due to intra-abdominal abscesses for which antibiotics were given. CONCLUSIONS: SPL appendectomy

is a safe and feasible procedure in children with acute appendicitis.

PMID: 26022247Huijsmans CJ, van den Brule AJ, Rigter H, Poodt J, van der Linden JC, Savelkoul PH, Hilbink M, Hermans MH. Allelic imbalance at the HER2/TOP2A locus in breast cancer. Diagn Pathol. 2015 May 29;10:56. doi: 10.1186/s13000-015-0289-x.

BACKGROUND: Breast cancer is a heterogeneous disease with various histological features and molecular markers. These

are utilized for the prediction of clinical outcome and therapeutic decision making. In addition to well established markers

such as HER2 overexpression and estrogen and progesterone receptor (ER and PR) status, chromosomal instability

is evolving as an important hallmark of cancers. The HER2/TOP2A locus is of great importance in breast cancer. The

copy number variability at this locus has been proposed to be a marker for the degree of chromosomal instability. We

therefore developed a Single Nucleotide Polymorphism (SNP) assay to evaluate allelic imbalance at the HER2/TOP2A

locus in three different entities of primary breast tumors. METHODS: Eleven SNPs were carefully selected and detected

by real time PCR using DNA extracted from paired (histologically normal and tumor) paraffin-embedded tissues. Primary

breast tumors of 44 patients were included, 15 tumors with HER2 overexpression, 16 triple negative tumors, defined

by the absence of HER2 overexpression and a negative ER and PR status and 13 ER and PR positive tumors without


HER2 overexpression. As controls, histologically normal breast tissues from 10 patients with no breast tumor were included.

RESULTS: Allelic imbalance was observed in 13/15 (87 %) HER2 positive tumors, the remaining 2 being inconclusive. Of the

16 triple negative tumors, 12 (75 %) displayed instability, 3 (19 %) displayed no instability, and 1 was inconclusive. Of the 13

hormone receptor positive tumors, 5 (38 %) displayed allelic imbalance, while 8 did not. CONCLUSIONS: We conclude that

the SNP assay is suitable for rapid testing of allelic (im)balance at the HER2/TOP2A locus using paraffin-embedded tissues.

Based on allelic imbalance at this locus, both triple negative and ER and PR positive breast tumors can be subcategorized.

The clinical relevance of the allelic (im)balance status at the HER2/TOP2A locus in breast cancer is subject of future study.

PMID: 26044837Hill CJ, Courtney AE, Cardwell CR, Maxwell AP, Lucarelli G, Veroux M, Furriel F, Cannon RM, Hoogeveen EK, Doshi M, McCaughan JA. Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015 Aug;30(8):1403-11. doi: 10.1093/ndt/gfv214. Epub 2015 Jun 4.

BACKGROUND: The prevalence of obesity is increasing globally and is associated with chronic kidney disease and premature

mortality. However, the impact of recipient obesity on kidney transplant outcomes remains unclear. This study aimed to

investigate the association between recipient obesity and mortality, death-censored graft loss and delayed graft function

(DGF) following kidney transplantation. METHODS: A systematic review and meta-analysis was conducted using Medline,

Embase and the Cochrane Library. Observational studies or randomized controlled trials investigating the association

between recipient obesity at transplantation and mortality, death-censored graft loss and DGF were included. Obesity was

defined as a body mass index (BMI) of ≥30 kg/m(2). Obese recipients were compared with those with a normal BMI (18.5-

24.9 kg/m(2)). Pooled estimates of hazard ratios (HRs) for patient mortality or death-censored graft loss and odds ratios

(ORs) for DGF were calculated. RESULTS: Seventeen studies including 138 081 patients were analysed. After adjustment,

there was no significant difference in mortality risk in obese recipients [HR = 1.24, 95% confidence interval (CI) = 0.90-1.70,

studies = 5, n = 83 416]. However, obesity was associated with an increased risk of death-censored graft loss (HR = 1.06,

95% CI = 1.01-1.12, studies = 5, n = 83 416) and an increased likelihood of DGF (OR = 1.68, 95% CI = 1.39-2.03, studies

= 4, n = 28 847). CONCLUSIONS: Despite having a much higher likelihood of DGF, obese transplant recipients have only a

slightly increased risk of graft loss and experience similar survival to recipients with normal BMI.

PMID: 26053481Drenth-van Maanen AC, van Marum RJ, Jansen PA, Zwart JE, van Solinge WW, Egberts TC. Adherence with Dosing Guideline in Patients with Impaired Renal Function at Hospital Discharge. PLoS One. 2015 Jun 8;10(6):e0128237. doi:10.1371/journal.pone.0128237. eCollection 2015.

OBJECTIVES: To determine the prevalence, determinants, and potential clinical relevance of adherence with the Dutch

dosing guideline in patients with impaired renal function at hospital discharge. DESIGN: Retrospective cohort study between

January 2007 and July 2011. SETTING: Academic teaching hospital in the Netherlands. SUBJECTS: Patients with an

estimated glomerular filtration rate (eGFR) between 10-50 ml/min/1.73 m(2) at discharge and prescribed one or more

medicines of which the dose is renal function dependent. MAIN OUTCOME MEASURES: The prevalence of adherence with

the Dutch renal dosing guideline was investigated, and the influence of possible determinants, such as reporting the eGFR

and severity of renal impairment (severe: eGFR<30 and moderate: eGFR 30-50 ml/min/1.73 m(2)). Furthermore, the po-

tential clinical relevance of non-adherence was assessed. RESULTS: 1327 patients were included, mean age 67 years, mean

eGFR 38 ml/min/1.73 m(2). Adherence with the guideline was present in 53.9% (n=715) of patients. Reporting the eGFR,

which was incorporated since April 2009, resulted in more adherence with the guideline: 50.7% vs. 57.0%, RR 1.12 (95% CI

1.02-1.25). Adherence was less in patients with severe renal impairment (46.0%), compared to patients with moderate renal

impairment (58.1%, RR 0.79; 95% CI 0.70-0.89). 71.4% of the cases of non-adherence had the potential to cause moderate


to severe harm. CONCLUSION: Required dosage adjustments in case of impaired renal function are often not performed at

hospital discharge, which may cause harm to the majority of patients. Reporting the eGFR can be a small and simple first

step to improve adherence with dosing guidelines.

PMID: 26072396Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team. (van Munster IP, Scheffer RC, Römkes TE, Schipper DL) Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002. Epub 2015 Jun 11.

BACKGROUND & AIMS: More than 20% of patients with inflammatory bowel disease (IBD) discontinue thiopurine therapy

because of severe adverse drug reactions (ADRs); leukopenia is one of the most serious ADRs. Variants in the gene encoding

thiopurine S-methyltransferase (TPMT) alter its enzymatic activity, resulting in higher levels of thiopurine metabolites,

which can cause leukopenia. We performed a prospective study to determine whether genotype analysis of TPMT before

thiopurine treatment, and dose selection based on the results, affects the outcomes of patients with IBD. METHODS: In

a study performed at 30 Dutch hospitals, patients were assigned randomly to groups that received standard treatment

(control) or pretreatment screening (intervention) for 3 common variants of TPMT (TPMT*2, TPMT*3A, and TPMT*3C).

Patients in the intervention group found to be heterozygous carriers of a variant received 50% of the standard dose of

thiopurine (azathioprine or 6-mercaptopurine), and patients homozygous for a variant received 0%-10% of the standard

dose. We compared, in an intention-to-treat analysis, outcomes of the intervention (n = 405) and control groups (n = 378)

after 20 weeks of treatment. Primary outcomes were the occurrence of hematologic ADRs (leukocyte count < 3.0*10(9)/L or

reduced platelet count < 100*10(9)/L) and disease activity (based on the Harvey-Bradshaw Index for Crohn’s disease [n =

356] or the partial Mayo score for ulcerative colitis [n = 253]). RESULTS: Similar proportions of patients in the intervention

and control groups developed a hematologic ADR (7.4% vs 7.9%; relative risk, 0.93; 95% confidence interval, 0.57-1.52)

in the 20 weeks of follow-up evaluation; the groups also had similar mean levels of disease activity (P = .18 for Crohn’s

disease and P = .14 for ulcerative colitis). However, a significantly smaller proportion of carriers of the TPMT variants in the

intervention group (2.6%) developed hematologic ADRs compared with patients in the control group (22.9%) (relative risk,

0.11; 95% confidence interval, 0.01-0.85). CONCLUSIONS: Screening for variants in TPMT did not reduce the proportions of

patients with hematologic ADRs during thiopurine treatment for IBD. However, there was a 10-fold reduction in hematologic

ADRs among variant carriers who were identified and received a dose reduction, compared with variant carriers who did not,

without differences in treatment efficacy. ClinicalTrials.gov number: NCT00521950.

PMID: 26079355Lechner TJ, van Wijk MG. Confirming Loss of Resistance for Epidural Analgesia: A New Role for Technology. Reg Anesth Pain Med. 2015 Jul-Aug;40(4):389-90. doi: 10.1097/AAP.0000000000000256.

PMID: 26091833Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N’Dow J, Oddens JR, Babjuk M. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. 2016 Feb;69(2):231-44. doi: 10.1016/j.eururo.2015.05.050.


CONTEXT: The European Association of Urology non-muscle-invasive bladder cancer (NMIBC) guidelines recommend that

all low- and intermediate-risk patients receive a single immediate instillation of chemotherapy after transurethral resection

of the bladder (TURB), but its use remains controversial. OBJECTIVE: To identify which NMIBC patients benefit from a single

immediate instillation. EVIDENCE ACQUISITION: A systematic review and individual patient data (IPD) meta-analysis of

randomized trials comparing the efficacy of a single instillation after TURB with TURB alone in NMIBC patients was carried

out. EVIDENCE SYNTHESIS: A total of 13 eligible studies were identified. IPD were obtained for 11 studies randomizing

2278 eligible patients, 1161 to TURB and 1117 to a single instillation of epirubicin, mitomycin C, pirarubicin, or thiotepa. A

total of 1128 recurrences, 108 progressions, and 460 deaths (59 due to bladder cancer [BCa]) occurred. A single instillation

reduced the risk of recurrence by 35% (hazard ratio [HR]: 0.65; 95% confidence interval [CI], 0.58-0.74; p<0.001) and the

5-yr recurrence rate from 58.8% to 44.8%. The instillation did not reduce recurrences in patients with a prior recurrence

rate of more than one recurrence per year or in patients with an European Organization for Research and Treatment of

Cancer (EORTC) recurrence score ≥5. The instillation did not prolong either the time to progression or death from BCa, but it

resulted in an increase in the overall risk of death (HR: 1.26; 95% CI, 1.05-1.51; p=0.015; 5-yr death rates 12.0% vs 11.2%),

with the difference appearing in patients with an EORTC recurrence score ≥5. CONCLUSIONS: A single immediate instillation

reduced the risk of recurrence, except in patients with a prior recurrence rate of more than one recurrence per year or

an EORTC recurrence score ≥5. It does not prolong either time to progression or death from BCa. The instillation may be

associated with an increase in the risk of death in patients at high risk of recurrence in whom the instillation is not effective

or recommended. PATIENT SUMMARY: A single instillation of chemotherapy immediately after resection reduces the risk of

recurrence in non-muscle-invasive bladder cancer; however, it should not be given to patients at high risk of recurrence due

to its lack of efficacy in this subgroup.

PMID: 26095016Keijsers CJ, Ross S. A pharmacological approach to education.Br J Clin Pharmacol. 2015 Sep;80(3):329-30. doi: 10.1111/bcp.12700. Epub 2015 Jul 22. No abstract available.

PMID: 26096416Dautzenberg L, Jessurum N, Dautzenberg PL, Keijsers CJ. Reversible Methotrexate-Induced Dementia: A Case Report. J Am Geriatr Soc. 2015 Jun;63(6):1273-4. doi: 10.1111/jgs.13517. No abstract available.

PMID: 26104005 Claassen B, Barneveld PC, Jager G, Rutten MJ. Abdominal splenosis. Ned Tijdschr Geneeskd. 2015;159:A8880.

Splenosis is a common benign finding that occurs after splenic trauma or after splenectomy. It is auto-transplantation of

splenic tissue and can be seen intra-abdominally, intra-thoracically and even subcutaneously. Splenosis is usually found

incidentally at laparoscopy, laparotomy or on radiological examination and is mostly asymptomatic. Treatment is only

required if a patient complains of abdominal pain, obstruction or bleeding. On radiological examination splenosis can mimic

a metastatic malignant disease. For this reason it is important to recognise splenosis and know the patient’s medical history

concerning splenic trauma or splenectomy, thus avoiding diagnostic laparoscopy or ultrasound guided biopsy. This paper

presents two patients with splenosis. Additionally, we describe how to diagnose this entity by scintigraphy with (99m)

Technetium-labelled heat-denatured erythrocytes.


PMID: 26105574 Kip MM, Kusters R, Ijzerman MJ, Steuten LM. A PCT algorithm for discontinuation of antibiotic therapy is a safe and cost-effective intervention to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ. 2015 Nov;18(11):944-53. doi: 10.3111/13696998.2015.1064934. Epub 2015 Jul 20.

OBJECTIVE: Procalcitonin (PCT) is a specific marker for differentiating bacterial from non-infective causes of inflammation. It

can be used to guide initiation and duration of antibiotic therapy in intensive care unit (ICU) patients with suspected sepsis,

and might reduce the duration of hospital stay. Limiting antibiotic treatment duration is highly important because antibiotic

over-use may cause patient harm, prolonged hospital stay, and resistance development. Several systematic reviews show

that a PCT algorithm for antibiotic discontinuation is safe, but upfront investment required for PCT remains an important

barrier against implementation. The current study investigates to what extent this PCT algorithm is a cost-effective use

of scarce healthcare resources in ICU patients with sepsis compared to current practice. METHODS: A decision tree was

developed to estimate the health economic consequences of the PCT algorithm for antibiotic discontinuation from a Dutch

hospital perspective. Input data were obtained from a systematic literature review. When necessary, additional information

was gathered from open interviews with clinical chemists and intensivists. The primary effectiveness measure is defined as

the number of antibiotic days, and cost-effectiveness is expressed as incremental costs per antibiotic day avoided. RESULTS:

The PCT algorithm for antibiotic discontinuation is expected to reduce hospital spending by circa κ 3503 per patient, indi-

cating savings of 9.2%. Savings are mainly due to reductions in length of hospital stay, number of blood cultures performed,

and, importantly, days on antibiotic therapy. Probabilistic and one-way sensitivity analyses showed the model outcome to be

robust against changes in model inputs. CONCLUSION: Proven safe, a PCT algorithm for antibiotic discontinuation is a cost-

effective means of reducing antibiotic exposure in adult ICU patients with sepsis, compared to current practice. Additional

resources required for PCT are more than offset by downstream cost savings. This finding is highly important given the aim

of preventing widespread antibiotic resistance.

PMID: 26123742Visser NC, Bulten J, van der Wurff AA, Boss EA, Bronkhorst CM, Feijen HW, Haartsen JE, van Herk HA, de Kievit IM, Klinkhamer PJ, Pijlman BM, Snijders MP, Vandenput I, Vos MC, de Wit PE, van de Poll-Franse LV, Massuger LF, Pijnenborg JM. PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study. BMC Cancer. 2015 Jun 30;15:487

BACKGROUND: Endometrial carcinoma is the most common gynaecologic malignancy in industrialised countries and the

incidence is still rising. Primary treatment is based on preoperative risk classification and consists in most cases of hyste-

rectomy with bilateral salpingo-oophorectomy. In patients with serous and clear cell histology a complete surgical staging is

mandatory. However, in routine clinical practice final histology regularly does not correspond with the preoperative histolo-

gical diagnosis. This results in both over and under treatment. METHODS/DESIGN: The aim of this multicentre, prospective

cohort study is to select a panel of prognostic biomarkers to improve preoperative diagnosis of endometrial carcinoma in

order to identify those patients that need extended surgery and/or additional treatment. Additionally, we will determine

whether incorporation of cervical cytology and comorbidity could improve this preoperative risk classification. All patients

treated for endometrial carcinoma in the participating hospitals from September 2011 till December 2013 are included.

Patient characteristics, as well as comorbidity are registered. Patients without preoperative histology, history of hysterectomy

and/or endometrial carcinoma or no surgical treatment including hysterectomy are excluded. The preoperative histology

and final pathology will be reviewed and compared by expert pathologists. Additional immunohistochemical analysis of

IMP3, p53, ER, PR, MLH1, PTEN, beta-catenin, p16, Ki-67, stathmin, ARID1A and L1CAM will be performed. Preoperative

histology will be compared with the final pathology results. Follow-up will be at least 24 months to determine risk factors for


recurrence and outcome. DISCUSSION: This study is designed to improve surgical treatment of endometrial carcinoma pa-

tients. A total of 432 endometrial carcinoma patients were enrolled between 2011 and 2013. Follow-up will be completed

in 2015. Preoperative histology will be evaluated systematically and background endometrium will be classified. This is the

first study incorporating immunohistochemistry, cervical cytology and comorbidity to define the optimal panel of prognostic

biomarkers that contribute in clinical decision making in the management of endometrial carcinoma. TRIAL REGISTRATION:

Netherlands Trial Register number NTR3503.

PMID: 26132155Morroy G, van der Hoek W, Albers J, Coutinho RA, Bleeker-Rovers CP, Schneeberger PM. Population Screening for Chronic Q-Fever Seven Years after a Major Outbreak. PLoS One. 2015 Jul 1;10(7):e0131777. doi: 10.1371/journal.pone.0131777. eCollection 2015.

INTRODUCTION: From 2007 through 2010, the Netherlands experienced a large Q-fever epidemic, with 4,107 notifications.

The most serious complication of Q-fever is chronic Q-fever. METHOD: In 2014, we contacted all 2,161 adult inhabitants

of the first village in the Netherlands affected by the Q-fever epidemic and offered to test for antibodies against Coxiella

burnetii using immunofluorescence assay (IFA) to screen for chronic infections and assess whether large-scale popula-

tion screening elsewhere is warranted. RESULTS: Of the 1,517 participants, 33.8% were IFA-positive. Six IFA-positive

participants had an IgG phase I titer ≥1:512. Two of these six participants were previously diagnosed with chronic Q-fever.

Chronic infection was diagnosed in one of the other four participants after clinical examination. CONCLUSIONS: Seven years

after the initial outbreak, seroprevalence remains high, but the yield of screening the general population for chronic Q-fever

is low. A policy of screening known high-risk groups for chronic Q-fever in outbreak areas directly following an outbreak

might be more efficient than population screening. A cost-effectiveness analysis should also be performed before initiating a

population screening program for chronic Q-fever.

PMID: 26149449Eppenga WL, Wester WN, Derijks HJ, Hoedemakers RM, Wensing M, De Smet PA, Van Marum RJ. Fluctuation of the renal function after discharge from hospital and its effects on drug dosing in elderly patients--study protocol. BMC Nephrol. 2015 Jul 7;16:95. doi: 10.1186/s12882-015-0095-4.

BACKGROUND: Chronic kidney disease (CKD) is associated with an increased mortality rate, risk of cardiovascular events

and morbidity. Impaired renal function is common in elderly patients, and their glomerular filtration rate (GFR) should be

taken into account when prescribing renally excreted drugs. In a hospital care setting the GFR may fluctuate substantially,

so that the renal function group and therefore the recommended dose, can change within a few days. The magnitude and

prevalence of the fluctuation of renal function in daily clinical practice and its potential effects on appropriateness of drug

prescriptions after discharge from the hospital is unknown. METHODS/DESIGN: This is a prospective observational study.

Patients ≥ 70 years with renal impairment (eGFR < 60 ml/min/1.73 m(2)) admitted to a geriatric ward are eligible to partici-

pate. Participants undergo blood sample collection to measure serum creatinine level at three time points: at discharge from

hospital, 14 days, and 2 months after discharge. At these time points the actual medication of the participants is assessed

and the number of incorrect prescriptions according to the Dutch guidelines in relation to their estimated renal function is

measured. In addition, for a hypothetical selection of drugs, the need for drug dose adaptation in relation to renal function

is measured. The outcome of interest is the percentage of patients that changes from renal function group after discharge

from hospital compared to the renal function at discharge. In addition, the percentages of patients whose actual medicati-

ons are incorrectly prescribed and for the hypothetical selection of drugs that would have required dose adaptation will be

determined at discharge, 14 days and 2 months after discharge. For each outcome, risk factors which may lead to increased


risk for fluctuation of renal function and/or incorrect drug prescribing will also be identified and analysed.DISCUSSION: This

study will provide data on changes in renal function in elderly patients after discharge from the hospital with a focus on the

medications used. The benefits for healthcare professionals comprise of the creation, adjustment or confirmation of recom-

mendations for the monitoring of the renal function after discharge from hospital of elderly patients.

PMID 26153882Jie KE, van Dam LF, Hammacher ER. Isolated fat pad sign in acute elbow injury: is it clinically relevant?Eur J Emerg Med. 2016 Jun;23(3):228-31.

An isolated fat pad sign (i.e. joint effusion without a visible fracture), commonly seen in acute elbow injury, is associated with

occult fracture and treated as such. However, the clinical relevance of an isolated fat pad is unclear, thereby questioning the

need for specialized follow-up. In this study, 111 patients (median age 15 years, interquartile range 9-27 years) with an

isolated fat pad sign after acute elbow injury were included. The clinical relevance of an isolated fat pad sign was derived

from descriptives on pain, elbow function, treatment change, number of revisits and recovery time after 1 week follow-up

and long-term follow-up. Treatment alterations were rarely made and none of the patients needed an operative interven-

tion; also, none of the patients had persistent symptoms. The median recovery time was 3 weeks (interquartile range 2-12

weeks). This study shows that, unless symptoms persist or worsen, regular follow-up at a specialized outpatient clinic is not

needed.

PMID: 26156651Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators (Biesma B.). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 16(8):897-907, 2015. doi: 10.1016/S1470-2045(15)00006-6.

BACKGROUND: There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the

lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase

inhibitor), as second-line treatment for patients with advanced squamous cell carcinoma of the lung. METHODS: We did

this open-label, phase 3 randomised controlled trial at 183 cancer centres in 23 countries worldwide. We enrolled adults

with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-

chemotherapy. Participants were randomly assigned (1:1) to receive afatinib (40 mg per day) or erlotinib (150 mg per day)

until disease progression. The randomisation was done centrally with an interactive voice or web-based response system

and stratified by ethnic origin (eastern Asian vs non-eastern Asian). Clinicians and patients were not masked to treatment

allocation. The primary endpoint was progression-free survival assessed by independent central review (intention-to-treat

population). The key secondary endpoint was overall survival. This trial is registered with ClinicalTrials.gov, NCT01523587.

FINDINGS: 795 eligible patients were randomly assigned (398 to afatinib, 397 to erlotinib). Median follow-up at the time

of the primary analysis of progression-free survival was 6•7 months (IQR 3•1-10•2), at which point enrolment was not

complete. Progression free-survival at the primary analysis was significantly longer with afatinib than with erlotinib (median

2•4 months [95% CI 1•9-2•9] vs 1•9 months [1•9-2•2]; hazard ratio [HR] 0•82 [95% CI 0•68-1•00], p=0•0427). At the

time of the primary analysis of overall survival (median follow-up 18•4 months [IQR 13•8-22•4]), overall survival was

significantly greater in the afatinib group than in the erloinib group (median 7•9 months [95% CI 7•2-8•7] vs 6•8 months

[5•9-7•8]; HR 0•81 [95% CI 0•69-0•95], p=0•0077), as were progression-free survival (median 2•6 months [95% CI 2•0-


2•9] vs 1•9 months [1•9-2•1]; HR 0•81 [95% CI 0•69-0•96], p=0•0103) and disease control (201 [51%] of 398 patients

vs 157 [40%] of 397; p=0•0020). The proportion of patients with an objective response did not differ significantly between

groups (22 [6%] vs 11 [3%]; p=0•0551). Tumour shrinkage occurred in 103 (26%) of 398 patients versus 90 (23%) of 397

patients. Adverse event profiles were similar in each group: 224 (57%) of 392 patients in the afatinib group versus 227 (57%)

of 395 in the erlotinib group had grade 3 or higher adverse events. We recorded higher incidences of treatment-related

grade 3 diarrhoea with afatinib (39 [10%] vs nine [2%]), of grade 3 stomatitis with afatinib (16 [4%] vs none), and of grade 3

rash or acne with erlotinib (23 [6%] vs 41 [10%]). INTERPRETATION: The significant improvements in progression-free sur-

vival and overall survival with afatinib compared with erlotinib, along with a manageable safety profile and the convenience

of oral administration suggest that afatinib could be an additional option for the treatment of patients with squamous cell

carcinoma of the lung. FUNDING: Boehringer Ingelheim.

PMID: 26158249Hinnen JW, Konickx MA, Meerwaldt R, Kolkert JL, van der Palen J, Huisman AB, Geelkerken RH. Long Term Results of Kissing Stents in the Aortic Bifurcation. Acta Chir Belg. 2015 May-Jun;115(3):191-7.

BACKGROUND: To evaluate the long-term outcome after aortoiliac kissing stent placement and to analyze variables, which

potentially influence the outcome of endovascular reconstruction of the aortic bifurcation. METHODS: All patients treated

with aortoiliac kissing stents at our institution between April 1995 and August 2011 were retrospectively identified from a

prospective single-center database. Data regarding patient characteristics (age, gender, smoking, cardio- and cerebrovas-

cular risk factors, hyperlipidaemia, diabetes mellitus and use of antihypertensive medication), symptoms, pre-interventional

examination and imaging, procedural details and follow-up were retrieved. Patency rates were calculated with Kaplan-

Meier analysis. Factors affecting the patency were determined with Cox uni- and multivariate analysis. RESULTS: A total of

215 patients (63% men, mean age 61 ± 10 years) were included. The median follow-up period was 31 (IQR 47.1) months.

Primary, primary assisted, and secondary patency rates were 97%, 97%, and 99%, respectively, at one month; 92%, 95% and

94% at four months; 75%, 86%, and 91% at two years; 70%, 81%, and 91% at 5 years; and 67%, 81%, and 91% at ten years.

Younger age and previous aortoiliac treatment were predictors for reduced primary and primary assisted patency. Smoking,

previous aortoiliac intervention, TASC C and D lesions were predictors for reduced secondary patency. CONCLUSIONS: Re-

construction of the aortoiliac bifurcation with kissing stents is feasible, safe and effective in all types of lesions with satisfying

long term patencies. TASC C and D lesions are associated with a higher occlusion rate. Younger age and previous aortoiliac

interventions are predictors for reduced primary and primary assisted patency.

PMID: 26156860Van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ. Rating scales to measure side effects of antipsychotic medication: A systematic review. J Psychopharmacol. 2015 Aug;29(8):857-66. doi: 10.1177/0269881115593893. Epub 2015 Jul 8. Review.

INTRODUCTION: Many patients experience side effects during treatment with antipsychotics. This article reviews the clinical

use and psychometric characteristics of rating scales used to assess side effects in patients treated with antipsychotics.

METHODS: A systematic literature search was performed using the electronic databases PubMed and Embase, with prede-

fined search terms. RESULTS: In total, 52 different scales were used in the 440 articles retrieved. For multiple side effects

measured with one scale, the Udvalg for Kliniske Undersøgelser Side Effects Rating Scale for Clinicians was used the most,

whereas the Liverpool University Neuroleptic Side Effect Rating Scale had the best psychometric characteristics (Cronbach’s

κ 0.81 and test-retest reliability 0.89). The Simpson Angus Scale was used the most to rate extrapyramidal side effects,

although the Maryland Psychiatric Research Center scale had the best characteristics (Cronbach’s κ 0.80, test-retest reli-

ability 0.92 and inter-rater reliability 0.81-0.90). The Arizona Sexual Experience Scale was used the most to assess sexual


dysfunction, but the Antipsychotics and Sexual Functioning Questionnaire and the Nagoya Sexual Functioning Questionnaire

had the best characteristics. CONCLUSION: This review will help researchers and clinicians make a purpose-oriented choice

of which scale to use. SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42014013010.

PMID: 26161658 Wielders CC, van Loenhout JA, Morroy G, Rietveld A, Notermans DW, Wever PC, Renders NH, Leenders AC, van der Hoek W, Schneeberger PM. Long-Term Serological Follow-Up of Acute Q-Fever Patients after a Large Epidemic. PLoS One. 2015 Jul 10;10(7):e0131848. doi: 10.1371/journal.pone.0131848. eCollection 2015.

BACKGROUND: Serological follow-up of acute Q-fever patients is important for detection of chronic infection but there is

no consensus on its frequency and duration. The 2007-2009 Q-fever epidemic in the Netherlands allowed for long-term

follow-up of a large cohort of acute Q-fever patients. The aim of this study was to validate the current follow-up strategy

targeted to identify patients with chronic Q-fever. METHODS: A cohort of adult acute Q-fever patients, diagnosed between

2007 and 2009, for whom a twelve-month follow-up sample was available, was invited to complete a questionnaire and

provide a blood sample, four years after the acute episode. Antibody profiles, determined by immunofluorescence assay in

serum, were investigated with a special focus on high titres of IgG antibodies against phase I of Coxiella burnetii, as these are

considered indicative for possible chronic Q-fever. RESULTS: Of the invited 1,907 patients fulfilling inclusion criteria, 1,289

(67.6%) were included in the analysis. At any time during the four-year follow-up period, 58 (4.5%) patients were classified

as possible, probable, or proven chronic Q-fever according to the Dutch Q-fever Consensus Group criteria (which uses IgG

phase I ≥1:1,024 to as serologic criterion for chronic Q-fever). Fifty-two (89.7%) of these were identified within the first year

after the acute episode. Of the six patients that were detected for the first time at four-year follow-up, five had an IgG phase

I titre of 1:512 at twelve months. CONCLUSIONS: A twelve-month follow-up check after acute Q-fever is recommended as

it adequately detects chronic Q-fever in patients without known risk factors. Additional serological and clinical follow-up is

recommended for patients with IgG phase I ≥1:512, as they showed the highest risk to progress to chronic Q-fever.

PMID: 26170033Reintjes W, Romijn MD, Hollander D, Ter Bruggen JP, van Marum RJ. Reversible Dementia: Two Nursing Home Patients With Voltage-Gated Potassium Channel Antibody-Associated Limbic Encephalitis. J Am Med Dir Assoc. 2015 Sep 1;16(9):790-4. doi: 10.1016/j.jamda.2015.06.008. Epub 2015 Jul 10.

Voltage-gated potassium channel antibody-associated limbic encephalitis (VGKC-LE) is a rare disease that is a diagnostic

and therapeutic challenge for medical practitioners. Two patients with VGKC-LE, both developing dementia are presented.

Following treatment, both patients showed remarkable cognitive and functional improvement enabling them to leave the

psychogeriatric nursing homes they both were admitted to. Patients with VGKC-LE can have a major cognitive and functional

improvement even after a diagnostic delay of more than 1 year. Medical practitioners who treat patients with unexplained

cognitive decline, epileptic seizures, or psychiatric symptoms should be aware of LE as an underlying rare cause.

PMID: 26177672Ebisch R, Rovers MM, Bosgraaf RP, van der Pluijm-Schouten HW, Melchers W, van den Akker P, Massuger L, Bekkers R. Evidence supporting see-and-treat management of cervical intraepithelial neoplasia: a systematic review and meta-analysis. BJOG. 2016 Jan;123(1):59-66. doi: 10.1111/1471-0528.13530. Epub 2015 Jul 14.

BACKGROUND: Studies of see-and-treat management of cervical intraepithelial neoplasia (CIN) vary in their inclusion

criteria, resulting in a broad range of overtreatment rates. OBJECTIVES: To determine overtreatment rates in see-and-treat

management of women referred for colposcopy because of suspected CIN, in order to define circumstances supporting see-


and-treat management. SEARCH STRATEGY: MEDLINE, EMBASE, and the Cochrane Library were searched from inception

up to 12 May 2014. SELECTION CRITERIA: Studies of see-and-treat management in women with a reported cervical

smear result, colposcopic impression, and histology result were included. DATA COLLECTION AND ANALYSIS: Methodological

quality was assessed with the Newcastle-Ottawa scale. We used the inverse variance method for pooling incidences, and a

random-effects model was used to account for heterogeneity between studies. Overtreatment was defined as treatment in

patients with no CIN or CIN1. MAIN RESULTS: Thirteen studies (n = 4611) were included. The overall overtreatment rate

in women with a high-grade cervical smear and a high-grade colposcopic impression was 11.6% (95% CI 7.8-15.3%). The

overtreatment rate in women with a high-grade cervical smear and low-grade colposcopic impression was 29.3% (95% CI

16.7-41.9%), and in the case of a low-grade smear and high-grade colposcopic impression it was 46.4% (95% CI 15.7-

77.1%). In women with a low-grade smear and low-grade colposcopic impression, the overtreatment rate was 72.9% (95%

CI 68.1-77.7%). AUTHOR’S CONCLUSIONS: The pooled overtreatment rate in women with a high-grade smear and high-

grade colposcopic impression is at least comparable with the two-step procedure, which supports the use of see-and-treat

management in this subgroup of women. TWEETABLE ABSTRACT: See-and-treat management is justified in the case of a

high-grade smear and a high-grade colposcopic impression.

PMID: 26183988Moyakine AV, Hermans DJ, Fuijkschot J, van der Vleuten CJ. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development. J Am Acad Dermatol. 2015 Aug;73(2):341-2

PMID: 26210894Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045.

BACKGROUND: There are no prognostic factor publications on stage Ta-T1 non-muscle-invasive bladder cancer (NMIBC)

treated with 1-3 yr of maintenance bacillus Calmette-Guérin (BCG). OBJECTIVE: To determine prognostic factors in NMIBC

patients treated with 1-3 yr of BCG after transurethral resection of the bladder (TURB), to derive nomograms and risk

groups, and to identify high-risk patients who should be considered for early cystectomy. DESIGN, SETTING, AND PAR-

TICIPANTS: Data for 1812 patients were merged from two European Organization for Research and Treatment of Cancer

randomized phase 3 trials in intermediate- and high-risk NMIBC. INTERVENTION: Patients received 1-3 yr of maintenance

BCG after TURB and induction BCG. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prognostic factors for risk of

early recurrence and times to late recurrence, progression, and death were identified in a training data set using multi-

variable models and applied to a validation data set. RESULTS AND LIMITATIONS: With a median follow-up of 7.4 yr, 762

patients recurred; 173 progressed; and 520 died, 83 due to bladder cancer (BCa). Statistically significant prognostic factors

identified by multivariable analyses were prior recurrence rate and number of tumors for recurrence, and tumor stage

and grade for progression and death due to BCa. T1G3 patients do poorly, with 1- and 5-yr disease-progression rates of

11.4% and 19.8%, respectively, and 1- and 5-yr disease-specific death rates of 4.8% and 11.3%. Limitations include lack of

repeat transurethral resection in high-risk patients and exclusion of patients with carcinoma in situ. CONCLUSIONS: NMIBC

patients treated with 1-3 yr of maintenance BCG have a heterogeneous prognosis. Patients at high risk of recurrence and/

or progression do poorly on currently recommended maintenance schedules. Alternative treatments are urgently required.

PATIENT SUMMARY: Non-muscle-invasive bladder cancer patients at high risk of recurrence and/or progression do poorly

on currently recommended bacillus Calmette-Guérin maintenance schedules, and alternative treatments are urgently

required. TRIAL REGISTRATION: Study 30911 was registered with the US National Cancer Institute clinical trials database


(protocol ID: EORTC 30911). Study 30962 was registered at ClinicalTrials.gov, number NCT00002990; http://clinicaltrials.

gov/ct2/show/record/NCT00002990.

PMID: 26230345Paulus VA, Franken RJPM, van der Heijden EP. A woman with a chronic wound on her index finger. Ned Tijdschr Geneeskd. 2015; 159:A9075.

A 79-year-old woman consulted a plastic surgeon, because since 3 years she had a large wound at the base of her left

index finger. Histology of a skin biopsy showed cutaneous squamous cell carcinoma. Because of the extension of the defect,

amputation of the index finger with a split-skin-graft was performed.

PMID: 26237632Gayet M, van der Aa A, Beerlage HP, Schrier BP, Mulders PF, Wijkstra H. The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review. BJU Int. 2016 Mar;117(3):392-400. doi: 10.1111/bju.13247.

Despite limitations considering the presence, staging and aggressiveness of prostate cancer, ultrasonography (US)-guided

systematic biopsies (SBs) are still the ‘gold standard’ for the diagnosis of prostate cancer. Recently, promising results have

been published for targeted prostate biopsies (TBs) using magnetic resonance imaging (MRI) and ultrasonography (MRI/

US)-fusion platforms. Different platforms are USA Food and Drug Administration registered and have, mostly subjec-

tive, strengths and weaknesses. To our knowledge, no systematic review exists that objectively compares prostate cancer

detection rates between the different platforms available. To assess the value of the different MRI/US-fusion platforms in

prostate cancer detection, we compared platform-guided TB with SB, and other ways of MRI TB (cognitive fusion or in-bore

MR fusion). We performed a systematic review of well-designed prospective randomised and non-randomised trials in the

English language published between 1 January 2004 and 17 February 2015, using PubMed, Embase and Cochrane Library

databases. Search terms included: ‘prostate cancer’, ‘MR/ultrasound(US) fusion’ and ‘targeted biopsies’. Extraction of articles

was performed by two authors (M.G. and A.A.) and were evaluated by the other authors. Randomised and non-randomised

prospective clinical trials comparing TB using MRI/US-fusion platforms and SB, or other ways of TB (cognitive fusion or MR

in-bore fusion) were included. In all, 11 of 1865 studies met the inclusion criteria, involving seven different fusion platforms

and 2626 patients: 1119 biopsy naïve, 1433 with prior negative biopsy, 50 not mentioned (either biopsy naïve or with prior

negative biopsy) and 24 on active surveillance (who were disregarded). The Quality Assessment of Diagnostic Accuracy

Studies (QUADAS-2) tool was used to assess the quality of included articles. No clear advantage of MRI/US fusion-guided

TBs was seen for cancer detection rates (CDRs) of all prostate cancers. However, MRI/US fusion-guided TBs tended to give

higher CDRs for clinically significant prostate cancers in our analysis. Important limitations of the present systematic review

include: the limited number of included studies, lack of a general definition of ‘clinically significant’ prostate cancer, the

heterogeneous study population, and a reference test with low sensitivity and specificity. Today, a limited number of pros-

pective studies have reported the CDRs of fusion platforms. Although MRI/US-fusion TB has proved its value in men with

prior negative biopsies, general use of this technique in diagnosing prostate cancer should only be performed after critical

consideration. Before bringing MRI/US fusion-guided TB in to general practice, there is a need for more prospective studies

on prostate cancer diagnosis.


PMID: 26244324Nieuwkamp DJ, Murk JL, van Oosten BW. PML in Patients Treated with Dimethyl Fumarate.N Engl J Med. 2015 Aug 6;373(6):584. doi: 10.1056/NEJMc1506151. No abstract available.

PMID: 26269539Tjon-Kon-Fat RI, Bensdorp AJ, Bossuyt PM, Koks C, Oosterhuis GJ, Hoek A, Hompes P, Broekmans FJ, Verhoeve HR, de Bruin JP, van Golde R, Repping S, Cohlen BJ, Lambers MD, van Bommel PF, Slappendel E, Perquin D, Smeenk J, Pelinck MJ, Gianotten J, Hoozemans DA, Maas JW, Groen H, Eijkemans MJ, van der Veen F, Mol BW, van Wely M. Is IVF-served two different ways-more cost-effective than IUI with controlled ovarian hyperstimulation? Hum Reprod. 2015 Oct;30(10):2331-9. doi: 10.1093/humrep/dev193. Epub 2015 Aug 12.

STUDY QUESTION: What is the cost-effectiveness of in vitro fertilization (IVF) with conventional ovarian stimulation, single

embryo transfer (SET) and subsequent cryocycles or IVF in a modified natural cycle (MNC) compared with intrauterine inse-

mination with controlled ovarian hyperstimulation (IUI-COH) as a first-line treatment in couples with unexplained subfertility

and an unfavourable prognosis on natural conception?. SUMMARY ANSWER: Both IVF strategies are significantly more

expensive when compared with IUI-COH, without being significantly more effective. In the comparison between IVF-MNC

and IUI-COH, the latter is the dominant strategy. Whether IVF-SET is cost-effective depends on society’s willingness to pay

for an additional healthy child. WHAT IS KNOWN ALREADY: IUI-COH and IVF, either after conventional ovarian stimulation or

in a MNC, are used as first-line treatments for couples with unexplained or mild male subfertility. As IUI-COH is less invasive,

this treatment is usually offered before proceeding to IVF. Yet, as conventional IVF with SET may lead to higher pregnancy

rates in fewer cycles for a lower multiple pregnancy rate, some have argued to start with IVF instead of IUI-COH. In addition,

IVF in the MNC is considered to be a more patient friendly and less costly form of IVF. STUDY DESIGN, SIZE, DURATION: We

performed a cost-effectiveness analysis alongside a randomized noninferiority trial. Between January 2009 and February

2012, 602 couples with unexplained infertility and a poor prognosis on natural conception were allocated to three cycles

of IVF-SET including frozen embryo transfers, six cycles of IVF-MNC or six cycles of IUI-COH. These couples were followed

until 12 months after randomization. PARTICIPANTS/MATERIALS, SETTING, METHODS: We collected data on resource

use related to treatment, medication and pregnancy from the case report forms. We calculated unit costs from various

sources. For each of the three strategies, we calculated the mean costs and effectiveness. Incremental cost-effectiveness

ratios (ICER) were calculated for IVF-SET compared with IUI-COH and for IVF-MNC compared with IUI-COH. Nonparametric

bootstrap resampling was used to investigate the effect of uncertainty in our estimates. MAIN RESULTS AND THE ROLE OF

CHANCE: There were 104 healthy children (52%) born in the IVF-SET group, 83 (43%) the IVF-MNC group and 97 (47%)

in the IUI-COH group. The mean costs per couple were €7187 for IVF-SET, €8206 for IVF-MNC and €5070 for IUI-COH.

Compared with IUI-COH, the costs for IVF-SET and IVF-MNC were significantly higher (mean differences €2117; 95% CI:

€1544-€2657 and €3136, 95% CI: €2519-€3754, respectively).The ICER for IVF-SET compared with IUI-COH was €43

375 for the birth of an additional healthy child. In the comparison of IVF-MNC to IUI-COH, the latter was the dominant

strategy, i.e. more effective at lower costs. LIMITATIONS, REASONS FOR CAUTION: We only report on direct health care

costs. The present analysis is limited to 12 months. WIDER IMPLICATIONS OF THE FINDINGS: Since we found no evidence

in support of offering IVF as a first-line strategy in couples with unexplained and mild subfertility, IUI-COH should remain

the treatment of first choice. STUDY FUNDING/COMPETING INTERESTS: The study was supported by a grant from ZonMw,

the Netherlands Organization for Health Research and Development, (120620027) and a grant from Zorgverzekeraars Ne-

derland, the Netherlands’ association of health care insurers (09-003).TRIAL REGISTRATION NUMBER: Current Controlled

Trials ISRCTN52843371; Nederlands Trial Register NTR939.


PMID: 26271177van Marum RJ. Treatment of patients with Alzheimer’s disease: a breakthrough or not? Ned Tijdschr Geneeskd. 2015;159(0):A9494. Dutch.

The results of an open-label extension study of the Expedition I and II studies with solanezumab in patients with Alzheimer’s

disease, neither of which had shown an effect on cognition and functional ability, were recently presented at the Alzheimer’s

Association International Conference in Toronto. Placebo and intervention patients with mild Alzheimer’s disease from

both studies were offered the option of continuing with solanezumab for 2 additional years. The data from this group were

re-analysed using a new analysis technique, the so-called ‘delayed start analysis’. On the basis of the re-analysis it was

concluded that solanezumab does show disease-modifying activity and should be considered a promising candidate for

treatment of Alzheimer’s disease in the near future. This conclusion, however, is poorly supported by the data presented in

the study. A more definite positioning of solanezumab will not be possible until data from the ongoing Expedition III study

becomes available in 2017 at the earliest.

PMID: 26277798 Kampschreur LM, Wegdam-Blans MC, Wever PC, Renders NH, Delsing CE, Sprong T, van Kasteren ME, Bijlmer H, Notermans D, Oosterheert JJ, Stals FS, Nabuurs-Franssen MH, Bleeker-Rovers CP; Dutch Q Fever Consensus Group. Chronic Q fever diagnosis— consensus guideline versus expert opinion. Emerg Infect Dis. 2015 Jul;21(7):1183-8.

Chronic Q fever, caused by Coxiella burnetii, has high mortality and morbidity rates if left untreated. Controversy about the

diagnosis of this complex disease has emerged recently. We applied the guideline from the Dutch Q Fever Consensus Group

and a set of diagnostic criteria proposed by Didier Raoult to all 284 chronic Q fever patients included in the Dutch National

Chronic Q Fever Database during 2006–2012. Of the patients who had proven cases of chronic Q fever by the Dutch

guideline, 46 (30.5%)would not have received a diagnosis by the alternative criteria designed by Raoult, and 14 (4.9%) would

have been considered to have possible chronic Q fever. Six patients with proven chronic Q fever died of related causes. Until

results from future studies are available, by which current guidelines can be modified, we believe that the Dutch literature-

based consensus guideline is more sensitive and easier to use in clinical practice.

PMID: 26279205Fliegauf M, L Bryant V, Frede N, Slade C, Woon ST, Lehnert K, Winzer S, Bulashevska A, Scerri T, Leung E, Jordan A, Keller B, de Vries E, Cao H, Yang F, Schäffer AA, Warnatz K, Browett P, Douglass J, Ameratunga RV, van der Meer JW, Grimbacher B. Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency. Am J Hum Genet. 2015 Sep 3;97(3):389-403. doi: 10.1016/j.ajhg.2015.07.008. Epub 2015 Aug 13.

Common variable immunodeficiency (CVID), characterized by recurrent infections, is the most prevalent symptomatic

antibody deficiency. In ∼90% of CVID-affected individuals, no genetic cause of the disease has been identified. In a Dutch-

Australian CVID-affected family, we identified a NFKB1 heterozygous splice-donor-site mutation (c.730+4A>G), causing

in-frame skipping of exon 8. NFKB1 encodes the transcription-factor precursor p105, which is processed to p50 (canonical

NF-κB pathway). The altered protein bearing an internal deletion (p.Asp191_Lys244delinsGlu; p105ΔEx8) is degraded,

but is not processed to p50ΔEx8. Altered NF-κB1 proteins were also undetectable in a German CVID-affected family with

a heterozygous in-frame exon 9 skipping mutation (c.835+2T>G) and in a CVID-affected family from New Zealand with

a heterozygous frameshift mutation (c.465dupA) in exon 7. Given that residual p105 and p50—translated from the non-

mutated alleles—were normal, and altered p50 proteins were absent, we conclude that the CVID phenotype in these families

is caused by NF-κB1 p50 haploinsufficiency.


PMID: 26286386 Van den Haak RF, Hamans BC, Zuurmond K, Verhoeven BA, Koning OH. Significant Radiation Dose Reduction in the Hybrid Operating Room Using a Novel X-ray Imaging Technology. Eur J Vasc Endovasc Surg. 2015 Oct;50(4):480-6. doi: 10.1016/j.ejvs.2015.06.025. Epub 2015 Aug 15.

OBJECTIVE/BACKGROUND: To prospectively quantify radiation dose change in aortoiliac endovascular procedures in the

hybrid operating room (OR) for patients and medical staff with a novel X-ray imaging technology (ClarityIQ technology), and

to assess whether procedure or fluoroscopy time or dose of iodinated contrast was affected. METHODS: A prospective study

including 138 patients was performed to compare radiation dose before and after installation of a novel X-ray imaging tech-

nology. Endovascular aneurysm repair (EVAR) was performed in 37 patients and an endovascular procedure for aortoiliac

occlusive disease (AIOD) in 101. Patient radiation dose in air kerma (AK) and dose area product (DAP), patient demographics,

and procedural data were recorded. Staff radiation dose was measured with real time personal dosimetry measurements.

In both the EVAR and AIOD groups the reference system, ALX (AlluraXper FD20; Philips Healthcare, Best, the Netherlands),

was compared with the upgraded X-ray system, CIQ (AlluraClarity FD20; Philips Healthcare). Procedure time, fluoroscopy

time, and iodinated contrast dose were recorded. RESULTS: Patient radiation dose reduction in the EVAR group, in median

AK, was 56% (ALX = 1,262.5 mGy; CIQ = 556.0 mGy [p < .01]); and in median DAP it was 57% (ALX = 224.4 Gycm(2) and

CIQ = 95.8 Gycm(2) [p < .01]). Patient radiation dose reduction in the AIOD group, in median AK, was 76% (ALX = 1,011.0

mGy; CIQ = 248.0 mGy [p < .01]); and in median DAP it was 73% (ALX = 138.1 Gycm(2); CIQ = 38.0 Gycm(2) [p < .01]). Staff

dose reduction in the EVAR group was 16% (ALX = 70.1 μSv; CIQ = 59.2 μSv [p = .43]) and in the AIOD group it was 69%

(ALX = 96.2 μSv; CIQ = 30.1 μSv [p < .01]). There was no statistically significant difference between patient demographics,

procedure time, fluoroscopy time, and iodinated contrast medium use in the two treatment groups before and after instal-

lation. CONCLUSION: A novel X-ray imaging technology in the hybrid OR suite resulted in a significant reduction of patient

and staff radiation dose without affecting procedure length, fluoroscopy time, or use of contrast.

PMID: 26294789Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015 Nov;9(11):945-65. doi: 10.1093/ecco-jcc/jjv141. Epub 2015 Aug 20.

PMID: 26304900Nicolaije KA, Ezendam NP, Vos MC, Pijnenborg JM, Boll D, Boss EA, Hermans RH, Engelhart KC, Haartsen JE, Pijlman BM, van Loon-Baelemans IE, Mertens HJ, Nolting WE, van Beek JJ, Roukema JA, Zijlstra WP, Kruitwagen RF, van de Poll-Franse LV. Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial. J Clin Oncol. 2015 Aug 24. pii: JCO.2014.60.3399. J Clin Oncol. 2015 Nov 1;33(31):3550-9. doi: 10.1200/JCO.2014.60.3399. Epub 2015 Aug 24.

PURPOSE: This study was conducted to longitudinally assess the impact of an automatically generated survivorship care

plan (SCP) on patient-reported outcomes in routine clinical practice. Primary outcomes were patient satisfaction with infor-

mation and care. Secondary outcomes included illness perceptions and health care use. METHODS: Twelve hospitals were

randomly assigned to SCP care or usual care in a pragmatic, cluster randomized trial. Newly diagnosed patients with endo-

metrial cancer completed questionnaires after diagnosis (n = 221; 75% response), 6 months (n = 158), and 12 months (n

= 147). An SCP application was built in the Web-based ROGY (Registration System Oncological Gynecology). By clicking the


SCP button, a patient-tailored SCP was generated. RESULTS: In the SCP care arm, 74% of patients received an SCP. They

reported receiving more information about their treatment (mean [M] = 57, standard deviation [SD] = 20 v M = 47, SD = 24;

P = .03), other services (M = 35, SD = 22 v M = 25, SD = 22; P = .03), and different places of care (M = 27, SD = 25 v M =

23, SD = 26; P = .04) than the usual care arm (scales, 0 to 100). However, there were no differences regarding satisfaction

with information or care. Patients in the SCP care arm experienced more symptoms (M = 3.3, SD = 2.0 v M = 2.6, SD =

1.6; P = .03), were more concerned about their illness (M = 4.4, SD = 2.3 v M = 3.9, SD = 2.1; P = .03), were more affected

emotionally (M = 4.0, SD = 2.2 v M = 3.7, SD = 2.2; P = .046), and reported more cancer-related contact with their primary

care physician (M = 1.8, SD = 2.0 v M = 1.1, SD = 0.9; P = .003) than those in the usual care arm (scale, 1 to 10). These

effects did not differ over time. CONCLUSION: The present trial showed no evidence of a benefit of SCPs on satisfaction with

information and care. Furthermore, SCPs increased patients’ concerns, emotional impact, experienced symptoms, and the

amount of cancer-related contact with the primary care physician. Whether this may ultimately lead to more empowered

patients should be investigated further. TRIAL REGISTRATION: ClinicalTrials.gov NCT01185626.

PMID: 26324356Kröger E, Mouls M, Wilchesky M, Berkers M, Carmichael PH, van Marum R, Souverein P, Egberts T, Laroche ML. Adverse Drug Reactions Reported with Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase. Ann Pharmacother. 2015 Aug 31. pii: 1060028015602274.

BACKGROUND: No worldwide pharmacovigilance study evaluating the spectrum of adverse drug reactions (ADRs) induced

by cholinesterase inhibitors (ChEI) in Alzheimer’s disease has been conducted since their emergence on the market. OBJEC-

TIVE: To describe ChEI related ADRs in Alzheimer’s disease (donepezil, rivastigmine, and galantamine) and characterize their

seriousness as reported by national pharmacovigilance systems to VigiBase, a World Health Organization International Drug

Monitoring Program database, between 1998 and 2013. METHODS: All ChEI RELATED REPORTS: submitted to VigiBase

between 1998 and 2013 from THE FIVE CONTINENTS: were extracted. Analyses were carried out for general, serious,

and nonserious ADRs. RESULTS: A total of 18 955 reports (43 753 ADRs) FROM 58 COUNTRIES: were reported: 60.1% in

women; mean age 77.4 ± 9.1 years. Most reports originated from Europe (47.6%) and North America (40.4%). Rivastigmine

and donepezil were involved in MOST: reports (41.4% each). The most frequently reported ADRs were neuropsychiatric

(31.4%), gastrointestinal (15.9%), general (11.9%), and cardiovascular (11.7%) disorders. During the 2006-2013 period,

serious ADRs remained more often reported than nonserious ones; the most serious were neuropsychiatric (34.0%), general

(14.0%), cardiovascular (12.1%), and gastrointestinal (11.6%) disorders. Medication errors were reported in 2.0% of serious

cases. Death occurred in 2.3% of the reports. CONCLUSIONS: This international pharmacovigilance study highlights the ADR

pattern induced by ChEIs. Neuropsychiatric events were the most frequently reported ADRs. Serious cardiovascular events

were frequently reported, suggesting that their significance has probably been previously underestimated. Given the frailty

of the patients and the frequent comedications, caution is advised before introducing a ChEI.

PMID: 26342018Kersten FA, Hermens RP, Braat DD, Hoek A, Mol BW, Goddijn M, Nelen WL; Improvement Study Group. Collaborators (23) (de Bruin JP). Overtreatment in couples with unexplained infertility. Hum Reprod. 2015 Sep 4. pii: dev185.


PMID: 26346870Merten H, Johannesma PC, Lubberding S, Zegers M, Langelaan M, Jukema GN, Heetveld MJ, Wagner C. High risk of adverse events in hospitalised hip fracture patients of 65 years and older: results of a retrospective record review study. BMJ Open. 2015 Sep 7;5(9).

OBJECTIVES: Hip fracture patients of 65 years and older are a complex patient group who often suffer from complications

and difficult rehabilitation with disappointing results. It is unknown to what extent suboptimal hospital care contributes to

these poor outcomes. This study reports on the scale, preventability, causes and prevention strategies of adverse events in

patients, aged 65 years and older, admitted to the hospital with a primary diagnosis of hip fracture. DESIGN, SETTING AND

OUTCOME MEASURES: A retrospective record review study was conducted of 616 hip fracture patients (≥65 years) admitted

to surgical or orthopaedic departments in four Dutch hospitals in 2007. Experienced physician reviewers determined the

presence and preventability of adverse events, causes and prevention strategies using a structured review form. The main

outcome measures were frequency of adverse events and preventable adverse events in hospitalised hip fracture patients of

65 years and older, and strategies to prevent them in the future. RESULTS: 114 (19%) of the 616 patients in the study ex-

perienced one or more adverse events; 49 of these were preventable. The majority of the adverse events (70%) was related

to the surgical procedure and many resulted in an intervention or additional treatment (67%). Human causes contributed

to 53% of the adverse events, followed by patient-related factors (39%). Training and close monitoring of quality of care and

the health professional’s performance were the most often selected strategies to prevent these adverse events in the future.

CONCLUSIONS: The high percentage of preventable adverse events found in this study shows that care for older hospitalised

hip fracture patients should be improved. More training and quality assurance is required to provide safer care and to reduce

the number of preventable adverse events in this vulnerable patient group.

PMID: 26347109Dingemans AM, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT 12 (NCT01171170). Ann Oncol. 2015 Nov;26(11):2286-93. doi: 10.1093/annonc/mdv370. Epub 2015 Sep 7.

BACKGROUND: Nitroglycerin (NTG) increases tumor blood flow and oxygenation by inhibiting hypoxia-inducible-factor

(HIF)-1. A randomized phase II study has shown improved outcome when NTG patches were added to vinorelbine/cispla-

tin in patients with advanced nonsmall-cell lung cancer (NSCLC). In addition, there is evidence that the combination of

bevacizumab and HIF-1 inhibitors increases antitumor activity. PATIENTS AND METHODS: In this randomized phase II trial,

chemo-naive patients with stage IV nonsquamous NSCLC were randomized to four cycles of carboplatin (area under the

curve 6)-paclitaxel (200 mg/m(2))-bevacizumab 15 mg/kg on day 1 every 3 weeks with or without NTG patches 15 mg (day

-2 to +2) followed by bevacizumab with or without NTG until progression. Response was assessed every two cycles. Primary

end point was progression-free survival (PFS). The study was powered (80%) to detect a decrease in the hazard of tumor

progression of 33% at κ = 0.05 with a two-sided log-rank test when 222 patients were enrolled and followed until 195

events were observed. RESULTS: Between 1 January 2011 and 1 January 2013, a total of 223 patients were randomized;

112 control arm and 111 experimental arm; response rate was 54% in control arm and 38% in experimental arm. Median

[95% confidence interval (CI)] PFS in control arm was 6.8 months (5.6-7.3) and 5.1 months (4.2-5.8) in experimental

arm, hazard ratio (HR) 1.27 (95% CI 0.96-1.67). Overall survival (OS) was 11.6 months (8.8-13.6) in control arm and 9.4

months (7.8-11.3) in experimental arm, HR 1.02 (95% CI 0.71-1.46). In the experimental arm, no additional toxicity was

observed except headache (6% versus 52% in patients treated with NTG). CONCLUSION: Adding NTG to first-line carboplatin-

paclitaxel-bevacizumab did not improve PFS and OS in patients with stage IV nonsquamous NSCLC. TRIAL REGISTRATION:

ClinicalTrials.gov NCT01171170.


PMID: 26364993Ammerdorffer A, Stappers MH, Oosting M, Schoffelen T, Hagenaars JC, Bleeker-Rovers CP, Wegdam-Blans MC, Wever PC, Roest HJ, van de Vosse E, Netea MG, Sprong T, Joosten LA. Genetic variation in TLR10 is not associated with chronic Q fever, despite the inhibitory effect of TLR10 on Coxiella burnetii-induced cytokines in vitro. Cytokine. 2016 Jan;77:196-202. doi: 10.1016/j.cyto.2015.09.005.

Coxiella burnetii, the causative agent of Q fever, is recognized by TLR2. TLR10 can act as an inhibitory receptor on TLR2-

derived immune responses. Therefore, we investigated the role of TLR10 on C. burnetii-induced cytokine production

and assessed whether genetic polymorphisms in TLR10 influences the development of chronic Q fever. HEK293 cells,

transfected with TLR2, TLR10 or TLR2/TLR10, and human peripheral blood mononuclear cells (PBMCs) in the presence of

anti-TLR10, were stimulated with C. burnetii. In both assays, the absence of TLR10 resulted in increased cytokine responses

after C. burnetii stimulation. In addition, the effect of single nucleotide polymorphisms (SNPs) in TLR10 was examined in

healthy volunteers whose PBMCs were stimulated with C. burnetii Nine Mile or the Dutch outbreak isolate C. burnetii 3262.

Individuals bearing SNPs in TLR10 displayed increased cytokine production upon C. burnetii 3262 stimulation. Further-

more, 139 chronic Q fever patients and 220 controls were genotyped for TLR10 N241H, I775V and I369L. None of these

polymorphisms were associated with increased susceptibility to chronic Q fever. In conclusion, TLR10 has an inhibitory effect

on in vitro cytokine production by C. burnetii, but the presence of TLR10 polymorphisms does not lead to an increased risk

of developing chronic Q fever.

PMID: 26365665Broos PP, Hagenaars JC, Kampschreur LM, Wever PC, Bleeker-Rovers CP, Koning OH, Teijink JA, Wegdam-Blans MC. Vascular complications and surgical interventions after world’s largest Q fever outbreak. J Vasc Surg. 2015 Nov;62(5):1273-80. doi: 10.1016/j.jvs.2015.06.217. Epub 2015 Sep 10

OBJECTIVE: Since chronic Q fever often develops insidiously, and symptoms are not always recognized at an early stage,

complications are often present at the time of diagnosis. We describe complications associated with vascular chronic Q fever

as found in the largest cohort of chronic Q fever patients so far. METHODS: Patients with proven or probable chronic Q fever

with a focus of infection in an aortic aneurysm or vascular graft were included in this study, using the Dutch national chronic

Q fever database. RESULTS: A total of 122 patients were diagnosed with vascular chronic Q fever between April 2008 and

June 2012. The infection affected a vascular graft in 62 patients (50.8%) and an aneurysm in 53 patients (43.7%). Seven

patients (5.7%) had a different vascular focus. Thirty-six patients (29.5%) presented with acute complications, and 35 of

these patients (97.2%) underwent surgery. Following diagnosis and start of antibiotic treatment, 26 patients (21.3%) presen-

ted with a variety of complications requiring surgical treatment during a mean follow-up of 14.1 ± 9.1 months. The overall

mortality rate was 23.7%. Among these patients, mortality was associated with chronic Q fever in 18 patients (62.1%).

CONCLUSIONS: The management of vascular infections with C. burnetii tends to be complicated. Diagnosis is often difficult

due to asymptomatic presentation. Patients undergo challenging surgical corrections and long-term antibiotic treatment.

Complication rates and mortality are high in this patient cohort.

PMID: 26381746 Van der Steen M, Leenstra T, Kluytmans JA, van der Bij AK; ISIS-AR study group (Renders NH). Trends in Expanded-Spectrum Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae among Dutch Clinical Isolates, from 2008 to 2012. PLoS One. 2015 Sep 18;10(9):e0138088. doi: 10.1371/journal.pone.0138088. eCollection 2015.


We investigated time trends in extended-spectrum cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae iso-

lates from different patient settings in The Netherlands from 2008-2012. E. coli and K. pneumoniae isolates from blood and

urine samples of patients > = 18 years were selected from the Dutch Infectious Disease Surveillance System-Antimicrobial

Resistance (ISIS-AR) database. We used multivariable Poisson regression to study the rate per year of blood stream infec-

tions by susceptible and resistant isolates, and generalized estimating equation (GEE) log-binomial regression for trends in

the proportion of extended-spectrum cephalosporin-resistant isolates. Susceptibility data of 197,513 E. coli and 38,244 K.

pneumoniae isolates were included. The proportion of extended-spectrum cephalosporin-resistant E. coli and K. pneumo-

niae isolates from urine and blood samples increased in all patient settings, except for K. pneumoniae isolates from patients

admitted to intensive care units. For K. pneumoniae, there was a different time trend between various patient groups

(p<0.01), with a significantly higher increase in extended-spectrum cephalosporin-resistant isolates from patients attending

a general practitioner than in isolates from hospitalized patients. For E. coli, the increasing time trends did not differ among

different patient groups. This nationwide study shows a general increase in extended-spectrum cephalosporin-resistant E.

coli and K. pneumoniae isolates. However, differences in trends between E. coli en K. pneumoniae underline the importance

of E. coli as a community-pathogen and its subsequent influence on hospital resistance level, while for K. pneumoniae the

level of resistance within the hospital seems less influenced by the resistance trends in the community.

PMID: 26384483Slok EN, Dijkstra F, de Vries E, Rietveld A, Wong A, Notermans DW, van Steenbergen JE. Estimation of acute and chronic Q fever incidence in children during a three-year outbreak in the Netherlands and a comparison with international literature. BMC Res Notes. 2015 Sep 18;8(1):456. doi: 10.1186/s13104-015-1389-0.

BACKGROUND: In the Dutch 2007-2009 Q fever outbreak Coxiella burnetii was transmitted aerogenically from dairy

goat farms to those living in the surrounding areas. Relatively few children were reported. The true number of pediatric

infections is unknown. In this study, we estimate the expected number of acute and chronic childhood infections. METHODS:

As Coxiella was transmitted aerogenic to those living near infected dairy goat farms, we could use adult seroprevalence

data to estimate infection risk for inhabitants, children and adults alike. Using Statistics Netherlands data we estimated the

number of children at (high) risk for developing chronic Q fever. Literature was reviewed for childhood (0-15 years) Q fever

reports and disease rates. We compared this with Dutch reported and our estimated data for 2007-2009. RESULTS: In The

Netherlands epidemic, 44 children were reported (1.2 % of total notifications). The childhood incidence was 0.15 compared

to 2.6 per 10,000 inhabitants for adults. No complications were reported. Based on the expected similarity in childhood

and adult exposure we assume that 9.8 % of children in the high-risk area had Q fever infection, resulting in 1562 acute

infections during the Q fever epidemic interval. Based on the prevalence of congenital heart disease, at least 13 children

are at high risk for developing chronic Q fever. In medical literature, 42 case reports described 140 childhood Q fever cases

with a serious outcome (four deaths). In chronic Q fever, cardiac infections were predominant. Four outbreaks were reported

involving children, describing 11 childhood cases. 36 National and/or regional studies reported seroprevalences varying

between 0 and 70 %. CONCLUSION: In the 3-year Dutch epidemic, few childhood cases were reported, with pulmonary

symptoms leading, and none with a serious presentation. With an estimated 13 high-risk children for chronic infection in

the high exposure area, and probably forty in the whole country, we may expect several chronic Q fever complications in the

coming years in paediatric practice.

PMID: 26391102van la Parra RF, de Wilt JH, Mol SJ, Mulder AH, de Roos WK, Bosscha K. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients? Breast J. 2015 Nov-Dec;21(6):621-6. doi: 10.1111/tbj.12496. Epub 2015 Sep 22.

The Z0011 trial demonstrated no difference in overall survival (OS) and locoregional recurrence in breast cancer patients


with a positive sentinel lymph node (SLN) randomized to axillary lymph node dissection (ALND) or no further surgery.

The aim of this study was to evaluate locoregional recurrence in a nonrandomized group of SLN positive patients,

in whom cALND was not performed, that were retrospectively categorized by the Z0011 eligibility criteria. From two

hospital breast cancer databases consisting of 656 consecutive SLN positive breast cancer patients, 88 patients, who did

not undergo cALND, were identified. This population was categorized by the Z0011 inclusion criteria (e.g., eligible versus

ineligible) and the groups were compared. Thirty-four patients (38.6%) were retrospectively eligible for omitting cALND

according to the Z0011 criteria and 54 (61.4%) were not. The median number of SLNs removed in both groups was 1

(range 1-5). The number of positive SLNs did not differ between the groups. Tumor size was slightly larger in the ine-

ligible group (21 mm versus 19 mm) and 76% of patients in the ineligible group underwent a mastectomy. At a median

follow-up of 26 months (range 1-84 months), one axillary recurrence was observed in the ineligible group versus 0 in

the eligible group. Axillary recurrence was low, even in patients who did not meet the Z0011 inclusion criteria. Future

trials that randomize Z0011 ineligible patients are needed to investigate long-term results.

PMID: 26395089Ranschaert ER, van Ooijen PM, Lee S, Ratib O, Parizel PM. Social media for radiologists: an introduction. Insights Imaging. 2015 Dec;6(6):741-752. Epub 2015 Sep 22.

Social media, which can be defined as dynamic and interactive online communication forums, are becoming increasingly

popular, not only for the general public but also for radiologists. In addition to assisting radiologists in finding useful pro-

fession-related information and interactive educational material in all kinds of formats, they can also contribute towards

improving communication with peers, clinicians, and patients. The growing use of social networking in healthcare also

has an impact on the visibility and engagement of radiologists in the online virtual community. Although many radiolo-

gists are already using social media, a large number of our colleagues are still unaware of the wide spectrum of useful

information and interaction available via social media and of the added value these platforms can bring to daily practice.

For many, the risk of mixing professional and private data by using social media creates a feeling of insecurity, which still

keeps radiologists from using them. In this overview we aim to provide information on the potential benefits, challenges,

and inherent risks of social media for radiologists. We will provide a summary of the different types of social media that

can be of value for radiologists, including useful tips on how to use them safely and efficiently. MAIN MESSAGES: • Online

social networking enhances communication and collaboration between peers • Social media facilitate access to educati-

onal and scientific information • Recommendations and guidelines from policymakers and professional organisations are

needed • Applications are desired for efficient and secure exchange of medical images in social media.

PMID: 26395570Hopstaken RM, van Balen JA, Kusters R. Point-of-care-testing in general practice. Ned Tijdschr Geneeskd. 2015;159:A9475. Dutch.

Point-of-care testing (POCT) is being used increasingly in general practice and other healthcare contexts outside the

hospital. Recommendations for correct and safe use of POCT in Dutch general practice have been laid down in the guide-

line ‘Point-of-care testing in general practice’. The recommendations in this guideline are based on existing regulations

and guidelines, both national and international, and respect the different roles and responsibilities within the healthcare

chain.


PMID: 26407752Derikx LA, Nissen LH, Smits LJ, Shen B, Hoentjen F. Risk of Neoplasia After Colectomy in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016 Jun;14(6):798-806.e20. doi: 10.1016/j.cgh.2015.08.042. Epub 2015 Sep 25.

BACKGROUND & AIMS: Colorectal neoplasia can still develop after colectomy for inflammatory bowel disease. However,

data on this risk are scare, and there have been few conclusive findings, so no evidence-based recommendations

have been made for postoperative surveillance. We conducted a systematic review and meta-analysis to determine

the prevalence and incidence of and risk factors for neoplasia in patients with inflammatory bowel disease who have

undergone colectomy, including the permanent-end ileostomy and rectal stump, ileorectal anastomosis (IRA), and ileal

pouch-anal anastomosis (IPAA) procedures. METHODS: We searched PubMed, Embase, Web of Science, and Cochrane

Library through May 2014 to identify studies that reported prevalence or incidence of colorectal neoplasia after colec-

tomy or specifically assessed risk factors for neoplasia development. Studies were selected, quality was assessed, and

data were extracted by 2 independent researchers. RESULTS: We calculated colorectal cancer (CRC) prevalence values

from 13 studies of patients who underwent rectal stump surgery, 35 studies of IRA, and 33 studies of IPAA. Signifi-

cantly higher proportions of patients in the rectal stump group (2.1%; 95% confidence interval [CI], 1.3%-3.0%) and in

the IRA group (2.4%; 95% CI, 1.7%-3.0%) developed CRC than in the IPAA group (0.5%; 95% CI, 0.3%-0.6%); the odds

ratio (OR) for CRC in the rectal stump or IRA groups compared with the IPAA group was 6.4 (95% CI, 4.3-9.5). A history

of CRC was the most important risk factor for development of CRC after colectomy (OR for patients receiving IRA, 12.8;

95% CI, 3.31-49.2 and OR for patients receiving IPAA, 15.0; 95% CI, 6.6-34.5). CONCLUSIONS: In a meta-analysis

of published studies, we found the prevalence and incidence of CRC after colectomy to be less than 3%; in patients

receiving IPAA it was less than 1%. Factors that increased risk of cancer development after colectomy included the

presence of a residual rectum and a history of CRC. These findings could aid in development of individualized strategies

for post-surgery surveillance.

PMID: 26438336Nieuwesteeg AM, Hartman EE, Aanstoot HJ, van Bakel HJ, Emons WH, van Mil E, Pouwer F. The relationship between parenting stress and parent-child interaction with health outcomes in the youngest patients with type 1 diabetes (0-7 years). Eur J Pediatr. 2016 Mar;175(3):329-38. doi: 10.1007/s00431-015-2631-4.

To test whether parenting stress and the quality of parent-child interaction were associated with glycemic control and

quality of life (QoL) in young children (0-7 years) with type 1 diabetes (T1DM), we videotaped 77 families with a young

child with T1DM during mealtime (including glucose monitoring and insulin administration). Parent-child interactions

were scored with a specifically designed instrument. Questionnaires assessed general and disease-related parenting

stress and (diabetes-specific (DS)) QoL. HbA(1c) (glycemic control) was extracted from the medical records. Both

general and disease-related parenting stress were associated with a lower (DS)QoL (r ranged from -0.39 to -0.70,

p < 0.05), but not with HbA(1c) levels. Furthermore, with regard to the parent-child interaction, emotional involvement

of parents (r = 0.23, p < 0.05) and expressed discomfort of the child (r = 0.23, p < 0.05) were related to suboptimal

HbA(1c) levels. There was no clear pattern in the correlations between parent-child interaction and (DS)QoL. CONCLU-

SION: The results support the notion that diabetes does not only affect the child with T1DM: T1DM is a family disease,

as parenting factors (like stress and parent-child interactions) are associated with important child outcomes. Therefore,

it is important for health-care providers to not only focus on the child with T1DM, but also on the family system.


PMID: 26447542Derikx LA, Nissen LH, Drenth JP, van Herpen CM, Kievit W, Verhoeven RH, Mulders PF, Hulsbergen-van de Kaa CA, Boers-Sonderen MJ, van den Heuvel TR, Pierik M, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis; PALGA Group. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget. 2015 Nov 10;6(35):38336-47. doi: 10.18632/oncotarget.5186.

BACKGROUND: Immunosuppressive therapy may impact cancer risk in inflammatory bowel disease (IBD). Cancer

specific data regarding risk and outcome are scarce and data for renal cell carcinoma (RCC) are lacking. We aimed(1)

to identify risk factors for RCC development in IBD patients (2) to compare RCC characteristics, outcome and survival

between IBD patients and the general population. METHODS: A PALGA (Dutch Pathology Registry) search was

performed to establish a case group consisting of all IBD patients with incident RCC in The Netherlands (1991-2013).

Cases were compared with two separate control groups: (A) with a population-based IBD cohort for identification

of risk factors (B) with a RCC cohort from the general population to compare RCC characteristics and outcomes.

RESULTS: 180 IBD patients with RCC were identified. Pancolitis (OR 1.8-2.5), penetrating Crohn’s disease (OR 2.8),

IBD related surgery (OR 3.7-4.5), male gender (OR 3.2-5.0) and older age at IBD onset (OR 1.0-1.1) were identified as

independent risk factors for RCC development. IBD patients had a significantly lower age at RCC diagnosis (p < 0.001),

lower N-stage (p = 0.025), lower M-stage (p = 0.020) and underwent more frequently surgical treatment for RCC (p

< 0.001) compared to the general population. This translated into a better survival (p = 0.026; HR 0.7) independent

of immunosuppression. CONCLUSIONS: IBD patients with a complex phenotype are at increased risk to develop RCC.

They are diagnosed with RCC at a younger age and at an earlier disease stage compared to the general population.

This translates into a better survival independent of immunosuppressive or anti-TNFκ therapy.

PMID: 26452336Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. Int J Cancer. 2016 May 15;138(10):2312-21. doi: 10.1002/ijc.29887.

Mammalian target of rapamycin inhibitors (mTORi) have clinically significant activity against various malignancies, such

as renal cell carcinoma and breast cancer, but their use can be complicated by several toxicities. Interstitial lung disease

(ILD) is an adverse event of particular importance. Mostly, mTORi-induced ILD remains asymptomatic or mildly symp-

tomatic, but it can also lead to severe morbidity and even mortality. Therefore, careful diagnosis and management of

ILD is warranted. The reported incidence of mTORi-induced ILD varies widely because of a lack of uniform diagnostic

criteria and active surveillance. Because of the nonspecific clinical features, a broad differential diagnosis that includes

(opportunistic) infections should be considered in case of suspicion of mTORi-induced ILD. The exact mechanism or

interplay of mechanisms leading to the development of ILD remains to be defined. Suggested mechanisms are either a

direct toxic effect or immune-mediated mechanisms, considering mTOR inhibitors have several effects on the immune

system. The clinical course of ILD varies widely and is difficult to predict. Consequently, the discrimination between

when mTOR inhibitors can be continued safely and when discontinuation is indicated is challenging. In this review,

we give a comprehensive review of the incidence, clinical presentation and pathophysiology of mTORi-induced ILD in

cancer patients. We present newly developed diagnostic criteria for ILD, which include clinical symptoms as well as

basic pulmonary function tests and radiological abnormalities. In conjunction with these diagnostic criteria, we provide

a detailed and easily applicable clinical management algorithm.


PMID: 26466011Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators (Biesma B.). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371; 2167-77, 2014. doi: 10.1056/NEJMoa1408440. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582. doi: 10.1056/NEJMx150034.

PMID: 26475650van Grinsven J, van Brunschot S, Bakker OJ, Bollen TL, Boermeester MA, Bruno MJ, Dejong CH, Dijkgraaf MG, van Eijck CH, Fockens P, van Goor H, Gooszen HG, Horvath KD, van Lienden KP, van Santvoort HC, Besselink MG; Dutch Pancreatitis Study Group (Cappendijk VC). Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. HPB (Oxford). 2015 Oct 17. doi: 10.1111/hpb.12491.

BACKGROUND: The optimal diagnostic strategy and timing of intervention in infected necrotizing pancreatitis are

subject to debate. A survey was performed on these topics amongst a group of international expert pancreatologists.

METHODS: An online survey including case vignettes was sent to 118 international pancreatologists. The use and

timing of fine-needle aspiration (FNA), antibiotics, catheter drainage and (minimally invasive) necrosectomy were

evaluated. RESULTS: The response rate was 74% (N = 87). None of the respondents use FNA routinely, 85% selectively

and 15% never. Most respondents (87%) use a step-up approach in patients with infected necrosis. Walled-off necrosis

(WON) is considered a prerequisite for endoscopic drainage and percutaneous drainage by 66% and 12%, respectively.

After diagnosing infected necrosis, 55% routinely postpone invasive interventions, whereas 45% proceed immediately

to intervention. A lack of consensus about timing of intervention was apparent on day 14 with proven infected necrosis

(58% intervention versus 42% non-invasive) as well as on day 20 with only clinically suspected infected necrosis (59%

intervention versus 41% non-invasive). DISCUSSION: The step-up approach is the preferred treatment strategy in

infected necrotizing pancreatitis amongst expert pancreatologists. There is no uniformity regarding the use of FNA and

timing of intervention in the first 2-3 weeks of infected necrotizing pancreatitis.

PMID: 26503733Boezeman RP, Boersma D, Wille J, Kelder JC, Visscher MI, Waanders FG, Moll FL, De Vries JP. The significance of regional hemoglobin oxygen saturation values and limb-to-arm ratios of near-infrared spectroscopy tp detect critical limb ischemia. Vascular. 2016 Oct;24(5):492-500. doi: 10.1177/1708538115613936. Epub 2015 Oct 25.

This study examines the application of near-infrared spectroscopy to noninvasively detect critical limb ischemia using

regional hemoglobin oxygen saturation in percentage values and regional hemoglobin oxygen saturation limb-to-arm

ratios. The regional hemoglobin oxygen saturation values and regional hemoglobin oxygen saturation limb-to-arm

ratios were calculated in 61 patients with critical limb ischemia (group A). Measurements were performed in rest at

four fixed spots at the most affected lower limb and at a reference spot at both upper arms. Similar measurements

were performed in the left lower limb of 30 age-matched control patients without peripheral arterial disease (group

B). The regional hemoglobin oxygen saturation values and regional hemoglobin oxygen saturation limb-to-arm ratios

were significantly different at all measured spots between the groups (all p < 0.001), except for the regional hemoglobin

oxygen saturation limb-to-arm ratios of the distal vastus lateralis (p = 0.056). However, a broad overlap of individual

regional hemoglobin oxygen saturation values and regional hemoglobin oxygen saturation limb-to-arm ratios was

found in both groups, which resulted in poor discriminative predictive value of single measurements. Single measure-


ments of regional hemoglobin oxygen saturation values and regional hemoglobin oxygen saturation limb-to-arm ratios

at all measured spots have poor discriminative predictive value in detection of critical limb ischemia. Measurement of

regional hemoglobin oxygen saturation values and regional hemoglobin oxygen saturation limb-to-arm ratios at any

of the measurement spots has no added value in detecting lower limb ischemia in individuals compared with current

diagnostic modalities.

PMID: 26504821Van Gestel NA, Geurts J, Hulsen DJ, van Rietbergen B, Hofmann S, Arts JJ. Clinical Applications of S53P4 Bioactive Glass in Bone Healing and Osteomyelitic Treatment: A Literature Review. Biomed Res Int. 2015;2015:684826

Nowadays, S53P4 bioactive glass is indicated as a bone graft substitute in various clinical applications. This review

provides an overview of the current published clinical results on indications such as craniofacial procedures, grafting of

benign bone tumour defects, instrumental spondylodesis, and the treatment of osteomyelitis. Given the reported re-

sults that are based on examinations, such as clinical examinations by the surgeons, radiographs, CT, and MRI images,

S53P4 bioactive glass may be beneficial in the various reported applications. Especially in craniofacial reconstructions

like mastoid obliteration and orbital floor reconstructions, in grafting bone tumour defects, and in the treatment of os-

teomyelitis very promising results are obtained. Randomized clinical trials need to be performed in order to determine

whether bioactive glass would be able to replace the current golden standard of autologous bone usage or with the use

of antibiotic containing PMMA beads (in the case of osteomyelitis).

PMID: 26508153De Rooij T, Tol JA, van Eijck CH, Boerma D, Bonsing BA, Bosscha K, van Dam RM, Dijkgraaf MG, Gerhards MF, van Goor H, van der Harst E, de Hingh IH, Kazemier G, Klaase JM, Molenaar IQ, Patijn GA, van Santvoort HC, Scheepers JJ, van der Schelling GP, Sieders E, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis. Ann Surg Oncol. 2016 Feb;23(2):585-91. doi: 10.1245/s10434-015-4930-4.

BACKGROUND: Large multicenter series on outcomes and predictors of survival after distal pancreatectomy (DP) for

pancreatic ductal adenocarcinoma (PDAC) are scarce. METHODS: Adults who underwent DP for PDAC in 17 Dutch

pancreatic centers between January 2005 and September 2013 were analyzed retrospectively. The primary outcome

was survival, and predictors of survival were identified using Cox regression analysis. RESULTS: In total, 761 conse-

cutive patients after DP were assessed, of whom 620 patients were excluded because of non-PDAC histopathology

(n = 616) or a lack of data (n = 4), leaving a total of 141 patients included in the study [45 % (n = 63) male, mean

age 64 years (SD = 10)]. Multivisceral resection was performed in 43 patients (30 %) and laparoscopic resection was

performed in 7 patients (5 %). A major complication (Clavien-Dindo score of III or higher) occurred in 46 patients (33

%). Mean tumor size was 44 mm (SD 23), and histopathological examination showed 70 R0 resections (50 %), while

30-day and 90-day mortality was 3 and 6 %, respectively. Overall, 63 patients (45 %) received adjuvant chemotherapy.

Median survival was 17 months [interquartile range (IQR) 13-21], with a median follow-up of 17 months (IQR 8-29).

Cumulative survival at 1, 3 and 5 years was 64, 29, and 22 %, respectively. Independent predictors of worse posto-

perative survival were R1/R2 resection [hazard ratio (HR) 1.6, 95 % confidence interval (CI) 1.1-2.4], pT3/pT4 stage

(HR 1.9, 95 % CI 1.3-2.9), a major complication (HR 1.7, 95 % CI 1.1-2.5), and not receiving adjuvant chemotherapy

(HR 1.5, 95 % CI 1.0-2.3). CONCLUSION: Survival after DP for PDAC is poor and is related to resection margin, tumor

stage, surgical complications, and adjuvant chemotherapy. Further studies should assess to what extent prevention of

surgical complications and more extensive use of adjuvant chemotherapy can improve survival.


PMID: 26509648Van Rossem et al and de Appendicitis Collaborative Study Group (B van de Wall). Prospective nationwide outcome audit of surgery for suspected acute appendicitis. Br J Surg. 2016 Jan;103(1):144-51. doi: 10.1002/bjs.9964. Epub 2015 Oct 28.

BACKGROUND: Studies comparing laparoscopic and open appendicectomy are difficult to interpret owing to several ty-

pes of bias, and the results often seem of limited clinical importance. National audits can be valuable to provide insight

into outcomes following appendicectomy at a population level. METHODS: A prospective, observational, resident-led,

nationwide audit was carried out over a period of 2 months, including all consecutive adult patients who had surgery

for suspected acute appendicitis. Complications after laparoscopic and open appendicectomy were compared by means

of logistic regression analysis; subgroup analyses were performed for patients with complicated appendicitis. RESULTS:

A total of 1975 patients were included from 62 participating Dutch hospitals. A normal appendix was seen in 3•3 per

cent of patients. Appendicectomy was performed for acute appendicitis in 1378 patients, who were analysed. All but

three patients underwent preoperative imaging. Laparoscopy was used in 79•5 per cent of patients; the conversion

rate was 3•4 per cent. A histologically normal appendix was found in 2•2 per cent. Superficial surgical-site infection

was less common in the laparoscopic group (odds ratio 0•25, 95 per cent c.i. 0•14 to 0•44; P < 0•001). The rate of

intra-abdominal abscess formation was not significantly different following laparoscopic or open surgery (odds ratio

1•71, 0•80 to 3•63; P = 0•166). Similar findings were observed in patients with complicated appendicitis. CONCLU-

SION: Management of acute appendicitis in the Netherlands is preferably performed laparoscopically, characterized by

a low conversion rate. Fewer superficial surgical-site infections occurred with laparoscopy, although the rate of abscess

formation was no different from that following open surgery. A low normal appendix rate is the presumed effect of a

mandatory preoperative imaging strategy.

PMID: 26541440Nijhof WH, Baltussen EJ, Kant IM, Jager GJ, Slump CH, Rutten MJ. Low dose CT angiography of the abdominal aorta and reduced contrast medium volume: Assessment of image quality and radiation dose. Clinical Radiology 2016; 71(1):64-73. doi: 10.1016/j.crad.2015.10.007.

AIM: To determine the effect of using 80 kV tube voltage and a reduced amount of contrast medium on the image

quality and radiation dose of computed tomography angiography (CTA) of the abdominal aorta. MATERIALS AND

METHODS: Patients who were referred for a CTA examination of the abdominal aorta were included in this technical

efficacy study. Thirty patients were divided randomly into two groups. Fifteen patients underwent a dual-energy CT

(DECT) protocol (Group A). Fifteen patients were scanned with the use of an automated tube potential selection algori-

thm tool (Group B). In both protocols, a test bolus injection of 10 ml ioversol (350 mg iodine/ml) was used, followed by

20 ml of 1:1 saline-diluted contrast medium. Quantitative analysis comprised determination of the mean attenua-

tion and contrast-to-noise ratio. Qualitative image analysis was performed independently by five radiologists. The

estimated radiation dose in terms of CT dose index and effective dose was recorded and compared with a standard

120 kV protocol. RESULTS: In Group B, six patients underwent CTA at 80 kV, seven patients underwent CTA at 100 kV

and two patients underwent CTA at 120 kV. The mean contrast-enhancement values of Group A (80 kV) and the 80 kV

subgroup of Group B were 16.5% and 27.6% higher compared to the 100 kV subgroup of Group B, these differences

were, however, not significant. There were no significant differences in mean image quality between groups. In patients

undergoing CTA at 80 kV the effective dose decreased by up to 51.3% compared to a conventional 120 kV CTA protocol.

CONCLUSIONS: The findings of this study support the hypothesis that 80 kV in CTA of the abdominal aorta can reliably

be used with only 30 ml contrast medium in total and a 50% reduction in radiation dose. The overall image quality was

diagnostically adequate; however, it appeared to be suboptimal in patients with a BMI above 28 kg/m(2).


PMID: 26541538Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, van Suylen RJ, Houben R, Damhuis RA, Speel EJ, Dingemans AM. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2016 Feb;47(2):615-24. doi: 10.1183/13993003.00618-2015.

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an orphan disease and few data are available on its clinical

characteristics. Therefore, we analysed LCNEC registered in the Netherlands Cancer Registry, and compared data with

small cell lung carcinoma (SCLC), squamous cell carcinoma (SqCC) and adenocarcinoma (AdC).Histologically confirmed

LCNEC (n=952), SCLC (n=11 844), SqCC (n=19 633) and AdC (n=24 253) cases were selected from the Netherlands

Cancer Registry (2003-2012). Patient characteristics, metastasis at diagnosis (2006 or later), overall survival (OS)

including multivariate Cox models and first-line treatment were compared for stage I-II, III and IV disease.The number

of LCNEC cases increased from 56 patients in 2003 to 143 in 2012, accounting for 0.9% of all lung cancers. Stage IV

LCNEC patients (n=383) commonly had metastasis in the liver (47%), bone (32%) and brain (23%), resembling SCLC.

Median OS (95% CI) of stage I-II, III and IV LCNEC patients was 32.4 (22.0-42.9), 12.6 (10.3-15.0) and 4.0 (3.5-4.6)

months, respectively. Multivariate-adjusted OS of LCNEC patients resembled that of SCLC patients, and was poorer

than those of SqCC and AdC patients. However, frequency of surgical resection and adjuvant chemotherapy resembled

SqCC and AdC more than SCLC.Diagnosis of LCNEC has increased in recent years. The metastatic pattern of LCNEC

resembles SCLC as does the OS. However, early-stage treatment strategies seem more comparable to those of SqCC

and AdC.

PMID: 26542765da Costa DW, Schepers NJ, Römkens TE, Boerma D, Bruno MJ, Bakker OJ; Dutch Pancreatitis Study Group. Endoscopic sphincterotomy and cholecystectomy in acute biliary pancreatitis. Surgeon. 2016 Apr;14(2):99-108. doi: 10.1016/j.surge.2015.10.002. Epub 2015 Nov 2. Review.

BACKGROUND: This review discusses current insights with regard to biliary tract management during and after

acute biliary pancreatitis. METHODS: A MEDLINE and EMBASE search was done and studies were selected based on

methodological quality and publication date. The recommendations of recent guidelines are incorporated in this review.

In absence of consensus in the literature, expert opinion is expressed. RESULTS: There is no role for early endoscopic

retrograde cholangiopancreatography (ERCP) in patients with (predicted) mild biliary pancreatitis to improve outcome.

In case of persisting choledocholithiasis, ERCP with stone extraction is scheduled electively when the acute event has

subsided. Whether early ERCP with sphincterotomy is beneficial in patients with predicted severe pancreatitis remains

subject to debate. Regardless of disease severity, in case of concomitant cholangitis urgent endoscopic sphinctero-

tomy (ES) is recommended. As a definitive treatment to reduce the risk of recurrent biliary events in the long term,

ES is inferior to cholecystectomy and should be reserved for patients considered unfit for surgery. After severe biliary

pancreatitis, cholecystectomy should be postponed until all signs of inflammation have subsided. In patients with mild

pancreatitis, cholecystectomy during the primary admission reduces the risk of recurrent biliary complications. CON-

CLUSION: Recent research has provided valuable data to guide biliary tract management in the setting of acute biliary

pancreatitis with great value and benefit for patients and clinicians. Some important clinical dilemmas remain, but it is

anticipated that on-going clinical trials will deliver some important insights and additional guidance soon.


PMID: 26553305Van der Stelt CA, Vermeulen Windsant-van den Tweel AM, Egberts AC, van den Bemt PM, Leendertse AJ, Hermens WA, van Marum RJ, Derijks HJ. The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study. Drug Saf. 2016 Jan;39(1):79-87. doi: 10.1007/s40264-015-0361-1.

INTRODUCTION: Medication-related problems can cause serious adverse drug events (ADEs) that may lead to

hospitalization of the patient. There are multiple screening methods to detect and reduce potentially inappropriate

medications (PIMs) and potential prescribing omissions (PPOs). Whether this will result in less medication-related

hospitalizations is unknown. The study objective was to assess the risk of preventable medication-related hospital

admissions associated with potentially inappropriate prescribing, using the Beers 2012 and the Screening Tool of Older

Person’s Prescriptions and the Screening Tool to Alert doctors to Right Treatment (STOPP & START) 2008 criteria.

DESIGN, SETTING AND PARTICIPANTS: A nested case-control study was conducted with a subset of Dutch participants

from the Hospital Admissions Related to Medication (HARM) study. Cases were defined as patients aged ≥65 years with

a potentially preventable medication-related hospital admission. For each case, one control was selected, matched

for age and sex. The primary determinant was the presence of one or more PIMs according to the Beers 2012 and

STOPP 2008 criteria. The secondary determinant was the presence of one or more PIMs and PPOs according to the

STOPP & START 2008 criteria. The strength of the association between inappropriate prescribing and medication-

related hospital admission was evaluated with multivariate logistic regression and expressed as odds ratios (ORs) with

95 % confidence intervals (CIs). RESULTS: The prevalence of Beers 2012 criteria PIMs in the total cohort was 44.4 %.

The prevalence of STOPP & START 2008 criteria PIMs and PPOs were, respectively, 34.1 and 57.7 %. STOPP 2008

criteria PIMs were associated with preventable medication-related hospital admissions [OR adjusted for number of

drugs and comorbidities (ORadj) 2.30, 95 % CI 1.30-4.07], whereas there was no association with Beers 2012 criteria

PIMs (ORadj 1.49, 95 % CI 0.90-2.47). STOPP PIMs and START PPOs together were also associated with preventable

medication-related hospital admissions (ORadj 3.47, 95 % CI 1.70-7.09). CONCLUSION: Our study shows that patients

with potentially inappropriate prescribing detected with the STOPP & START 2008 criteria are at risk of preventable

medication-related hospital admissions. The STOPP & START 2008 criteria can be used to identify older people at risk

of medication-related problems.

PMID: 26553486De Wit HM, Vervoort GM, Jansen HJ, de Galan BE, Tack CJ. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes’ (ELEGANT) randomized controlled trial. J Intern Med. 2016 Mar;279(3):283-92. doi: 10.1111/joim.12447. Epub 2015 Nov 9.

BACKGROUND: Pronounced weight gain frequently complicates insulin therapy in patients with type 2 diabetes

(T2DM). We have previously reported that addition of liraglutide for 26 weeks can reverse insulin-associated weight

gain, decrease insulin dose and improve glycaemic control, as compared with continuation of standard insulin

treatment. OBJECTIVES: To investigate whether the beneficial effects of liraglutide are sustained up to 52 weeks and

whether similar effects could be obtained when liraglutide is added 6 months later. METHODS: Adult T2DM patients

with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label

addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated

with liraglutide for another 26 weeks. Results were analysed according to the intention-to-treat principle. RESULTS:


Overall, 24 (92%) and 18 (75%) patients originally assigned to liraglutide and standard therapy, respectively, completed

the study. Addition of liraglutide decreased body weight to a similar extend when given in the first 26 weeks (liraglutide

group) or second 26 weeks (original standard therapy group): -4.4 vs. -4.3 kg (difference -0.32 kg, 95% confidence in-

terval -2.2 to 1.6 kg; P = 0.74). Similar results were also seen in the two groups with regard to decrease in haemoglo-

bin A1c (HbA1c ) (-0.77 vs. -0.66%; P = 0.23) and insulin dose (-28 vs. -26 U day(-1) ; P = 0.32). In both groups, 22%

of patients could discontinue insulin. Continuation of liraglutide until 52 weeks led to sustained effects on body weight,

HbA1c and insulin-dose requirements. CONCLUSION: In T2DM patients with pronounced insulin-associated weight

gain, addition of liraglutide within 2 years leads to sustained reversal of body weight, improved glycaemic control and

decrease in insulin dose. Thus, liraglutide offers a valuable therapeutic option.

PMID: 26560803Morroy G, Van Der Hoek W, Nanver ZD, Schneeberger PM, Bleeker-Rovers CP, Van Der Velden J, Coutinho RA. The health status of a village population, 7 years after a major Q fever outbreak. Epidemiol Infect. 2015 Nov 12:1-10.

From 2007 to 2010, The Netherlands experienced a major Q fever outbreak with more than 4000 notifications.

Previous studies suggested that Q fever patients could suffer long-term post-infection health impairments, especially

fatigue. Our objective was to assess the Coxiella burnetii antibody prevalence and health status including fatigue, and

assess their interrelationship in Herpen, a high-incidence village, 7 years after the outbreak began. In 2014, we invited

all 2161 adult inhabitants for a questionnaire and a C. burnetii indirect fluorescence antibody assay (IFA). The health

status was measured with the Nijmegen Clinical Screening Instrument (NCSI), consisting of eight subdomains including

fatigue. Of the 70•1% (1517/2161) participants, 33•8% (513/1517) were IFA positive. Of 147 participants who were

IFA positive in 2007, 25 (17%) seroreverted and were now IFA negative. Not positive IFA status, but age <50 years,

smoking and co-morbidity, were independent risk factors for fatigue. Notified participants reported significantly more

often fatigue (31/49, 63%) than non-notified IFA-positive participants (150/451, 33%). Although fatigue is a common

sequel after acute Q fever, in this community-based survey we found no difference in fatigue levels between partici-

pants with and without C. burnetii antibodies.

PMID: 26564912Boersma D, Kornmann VN, van Eekeren RR, Tromp E, Ünlü Ç, Reijnen MM, de Vries JP. Treatment Modalities for Small Saphenous Vein Insufficiency: Systematic Review and Meta-analysis. J Endovasc Ther. 2016;23:199-211.

PURPOSE: To investigate and compare the anatomical success rates and complications of the treatment modalities

for small saphenous vein (SSV) incompetence. METHODS: A systematic literature search was performed in PubMed,

EMBASE, and the Cochrane Library on the following therapies for incompetence of SSVs: surgery, endovenous laser

ablation (EVLA), radiofrequency ablation (RFA), ultrasound-guided foam sclerotherapy (UGFS), steam ablation, and

mechanochemical endovenous ablation (MOCA). The search found 49 articles (5 randomized controlled trials, 44

cohort studies) reporting on the different treatment modalities: surgery (n=9), EVLA (n=28), RFA (n=9), UGFS (n=6),

and MOCA (n=1). A random-effects model was used to estimate the primary outcome of anatomical success, which

was defined as closure of the treated vein on follow-up duplex ultrasound imaging. The estimate is reported with the

95% confidence interval (CI). Secondary outcomes were technical success and major complications [paresthesia and

deep vein thrombosis (DVT)], given as the weighted means. RESULTS: The pooled anatomical success rate was 58.0%

(95% CI 40.9% to 75.0%) for surgery in 798 SSVs, 98.5% (95% CI 97.7% to 99.2%) for EVLA in 2950 SSVs, 97.1% (95%


CI 94.3% to 99.9%) for RFA in 386 SSVs, and 63.6% (95% CI 47.1% to 80.1%) for UGFS in 494 SSVs. One study reported

results of MOCA, with an anatomical success rate of 94%. Neurologic complications were most frequently reported

after surgery (mean 19.6%) and thermal ablation (EVLA: mean 4.8%; RFA: mean 9.7%). Deep venous thrombosis was

a rare complication (0% to 1.2%). CONCLUSION: Endovenous thermal ablation (EVLA/RFA) should be preferred to

surgery and foam sclerotherapy in the treatment of SSV incompetence. Although data on nonthermal techniques in

SSV are still sparse, the potential benefits, especially the reduced risk of nerve injury, might be of considerable clinical

importance.

PMID: 26580850Van Rossem CC et al and the Snapshot Appendicitis Collaborative Study Group (B van de Wall). Antibiotic Duration After Laparoscopic Appendectomy for Acute Complicated Appendicitis. JAMA Surg. 2016 Apr;151(4):323-9. doi: 10.1001/jamasurg.2015.4236

IMPORTANCE: Optimal duration of antibiotic treatment to reduce infectious complications after an appendectomy for

acute complicated appendicitis remains unclear. OBJECTIVE: To investigate the effect of antibiotic duration on infecti-

ous complications after laparoscopic appendectomy for acute complicated appendicitis. DESIGN, SETTING, AND PAR-

TICIPANTS: National multicenter prospective, observational, surgical resident-led cohort study conducted in June and

July 2014. This study involved academic teaching hospitals (n = 8), community teaching hospitals (n = 38), and com-

munity nonteaching hospitals (n = 16), and all consecutive patients (n = 1975) who underwent surgery for suspected

acute appendicitis. EXPOSURES: Patients treated laparoscopically for whom the antibiotic regimens were prolonged

postoperatively because of complicated appendicitis. MAIN OUTCOMES AND MEASURES: Receiving either 3 or 5 days

of antibiotic treatment as planned and additional variables were explored as risk factors for infectious complications

using regression analyses. RESULTS: A total of 1975 patients were included in 62 participating Dutch hospitals; 1901

(96.3%) of these underwent an appendectomy for acute appendicitis and laparoscopy was used in 74.4% of these pa-

tients (n = 1415). In 415 laparoscopically treated patients, antibiotic treatment was continued for more than 24 hours

because of acute complicated appendicitis (29.3%). The prescribed antibiotic duration varied between 2 and 6 days

in all of these patients. In 123 patients (29.6%), the length of treatment was adjusted. A shorter duration of antibiotic

treatment (3 days instead of 5) had no significant effect on any infectious complication (odds ratio [OR], 0.93; 95% CI,

0.38-2.32; P = .88) or on intra-abdominal abscess development (OR, 0.89; 95% CI, 0.34-2.35; P = .81). Perforation of

the appendix was the only independent risk factor for the development of an infectious complication (OR, 4.90; 95% CI,

1.41-17.06; P = .01) and intra-abdominal abscess (OR, 7.46; 95% CI, 1.65-33.66; P = .009) in multivariable regres-

sion analysis. CONCLUSIONS AND RELEVANCE: Lengthening of postoperative antibiotic treatment to 5 days was not

associated with a reduction in infectious complications. Further restriction of antibiotic treatment can be considered in

nonperforated complicated appendicitis.

PMID: 26603437Johannesma PC, Houweling AC, Menko FH, van de Beek I, Reinhard R, Gille JJ, van Waesberghe JT, Thunnissen E, Starink TM, Postmus PE, van Moorselaar RJ. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis? Fam Cancer. 2016 Apr;15(2):297-300.

PMID: 26608220Beernink TM, Wever PC, Hermans MH, Bartholomeus MG. Capnocytophaga canimorsus meningitis diagnosed by 16S rRNA PCR. Pract Neurol. 2016 Apr;16(2):136-8.


PMID: 26609180 Kist JW, de Keizer B, van der Vlies M, Brouwers AH, Huysmans DA, van der Zant FM, Hermsen R, Stokkel MP, Hoekstra OS, Vogel WV; THYROPET Study Group; other members of the THYROPET Study group are John M.H. de Klerk. Collaborators: van Tinteren H, Paul de Boer J, Morreau H, Huisman MC, Lentjes EG, Links TP, Smit JW, Lavalaye J, de Jager PL, Hoekstra CJ, Gotthardt M, Schelfhout VJ, de Bruin WI, Sivro F, Adam JA, Phan HT, Sloof GW, Wagenaar NR. Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). J Nucl Med. 2016 May;57(5):701-7. doi: 10.2967/jnumed.115.168138. Epub 2015 Nov 25.

PMID: 26616040Wielders CC, Teunis PF, Hermans MH, van der Hoek W, Schneeberger PM. Kinetics of antibody response to Coxiella burnetii infection (Q fever): Estimation of the seroresponse onset from antibody levels. Epidemics. 2015 Dec;13:37-43.

PMID: 26661393 Van der Bij AK, Frentz D, Bonten MJ; ISIS-AR Study Group (Renders NH). Gram-positive cocci in Dutch ICUs with and without selective decontamination of the oropharyngeal and digestive tract: a retrospective database analysis. J Antimicrob Chemother. 2016 Mar;71(3):816-20. doi: 10.1093/jac/dkv396. Epub 2015 Dec 11.

PMID: 26662794Van Eijk JJ, Groothuis JT, Van Alfen N. Neuralgic amyotrophy: An update on diagnosis, pathophysiology, and treatment. Muscle Nerve. 2016 Mar;53(3):337-50. doi: 10.1002/mus.25008. Epub 2016 Jan 20. Review.

PMID: 26663464Brinkman DJ, Keijsers CJ, Tichelaar J, Richir MC, van Agtmael MA. Evaluating pharmacotherapy education: urgent need for hard outcomes. Br J Clin Pharmacol. 2016 May;81(5):1000-1. doi: 10.1111/bcp.12862. Epub 2016 Feb 17. No abstract available.

PMID: 26681732D’Agnolo HM, Drenth JP. Risk factors for progressive polycystic liver disease: where do we stand? Nephrol Dial Transplant. 2016 Jun;31(6):857-9. doi: 10.1093/ndt/gfv417. Epub 2015 Dec 17.

PMID: 26707528Van Dongen MJ, Falger-Veeken SN. The Risk of a Bicycle Helmet: Hyoid Bone Fracture. Ann Emerg Med. 2016 Jan;67(1):145-6. doi: 10.1016/j.annemergmed.2015.09.012.

PMID: 26711839Dalton HR, Kamar N, van Eijk JJ, Mclean BN, Cintas P, Bendall RP, Jacobs BC. Hepatitis E virus and neurological injury. Nat Rev Neurol. 2016 Feb;12(2):77-85. doi: 10.1038/nrneurol.2015.234. Epub 2015 Dec 29. Review.

PMID: 26716438Vogelaar F, Van Erning F, Reimers M, Van Der Linden J, Pruijt J, Van Den Brule A, Bosscha K. The prognostic value of Microsatellite instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients. Mol Med. 2015 Dec 17:1-26. Doi. 10.2119/molmed.2015.00220


PMID: 26723240Derks JL, Speel EJ, Thunnissen E, van Suylen RJ, Buikhuisen WA, van Velthuysen ML, Dingemans AM. Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle. J Thorac Oncol. 2016 Mar;11(3):e35-8. doi: 10.1016/j.jtho.2015.10.013.

PMID: 26729193 Schepers NJ, Bakker OJ, Besselink MG, Bollen TL, Dijkgraaf MG, van Eijck CH, Fockens P, van Geenen EJ, van Grinsven J, Hallensleben ND, Hansen BE, van Santvoort HC, Timmer R, Anten MP, Bolwerk CJ, van Delft F, van Dullemen HM, Erkelens GW, van Hooft JE, Laheij R, van der Hulst RW, Jansen JM, Kubben FJ, Kuiken SD, Perk LE, de Ridder RJ, Rijk MC, Römkens TE, Schoon EJ, Schwartz MP, Spanier BW, Tan AC, Thijs WJ, Venneman NG, Vleggaar FP, van de Vrie W, Witteman BJ, Gooszen HG, Bruno MJ; Dutch Pancreatitis Study Group. Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial. Trials. 2016 Jan 5;17:5. doi: 10.1186/s13063-015-1132-0.

PMID: 26732217Keijsers CJ, Jansen PA, Brouwers JR, de Wildt DJ. Need for improvement in education on appropriate prescribing in elderly patients. Ned Tijdschr Geneeskd. 2015;159:A9609.

PMID: 26738757Van der Have M, Oldenburg B, Kaptein AA, Jansen JM, Scheffer RC, van Tuyl BA, van der Meulen-de Jong AE, Pierik M, Siersema PD, van Oijen MG, Fidder HH. Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. J Crohns Colitis. 2016 May;10(5):549-55. doi: 10.1093/ecco-jcc/jjw002. Epub 2016 Jan 6.

PMID: 26760181Harder E, Thomsen LT, Frederiksen K, Munk C, Iftner T, van den Brule A, Kjaer SK. Risk Factors for Incident and Redetected Chlamydia trachomatis Infection in Women: Results of a Population-Based Cohort Study. Sex Transm Dis. 2016 Feb;43(2):113-9. doi: 10.1097/OLQ.0000000000000394.

PMID: 26776851 van Grinsven J, van Brunschot S, Bakker OJ, Bollen TL, Boermeester MA, Bruno MJ, Dejong CH, Dijkgraaf MG, van Eijck CH, Fockens P, van Goor H, Gooszen HG, Horvath KD, van Lienden KP, van Santvoort HC, Besselink MG; Dutch Pancreatitis Study Group (Cappendijk VC). Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. HPB (Oxford). 2016 Jan;18(1):49-56. doi: 10.1016/j.hpb.2015.07.003. Epub 2015 Dec 20.

PMID: 26776865Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Smit EF, Groen HJ, Speel EJ, Dingemans AM. A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors. J Thorac Oncol. 2016 Apr;11(4):593-602. doi: 10.1016/j.jtho.2015.12.106. Epub 2016 Jan 9.


PMID: 26783742Melman S, Schoorel EC, de Boer K, Burggraaf H, Derks JB, van Dijk D, van Dillen J, Dirksen CD, Duvekot JJ, Franx A, Hasaart TH, Huisjes AJ, Kolkman D, van Kuijk S, Kwee A, Mol BW, van Pampus MG, de Roon-Immerzeel A, van Roosmalen JJ, Roumen FJ, Smid-Koopman E, Smits L, Spaans WA, Visser H, van Wijngaarden WJ, Willekes C, Wouters MG, Nijhuis JG, Hermens RP, Scheepers HC. Development and Measurement of Guidelines-Based Quality Indicators of Caesarean Section Care in the Netherlands: A RAND-Modified Delphi Procedure and Retrospective Medical Chart Review. PLoS One. 2016 Jan 19;11(1):e0145771. doi: 10.1371/journal.pone.0145771. eCollection 2016.

PMID: 26798868Murk JL, Nieuwkamp DJ, van Oosten BW. Dr. Murk and colleagues reply. N Engl J Med. 2016 Jan 21;374(3):296. No abstract available.

PMID: 26802176Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016 Mar 3;127(9):1109-16. doi: 10.1182/blood-2015-11-679415. Epub 2016 Jan 22.

PMID: 26811519Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25.

PMID: 26810721Wijburg MT, Siepman D, van Eijk JJ, Killestein J, Wattjes MP Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. J Neurol. 2016 Apr;263(4):649-56. doi: 10.1007/s00415-015-8001-3. Epub 2016 Jan 25.

PMID: 26811669Römkens TE, Bulte GJ, Nissen LH, Drenth JP. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol. 2016 Jan 21;22(3):1321-30. doi: 10.3748/wjg.v22.i3.1321.

PMID: 26822612Derikx LA, Nissen LH, Oldenburg B, Hoentjen F. Controversies in pouch surveillance for patients with inflammatory bowel disease. J Crohns Colitis. 2016 Jun;10(6):747-51. doi: 10.1093/ecco-jcc/jjw035. Epub 2016 Jan 28.


PMID: 26823272Lodewijkx PJ, Besselink MG, Witteman BJ, Schepers NJ, Gooszen HG, van Santvoort HC, Bakker OJ; Dutch Pancreatitis Study Group. Nutrition in acute pancreatitis: a critical review. Expert Rev Gastroenterol Hepatol. 2016;10(5):571-80. doi: 10.1586/17474124.2016.1141048. Epub 2016 Mar 15.

PMID: 26826945Huijbregts HJ, Khan RJ, Fick DP, Jarrett OM, Haebich S. Prosthetic alignment after total knee replacement is not associated with dissatisfaction or change in Oxford Knee Score: A multivariable regression analysis. Knee. 2016 Jun;23(3):535-9. doi: 10.1016/j.knee.2015.12.007. Epub 2016 Jan 27.

PMID: 26843001Vermeij A, Kessels RP, Heskamp L, Simons EM, Dautzenberg PL, Claassen JA. Prefrontal activation may predict working-memory training gain in normal aging and mild cognitive impairment. Brain Imaging Behav. 2016 Feb 3. [Epub ahead of print]

PMID: 26847183Gayet M, van der Aa A, Schmitz P, Beerlage HP, Schrier, BP, Mulders PF, Mischi M, Wijkstra. 3D Navigo™ versus TRUS-guided prostate biopsy in prostate cancer detection. World J Urol. 2016 Sep;34(9): 1255-60. doi: 10.1007/s00345-016-1775-9. Epub 2016 Feb 4.

PMID: 26846287Schatorjé EJ, de Jong E, van Hout RW, García Vivas Y, de Vries E. The Challenge of Immunoglobulin-G Subclass Deficiency and Specific Polysaccharide Antibody Deficiency--a Dutch Pediatric Cohort Study. J Clin Immunol. 2016 Feb;36(2):141-8. doi: 10.1007/s10875-016-0236-y. Epub 2016 Feb 4

PMID: 26850983Ten Eikelder ML, Oude Rengerink K, Jozwiak M, de Leeuw JW, de Graaf IM, van Pampus MG, Holswilder M, Oudijk MA, van Baaren GJ, Pernet PJ, Bax C, van Unnik GA, Martens G, Porath M, van Vliet H, Rijnders RJ, Feitsma AH, Roumen FJ, van Loon AJ, Versendaal H, Weinans MJ, Woiski M, van Beek E, Hermsen B, Mol BW, Bloemenkamp KW. Induction of labour at term with oral misoprostol versus a Foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trial. Lancet. 2016 Apr 16;387(10028):1619-28. doi: 10.1016/S0140-6736(16)00084-2. Epub 2016 Feb 3.

PMID: 26854825Loonen AJ, Schuurman R, van den Brule AJ. Multidisciplinary molecular diagnostics: the 9th European meeting on molecular diagnostics. Expert Rev Mol Diagn. 2016;16(4):395-7. doi: 10.1586/14737159.2016.1152185. Epub 2016 Feb 26.

PMID: 26863398de Rooij T, Lu MZ, Steen MW, Gerhards MF, Dijkgraaf MG, Busch OR, Lips DJ, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. Minimally Invasive Versus Open Pancreatoduodenectomy: Systematic Review and Meta-analysis of Comparative Cohort and Registry Studies. Ann Surg. 2016 Aug;264(2):257-67. doi: 10.1097/SLA.0000000000001660.


PMID: 26874805Sylvester R, Gontero P, Oddens J. Reply to Stephen B. Williams and Ashish M. Kamat’s Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9. Eur Urol. 2016 Jun;69(6):e123-4. doi: 10.1016/j.eururo.2016.01.055. Epub 2016 Feb 10. No abstract available.

PMID: 26895652Simons KS, Laheij RJ, van den Boogaard M, Moviat MA, Paling AJ, Polderman FN, Rozendaal FW, Salet GA, van der Hoeven JG, Pickkers P, de Jager CP. Dynamic light application therapy to reduce the incidence and duration of delirium in intensive-care patients: a randomised controlled trial. Lancet Respir Med. 2016 Mar;4(3):194-202. doi: 10.1016/S2213-2600(16)00025-4. Epub 2016 Feb 16.

PMID: 26914273Verhoeff SR, van Erning FN, Lemmens VE, de Wilt JH, Pruijt JF. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 2016 Jul 1;139(1):187-93. doi: 10.1002/ijc.30053. Epub 2016 Mar 12.

PMID: 26915339Cissen M, Bensdorp A, Cohlen BJ, Repping S, de Bruin JP, van Wely M. Assisted reproductive technologies for male subfertility. Cochrane Database Syst Rev. 2016 Feb 26;2:CD000360. doi: 10.1002/14651858.CD000360.pub5. Review.

PMID: 26926110Meuwese CL, Meijburg H, Kort E, van Dijk J. Are superior outcomes of early coronary angiography versus a conservative approach in survivors after out-of-hospital cardiac arrest driven by subsets of patients with ST-elevations? Resuscitation. 2016 Jun;103:e11-2. doi: 10.1016/j.resuscitation.2016.02.016. Epub 2016 Feb 27. No abstract available.

PMID: 26928565 Braamse AM, van Turenhout ST, Terhaar Sive Droste JS, de Groot GH, van der Hulst RW, Klemt-Kropp M, Kuiken SD, Loffeld RJ, Uiterwaal MT, Mulder CJ, Dekker J. Factors associated with anxiety and depressive symptoms in colorectal cancer survivors. Eur J Gastroenterol Hepatol. 2016 Jul;28(7):831-5. doi: 10.1097/MEG.0000000000000615.

PMID: 26934436Dumont EA. Sir Harold Gillies, pionier van plastische chirurgie. Ned Tijdschr Geneeskd. 2016;160:A9547.

PMID: 26936156 Vainer J, Habets JH, Schalla S, Lousberg AH, de Pont CD, Vöö SA, Brans BT, Hoorntje JC, Waltenberger J. Cardiac shockwave therapy in patients with chronic refractory angina pectoris. Neth Heart J. 2016 May;24(5):343-9.


PMID: 26945890Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Alfred Witjes J, Oosterlinck W. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. BJU Int. 2016 Sep;118(3):423-8. doi: 10.1111/bju.13474. Epub 2016 Apr 2.

PMID: 26959411Boers-Sonderen M, Mulder SF, Nagtegaal ID, Derikx LA, Wanten G, Mulders P, van der Graaf WT, Hoentjen F, van Herpen CM. Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: is the cause in the mucosa. Acta Oncol. 2016;55(4):444-8. doi: 10.3109/0284186X.2015.1119883.

PMID: 26969198van Baaren GJ, Broekhuijsen K, van Pampus MG, Ganzevoort W, Sikkema JM, Woiski MD, Oudijk MA, Bloemenkamp K, Scheepers H, Bremer HA, Rijnders R, van Loon AJ, Perquin D, Sporken J, Papatsonis D, van Huizen ME, Vredevoogd CB, Brons J, Kaplan M, van Kaam AH, Groen H, Porath M, van den Berg PP, Mol B, Franssen M, Langenveld J; HYPITAT-II Study Group. An economic analysis of immediate delivery and expectant monitoring in women with hypertensive disorders of pregnancy, between 34 and 37 weeks of gestation (HYPITAT-II). BJOG. 2016 Mar 10. doi: 10.1111/1471-0528.13957. [Epub ahead of print]

PMID: 26970318Santosaningsih D, Santoso S, Budayanti NS, Suata K, Lestari ES, Wahjono H, Djamal A, Kuntaman K, van Belkum A, Laurens M, Snijders SV, Willemse-Erix D, Goessens WH, Verbrugh HA, Severin JA. Characterisation of clinical Staphylococcus aureus isolates harbouring mecA or Panton-Valentine leukocidin genes from four tertiary care hospitals in Indonesia. Trop Med Int Health. 2016 May;21(5):610-8. doi: 10.1111/tmi.12692. Epub 2016 Mar 30.

PMID: 26972764Hulsen DJ, Geurts J, van Gestel NA, van Rietbergen B, Arts JJ. Mechanical behaviour of Bioactive Glass granules and morselized cancellous bone allograft in load bearing defects. J Biomech. 2016 May 3;49(7):1121-7.

PMID: 26973841Boulaksil M, Bierhuizen MF, Engelen MA, Stein M, Kok BJ, van Amersfoorth SC, Vos MA, van Rijen HV, de Bakker JM, van Veen TA. Spatial Heterogeneity of Cx43 is an Arrhythmogenic Substrate of Polymorphic Ventricular Tachycardias during Compensated Cardiac Hypertrophy in Rats. Front Cardiovasc Med. 2016 Mar 2;3:5. doi: 10.3389/fcvm.2016.00005. eCollection 2016.

PMID: 26984911Delawi D, Jacobs W, van Susante JL, Rillardon L, Prestamburgo D, Specchia N, Gay E, Verschoor N, Garcia-Fernandez C, Guerado E, Quarles van Ufford H, Kruyt MC, Dhert WJ, Oner FC. OP-1 Compared with Iliac Crest Autograft in Instrumented Posterolateral Fusion: A Randomized, Multicenter Non-Inferiority Trial. J Bone Joint Surg Am. 2016 Mar 16;98(6):441-8. doi: 10.2106/JBJS.O.00209.


PMID: 26989852Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, Arnold WP, Berends MA, Weppner-Parren L, Ossenkoppele PM, Njoo MD, Mommers JM, van Lümig PP, Driessen RJ, Kievit W, de Jong EM. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016 Aug;175(2):340-7. doi: 10.1111/bjd.14552. Epub 2016 Jun 25.

PMID: 26991464Ebisch RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, IntHout J, Verhoef VM, Heideman DA, Snijders PJ, Meijer CJ, van Kemenade FJ, Bulten J, Siebers AG, Bekkers RL, Melchers WJ. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. Int J Cancer. 2016 Aug 1;139(3):691-9. doi: 10.1002/ijc.30090. Epub 2016 Apr 7.

PMID: 26992110Derikx LA, Vierdag WM, Kievit W, Bosch S, Hoentjen F, Nagtegaal ID. Increased prevalence of colonic neuroendocrine tumors in inflammatory bowel disease. Int J Cancer. 2016 Aug 1;139(3):535-42. doi: 10.1002/ijc.30096. Epub 2016 Apr 4.

PMID: 26995271Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016 Jun;21(6):962-76. doi: 10.1016/j.drudis.2016.03.002. Epub 2016 Mar 17. Review.

PMID: 27005591De Bruin JL, Karthikesalingam A, Holt PJ, Prinssen M, Thompson MM, Blankensteijn JD; Dutch RandomisedEndovascular Aneurysm Management (DREAM) Study Group. Bak AA, Buth J, Pattynama PM, Verhoeven EL, van Voorthuisen AE, Blankensteijn JD, Balm R, Buth J, Cuypers PW, Grobbee DE, Prinssen M, van Sambeek MR, Verhoeven EL, Baas AF, Hunink MG, van Engelshoven JM, Jacobs MJ, de Mol BA, van Bockel JH, Balm R, Reekers J, Tielbeek X, Verhoeven EL, Wisselink W, Boekema N, Heuveling LM, Sikking I, Prinssen M, Balm R, Blankensteijn JD, Buth J, Cuypers PW, van Sambeek MR, Verhoeven EL, de Bruin JL, Baas AF, Blankensteijn JD, Prinssen M, Buth J, Tielbeek AV, Blankensteijn JD, Balm R, Reekers JA, van Sambeek MR, Pattynama P, Verhoeven EL, Prins T, van der Ham AC, van der Velden JJ, van Sterkenburg SM, Ten Haken GB, Bruijninckx CM, van Overhagen H, Tutein Nolthenius RP, Hendriksz TR, Teijink JA, Odink HF, de Smet AA, Vroegindeweij D, van Loenhout RM, Rutten MJ, Hamming JF, Lampmann LE, Bender MH, Pasmans H, Vahl AC, de Vries C, Mackaay AJ, van Dortmont LM, van der Vliet AJ, Schultze Kool LJ, Boomsma JH, van HR, de Mol van Otterloo JC, de Rooij TP, Smits TM, Yilmaz EN, Wisselink W, van den Berg FG, Visser MJ, van der Linden E, Schurink GW, de Haan M, Smeets HJ, Stabel P, van Elst F, Poniewierski J, Vermassen FE. Predicting reinterventions after open and endovascular aneurysm repair using the St George’s Vascular Institute score. J Vasc Surg. 2016 Jun;63(6):1428-1433. doi: 10.1016/j.jvs.2015.12.028.


PMID: 27027209Groothuis JT, van Eijk JJ, van de Laar FA, van Alfen N [Incidence of neuralgic amyotrophy in a primary care setting: a prospective cohort study]. Ned Tijdschr Geneeskd. 2015;160:A9957. Dutch.

PMID: 27048897Derikx LA, Dieleman LA, Hoentjen F. Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):55-71. doi: 10.1016/j.bpg.2016.02.005. Epub 2016 Feb 9.

PMID: 27048744Leenders AC. Prevention of Surgical Site Infections: Universal Decontamination Not for All, but for a Selection of Surgical Patients. Clin Infect Dis. 2016 Jun 1;62(11):1469-70. doi: 10.1093/cid/ciw214. Epub 2016 Apr 5. No abstract available.

PMID: 27049170Stam H, Harting T, Sluijs Mv, Marum Rv, Horst Hv, Wouden JC, Maarsingh OR. Usual care and management of fall risk increasing drugs in older dizzy patients in Dutch general practice. Scand J Prim Health Care. 2016 Jun;34(2):165-71. doi: 10.3109/02813432.2016.1160634. Epub 2016 Apr 6.

PMID: 27050045Korterink JJ, Ockeloen LE, Hilbink M, Benninga MA, Deckers-Kocken JM. Yoga Therapy for Abdominal Pain Related-Functional Gastrointestinal Disorders in Children. A Randomized Controlled Trial. J Pediatr Gastroenterol Nutr. 2016 Apr 4. [Epub ahead of print]

PMID: 27055805Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand’Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group. Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler. 2016 Apr 7. pii: 1352458516643392.

PMID: 27059152de Bruin JL, Groenwold RH, Baas AF, Brownrigg JR, Prinssen M, Grobbee DE, Blankensteijn JD; DREAM Study Group. Bak AA, Buth J, Pattynama PM, Verhoeven EL, van Voorthuisen AE, Blankensteijn JD, Balm R, Buth J, Cuypers PW, Grobbee DE, Prinssen M, van Sambeek MR, G Verhoeven EL, Baas AF, Hunink MG, van Engelshoven JM, Jacobs MJ, de Mol BA, van Bockel JH, Balm R, Reekers J, Tielbeek X, Verhoeven EL, Wisselink W, Boekema N, Heuveling I Sikking LM, Prinssen M, Balm R, Blankensteijn JD, Buth J, Cuypers PW, van Sambeek MR, Verhoeven EL, de Bruin JL, Baas AF, Blankensteijn JD, Prinssen M, Buth J, Tielbeek AV, Blankensteijn JD, Balm R, Reekers JA, van Sambeek MR, Pattynama P, Verhoeven EL, Prins T, van der Ham AC, van der Velden JJ, van Sterkenburg SM, Ten Haken GB, Bruijninckx CM, van Overhagen H, Tutein Nolthenius RP, Hendriksz TR, Teijink JA, Odink HF, de Smet AA, Vroegindeweij D, van Loenhout RM, Rutten MJ, Hamming JF, Lampmann LE, Bender MH, Pasmans H, Vahl AC, de Vries C, Mackaay AJ, van Dortmont


LM, van der Vliet AJ, Schultze Kool LJ, Boomsma JH, van Dop HR, de Mol van Otterloo JC, de Rooij TP, Smits TM, Yilmaz EN, Wisselink W, van den Berg Vrije FG, Visser MJ, van der Linden E, Schurink GW, de Haan M, Smeets HJ, Stabel P, van Elst F, Poniewierski J, Vermassen FE. Quality of life from a randomized trial of open and endovascular repair for abdominal aortic aneurysm. Br J Surg. 2016 Jul;103(8):995-1002. doi: 10.1002/bjs.10130.

PMID: 27059387Mourits MM, Nijhof WH, van Leuken MH, Jager GJ, Rutten MJ. Reducing contrast medium volume and kilo voltage in CTA of the pulmonary artery. Clinical Radiology 2016 Jun;71(6):615.e7-615.e13. doi: 10.1016/j.crad.2016.03.005.

AIM: To evaluate image quality after contrast medium (CM) and tube voltage reduction in computed tomography

angiography (CTA) of the pulmonary artery. MATERIALS AND METHODS: Thirty-three patients referred for CTA of the

pulmonary artery for suspected pulmonary embolism were included. Patients were randomly assigned to Protocol

I (100 ml of 350 mg iodine/ml iodinated CM; n=16) or Protocol II (50 ml of 350 mg iodine/ml iodinated CM; n=17).

Dual-energy CT (80 kV and 140 kV) was performed in all patients. An averaged weighted series equivalent to a 120 kV

image acquisition was reconstructed. The mean attenuation value of CM was measured at eight positions in the pul-

monary trunk and pulmonary arteries. Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were calculated.

Qualitative assessment of the vascular enhancement was performed independently by two experienced radiologists

using a three-point scale. Mean attenuation values, image noise, CNR, and SNR of images with 50 ml CM and images

with 100 ml CM were compared and mean attenuation values, image noise, CNR, and SNR in 80 kV images and

120 kV images were compared. For qualitative analysis, interobserver variability was analysed using Cohen’s kappa

statistics. RESULTS: The mean attenuation values in Protocol I and Protocol II were not significantly different at 80 kV

(634.6±168.3 versus 537.9±146.7 HU; p=0.088) and 120 kV (482.8±127.7 versus 410.4±106.0 HU; p=0.085). The

mean attenuation value at 80 kV was significantly higher than the mean attenuation value at 120 kV in Protocols I

and II (p<0.001). The CNR and SNR were higher at 120 kV than at 80 kV in both protocols (p=0.000-0.019); however,

there were no significant differences in the CNR and SNR between both protocols (p=0.600-0.952). Qualitative (sub-

jective) analysis showed no statistical significant difference between Protocols I and II (p=0.524-1.000). CONCLUSION:

Low tube voltage (80 kV) CTA using 50 ml CM is not inferior to CTA at 120 kV using 100 ml CM.

PMID: 27067656Osterthun R, van Asbeck FW, Nijendijk JH, Post MW. In-hospital end-of-life decisions after new traumatic spinal cord injury in the Netherlands. Spinal Cord. 2016 Apr 12. doi: 10.1038/sc.2016.37. [Epub ahead of print]

STUDY DESIGN: Explorative retrospective files study. OBJECTIVES: To document end-of-life decisions (ELDs) in

in-hospital deaths after new traumatic spinal cord injury (TSCI). SETTING: The Netherlands. METHODS: Discharge

letters concerning patients with TSCI discharged from Dutch acute hospitals in 2010 were analysed. Data were

extracted on survival, personal and lesion characteristics, comorbidities, other injuries, preexisting spinal stenosis,

stabilising surgery, length of hospital stay and the presence and types of ELDs. Characteristics of deceased patients

and survivors were compared using κ2 and T-tests. Characteristics of the deceased patients and ELDs were further

explored. RESULTS: A total of 185 patients with new TSCI were identified. Twenty-six patients were excluded as their

survival status at discharge was unknown-for example, because of discharge to another hospital without information

about their final discharge. Thirty of the remaining 159 patients died during their initial hospital stay (18.9%). Deceased

patients were older and had more often high cervical and motor complete injuries than survivors. The circumstances


of death were sparsely documented, and in nine cases, it was not possible to determine the absence or the presence

of an ELD. ELDs were reported in 19 deaths (63.3%). All were non-treatment decisions, and almost all (89.5%) were

decisions of withdrawal of treatment. There were no cases of documented euthanasia or physician-assisted suicide.

CONCLUSION: ELDs were reported in the majority of in-hospital deaths after new TSCI in the Netherlands (63.3%),

and all were non-treatment decisions.

PMID: 27075042Brandwagt DA, Herremans T, Schneeberger PM, Hackert VH, Hoebe CJ, Paget J, van der Hoek W. Waning population immunity prior to a large Q fever epidemic in the south of The Netherlands. Epidemiol Infect. 2016 Apr 14:1-7. [Epub ahead of print]

Historical survey data suggest that the seroprevalence of antibodies against Coxiella burnetii in the general population of The Netherlands decreased from more than 40% in 1983 to 2•4% in 2007, just before the start of the large 2007-2010 Q fever epidemic. To assess whether the sharp decline in seroprevalence was real, we performed a cross-sectional study using historical samples. We tested samples using a contemporary commercial indirect immunofluorescence assay. In plasma samples from the south of The Netherlands from 1987, we found an age- and sex-standardized seroprevalence of 14•4% (95% confidence interval 11•2-18•3). This was significantly lower than a 1983 estimate from the same area (62•5%), but significantly higher than 2008 (1•0%) and 2010 (2•3%) estimates from the same area. The study suggests that there was a steady and sharp decline in Q fever seroprevalence in the south of The Netherlands from 1987 to 2008. We assume that seroprevalence has decreased in other parts of The Netherlands as well and seroprevalence surveys in other European countries have shown a similar declining trend. Waning population immunity in The Netherlands may have contributed to the scale of the 2007-2010 Q fever epidemic. For a better understanding of the infection dynamics of Q fever, we advocate an international comparative study of the seroprevalence of C. burnetii.

PMID: 27075218Graveland PE, Beex-Oosterhuis MM, Gosker-Venis A, van Marum RJ, van Gool AR. Medication review in the mental health care service: experiences on long-stay units. Tijdschr Psychiatr. 2016;58(4):262-71. Dutch.

BACKGROUND: Medication review is a recurrent, structured and critical evaluation of pharmacotherapy by patient,

physician and pharmacist. The Dutch Health Care Inspectorate considers medication review to be a way of improving

the quality and safety of drug treatment. However, little is known about the costs, effectiveness and feasibility of

medication review in the practice of mental health care. AIM: To obtain an impression of the costs and benefits of a first

medication review in a clinical mental health care setting with chronic patients. METHOD: In 2013, the mental health

organisation Yulius enrolled 70 hospitalised chronic patients for a first medication review. A detailed record was kept

of the prescribed medication, medication changes, and the time invested. RESULTS: More than half of the proposed

changes in medication were eventually implemented; 20% of these changes were made during a planned evaluation

after three months. The number of drugs prescribed decreased after medication review; the reduction applied more

often to somatic medication than to psychotropic medication. Costs relating to medication reviews seemed to be at

least in balance with the benefits. CONCLUSION: In the group of patients with severe mental disorder, medication re-

view seems to provide a good opportunity to assess the rationality of pharmacotherapy in a multidisciplinary approach.

The time invested appears to be offset by the benefits of medication review.


PMID: 27076253Nijhof WH, Hilbink M, Jager GJ, Slump CH, Rutten MJ. A non-invasive Cardiac Output measurement as an alternative to the test bolus technique during CT angiography. Clinical Radiology 2016 Sep;71(9):940.e1-5. doi: 10.1016/j.crad.2016.03.007. Epub 2016 Apr 10.

AIM: To investigate the association between a non-invasive cardiac output (CO) measurement and the scan delay, as

derived from a test bolus injection protocol. The secondary objective was to determine which factors affect the relati-

onship between the CO and scan delay. MATERIALS AND METHODS: Fifty-five patients referred for a contrast-enhan-

ced (thorax-)abdomen CT examination were included in this feasibility study. A test bolus examination was performed

prior to the abdominal CT. During the test bolus injection, the CO of the patient was measured using a non-invasive

finger-cuff measurement. Associations were analysed using linear regression analyses. Age, gender, height, weight,

and blood pressure were included as potential confounders. RESULTS: Linear regression analysis showed a negative

and significant association between CO and delay. The regression formula was as follows: scan delay (seconds) = 26.8-

1.6 CO (l/min), with a 95% CI between -2.3 and -1.0 (p<0.001). Weight appeared to be a confounder in this relation,

and gender and blood pressure were effect modifiers. There was no interaction between scan delay and age, height

and weight. CONCLUSIONS: There is a negative and significant association between the non-invasive CO measurement

and the CT scan delay; however, to validate these findings a larger cohort study is needed to investigate whether the

non-invasively determined scan delay is as accurate as the use of a test bolus.

PMID: 27084843Wever PC, Hodges AJ. The First World War years of Sydney Domville Rowland: an early case of possible laboratory-acquired meningococcal disease. J R Army Med Corps. 2016 Aug;162(4):310-5. doi: 10.1136/jramc-2016-000634. Epub 2016 Apr 15.

Sydney Domville Rowland was a bacteriologist and staff member at the Lister Institute of Preventive Medicine when

the First World War broke out in 1914. Following a request to the Director of the Lister Institute to staff and equip a

mobile field laboratory as quickly as possible, Rowland was appointed to take charge of No. 1 Mobile Laboratory and

took up a temporary commission at the rank of Lieutenant in the Royal Army Medical Corps. On 9 October 1914,

Rowland set out for the European mainland and was subsequently attached to General Headquarters in Saint-Omer,

France (October 1914-June 1915), No. 10 Casualty Clearing Station in Lijssenthoek, Belgium (June 1915-Febru-

ary 1916, during which period he was promoted Major), and No. 26 General Hospital in Étaples, France (February

1916-March 1917). His research focused on gas gangrene, typhoid fever, trench fever, wound infection and cerebro-

spinal fever. In February of 1917, while engaged in identifying meningococcal carriers, Rowland contracted cerebro-

spinal meningitis to which he succumbed at age 44 on 6 March 1917. His untimely death might have been caused by

laboratory-acquired meningococcal disease, especially since Rowland’s work with Neisseria meningitidis isolates had

extended beyond routine laboratory techniques and included risk procedures like immunisation of rabbits with patho-

genic strains isolated from cerebrospinal fluid. Currently, microbiology laboratory workers who are routinely exposed

to N. meningitidis isolates are recognised as a population at increased risk for meningococcal disease, for which reason

recommended preventive measures include vaccination and handling of isolates within a class II biosafety cabinet.


PMID: 27087571Balan TA, Jonker MA, Johannesma PC, Putter H. Ascertainment correction in frailty models for recurrent events data. Stat Med. 2016 Oct 15;35(23):4183-201.

In retrospective studies involving recurrent events, it is common to select individuals based on their event history up to

the time of selection. In this case, the ascertained subjects might not be representative for the target population, and

the analysis should take the selection mechanism into account. The purpose of this paper is two-fold. First, to study

what happens when the data analysis is not adjusted for the selection and second, to propose a corrected analysis. Un-

der the Andersen-Gill and shared frailty regression models, we show that the estimators of covariate effects, incidence,

and frailty variance can be biased if the ascertainment is ignored, and we show that with a simple adjustment of the

likelihood, unbiased and consistent estimators are obtained. The proposed method is assessed by a simulation study

and is illustrated on a data set comprising recurrent pneumothoraces. Copyright © 2016 John Wiley & Sons, Ltd.

PMID: 27095751Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016 Nov;10(11):1287-1293. Epub 2016 Apr 19.

BACKGROUND AND AIMS: The biosimilar of Remicade®, CT-P13, recently entered the European market. Clinical data

on switching from Remicade® to CT-P13 in inflammatory bowel disease [IBD] are scarce. We aimed to prospectively

investigate efficacy, safety, pharmacokinetic profile, and immunogenicity following a switch from Remicade® to CT-P13

in IBD patients. METHODS: Remicade®-treated IBD patients at the Radboud university medical centre who switched

to CT-P13 were included in this prospective observational cohort study. Primary endpoint was change in Harvey-

Bradshaw Index for Crohn’s disease [CD] and Simple Clinical Colitis Activity Index for ulcerative colitis [UC] at week 16.

We measured C-reactive protein [CRP], faecal calprotectin [FCP], infliximab trough level [TL] and anti-drug antibodies

[ADAs] and documented adverse events. RESULTS: Our cohort consisted of 83 patients (28 males, 57 CD, 24 UC,

2 IBD-unclassified [IBD-U]). The median age was 36 years, range 18-79. Median change in disease activity was 0

[range -23 to +7] for CD and 0 [range -3 to +6] for UC/IBD-U. Median CRP and FCP levels did not change significantly

during follow-up. Median TL increased from 3.5 μg/ml [range 0-18] to 4.2 μg/ml [range 0-21] at week 16 [p = 0.010].

Two patients developed a new detectable ADA response during follow-up and five patients discontinued CT-P13. No

serious adverse events occurred. CONCLUSIONS: We demonstrated that switching from Remicade® to CT-P13 in a

real-life cohort of IBD patients did not have a significant impact on short-term clinical outcomes. These results suggest

that switching from Remicade® to CT-P13 for the treatment of IBD is feasible.

PMID: 27098045Levy ML, Dekhuijzen PN, Barnes PJ, Broeders M, Corrigan CJ, Chawes BL, Corbetta L, Dubus JC, Hausen T, Lavorini F, Roche N, Sanchis J, Usmani OS, Viejo J, Vincken W, Voshaar T, Crompton GK, Pedersen S. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). NPJ Prim Care Respir Med. 2016 Apr 21;26:16017. doi: 10.1038/npjpcrm.2016.17. Review.

Health professionals tasked with advising patients with asthma and chronic obstructive pulmonary disease (COPD)

how to use inhaler devices properly and what to do about unwanted effects will be aware of a variety of commonly

held precepts. The evidence for many of these is, however, lacking or old and therefore in need of re-examination. Few

would disagree that facilitating and encouraging regular and proper use of inhaler devices for the treatment of asthma

and COPD is critical for successful outcomes. It seems logical that the abandonment of unnecessary or ill-founded


practices forms an integral part of this process: the use of inhalers is bewildering enough, particularly with regular

introduction of new drugs, devices and ancillary equipment, without unnecessary and pointless adages. We review

the evidence, or lack thereof, underlying ten items of inhaler ‘lore’ commonly passed on by health professionals to

each other and thence to patients. The exercise is intended as a pragmatic, evidence-informed review by a group of

clinicians with appropriate experience. It is not intended to be an exhaustive review of the literature; rather, we aim

to stimulate debate, and to encourage researchers to challenge some of these ideas and to provide new, updated evi-

dence on which to base relevant, meaningful advice in the future. The discussion on each item is followed by a formal,

expert opinion by members of the ADMIT Working Group.

PMID: 27121067Lobbezoo D, Truin W, Voogd A, Roumen R, Vreugdenhil G, Dercksen MW, van den Berkmortel F, Smilde T, van de Wouw A, van Kampen R, van Riel J, Peters N, Peer P, Tjan-Heijnen VC. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. Oncotarget. 2016 May 17;7(20):29412-9. doi: 10.18632/oncotarget.8838.

INTRODUCTION: This study describes the differences between the two largest histological breast cancer subtypes (in-

vasive ductal carcinoma (IDC) and invasive (mixed) lobular carcinoma (ILC) with respect to patient and tumor characte-

ristics, treatment-choices and outcome in metastatic breast cancer. RESULTS: Patients with ILC were older at diagnosis

of primary breast cancer and had more often initial bone metastasis (46.5% versus 34.8%, P = 0.01) and less often

multiple metastatic sites compared to IDC (23.7% versus 30.9%, P = 0.11). Six months after diagnosis of metastatic

breast cancer, 28.1% of patients with ILC and 39.8% of patients with IDC had received chemotherapy with a longer me-

dian time to first chemotherapy for those with ILC (P = 0.001). After six months 84.8% of patients with ILC had received

endocrine therapy versus 72.5% of patients with IDC (P = 0.0001). Median overall survival was 29 months for ILC and

25 months for IDC (P = 0.53). MATERIALS AND METHODS: We included 437 patients with hormone receptor-positive

IDC and 131 patients with hormone receptor-positive ILC, all diagnosed with metastatic breast cancer between 2007-

2009, irrespective of date of the primary diagnosis. Patient and tumor characteristics and data on treatment and

outcome were collected. Survival curves were obtained using the Kaplan-Meier method. CONCLUSIONS: Treatment

strategies of hormone receptor-positive metastatic breast cancer were remarkably different for patients with ILC and

IDC. Further research is required to understand tumor behavior and treatment-choices in real-life.

PMID: 27128782Van Erning FN, Razenberg LG, Lemmens VE, Creemers GJ, Pruijt JF, Maas HA, Janssen-Heijnen ML. Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients. Eur J Cancer. 2016 Jul;61:1-10. doi: 10.1016/j.ejca.2016.03.074. Epub 2016 Apr 27.

PURPOSE: The aim of this study was to provide insight in the use, intensity and toxicity of therapy with capecitabine

and oxaliplatin (CAPOX) and capecitabine monotherapy (CapMono) among elderly stage III colon cancer patients

treated in everyday clinical practice. METHODS: Data from the Netherlands Cancer Registry were used. All stage III

colon cancer patients aged ≥70 years diagnosed in the southeastern part between 2005 and 2012 and treated with

CAPOX or CapMono were included. Differences in completion of all planned cycles, cumulative dosages and toxicity

between both regimens were evaluated. RESULTS: One hundred ninety-three patients received CAPOX and 164

patients received CapMono; 33% (n = 63) of the patients receiving CAPOX completed all planned cycles of both agents,

whereas 55% (n = 90) of the patients receiving CapMono completed all planned cycles (P < 0.0001). The median

cumulative dosage capecitabine was lower for patients treated with CAPOX (163,744 mg/m(2), interquartile range

[IQR] 83,397-202,858 mg/m(2)) than for patients treated with CapMono (189,195 mg/m(2), IQR 111,667-228,125


mg/m(2), P = 0.0003); 54% (n = 105) of the patients treated with CAPOX developed grade III-V toxicity, whereas 38%

(n = 63) of the patients treated with CapMono developed grade III-V toxicity (P = 0.0026). After adjustment for patient

and tumour characteristics, CapMono was associated with a lower odds of developing grade III-V toxicity than CAPOX

(odds ratio 0.54, 95% confidence interval 0.33-0.89). For patients treated with CAPOX, the most common toxicities

were gastrointestinal (29%), haematological (14%), neurological (11%) and other toxicity (13%). For patients treated with

CapMono, dermatological (17%), gastrointestinal (13%) and other toxicity (11%) were the most common. CONCLUSION:

CAPOX is associated with significantly more grade III-V toxicities than CapMono, which had a pronounced impact on the

cumulative dosage received and completion of all planned cycles. In this light, CapMono seems preferable over CAPOX.

PMID: 27135753Ploos van Amstel FK, Tol J, Sessink KH, van der Graaf WT, Prins JB, Ottevanger PB. A Specific Distress Cutoff Score Shortly After Breast Cancer Diagnosis. Cancer Nurs. 2016 Apr 29. [Epub ahead of print]

BACKGROUND: High levels of distress are expected shortly after the diagnosis breast cancer. The Distress Thermome-

ter (DT) is commonly used to screen for distress, using a cutoff score of 4 or 5; however, this score might not be appro-

priate for detecting distress in women with recently diagnosed breast cancer. OBJECTIVES: The aims of this study were

to establish the optimal DT cutoff score for detecting high distress shortly after breast cancer diagnosis and to correlate

this score with the reported problems. METHODS: We selected for this study Dutch women who completed the DT and

the Hospital Anxiety and Depression Scale within 1 month after breast cancer diagnosis. Receiver operating characte-

ristic analysis of DT scores was performed, with the Hospital Anxiety and Depression Scale being used as the criterion

standard for the level of distress. The sensitivity, specificity, positive predictive value, and negative predictive value of

each DT score were calculated. RESULTS: In total, 181 women participated in the study. The optimal DT cutoff score

for detecting distress was 7 with a sensitivity of 0.73, specificity of 0.84, positive predictive value of 69%, and negative

predictive value of 87%. Emotional problems were the most frequently reported concerns. CONCLUSION: We consider

a cutoff score of 7, shortly after breast cancer is diagnosed, optimal to identify those women with high distress and

therefore at risk of chronic distress. IMPLICATIONS FOR PRACTICE: The findings are clinically important because they

can enable healthcare professionals to direct their time and resources to those most in need of their assistance.

PMID: 27144614Van Eijk JJ, Groothuis J, van Alfen N. Reply. Muscle Nerve. 2016 Aug;54(2):342-3. doi: 10.1002/mus.25172. Epub 2016. May 27. No abstract available.

PMID: 27165453Kerkenaar ME, van Marum RJ, Sprong T, Bootsma JE. Spondylodiscitis bij de oudere patiënt. Ned Tijdschr Geneeskd. 2016;160:A9375

The incidence of spondylodiscitis is highest among the elderly. Because of the ageing population the incidence of

spondylodiscitis is rising. In this article, we illustrate dilemmas which may occur when treating older patients with

spondylodiscitis by presenting two cases. The first patient is a 74-year-old man in whom there was uncertainty about

the diagnosis on the basis of imaging results. The second patient is an 82-year-old man with dementia in whom long-

standing intravenous treatment was too burdensome and treatment with oral antibiotics was started. The diagnosis of

spondylodiscitis in elderly can be challenging because of frequent atypical presentation and comorbidity. So far, there is

not much known about the prognosis of spondylodiscitis in the elderly, which make decisions about treatment difficult.

The prognosis seems worse in elderly with multimorbidity. A comprehensive geriatric assessment can help to guide

treatment decisions by estimating the chance of good functional recovery.


PMID: 27179265Groenewoud ER, Cohlen BJ, Al-Oraiby A, Brinkhuis EA, Broekmans FJ, de Bruin JP, van den Dool G, Fleisher K, Friederich J, Goddijn M, Hoek A, Hoozemans DA, Kaaijk EM, Koks CA, Laven JS, van der Linden PJ, Manger AP, Slappendel E, Spinder T, Kollen BJ, Macklon NS. A randomized controlled, non-inferiority trial of modified natural versus artificial cycle for cryo-thawed embryo transfer. Hum Reprod. 2016 Jul;31(7):1483-92. doi: 10.1093/humrep/dew120. Epub 2016 May 13.

STUDY QUESTION: Are live birth rates (LBRs) after artificial cycle frozen-thawed embryo transfer (AC-FET) non-

inferior to LBRs after modified natural cycle frozen-thawed embryo transfer (mNC-FET)? SUMMARY ANSWER: AC-FET

is non-inferior to mNC-FET with regard to LBRs, clinical and ongoing pregnancy rates (OPRs) but AC-FET does result

in higher cancellation rates. WHAT IS ALREADY KNOWN: Pooling prior retrospective studies of AC-FET and mNC-FET

results in comparable pregnancy and LBRs. However, these results have not yet been confirmed by a prospective

randomized trial. STUDY DESIGN, SIZE AND DURATION: In this non-inferiority prospective randomized controlled trial

(acronym ‘ANTARCTICA’ trial), conducted from February 2009 to April 2014, 1032 patients were included of which 959

were available for analysis. The primary outcome of the study was live birth. Secondary outcomes were clinical and

ongoing pregnancy, cycle cancellation and endometrium thickness. A cost-efficiency analysis was performed. PARTICI-

PANT/MATERIALS, SETTING, METHODS: This study was conducted in both secondary and tertiary fertility centres in

the Netherlands. Patients included in this study had to be 18-40 years old, had to have a regular menstruation cycle

between 26 and 35 days and frozen-thawed embryos to be transferred had to derive from one of the first three IVF or

IVF-ICSI treatment cycles. Patients with a uterine anomaly, a contraindication for one of the prescribed medications in

this study or patients undergoing a donor gamete procedure were excluded from participation. Patients were rando-

mized based on a 1:1 allocation to either one cycle of mNC-FET or AC-FET. All embryos were cryopreserved using a

slow-freeze technique. MAIN RESULTS AND THE ROLE OF CHANCE: LBR after mNC-FET was 11.5% (57/495) versus

8.8% in AC-FET (41/464) resulting in an absolute difference in LBR of -0.027 in favour of mNC-FET (95% confidence

interval (CI) -0.065-0.012; P = 0.171). Clinical pregnancy occurred in 94/495 (19.0%) patients in mNC-FET versus

75/464 (16.0%) patients in AC-FET (odds ratio (OR) 0.8, 95% CI 0.6-1.1, P = 0.25). 57/495 (11.5%) mNC-FET resulted

in ongoing pregnancy versus 45/464 (9.6%) AC-FET (OR 0.7, 95% CI 0.5-1.1, P = 0.15). χ(2) test confirmed the lack of

superiority. Significantly more cycles were cancelled in AC-FET (124/464 versus 101/495, OR 1.4, 95% CI 1.1-1.9, P =

0.02). The costs of each of the endometrial preparation methods were comparable (κ617.50 per cycle in NC-FET ver-

sus €625.73 per cycle in AC-FET, P = 0.54). LIMITATIONS, REASONS FOR CAUTION: The minimum of 1150 patients

required for adequate statistical power was not achieved. Moreover, LBRs were lower than anticipated in the sample

size calculation. WIDER IMPLICATIONS OF THE FINDINGS: LBRs after AC-FET were not inferior to those achieved by

mNC-FET. No significant differences in clinical and OPR were observed. The costs of both treatment approaches were

comparable. STUDY FUNDING/COMPETING INTERESTS: An educational grant was received during the conduct of this

study. Merck Sharpe Dohme had no influence on the design, execution and analyses of this study. E.R.G. received an

education grant by Merck Sharpe Dohme (MSD) during the conduct of the present study. B.J.C. reports grants from

MSD during the conduct of the study. A.H. reports grants from MSD and Ferring BV the Netherlands and personal fees

from MSD. Grants from ZonMW, the Dutch Organization for Health Research and Development. J.S.E.L. reports grants

from Ferring, MSD, Organon, Merck Serono and Schering-Plough during the conduct of the study. F.J.M.B. receives

monetary compensation as member of the external advisory board for Merck Serono, consultancy work for Gedeon

Richter, educational activities for Ferring BV, research cooperation with Ansh Labs and a strategic cooperation with Ro-

che on automated anti Mullerian hormone assay development. N.S.M. reports receiving monetary compensations for

external advisory and speaking work for Ferring BV, MSD, Anecova and Merck Serono during the conduct of the study.

All reported competing interests are outside the submitted work. No other relationships or activities that could appear

to have influenced the submitted work. TRIAL REGISTRATION NUMBER: Netherlands trial register, number NTR 1586.

TRIAL REGISTRATION DATE: 13 January 2009. FIRST PATIENT INCLUDED: 20 April 2009.


PMID: 27189850Boersma D, de Borst GJ, Moll FL. A proof-of-concept study of the VeinScrew: A new percutaneous venous closure device. Vascular. 2016 Apr 11. pii: 1708538116644117. [Epub ahead of print]

Objective This study evaluated the concept of percutaneous closure of insufficient veins using the VeinScrew principle.

Methods The VeinScrew is designed to place a spring-shaped implant that contracts and clamps around the vein. The

ability of the device to occlude adequately was tested in a bench model experiment. The feasibility of accurate place-

ment and adequate venous occlusion was evaluated in an animal experiment and in a human cadaveric experiment.

Results The VeinScrew implant occluded up to a pressure of 135 mmHg. In vivo studies confirmed that deployment

was challenging but technically feasible, and subsequent phlebography showed closure of the vein. The cadaveric

study showed that percutaneous placement of the evolved VeinScrew around the great saphenous vein was feasible

and accurate. Conclusions The current studies show the feasibility of the VeinScrew concept. Future developments and

translational studies are necessary to determine the potential of this technique as a new option in the phlebologist’s

toolbox.

PMID: 27198257Hendriks L, Brouns A, Amini M, Uyterlinde W, Wijsman R, Biesma B, Stigt J, Ruysscher DD, Heuvel Mv, Dingemans AM. 115PD: Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter? J Thorac Oncol. 2016 Apr;11(4 Suppl):S106. doi: 10.1016/S1556-0864(16)30228-3. Epub 2016 Apr 15. No abstract available.

PMID: 27212247D’Agnolo, HMA, Kievit, W, Takkenberg RB, Riaño I, Bujanda L, Neijenhuis MK, Brunenberg EJL, Beuers U, Banales JM, Drenth JPH. Ursodeoxycholic acid in advanced polycystic liver disease: an international multicenter randomized controlled phase 2 trial: CURSOR: Controlled trial of URSOdeoxycholic acid to Reduce liver volume in polycystic liver disease. J Hepatol. 2016 Sep;65(3):601-7. doi: 10.1016/j.jhep.2016.05.009. Epub 2016 May 17.

BACKGROUND & AIMS: Ursodeoxycholic acid (UDCA) inhibits proliferation of polycystic human cholangiocytes in vitro

and hepatic cystogenesis in a rat model of polycystic liver disease (PLD) in vivo. Our aim was to test whether UDCA

may beneficially affect liver volume in patients with advanced PLD. METHODS: We conducted an international, multi-

center, randomized controlled trial in symptomatic PLD patients from three tertiary referral centers. Patients with PLD

and total liver volume (TLV) κ2500ml were randomly assigned to UDCA treatment (15-20mg/kg/day) for 24weeks, or

to no treatment. Primary endpoint was proportional change in TLV. Secondary endpoints were change in symptoms

and health-related quality of life. We performed a post-hoc analysis of the effect of UDCA on liver cyst volume (LCV).

RESULTS: We included 34 patients and were able to assess primary endpoint in 32 patients, 16 with autosomal

dominant polycystic kidney disease (ADPKD) and 16 with autosomal dominant polycystic liver disease (ADPLD). Pro-

portional TLV increased by 4.6±7.7% (mean TLV increased from 6697ml to 6954ml) after 24weeks of UDCA treatment

compared to 3.1±3.8% (mean TLV increased from 5512ml to 5724ml) in the control group (p=0.493). LCV was not

different after 24weeks between controls and UDCA treated patients (p=0.848). However, UDCA inhibited LCV growth

in ADPKD patients compared to ADPKD controls (p=0.049). CONCLUSIONS: UDCA administration for 24weeks did not

reduce TLV in advanced PLD, but UDCA reduced LCV growth in ADPKD patients. Future studies might explore whether

ADPKD and ADPLD patients respond differently to UDCA treatment. LAY SUMMARY: Current therapies for polycystic

liver disease are invasive and have high recurrence risks. Our trial showed that the drug, ursodeoxycholic acid, was


not able to reduce liver volume in patients with polycystic liver disease. However, a subgroup analysis in patients that

have kidney cysts as well showed that liver cyst volume growth was reduced in patients who received ursodeoxycho-

lic acid in comparison to patients who received no treatment. Trial registration number https://www.clinicaltrials.gov/:

NCT02021110. EudraCT Number https://www.clinicaltrialsregister.eu/: 2013-003207-19.

PMID: 27227425Levy ML, Dekhuijzen P, Barnes PJ, Broeders M, Corrigan CJ, Chawes BL, Corbetta L, Dubus JC, Hausen T, Lavorini F, Roche N, Sanchis J, Usmani OS, Viejo J, Vincken W, Voshaar T, Crompton GK, Pedersen S. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). NPJ Prim Care Respir Med. 2016 May 26;26:16028. doi: 10.1038/npjpcrm.2016.28. No abstract available.

PMID: 27236775Roerdink RL, Douw CM, Leenders AC, Dekker RS, Dietvorst M, Oosterbos CJ, Roerdink HT, Kempen RW, Bom LP. Bilateral periprosthetic joint infection with Ureaplasma urealyticum in an immunocompromised patient. Infection. 2016 Dec;44(6):807-810. Epub 2016 May 28.

This case study discusses how we diagnosed and treated a patient with a late haematogenous bilateral periprosthetic

joint infection (PJI) after total knee arthroplasties caused by Ureaplasma urealyticum. This has never been reported

before. We will discuss how we used a PET-CT, synovial fluid cell count, and synovial fluid analysis by 16S rRNA gene

sequencing to diagnose this PJI. We will also discuss how we treated this patient to obtain full recovery.

PMID: 27239732Nieuwland AJ, Kokje VB, Koning OH, Hamming JF, Szuhai K, Claas FH, Lindeman JH. Activation of the vitamin D receptor selectively interferes with calcineurin-mediated inflammation: a clinical evaluation in the abdominal aortic aneurysm. Lab Invest. 2016 Jul;96(7):784-90. doi: 10.1038/labinvest.2016.55. Epub 2016 May 30.

In vitro and in vivo studies attribute potent immune regulatory properties to the vitamin D receptor (VDR). Yet, it is

unclear to what extend these observations translate to the clinical context of (vascular) inflammation. This clinical study

evaluates the potential of a VDR agonist to quench vascular inflammation. Patients scheduled for open abdominal

aneurysm repair received paricalcitol 1 μg daily during 2-4 weeks before repair. Results were compared with matched

controls. Evaluation in a parallel group showed that AAA patients are vitamin D insufficient (median plasma vitamin D:

43 (30-62 (IQR)) nmol/l). Aneurysm wall samples were collected during surgery, and the inflammatory footprint was

studied. The brief paricalcitol intervention resulted in a selective 73% reduction in CD4+ T-helper cell content (P<0.024)

and a parallel 35% reduction in T-cell (CD3+) content (P<0.032). On the mRNA level, paricalcitol reduced expression of

T-cell-associated cytokines IL-2, 4, and 10 (P<0.019). No effect was found on other inflammatory mediators. On the pro-

tease level, selective effects were found for cathepsin K (P<0.036) and L (P<0.005). Collectively, these effects converge at

the level of calcineurin activity. An effect of the VDR agonist on calcineurin activity was confirmed in a mixed lymphocyte

reaction. In conclusion, brief course of the VDR agonist paricalcitol has profound effects on local inflammation via reduced

T-cell activation. The anti-inflammatory potential of VDR activation in vitamin D insufficient patients is highly selective

and appears to be mediated by an effect on calcineurin-mediated responses.


PMID: 27249110Huijbregts HJ, Khan RJ, Sorensen E, Fick DP, Haebich S. Patient-specific instrumentation does not improve radiographic alignment or clinical outcomes after total knee arthroplasty. Acta Orthop. 2016 Aug;87(4):386-94. doi: 10.1080/17453674.2016.1193799. Epub 2016 Jun.

Background and purpose - Patient-specific instrumentation (PSI) for total knee arthroplasty (TKA) has been intro-

duced to improve alignment and reduce outliers, increase efficiency, and reduce operation time. In order to improve

our understanding of the outcomes of patient-specific instrumentation, we conducted a meta-analysis. Patients and

methods - We identified randomized and quasi-randomized controlled trials (RCTs) comparing patient-specific and

conventional instrumentation in TKA. Weighted mean differences and risk ratios were determined for radiographic

accuracy, operation time, hospital stay, blood loss, number of surgical trays required, and patient-reported outcome

measures. Results - 21 RCTs involving 1,587 TKAs were included. Patient-specific instrumentation resulted in slightly

more accurate hip-knee-ankle axis (0.3°), coronal femoral alignment (0.3°, femoral flexion (0.9°), tibial slope (0.7°),

and femoral component rotation (0.5°). The risk ratio of a coronal plane outlier (> 3° deviation of chosen target) for

the tibial component was statistically significantly increased in the PSI group (RR =1.64). No significance was found for

other radiographic measures. Operation time, blood loss, and transfusion rate were similar. Hospital stay was signifi-

cantly shortened, by approximately 8 h, and the number of surgical trays used decreased by 4 in the PSI group. Knee

Society scores and Oxford knee scores were similar. Interpretation - Patient-specific instrumentation does not result

in clinically meaningful improvement in alignment, fewer outliers, or better early patient-reported outcome measures.

Efficiency is improved by reducing the number of trays used, but PSI does not reduce operation time.

PMID: 27263033Duijghuisen JJ, Greebe P, Nieuwkamp DJ, Algra A, Rinkel GJ. Sex-Related Differences in Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage. J Stroke Cerebrovasc Dis. 2016 Aug;25(8):2067-70. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.018. Epub 2016 Jun 1.

BACKGROUND: Several population-based studies found a higher case fatality after aneurysmal subarachnoid hemorr-

hage (ASAH) in women than in men. This may relate to differences in prognostic characteristics. We therefore assessed

sex differences in prognosticators and outcome in ASAH patients. METHODS: From a prospectively collected ASAH

database, we retrieved data on patients admitted from 1990 to 2010. We calculated prevalence ratios (PRs) with cor-

responding 95% confidence intervals (CIs) for prognosticators (clinical condition on admission, site and treatment of the

aneurysm, and complications during the clinical course) and risk ratios (RRs) for in-hospital death and poor outcome

(death or dependence) at 3 months. RRs were adjusted for possible confounding with Poisson regression analysis.

RESULTS: Of the 1761 included patients, 1211 (68.8%) were women, who were 1.9 (95% CI: .5↔3.3) years older than

men. PRs for women for the site of the aneurysm were 1.71 (95% CI: 1.38↔2.13) for the carotid artery, .68 (95% CI:

.60κ.77) for the anterior communicating artery, 1.14 (95% CI: .92↔1.41) for the middle cerebral artery, and .85 (95%

CI: .63↔1.13) for posterior circulation. PRs of other prognosticators were similar between sexes. The crude RR for in-

hospital death for women was .91 (95% CI: .78↔1.05) and for poor outcome at 3 months was .95 (95% CI: .85↔1.06);

both remained similar after adjustment. CONCLUSIONS: In this study, in-hospital death and poor outcome at 3 months

did not differ between men and women. Women were slightly older than men and had different distributions of aneu-

rysm sites, but not to an extent that it explained a sex difference in outcome.


PMID: 27264038Evers D, Middelburg RA, de Haas M, Zalpuri S, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, Schonewille H, Zwaginga JJ, van der Bom JG. Red-blood-cell alloimmunisation in relation to antigens’ exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016 Jun;3(6):e284-92. doi: 10.1016/S2352-3026(16)30019-9. Epub 2016 May 9.

BACKGROUND: Matching donor red blood cells based on recipient antigens prevents alloimmunisation. Knowledge

about the immunogenicity of red-blood-cell antigens can help optimise risk-adapted matching strategies. We set out

to assess the immunogenicity of red-blood-cell antigens. METHODS: In an incident new-user cohort of previously

non-transfused, non-alloimmunised white patients receiving non-extended matched red-blood-cell transfusions in six

Dutch hospitals between 2006 and 2013, we determined the cumulative number of mismatched red-blood-cell units

per patient. We used multiple imputation to address missing antigen data. Using Kaplan-Meier analysis, we estimated

cumulative alloimmunisation incidences per mismatched antigen dose as a measure of immunogenicity. FINDINGS: Of

54 347 patients assessed, 21 512 were included in our study. Alloantibodies occurred in 474 (2•2%) of all transfused

patients, with cumulative alloimmunisation incidences increasing up to 7•7% (95% CI 4•9-11•2) after 40 units re-

ceived. The antigens C, c, E, K, and Jk(a) were responsible for 78% of all alloimmunisations in our cohort. K, E, and C(w)

were the most immunogenic antigens (cumulative immunisation incidences after 2 mismatched units of 2•3% [95%

CI 1•0-4•8] for K, 1•5% [0•6-3•0] for E, and 1•2% [0•0-10•8] for C(w)). These antigens were 8•7 times (for K), 5•4

times (for E), and 4•6 times (for C(w)) as immunogenic as Fy(a). The next most immunogenic antigens were, in order, e

(1•9 times as immunogenic as Fy(a)), Jk(a) (1•9 times), and c (1•6 times). INTERPRETATION: Red-blood-cell antigens

vary in their potency to evoke a humoral immune response. Our findings highlight that donor-recipient red-blood-cell

matching strategies will be most efficient when primarily focusing on prevention of C, c, E, K, and Jk(a) alloimmunisati-

on. Matching for Fy(a) is of lower clinical relevance. Variations of antigen frequencies determined by ethnic background

prevent extrapolating these conclusions to non-white populations. FUNDING: None.

PMID: 27272956Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, Sinnige LG, Verhagen WI, Visser LH, van der Kruijk R, Verheul F, Boringa J, Heerings M, Gladdines W, Lönnqvist F, Gaillard P. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. J Neurol. 2016 Aug;263(8):1641-51. doi: 10.1007/s00415-016-8183-3. Epub 2016 Jun 7.

In a prospective multi-center observational study, we evaluated the frequency, severity, and impact on activities of

daily living (ADL) of adverse effects (AEs) of high-dose intravenous methylprednisolone (IVMP) in relapsing remitting

multiple sclerosis (MS) patients with a relapse. Online self-report questionnaires stating IVMP’s most common AEs

were completed at baseline, the 2nd day of treatment, and 1 day and 1 week after treatment. Eighty-five patients

were included, 66 completed the baseline questionnaire, and 59 completed at least one post-baseline questionnaire.

Patients reported on average 4 (median) AEs; two (3.4 %) reported no AE. Most frequent was change in taste (61 %),

facial flushing (61 %), sick/stomach pain (53 %), sleep disturbance (44 %), appetite change (37 %), agitation (36 %), and

behavioral changes (36 %). Of all AEs, 34.3 % were severe and 37.9 % impacted on ADL. A 3-day course resulted in 4

(median) AEs and a 5-day course in 7. All patients with high disease impact had two or more AEs, compared with 79 %

of those with low impact (p < 0.01). Of patients with high disability, 45 % had severe AEs, compared with 16 % of those

with low disability. Severe central nervous system (CNS)-related AEs occurred two times more frequently in patients

with high disease impact, and two-and-a-half times more frequently in patients with high disability. Therefore, in

virtually all patients, high-dose IVMP leads to AEs, with about one of three AEs being severe with impact on ADL.


Patients with high disease impact or high disability may experience more (severe) AEs, due to a higher occurrence of

severe CNS-related AEs.

PMID: 27279397Van der Linden YT, Boersma D, Prins HA, Bosscha K, Lips DJ. Use of a multi-instrument access device in abdominoperineal resections. J Min Access Surg 2016;12:248-53

BACKGROUND: Laparoscopic colorectal surgery results in less post-operative pain, faster recovery, shorter length

of stay and reduced morbidity compared with open procedures. Less or minimally invasive techniques have been

developed to further minimise surgical trauma and to decrease the size and number of incisions. This study describes

the safety and feasibility of using an umbilical multi-instrument access (MIA) port (Olympus TriPort+) device with the

placement of just one 12-mm suprapubic trocar in laparoscopic (double-port) abdominoperineal resections (APRs) in

rectal cancer patients. PATIENTS AND METHODS: The study included 20 patients undergoing double-port APRs for

rectal cancer between June 2011 and August 2013. Preoperative data were gathered in a prospective database, and

post-operative data were collected retrospectively. RESULTS: The 20 patients (30% female) had a median age of 67

years (range 46-80 years), and their median body mass index (BMI) was 26 kg/m2 (range 20-31 kg/m2). An additional

third trocar was placed in 2 patients. No laparoscopic procedures were converted to an open procedure. Median ope-

rating time was 195 min (range 115-306 min). A radical resection (R0 resection) was achieved in all patients, with a

median of 14 lymph nodes harvested. Median length of stay was 8 days (range 5-43 days). CONCLUSION: Laparo-

scopic APR using a MIA trocar is a feasible and safe procedure. A MIA port might be of benefit as an extra option in the

toolbox of the laparoscopic surgeon to further minimise surgical trauma.

PMID: 27336008Bart IY, Mourits M, van Gent R, van Leuken MH, Hilbink M, Warris A, Wever PC, de Vries E. Sputum Induction in Children Is Feasible and Useful in a Bustling General Hospital Practice. Glob Pediatr Health. 2016 Mar 4;3:2333794X16636504. doi: 10.1177/2333794X16636504. eCollection 2016.

We prospectively studied the feasibility and effectiveness of sputum induction in obtaining good quality sputum and its

subsequent bacterial yield in children with clinically suspected acute lower-respiratory-tract infection (aLRTI). Good

quality sputum was collected in 89/98 (91%) patients. Sputum cultures revealed ≥1 bacterial pathogens in 22 cases

(25%). Adverse events were infrequent and mild (6%). Sputum induction is feasible in young children and leads to an

increased number of etiological diagnoses of aLRTI.

PMID: 27339671Parren LJ, Munte K, Winnepenninckx V, van Geel M, Steijlen PM, Frank J, van Steensel MA. Clustered unilateral trichoepitheliomas indicate Type 1 segmental manifestation of multiple familial trichoepithelioma. Clin Exp Dermatol. 2016 Aug;41(6):682-4. doi: 10.1111/ced.12856. Epub 2016 Jun 24.

PMID: 27341122Ten Eikelder ML, van de Meent MM, Mast K, Rengerink KO, Jozwiak M, de Graaf IM, Scholtenhuis MA, Roumen FJ, Porath MM, van Loon AJ, van den Akker ES, Rijnders RJ, Feitsma AH, Adriaanse AH, Muller MA, de Leeuw JW, Visser H, Woiski MD, Weerd SR, van Unnik GA, Pernet PJ, Versendaal H, Mol BW, Bloemenkamp KW. Women’s Experiences with and Preference for Induction of Labor with Oral Misoprostol or Foley Catheter at Term. Am J Perinatol. 2016 Jun 24.


OBJECTIVE: We assessed experience and preferences among term women undergoing induction of labor with oral

misoprostol or Foley catheter. STUDY DESIGN: In 18 of the 29 participating hospitals in the PROBAAT-II trial, women

were asked to complete a questionnaire within 24 hours after delivery. We adapted a validated questionnaire about

expectancy and experience of labor and asked women whether they would prefer the same method again in a future

pregnancy. RESULTS: The questionnaire was completed by 502 (72%) of 695 eligible women; 273 (54%) had been

randomly allocated to oral misoprostol and 229 (46%) to Foley catheter. Experience of the duration of labor, pain during

labor, general satisfaction with labor, and feelings of control and fear related to their expectation were comparable

between both the groups. In the oral misoprostol group, 6% of the women would prefer the other method if induction

is necessary in future pregnancy, versus 12% in the Foley catheter group (risk ratio: 0.70; 95% confidence interval:

0.55-0.90; p = 0.02). CONCLUSION: Women’s experiences of labor after induction with oral misoprostol or Foley

catheter are comparable. However, women in the Foley catheter group prefer more often to choose a different method

for future inductions.

PMID: 27348762Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016 Aug 1;2(8):1030-7. doi: 10.1001/jamaoncol.2016.1726.

IMPORTANCE: This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention

of trastuzumab-related cardiotoxic effects. OBJECTIVE: To determine as the primary end point whether angiotensin

II antagonist treatment with candesartan can prevent or ameliorate trastuzumab-related cardiotoxic effects, defined

as a decline in left ventricular ejection fraction (LVEF) of more than 15% or a decrease below the absolute value 45%.

DESIGN: This randomized, placebo-controlled clinical study was conducted between October 2007 and October 2011

in 19 hospitals in the Netherlands, enrolling 210 women with early breast cancer testing positive for human epidermal

growth factor receptor 2 (HER2) who were being considered for adjuvant systemic treatment with anthracycline-

containing chemotherapy followed by trastuzumab. INTERVENTIONS: A total of 78 weeks of candesartan (32 mg/d)

or placebo treatment; study treatment started at the same day as the first trastuzumab administration and continued

until 26 weeks after completion of trastuzumab treatment. MAIN OUTCOMES AND MEASURES: The primary outcome

was LVEF. Secondary end points included whether the N-terminal of the prohormone brain natriuretic peptide (NT-

proBNP) and high-sensitivity troponin T (hs-TnT) can be used as surrogate markers and whether genetic variability in

germline ERBB2 (formerly HER2 or HER2/neu) correlates with trastuzumab-related cardiotoxic effects. RESULTS: A

total of 206 participants were evaluable (mean age, 49 years; age range, 25-69 years) 103 in the candesartan group

(mean age, 50 years; age range, 25-69 years) and 103 in the placebo group (mean age, 50 years; age range, 30-67

years). Of these, 36 manifested at least 1 of the 2 primary cardiac end points. There were 3.8% more cardiac events in

the candesartan group than in the placebo group (95% CI, -7% to 15%; P = .58): 20 events (19%) and 16 events (16%),

respectively. The 2-year cumulative incidence of cardiac events was 0.28 (95% CI, 0.13-0.40) in the candesartan

group and 0.16 (95% CI, 0.08-0.22) in the placebo group (P = .56). Candesartan did not affect changes in NT-proBNP

and hs-TnT values, and these biomarkers were not associated with significant changes in LVEF. The Ala1170Pro ho-

mozygous ERBB2 genotype was associated with a lower likelihood of the occurrence of a cardiac event compared with

Pro/Pro + Ala/Pro genotypes in multivariate analysis (odds ratio, 0.09; 95% CI, 0.02-0.45; P = .003). CONCLUSIONS

AND RELEVANCE: The findings do not support the hypothesis that concomitant use of candesartan protects against a

decrease in left ventricular ejection fraction during or shortly after trastuzumab treatment in early breast cancer. The


ERBB2 germline Ala1170Pro single nucleotide polymorphism may be used to identify patients who are at increased

risk of trastuzumab-related cardiotoxic effects. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00459771.

PMID: 27357638Takanari H, Bourgonje VJ, Fontes MS, Raaijmakers AJ, Driessen H, Jansen JA, van der Nagel R, Kok B, van Stuijvenberg L, Boulaksil M, Takemoto Y, Yamazaki M, Tsuji Y, Honjo H, Kamiya K, Kodama I, Anderson ME, van der Heyden MA, van Rijen HV, van Veen TA, Vos MA. Calmodulin/CaMKII inhibition improves intercellular communication and impulse propagation in the heart and is antiarrhythmic under conditions when fibrosis is absent. Cardiovasc Res. 2016 Sep;111(4):410-21. doi: 10.1093/cvr/cvw173.

AIM: In healthy hearts, ventricular gap junctions are mainly composed by connexin43 (Cx43) and localize in the inter-

calated disc, enabling appropriate electrical coupling. In diseased hearts, Cx43 is heterogeneously down-regulated,

whereas activity of calmodulin/calcium-calmodulin protein kinase II (CaM/CaMKII) signalling increases. It is unclear

if CaM/CaMKII affects Cx43 expression/localization or impulse propagation. We analysed different models to assess

this. METHODS AND RESULTS: AC3-I mice with CaMKII genetically inhibited were subjected to pressure overload

(16 weeks, TAC vs. sham). Optical and epicardial mapping was performed on Langendorff-perfused rabbit and AC3-I

hearts, respectively. Cx43 subcellular distribution from rabbit/mouse ventricles was evaluated by immunoblot after

Triton X-100-based fractionation. In mice with constitutively reduced CaMKII activity (AC3-I), conduction velocity

(CV) was augmented (n = 11, P < 0.01 vs. WT); in AC3-I, CV was preserved after TAC, in contrast to a reduction seen

in TAC-WT mice (-20%). Cx43 expression was preserved after TAC in AC3-I mice, though arrhythmias and fibrosis

were still present. In rabbits, W7 (CaM inhibitor, 10 μM) increased CV (6-13%, n= 6, P< 0.05), while susceptibility to

arrhythmias decreased. Immunoconfocal microscopy revealed enlarged Cx43 cluster sizes at intercalated discs of those

hearts. Total Cx43 did not change by W7 (n= 4), whereas Triton X-100 insoluble Cx43 increased (+21%, n= 4, P< 0.01).

Similar findings were obtained in AC3-I mouse hearts when compared with control, and in cultured dog cardiomyocy-

tes. Functional implication was shown through increased intercellular coupling in cultured neonatal rat cardiomyocytes.

CONCLUSION: Both acute and chronic CaM/CaMKII inhibition improves conduction characteristics and enhances locali-

zation of Cx43 in the intercalated disc. In the absence of fibrosis, this reduced the susceptibility for arrhythmias.

PMID: 27378260Van der Wardt J, Olde Dubbelink TB, Visée HF, Schneeberger PM, Lutgens SP, van Eijk JJ. Neurological symptoms with a hepatitis E virus infection]. Ned Tijdschr Geneeskd. 2016;160(0):D107. Dutch.

BACKGROUND: Infection with hepatitis E virus genotype 3 (HEV3) is an emerging zoonosis in the industrialized world.

The infection usually proceeds asymptomatically. Extrahepatic sequelae including neurological symptoms have been

described. CASE DESCRIPTION: A 52-year-old man presented at the emergency department with pain, muscle

weakness and sensory disorders in both shoulders and arms. He was found to have bilateral neuralgic amyotrophy

accompanying an HEV3 infection. CONCLUSION: An HEV3 infection can have neurological sequelae, but very little is

known about its incidence and spectrum of symptoms.

PMID: 27403298D’Agnolo HMA, Kievit W, Andrade RJ, Karlsen TH, Wedemeyer H, Drenth JPH. Creating an effective clinical registry for rare diseases. United European Gastroenterol J. 2016 Jun;4(3):333-8. doi: 10.1177/2050640615618042. Epub 2015 Nov 13


The exposure of clinicians to patients with rare gastrointestinal diseases is limited. This hurts clinical studies, which

impedes accumulation of scientific knowledge on the natural disease course, treatment outcomes and prognosis in

these patients. An excellent method to detect patterns on an aggregate level that would not be possible to discover in

individual cases, is a registry study. This paper aims to describe a template to create a successful international registry

for rare diseases. We focus mainly on rare hepatic diseases, but lessons from this paper serve other fields in medicine,

as well.

PMID: 27406949Meijerink AM, Cissen M, Mochtar MH, Fleischer K, Thoonen I, de Melker AA, Meissner A, Repping S, Braat DD, van Wely M, Ramos L. Prediction model for live birth in ICSI using testicular extracted sperm. Hum Reprod. 2016 Sep;31(9):1942-51. doi: 10.1093/humrep/dew146. Epub 2016 Jul 12.

STUDY QUESTION: Which parameters have a predictive value for live birth in couples undergoing ICSI after successful

testicular sperm extraction (TESE-ICSI)? SUMMARY ANSWER: Female age, a first or subsequent started TESE-ICSI

cycle, male LH, male testosterone, motility of the spermatozoa during the ICSI procedure and the initial male diagnosis

before performing TESE were identified as relevant and independent parameters for live birth after TESE-ICSI. WHAT

IS KNOWN ALREADY: In reproductive medicine prediction models are used frequently to predict treatment success, but

no prediction model currently exists for live birth after TESE-ICSI. STUDY DESIGN, SIZE, DURATION: A retrospective

cohort study between 2007 and 2015 in two academic hospitals including 1559 TESE-ICSI cycles. The prediction

model was developed using data from one centre and validation was performed with data from the second centre.

PARTICIPANTS/MATERIALS, SETTING, METHODS: We included couples undergoing ICSI treatment with surgically

retrieved sperm from the testis for the first time. In the development set we included 526 couples undergoing 1006

TESE-ICSI cycles. In the validation set we included 289 couples undergoing 553 TESE-ICSI cycles. Multivariable

logistic regression models were constructed in a stepwise fashion (P < 0.2 for entry). The external validation was based

on discrimination and calibration. MAIN RESULTS AND THE ROLE OF CHANCE: We included 224 couples (22.3%) with

a live birth in the development set. The occurrence of a live birth was associated with lower female age, first TESE-

ICSI cycle, lower male LH, higher male testosterone, the use of motile spermatozoa for ICSI and having obstructive

azoospermia as an initial suspected diagnosis. The area under the receiver operating characteristic (ROC) curve was

0.62. From validation data, the model had moderate discriminative capacity (c-statistic 0.67, 95% confidence interval:

0.62-0.72) but calibrated well, with a range from 0.06 to 0.56 in calculated probabilities. LIMITATIONS, REASONS

FOR CAUTION: We had a lack of data about the motility of spermatozoa during TESE, therefore, we used motility of

the spermatozoa used for ICSI after freeze-thawing, information which is only available during treatment. We had to

exclude data on paternal BMI in the model because too many missing values in the validation data hindered testing.

We did not include a histologic diagnosis, which would have made our data set less heterogeneous and, finally, our

model may not be applicable in centres which have a different policy for the indication for performing sperm extraction.

The prognostic value of the model is limited because of a low ‘area under the curve’. WIDER IMPLICATIONS OF THE

FINDINGS: This model enables the differentiation between couples with a low or high chance to reach a live birth

using TESE-ICSI. As such it can aid in the counselling of patients and in clinical decision-making. STUDY FUNDING/

COMPETING INTERESTS: This study was partly supported by an unconditional grant from Merck Serono (to D.D.M.B.

and K.F.) and by the Department of Obstetrics and Gynaecology of Radboud University Medical Center, Nijmegen, The

Netherlands, the Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, Den Bosch, The Netherlands, and

the Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, The Netherlands. Merck Serono

had no influence in concept, design, nor elaboration of this study. TRIAL REGISTRATION NUMBER: Not applicable.


PMID: 27406950Cissen M, Meijerink AM, D’Hauwers KW, Meissner A, van der Weide N, Mochtar MH, de Melker AA, Ramos L, Repping S, Braat DD, Fleischer K, van Wely M. Prediction model for obtaining spermatozoa with testicular sperm extraction in men with non-obstructive azoospermia. Hum Reprod. 2016 Sep;31(9):1934-41. doi: 10.1093/humrep/dew147. Epub 2016 Jul 12.

STUDY QUESTION: Can an externally validated model, based on biological variables, be developed to predict succes-

sful sperm retrieval with testicular sperm extraction (TESE) in men with non-obstructive azoospermia (NOA) using

a large nationwide cohort? SUMMARY ANSWER: Our prediction model including six variables was able to make a

good distinction between men with a good chance and men with a poor chance of obtaining spermatozoa with TESE.

WHAT IS KNOWN ALREADY: Using ICSI in combination with TESE even men suffering from NOA are able to father

their own biological child. Only in approximately half of the patients with NOA can testicular sperm be retrieved

successfully. The few models that have been developed to predict the chance of obtaining spermatozoa with TESE

were based on small datasets and none of them have been validated externally. STUDY DESIGN, SIZE, DURATION:

We performed a retrospective nationwide cohort study. Data from 1371 TESE procedures were collected between

June 2007 and June 2015 in the two fertility centres. PARTICIPANTS/MATERIALS, SETTING, METHODS: All men

with NOA undergoing their first TESE procedure as part of a fertility treatment were included. The primary end-point

was the presence of one or more spermatozoa (regardless of their motility) in the testicular biopsies.We constructed

a model for the prediction of successful sperm retrieval, using univariable and multivariable binary logistic regression

analysis and the dataset from one centre. This model was then validated using the dataset from the other centre.

The area under the receiver-operating characteristic curve (AUC) was calculated and model calibration was assessed.

MAIN RESULTS AND THE ROLE OF CHANCE: There were 599 (43.7%) successful sperm retrievals after a first TESE

procedure. The prediction model, built after multivariable logistic regression analysis, demonstrated that higher

male age, higher levels of serum testosterone and lower levels of FSH and LH were predictive for successful sperm

retrieval. Diagnosis of idiopathic NOA and the presence of an azoospermia factor c gene deletion were predictive for

unsuccessful sperm retrieval. The AUC was 0.69 (95% confidence interval (CI): 0.66-0.72). The difference between

the mean observed chance and the mean predicted chance was <2.0% in all groups, indicating good calibration. In

validation, the model had moderate discriminative capacity (AUC 0.65, 95% CI: 0.62-0.72) and moderate calibration:

the predicted probability never differed by more than 9.2% of the mean observed probability. LIMITATIONS, REASONS

FOR CAUTION: The percentage of men with Klinefelter syndrome among men diagnosed with NOA is expected to be

higher than in our study population, which is a potential selection bias. The ability of the sperm retrieved to fertilize

an oocyte and produce a live birth was not tested. WIDER IMPLICATIONS OF THE FINDINGS: This model can help

in clinical decision-making in men with NOA by reliably predicting the chance of obtaining spermatozoa with TESE.

STUDY FUNDING/COMPETING INTEREST: This study was partly supported by an unconditional grant from Merck

Serono (to D.D.M.B. and K.F.) and by the Department of Obstetrics and Gynaecology of Radboud University Medical

Center, Nijmegen, The Netherlands, the Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, Den

Bosch, The Netherlands, and the Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam,

The Netherlands. Merck Serono had no influence in concept, design nor elaboration of this study. TRIAL REGISTRA-

TION NUMBER: Not applicable.

PMID: 27412247Franik S, Hoeijmakers Y, D’Hauwers K, Braat DD, Nelen WL, Smeets D, Claahsen-van der Grinten HL, Ramos L, Fleischer K. Klinefelter syndrome and fertility: sperm preservation should not be offered to children with Klinefelter syndrome. Hum Reprod. 2016 Sep;31(9):1952-9. doi: 10.1093/humrep/dew179. Epub 2016 Jul 13.


STUDY QUESTION: Should fertility preservation be offered to children with Klinefelter syndrome (KS)? SUMMARY

ANSWER: Current evidence shows that fertility preservation should not be offered to adolescents with KS younger

than 16 years because of lower retrieval rates for germ cells by testicular sperm extraction (TESE) compared with

retrieval rates for adolescents and adults between 16 and 30 years. WHAT IS KNOWN ALREADY: KS, the most com-

mon chromosomal disorder in men leading to non-obstructive azoospermia, is caused by the presence of at least

one additional X chromosome. The onset of puberty in adolescents with KS leads to progressive degeneration of the

testicular environment. The impact of the subsequent tissue degeneration on fertility potential of patients with KS is

unknown, but in previous literature it has been suggested that fertility preservation should be started in adolescents as

early as possible. However spermatozoa can be found by TESE in about 50% of adults with KS despite severe testicular

degeneration. This review discusses the current evidence for fertility preservation in children and adolescents and pos-

sible prognostic markers for fertility treatment in KS. STUDY DESIGN, SIZE, DURATION: An extensive literature search

was conducted, searching Pubmed, Embase, Cinahl and Web of Science from origin until April 2016 for ‘Klinefelter

syndrome’ and ‘fertility’ and various synonyms. Titles and abstracts have been scanned manually by the authors for

eligibility. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total 76 studies were found to be eligible for inclusion

in this review. Information from the papers was extracted separately by two authors. MAIN RESULTS AND THE ROLE

OF CHANCE: Various studies have shown that pre-pubertal children with KS already have a reduced number of germ

cells despite a normal hormonal profile during childhood. The presence of spermatozoa in the ejaculate of adolescents

with KS is extremely rare. Using TESE, the retrieval rates of spermatozoa for adolescents younger than 16 years old

are much lower (0-20%) compared with those for adolescents and young adults between 16 and 30 years old (40-

70%). Although spermatogonia can be found by TESE in about half of the peri-pubertal adolescents, there are currently

no clinically functional techniques for their future use. Children and adolescents need to be informed that early fertility

preservation before the age of 16 cannot guarantee fertility later in life and may even reduce the chances for offspring

by removing functional immature germ cells which may possibly develop into spermatozoa after puberty. Furthermore,

except for the age of patients with KS, there are no identified factors that can reliably be used as a predictive marker

for fertility preservation. LIMITATIONS, REASONS FOR CAUTION: Most of the evidence presented in this review is

based on studies including a small number of adolescents with KS. Therefore, the studies may have been underpo-

wered to detect clinically significant differences for their various outcomes, especially for potential predictive factors

for fertility preservation, such as hormone levels. Furthermore, the population of patients with KS diagnosed during

childhood might be different from the adult population with KS where the diagnosis is based on infertility. Results

based on comparisons between the two groups must be interpreted with caution. WIDER IMPLICATIONS OF THE

FINDINGS: Despite the limitations, this review summarizes the current evidence for managing fertility preservation in

patients with KS to provide optimal health care. STUDY FUNDING/COMPETING INTERESTS: There was no funding for

this study. S.F., Y.H., K.D., W.L.M.N., D.S., H.L.C.-v.d.G. and L.R. declare to have no conflicts of interests. D.D.M.B. reports

grants from Merck Serono, grants from Ferring and grants from MSD, outside the submitted work. K.F. reports perso-

nal fees from MSD (commercial sponsor), personal fees from Ferring (commercial sponsor), grants from Merck-Serono

(commercial sponsor), grants from Ferring (commercial sponsor) and grants from MSD (commercial sponsor), outside

the submitted work.

PMID: 27429027de Rooij T, van Hilst J, Boersma D, Bonsing BA, Daams F, van Dam RM, Dijkgraaf MG, van Eijck CH, Festen S, Gerhards MF, Koerkamp BG, van der Harst E, de Hingh IH, Kazemier G, Klaase J, de Kleine RH, van Laarhoven CJ, Lips DJ, Luyer MD, Molenaar IQ, Patijn GA, Roos D, Scheepers JJ, van der Schelling GP, Steenvoorde P, Vriens MR, Wijsman JH, Gouma DJ, Busch OR, Abu Hilal M, Besselink MG; Dutch Pancreatic Cancer Group. Impact of a Nationwide Training Program in Minimally Invasive Distal Pancreatectomy (LAELAPS). Ann Surg. 2016 Aug 1.


OBJECTIVE: To study the feasibility and impact of a nationwide training program in minimally invasive distal pan-

createctomy (MIDP). SUMMARY OF BACKGROUND DATA: Superior outcomes of MIDP compared with open distal

pancreatectomy have been reported. In the Netherlands (2005 to 2013) only 10% of distal pancreatectomies were in

a minimally invasive fashion and 85% of surgeons welcomed MIDP training. The feasibility and impact of a nationwide

training program is unknown. METHODS: From 2014 to 2015, 32 pancreatic surgeons from 17 centers participated in

a nationwide training program in MIDP, including detailed technique description, video training, and proctoring on-site.

Outcomes of MIDP before training (2005-2013) were compared with outcomes after training (2014-2015). RESULTS:

In total, 201 patients were included; 71 underwent MIDP in 9 years before training versus 130 in 22 months after

training (7-fold increase, P < 0.001). The conversion rate (38% [n = 27] vs 8% [n = 11], P < 0.001) and blood loss

were lower after training and more pancreatic adenocarcinomas were resected (7 [10%] vs 28 [22%], P = 0.03), with

comparable R0-resection rates (4/7 [57%] vs 19/28 [68%], P = 0.67). Clavien-Dindo score ≥III complications (15 [21%]

vs 19 [15%], P = 0.24) and pancreatic fistulas (20 [28%] vs 41 [32%], P = 0.62) were not significantly different. Length

of hospital stay was shorter after training (9 [7-12] vs 7 [5-8] days, P < 0.001). Thirty-day mortality was 3% vs 0% (P

= 0.12). CONCLUSION: A nationwide MIDP training program was feasible and followed by a steep increase in the use

of MIDP, also in patients with pancreatic cancer, and decreased conversion rates. Future studies should determine

whether such a training program is applicable in other settings.

PMID: 27439975Borstlap WA, Tanis PJ, Koedam TW, Marijnen CA, Cunningham C, Dekker E, van Leerdam ME, Meijer G, van Grieken N, Nagtegaal ID, Punt CJ, Dijkgraaf MG, De Wilt JH, Beets G, de Graaf EJ, van Geloven AA, Gerhards MF, van Westreenen HL, van de Ven AW, van Duijvendijk P, de Hingh IH, Leijtens JW, Sietses C, Spillenaar-Bilgen EJ, Vuylsteke RJ, Hoff C, Burger JW, van Grevenstein WM, Pronk A, Bosker RJ, Prins H, Smits AB, Bruin S, Zimmerman DD, Stassen LP, Dunker MS, Westerterp M, Coene PP, Stoot J, Bemelman WA, Tuynman JB. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. BMC Cancer. 2016 Jul 21;16:513. doi: 10.1186/s12885-016-2557-x.

BACKGROUND: Rectal cancer surgery is accompanied with high morbidity and poor long term functional outcome.

Screening programs have shown a shift towards more early staged cancers. Patients with early rectal cancer can

potentially benefit significantly from rectal preserving therapy. For the earliest stage cancers, local excision is sufficient

when the risk of lymph node disease and subsequent recurrence is below 5 %. However, the majority of early cancers

are associated with an intermediate risk of lymph node involvement (5-20 %) suggesting that local excision alone is

not sufficient, while completion radical surgery, which is currently standard of care, could be a substantial overtre-

atment for this group of patients. METHODS/STUDY DESIGN: In this multicentre randomised trial, patients with an

intermediate risk T1-2 rectal cancer, that has been locally excised using an endoluminal technique, will be randomized

between adjuvant chemo-radiotherapylimited to the mesorectum and standard completion total mesorectal excision

(TME). To strictly monitor the risk of locoregional recurrence in the experimental arm and enable early salvage surgery,

there will be additional follow up with frequent MRI and endoscopy. The primary outcome of the study is three-year

local recurrence rate. Secondary outcomes are morbidity, disease free and overall survival, stoma rate, functional

outcomes, health related quality of life and costs. The design is a non inferiority study with a total sample size of 302

patients. DISCUSSION: The results of the TESAR trial will potentially demonstrate that adjuvant chemoradiotherapy

is an oncological safe treatment option in patients who are confronted with the difficult clinical dilemma of a radically

removed intermediate risk early rectal cancer by polypectomy or transanal surgery that is conventionally treated with

subsequent radical surgery. Preserving the rectum using adjuvant radiotherapy is expected to significantly improve

morbidity, function and quality of life if compared to completion TME surgery. TRIAL REGISTRATION: NCT02371304 ,

registration date: February 2015.


PMID: 27457690Joustra R, Boulaksil M, Meijburg HW, Daniëls MC. Left bundle branch block in serious hyperkalaemia: rate-dependency? Neth Heart J. 2016 Sep;24(9):559-60. doi: 10.1007/s12471-016-0865-z.

PMID: 27481229Van der Feen C, van der Doef HP, van der Ent CK, Houwen RH. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros. 2016 Nov;15(6):834-838. doi: 10.1016/j.jcf.2016.07.009.

BACKGROUND: Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, but objective

parameters for its effect are lacking. METHODS: We used liver stiffness measurements to evaluate the effect of Urso-

deoxycholic acid. RESULTS: Paired measurements of liver stiffness were done in 73 patients without UDCA and in 32

patients with UDCA. In the latter group, 6 patients had cirrhosis; in 15 patients, UDCA was started based on Colombo

criteria, and in 11 patients for other reasons. In patients without UDCA, liver stiffness increased: 0.19 (-0.03 to 0.59)

kPa/year. Liver stiffness also increased in patients with cirrhosis: 4.6 (0.67-12.4)kPa/year. In patients who had UDCA

based on Colombo criteria, a decrease of liver stiffness was observed: 0.70 (-1.6 to 0.55)kPa/year (P=0.01). In pa-

tients on UDCA for other reasons, liver stiffness increased: 0.23 (-0.20 to 0.51)kPa/year. CONCLUSION: UDCA reduced

liver stiffness in patients with well-defined, mild liver disease.

PMID: 27482015Huijbregts HJ, Khan RJ, Fick DP, Hall MJ, Punwar SA, Sorensen E, Reid MJ, Vedove SD, Haebich S. Component alignment and clinical outcome following total knee arthroplasty: a randomised controlled trial comparing an intramedullary alignment system with patient-specific instrumentation. Bone Joint J. 2016 Aug;98-B(8):1043-9. doi: 10.1302/0301-620X.98B8.37240.

AIMS: We conducted a randomised controlled trial to assess the accuracy of positioning and alignment of the compo-

nents in total knee arthroplasty (TKA), comparing those undertaken using standard intramedullary cutting jigs and

those with patient-specific instruments (PSI). PATIENTS AND METHODS: There were 64 TKAs in the standard group

and 69 in the PSI group. The post-operative hip-knee-ankle (HKA) angle and positioning was investigated using CT

scans. Deviation of > 3° from the planned position was regarded as an outlier. The operating time, Oxford Knee Scores

(OKS) and Short Form-12 (SF-12) scores were recorded. RESULTS: There were 14 HKA-angle outliers (22%) in the

standard group and nine (13%) in the PSI group (p = 0.251). The mean HKA-angle was 0.5° varus in the standard

group and 0.2° varus in the PSI group (p = 0.492). The accuracy of alignment in the coronal and axial planes and the

proportion of outliers was not different in the two groups. The femoral component was more flexed (p = 0.035) and

there were significantly more tibial slope outliers (29% versus 13%) in the PSI group (p = 0.032). Operating time and

the median three-month OKS were similar (p = 0.218 and p = 0.472, respectively). Physical and mental SF-12 scores

were not significantly different at three months (p = 0.418 and p = 0.267, respectively) or at one year post-operatively

(p = 0.114 and p = 0.569). The median one-year Oxford knee score was two points higher in the PSI group (p =

0.049). CONCLUSION: Compared with standard intramedullary jigs, the use of PSI did not significantly reduce the

number of outliers or the mean operating time, nor did it clinically improve the accuracy of alignment or the median

Oxford Knee Scores. Our data do not support the routine use of PSI when undertaking TKA. Cite this article: Bone Joint

J 2016;98-B:1043-9.


PMID: 27484815Schatorjé E, van der Flier M, Seppänen M, Browning M, Morsheimer M, Henriet S, Neves JF, Vinh DC, Alsina L, Grumach A, Soler-Palacin P, Boyce T, Celmeli F, Goudouris E, Hayman G, Herriot R, Förster-Waldl E, Seidel M, Simons A, de Vries E. Primary immunodeficiency associated with chromosomal aberration - an ESID survey. Orphanet J Rare Dis. 2016 Aug 2;11(1):110.

BACKGROUND: Patients with syndromic features frequently suffer from recurrent respiratory infections, but little is

known about the spectrum of immunological abnormalities associated with their underlying chromosomal aberrations

outside the well-known examples of Down and DiGeorge syndromes. Therefore, we performed this retrospective, ob-

servational survey study. METHODS: All members of the European Society for Immunodeficiencies (ESID) were invited

to participate by reporting their patients with chromosomal aberration (excluding Down and DiGeorge syndromes) in

combination with one or more identified immunological abnormalities potentially relating to primary immunodefici-

ency. An online questionnaire was used to collect the patient data. RESULTS: Forty-six patients were included from

16 centers (24 males, 22 females; median age 10.4 years [range 1.0-69.2 years]; 36 pediatric, 10 adult patients).

A variety of chromosomal aberrations associated with immunological abnormalities potentially relating to primary

immune deficiency was reported. The most important clinical presentation prompting the immunological evaluation

was ‘recurrent ear-nose-throat (ENT) and airway infections’. Immunoglobulin isotype and/or IgG-subclass deficiencies

were the most prevalent immunological abnormalities reported. CONCLUSIONS: Our survey yielded a wide variety of

chromosomal aberrations associated with immunological abnormalities potentially relating to primary immunode-

ficiency. Although respiratory tract infections can often also be ascribed to other causes (e.g. aspiration or structural

abnormalities), we show that a significant proportion of patients also have an antibody deficiency requiring specific tre-

atment (e.g. immunoglobulin replacement, antibiotic prophylaxis). Therefore, it is important to perform immunological

investigations in patients with chromosomal aberrations and recurrent ENT or airway infections, to identify potential

immunodeficiency that can be specifically treated.

PMID: 27487525Holleman M, Vink M, Nijland R, Schmand B. Effects of intensive neuropsychological rehabilitation for acquired brain injury. Neuropsychol Rehabil. 2016 Aug 3:1-14.

The objective of the study was to examine the effects of a comprehensive neuropsychological rehabilitation programme

(Intensive NeuroRehabilitation, INR) on the emotional and behavioural consequences of acquired brain injury (ABI). The

participants were 75 adult patients suffering from ABI (33 traumatic brain injury, 14 stroke, 10 tumour, 6 hypoxia, 12

other), all of whom were admitted to the INR treatment programme. The main outcome measures were: general psy-

chological well-being (Symptom-Checklist-90), depression and anxiety (Beck Depression Inventory-II, Hospital Anxiety

and Depression Scale, State Trait Anxiety Inventory), and quality of life (Quality of Life in Brain Injury). The study was

a non-blinded, waiting-list controlled trial. During the waiting-list period no or minimal care was provided. Multivari-

ate analysis of the main outcome measures showed large effect sizes for psychological well-being (partial η2 = .191,

p < .001), depression (partial η2 = .168, p < .001), and anxiety (partial η2 = .182, p < .001), and a moderate effect size for

quality of life (partial η2 = .130, p = .001). Changes on neuropsychological tests did not differ between the groups. It

was concluded that the INR programme improved general psychological well-being, depressive symptoms, anxiety, and

quality of life. The programme does not affect cognitive functioning.


PMID: 27496940 Stein CE, Keijsers CJ, Bootsma JE, Schouten HJ. Missed diagnosis of pulmonary embolism with age-adjusted d-dimer cut-off value; Age Ageing. 2016 Nov;45(6):910-911.

Pulmonary embolism (PE) is a potentially severe diagnosis with high short-term mortality. Recently, age-adjusted

cut-off values (age × 10 μg/l) of D-dimer were introduced to improve the diagnostic workup in older patients. In clinical

practice, PE is considered ‘ruled out’ in patients with a non-high clinical probability and a normal D-dimer. However,

all diagnostic tests have a small false-negative rate. This small probability of misdiagnosis might be easily overlooked

by clinicians when using simplified dichotomized flow charts. This case illustrates a normal D-dimer (age-adjusted) but

with a PE. We recommend clinicians using the D-dimer test-either conventional or age-adjusted in a rule-out strategy

to be aware of the-albeit small probability of a false-negative result.

PMID: 27497436van Balveren JA, Huijskens MJ, Gemen EF, Péquériaux NC, Kusters R. Effects of time and temperature on 48 routine chemistry, haematology and coagulation analytes in whole blood samples. Ann Clin Biochem. 2016 Aug 5. pii: 0004563216665868.

Background Phlebotomy for the purpose of blood analysis is often performed at remote locations, and samples are

usually temporarily stored before transport to a central laboratory for analysis. The circumstances during storage and

shipment may not meet the necessary requirements. If analysed anyway, false results may be generated. We therefore

examined the influence of precentrifugation time and temperature of the most frequently requested tests in whole

blood. Methods Healthy volunteers donated blood in which 48 analytes were tested. Routine chemistry was performed

in lithium heparin tubes, haematology in ethylenediaminetetraacetic acid tubes, coagulation in citrate tubes and glu-

cose in sodium fluoride tubes. One tube was measured directly. The others were kept at different temperatures (4, 8,

20 or 30κ) and stored for 4, 6, 8 or 24 h before analysis. Additionally, some analytes were examined at 12, 16, 24 and

28κ. The mean percentage deviation was compared with different decision levels, including the total allowable error.

Results When using the total allowable error as an acceptable limit, most of the investigated analytes remained stable.

However, bicarbonate is unstable at almost all tested time-points and temperatures. Calcium, lactate dehydrogenase,

potassium and sodium are particularly affected at low temperatures, while phosphate is mainly affected at and above

room temperature after 8 h. Conclusion We established the influence of time and temperature on a broad range of

analytes, which may be applied to set the limits in transportation and storage of whole blood samples.

PMID: 27539877Evers D, van der Bom JG, Tijmensen J, Middelburg RA, de Haas M, Zalpuri S, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, Zwaginga JJ. Red cell alloimmunisation in patients with different types of infections. Br J Haematol. 2016 Aug 18. doi: 10.1111/bjh.14307.

Red cell alloantigen exposure can cause alloantibody-associated morbidity. Murine models have suggested that inflam-

mation modulates red cell alloimmunisation. This study quantifies alloimmunisation risks during infectious episodes in

humans. We performed a multicentre case-control study within a source population of patients receiving their first and

subsequent red cell transfusions during an 8-year follow-up period. Patients developing a first transfusion-induced

red cell alloantibody (N = 505) were each compared with two similarly exposed, but non-alloimmunised controls (N

= 1010) during a 5-week ‘alloimmunisation risk period’ using multivariate logistic regression analysis. Transfusions

during ‘severe’ bacterial (tissue-invasive) infections were associated with increased risks of alloantibody development


[adjusted relative risk (RR) 1•34, 95% confidence interval (95% CI) 0•97-1•85], especially when these infections were

accompanied with long-standing fever (RR 3•06, 95% CI 1•57-5•96). Disseminated viral disorders demonstrated a

trend towards increased risks (RR 2•41, 95% CI 0•89-6•53), in apparent contrast to a possible protection associ-

ated with Gram-negative bacteraemia (RR 0•58, 95% CI 0•13-1•14). ‘Simple’ bacterial infections, Gram-positive

bacteraemia, fungal infections, maximum C-reactive protein values and leucocytosis were not associated with red cell

alloimmunisation. These findings are consistent with murine models. Confirmatory research is needed before patients

likely to develop alloantibodies may be identified based on their infectious conditions at time of transfusion.

PMID: 27541801Mertens JS, Zweers MC, Kievit W, Knaapen HK, Gerritsen M, Radstake TR, van den Hoogen FH, Creemers MC, de Jong EM. High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis. JAMA Dermatol. 2016 Aug 17. doi: 10.1001/jamadermatol.2016.2873.

IMPORTANCE: Eosinophilic fasciitis (EF) is a connective tissue disorder in which conventional treatment leads to disap-

pointing results in a proportion of patients. Therefore, we investigated high-dose intravenous (IV) pulse methotrexate

(MTX) as a treatment for EF. OBJECTIVE: To examine safety and effects of monthly high-dose IV pulse MTX in EF.

DESIGN, SETTING, AND PARTICIPANTS: For this prospective single-arm study, we recruited 12 patients diagnosed

with biopsy specimen-proven EF between 2006 and 2009 from the Department of Dermatology and Rheumatology

at the Radboud University Medical Centre. INTERVENTIONS: Intravenous MTX (4 mg/kg) monthly for 5 months with

folinic acid rescue 24 hours after MTX administration. MAIN OUTCOMES AND MEASURES: The primary outcome

was improvement of the modified skin score at month 5 vs baseline. Secondary outcomes were durometry, range

of motion, visual analog scale scores for disease activity, and 36-Item Short Form Survey health questionnaires.

RESULTS: Overall, 12 patients (11 women between 37-69 years old) received a median (range) monthly dose of 288

(230-336) mg MTX. Median (range) modified skin score improved from 17.5 (8.0-24.0) at baseline to 8.5 (1.0-20.0)

at month 5 (P = .001). Secondary outcome measures improved significantly, except for durometer scores and range of

motion of the elbows. Adverse events included gastrointestinal symptoms (n = 9), mild stomatitis (n = 5), and alopecia

(n = 4). CONCLUSIONS AND RELEVANCE: High-dose IV pulse MTX is a safe and effective treatment option in EF. TRIAL

REGISTRATION: clinicaltrials.gov Identifier: NCT00441961.

PMID: 27549241Brooke RJ, Teunis PF, Kretzschmar ME, Wielders CC, Schneeberger PM, Waller LA. Use of a Dose-Response Model to Study Temporal Trends in Spatial Exposure to Coxiella burnetii: Analysis of a Multiyear Outbreak of Q Fever. Zoonoses Public Health. Epub 2016 Aug 23.

The Netherlands underwent a large Q fever outbreak between 2007 and 2009. In this paper, we study spatial and

temporal Coxiella burnetii exposure trends during this large outbreak as well as validate outcomes against other

published studies and provide evidence to support hypotheses on the causes of the outbreak. To achieve this, we

develop a framework using a dose-response model to translate acute Q fever case incidence into exposure estimates.

More specifically, we incorporate a geostatistical model that accounts for spatial and temporal correlation of exposure

estimates from a human Q fever dose-response model to quantify exposure trends during the outbreak. The 2051

cases, with the corresponding age, gender and residential addresses, reside in the region with the highest attack rates

during the outbreak in the Netherlands between 2006 and 2009. We conclude that the multiyear outbreak in the

Netherlands is caused by sustained release of infectious bacteria from the same sources, which suggests that earlier

implementation of interventions may have prevented many of the cases. The model predicts the risk of infection


and acute symptomatic Q fever from multiple exposure sources during a multiple-year outbreak providing a robust,

evidence-based methodology to support decision-making and intervention design.

PMID: 27557300Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

BACKGROUND: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in

women with early-stage breast cancer. We sought to provide prospective evidence of the clinical utility of the addition

of the 70-gene signature to standard clinical-pathological criteria in selecting patients for adjuvant chemotherapy.

METHODS:

In this randomized, phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their

genomic risk (using the 70-gene signature) and their clinical risk (using a modified version of Adjuvant! Online).

Women at low clinical and genomic risk did not receive chemotherapy, whereas those at high clinical and genomic

risk did receive such therapy. In patients with discordant risk results, either the genomic risk or the clinical risk was

used to determine the use of chemotherapy. The primary goal was to assess whether, among patients with high-risk

clinical features and a low-risk gene-expression profile who did not receive chemotherapy, the lower boundary of the

95% confidence interval for the rate of 5-year survival without distant metastasis would be 92% (i.e., the noninfe-

riority boundary) or higher. RESULTS: A total of 1550 patients (23.2%) were deemed to be at high clinical risk and

low genomic risk. At 5 years, the rate of survival without distant metastasis in this group was 94.7% (95% confidence

interval, 92.5 to 96.2) among those not receiving chemotherapy. The absolute difference in this survival rate between

these patients and those who received chemotherapy was 1.5 percentage points, with the rate being lower without

chemotherapy. Similar rates of survival without distant metastasis were reported in the subgroup of patients who had

estrogen-receptor-positive, human epidermal growth factor receptor 2-negative, and either node-negative or node-

positive disease. CONCLUSIONS: Among women with early-stage breast cancer who were at high clinical risk and low

genomic risk for recurrence, the receipt of no chemotherapy on the basis of the 70-gene signature led to a 5-year

rate of survival without distant metastasis that was 1.5 percentage points lower than the rate with chemotherapy.

Given these findings, approximately 46% of women with breast cancer who are at high clinical risk might not require

chemotherapy. (Funded by the European Commission Sixth Framework Program and others; ClinicalTrials.gov number,

NCT00433589; EudraCT number, 2005-002625-31.).

PMID: 27567361Bensdorp AJ, Tjon-Kon-Fat R, Verhoeve H, Koks C, Hompes P, Hoek A, de Bruin JP, Cohlen B, Hoozemans D, Broekmans F, van Bomme P, Smeenk J, Mol BW, van der Veen F, van Wely M; INeS group. Dropout rates in couples undergoing in vitro fertilization and intrauterine insemination. Eur J Obstet Gynecol Reprod Biol. 2016 Aug 10;205:66-71. doi: 10.1016/j.ejogrb.2016.08.018.

OBJECTIVE: To compare dropout rates in couples undergoing conventional in vitro fertilization with single embryo

transfer (IVF-SET), in vitro fertilization in a modified natural cycle (IVF-MNC) or intrauterine insemination with ovarian

stimulation (IUI-OS). STUDY DESIGN: Secondary analysis of a multicentre randomized controlled trial between January


2009 and February 2012. 602 couples with unexplained or mild male subfertility, allocated to IVF-SET (N=201), IVF-

MNC (N=194) and IUI-OS (N=207). MAIN OUTCOME MEASURES: Dropouts, defined as couples who discontinued their

allocated three cycles of IVF-SET, six cycles of IVF-MNC or IUI-OS, without having achieved a pregnancy. We classified

dropouts as “following medical advice” or “patient initiated”. RESULT(S): Thirty couples (15%) allocated to IVF-SET drop-

ped out and 45 couples (23%) allocated to IVF-MNC, compared to 26 couples (13%) allocated to IUI-OS; relative risk (RR)

1.2 (95%CI; 0.73-1.9) for IVF-SET and 1.9 (95%CI; 1.2-2.9) for IVF-MNC, both compared to IUI-OS. Nine couples (4.5%)

allocated to IVF-SET, 14 (7.2%) allocated to IVF-MNC and 14 (6.8%) allocated to IUI-OS dropped out following medical

advice; RR of 0.51 (95%CI; 0.21-1.2) for IVF-SET and 0.84 (95%CI; 0.39-1.80) for IVF-MNC, both versus IUI-OS.

Twenty-one couples (10%) allocated to IVF-SET were patient initiated dropouts, as were 31 (16%) allocated to IVF-MNC

and 12 (5.8%) allocated to IUI-COS; RR 1.8 (95%CI; 0.91-3.6) for IVF-SET and 2.8 (95%CI; 1.5-5.2) for IVF-MNC both

versus IUI-OS. CONCLUSION(S): IVF-SET and IUI-OS result in comparable drop-out rates, while drop-out rates after

IVF-MNC are almost twice as high, mainly driven by patient preferences.

PMID: 27568310Eppenga WL, Kramers C, Derijks HJ, Wensing M, Wetzels JF, De Smet PA. Drug therapy management in patients with renal impairment: how to use creatinine-based formulas in clinical practice. Eur J Clin Pharmacol 2016; 72(12):1433-39

PURPOSE: The use of estimated glomerular filtration rate (eGFR) in daily clinical practice. METHODS: eGFR is a key com-

ponent in drug therapy management (DTM) in patients with renal impairment. eGFR is routinely reported by laboratories

whenever a serum creatinine testing is ordered. In this paper, we will discuss how to use eGFR knowing the limitations

of serum creatinine-based formulas. RESULTS: Before starting a renally excreted drug, an equally effective drug which

can be used more safely in patients with renal impairment should be considered. If a renally excreted drug is needed, the

reliability of the eGFR should be assessed and when needed, a 24-h urine creatinine clearance collection should be per-

formed. After achieving the best approximation of the true GFR, we suggest a gradual drug dose adaptation according to

the renal function. A different approach for drugs with a narrow therapeutic window (NTW) is recommended compared

to drugs with a broad therapeutic window. For practical purposes, a therapeutic window of 5 or less was defined as

a NTW and a list of NTW drugs is presented. Considerations about the drug dose may be different at the start of the

therapy or during the therapy and depending on the indication. Monitoring effectiveness and adverse drug reactions

are important, especially for NTW drugs. Dose adjustment should be based on an ongoing assessment of clinical status

and risk versus the benefit of the used regimen. CONCLUSION: When determining the most appropriate dosing regimen

serum creatinine-based formulas should never be used naively but always in combination with clinical and pharmacolo-

gical assessment of the individual patient.

PMID: 27571249Van der Aa MP, Elst MA, van de Garde EM, van Mil EG, Knibbe CA, van der Vorst MM. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes. 2016 Aug 29;6(8):e228. doi: 10.1038/nutd.2016.37.

BACKGROUND: As adolescents with obesity and insulin resistance may be refractory to lifestyle intervention therapy

alone, additional off-label metformin therapy is often used. In this study, the long-term efficacy and safety of metformin

versus placebo in adolescents with obesity and insulin resistance is studied. METHODS: In a randomized placebo-

controlled double-blinded trial, 62 adolescents with obesity aged 10-16 years old with insulin resistance received

2000 mg of metformin or placebo daily and physical training twice weekly over 18 months. Primary end points were


change in body mass index (BMI) and insulin resistance measured by the Homeostasis Model Assessment for Insulin

Resistance (HOMA-IR). Secondary end points were safety and tolerability of metformin. Other end points were body

fat percentage and HbA1c. RESULTS: Forty-two participants completed the 18-month study (66% girls, median age

13 (12-15) years, BMI 30.0 (28.3 to 35.0) kg m(-2) and HOMA-IR 4.08 (2.40 to 5.88)). Median ΔBMI was +0.2 (-2.9

to 1.3) kg m(-2) (metformin) versus +1.2 (-0.3 to 2.4) kg m(-2) (placebo) (P=0.015). No significant difference was

observed for HOMA-IR. No serious adverse events were reported. Median change in fat percentage was -3.1 (-4.8 to

0.3) versus -0.8 (-3.2 to 1.6)% (P=0.150), in fat mass -0.2 (-5.2 to 2.1) versus +2.0 (1.2-6.4) kg (P=0.007), in fat-

free mass +2.0 (-0.1 to 4.0) versus +4.5 (1.3 to 11.6) kg (P=0.047) and in ΔHbA1c +1.0 (-1.0 to 2.3) versus +3.0

(0.0 to 5.0) mmol mol(-1) (P=0.020) (metformin versus placebo). CONCLUSIONS: Long-term treatment with metfor-

min in adolescents with obesity and insulin resistance results in stabilization of BMI and improved body composition

compared with placebo. Therefore, metformin may be useful as an additional therapy in combination with lifestyle

intervention in adolescents with obesity and insulin resistance.

PMID: 27571945 Hagenaars JC, Wever PC, Vlake AW, Renders NH, van Petersen AS, Hilbink M, de Jager-Leclercq MG, Moll FL, Koning OH, Hoekstra CJ. Value of 18F-FDG PET/CT in diagnosing chronic Q fever in patients with central vascular disease. Neth J Med. 2016 Aug;74(7):301-8.

BACKGROUND: The aim of this study is to describe the value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission

tomography/computed tomography (18F-FDG PET/CT) in diagnosing chronic Q fever in patients with central vascular

disease and the added value of 18F-FDG PET/CT in the diagnostic combination strategy as described in the Dutch

consensus guideline for diagnosing chronic Q fever. METHODS: 18F-FDG PET/CT was performed in patients with

an abdominal aortic aneurysm or aorto-iliac reconstruction and chronic Q fever, diagnosed by serology and positive

PCR for Coxiella burnetii DNA in blood and/or tissue (PCR-positive study group). Patients with an abdominal aortic

aneurysm or aorto-iliac reconstruction without clinical and serological findings indicating Q fever infection served

as a control group. Patients with a serological profile of chronic Q fever and a negative PCR in blood were included

in additional analyses (PCR-negative study group). RESULTS: Thirteen patients were evaluated in the PCR-positive

study group and 22 patients in the control group. 18F-FDG PET/CT indicated vascular infection in 6/13 patients in

the PCR-positive study group and 2/22 patients in the control group. 18F-FDG PET/CT demonstrated a sensitivity

of 46% (95% CI: 23-71%), specificity of 91% (95% CI: 71-99%), positive predictive value of 75% (95% CI:41-93%) and

negative predictive value of 74% (95% CI: 55-87%). In the PCR-negative study group, 18F-FDG PET/CT was positive

in 10/20 patients (50%). CONCLUSION: The combination of 18F-FDG PET/CT, as an imaging tool for identifying a

focus of infection, and Q fever serology is a valid diagnostic strategy for diagnosing chronic Q fever in patients with

central vascular disease.

PMID: 27571950Van der Toorn M, de Klerk S. A 43-year-old woman with a quadriparesis. Neth J Med. 2016 Aug;74(7):318. No abstract available.

PMID: 27590006Vos MC, Hollemans E, Ezendam N, Feijen H, Boll D, Pijlman B, van der Putten H, Klinkhamer P, van Kuppevelt TH, van der Wurff AA, Massuger LF. MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer. J Ovarian Res. 2016 Sep 2;9(1):53. doi: 10.1186/s13048-016-0262-7.


BACKGROUND: To investigate the expression of MMP-14 and CD44 as well as epithelial-to-mesenchymal

transition(EMT)-like changes in ovarian cancer and to determine correlations with clinical outcome. METHODS: In 97

patients with ovarian cancer, MMP-14 and CD44 expression as determined by immunohistochemistry was investi-

gated in relation to EMT-like changes. To determine this, immunohistochemical staining of E-cadherin and vimentin

was performed. RESULTS: Patients with expression of both MMP-14 and CD44 in their tumors had a poor prognosis

despite complete debulking. Serous histology in advanced-stage tumors (FIGO IIB-IV) correlated with CD44 (rho

.286, p < 0.01). Also, CD44 correlated with percentage vimentin expression (rho .217, p < 0.05). In logistic regression

analysis with complete debulking as the outcome parameter, CD44 expression was found to be significant (OR 3,571

(95 % Confidence Interval 1,112-11,468) p = 0.032), though this was not the case for MMP-14 and EMT parameters.

CONCLUSION: The subgroup of patients with double expression of MMP-14 and CD44 had a poor prognosis despite

complete debulking. Serous subtype in advanced-stage patients and CD44 expression were found to be correlated with

vimentin expression, and CD44 expression was found to be significantly correlated with complete debulking. However,

a significant correlation between EMT and clinical parameters was not found.

PMID: 27590524Jessurun N, van Marum R, Hermens W, van Puijenbroek E. Advanced Age and Female Sex As Risk Factors for High Anion Gap Metabolic Acidosis After a Drug Interaction Between Paracetamol and Flucloxacillin: A Case Series. J Am Geriatr Soc. 2016 Sep 2. doi: 10.1111/jgs.14332. No abstract available.

PMID: 27593688Araújo T, Abayazid M, Rutten MJ, Misra S. Segmentation and three-dimensional reconstruction of lesions using the automated breast volume scanner (ABVS). Int J Med Robot. 2016 Sep 4. doi: 10.1002/rcs.1767.

BACKGROUND: Ultrasound is an effective tool for breast cancer diagnosis. However, its relatively low image quality

makes small lesion analysis challenging. This promotes the development of tools to help clinicians in the diagnosis.

METHODS: We propose a method for segmentation and three-dimensional (3D) reconstruction of lesions from ultra-

sound images acquired using the automated breast volume scanner (ABVS). Segmentation and reconstruction algori-

thms are applied to obtain the lesion’s 3D geometry. A total of 140 artificial lesions with different sizes and shapes are

reconstructed in gelatin-based phantoms and biological tissue. Dice similarity coefficient (DSC) is used to evaluate the

reconstructed shapes. The algorithm is tested using a human breast phantom and clinical data from six patients. RE-

SULTS: DSC values are 0.86 ± 0.06 and 0.86 ± 0.05 for gelatin-based phantoms and biological tissue, respectively. The

results are validated by a specialized clinician. CONCLUSIONS: Evaluation metrics show that the algorithm accurately

segments and reconstructs various lesions. Copyright © 2016 John Wiley & Sons, Ltd.

PMID: 27610695Castermans E, Coenders M, Beerlage HP, De Vries J. Psychosocial Screening for Patients with Prostate Cancer: the Development and Validation of the Psychosocial Distress Questionnaire-Prostate Cancer (PDQ-PC). J Psychosoc Oncol. 2016 Sep 9:0. We describe the psychosocial distress questionnaire-prostate cancer (PDQ-PC), a psychosocial screening list developed and validated specifically for prostate cancer patients. An existing screening list, the psychosocial distress questionnaire-breast cancer (PDQ-BC), was used as a starting point. Two focus groups were then implemented to investigate which items of the PDQ-BC were relevant for the PDQ-PC and which new items were needed. Validity and reliability of the questionnaire were assessed on 278 prostate cancer patients. Factor analysis showed that the 36-item PDQ-PC comprises eight subscales, for which the internal consistency ranged from α = 0.48-0.88. Moreover, moderate to high convergent validity was found.


PMID: 27611610Govaert JA, Fiocco M, van Dijk WA, Kolfschoten NE, Prins HA, Dekker JT, Tollenaar RA, Tanis PJ, Wouters MW; Dutch Value Based Healthcare Study Group. Multicenter Stratified Comparison of Hospital Costs Between Laparoscopic and Open Colorectal Cancer Resections: Influence of Tumor Location and Operative Risk. Ann Surg. 2016 Sep 8.

OBJECTIVE: To compare actual 90-day hospital costs between elective open and laparoscopic colon and rectal cancer

resection in a daily practice multicenter setting stratified for operative risk. BACKGROUND: Laparoscopic resection has

developed as a commonly accepted surgical procedure for colorectal cancer. There are conflicting data on the influence

of laparoscopy on hospital costs, without separate analyses based on operative risk. METHODS: Retrospective analyses

using a population-based database (Dutch Surgical Colorectal Audit). All elective resections for a T1-3N0-2M0 stage

colorectal cancer were included between 2010 and 2012 in 29 Dutch hospitals. Operative risk was stratified for age

(<75 years or ≥75 years) and ASA status (I-II/III-IV). Ninety-day hospital costs were measured uniformly in all hospitals

based on time-driven activity-based costing. RESULTS: Total 90-day hospital costs ranged from &OV0556;10474 to

&OV0556;20865 in the predefined subgroups. For colon cancer surgery (N = 4202), laparoscopic resection was signi-

ficant less expensive than open resection in all subgroups, savings because of laparoscopy ranged from &OV0556;409

(<75 years ASA I-II) to &OV0556;1932 (≥75 years ASA I-II). In patients ≥75 years and ASA I-II, laparoscopic resection

was associated with 46% less mortality (P = 0.05), 41% less severe complications (P < 0.001), 25% less hospital stay (P

= 0.013), and 65% less ICU stay (P < 0.001). For rectal cancer surgery (N=2328), all laparoscopic subgroups had signi-

ficantly higher total hospital costs, ranging from &OV0556;501 (<75 years ASA I-II) to &OV0556;2515 (≥75 years ASA

III-IV). CONCLUSIONS: Laparoscopic resection resulted in the largest cost reduction in patients over 75 years with ASA

I-II undergoing colonic resection, and the largest cost increase in patients over 75 years with ASA III-IV undergoing

rectal resection as compared with an open approach.

PMID: 27615021Van Erning FN, Janssen-Heijnen ML, Creemers GJ, Pruijt JF, Maas HA, Lemmens VE. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy. Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30423.

The aim of this study is to investigate the effects of CAPOX and capecitabine on recurrence-free survival (RFS) and

overall survival (OS) among elderly stage III colon cancer patients and to evaluate the effect of (non-)completion. Pa-

tients aged ≥70 years who underwent resection only or who were subsequently treated with CAPOX or capecitabine in

10 large non-academic hospitals were included. RFS and OS were analyzed with Kaplan-Meier curves and multivaria-

ble Cox regression adjusted for patient and tumor characteristics. 982 patients were included: 630 underwent surgery

only, 191 received CAPOX and 161 received capecitabine. Five-year RFS and OS did not differ between capecitabine

and CAPOX (RFS: 63% vs. 60% (p = 0.91), adjusted HR = 0.99 (95%CI 0.68-1.44); OS: 66% vs. 66% (p = 0.76), adjusted

HR = 0.93 (95%CI 0.64-1.34)). After resection only, RFS was 38% and OS 37%. Completion rates were 48% for CAPOX

and 68% for capecitabine. Three-year RFS and OS did not differ between patients who discontinued CAPOX early and

patients who completed treatment with CAPOX (RFS: 61% vs. 69% (p = 0.21), adjusted HR = 1.42 (95%CI 0.85-2.37);

OS: 68% vs. 78% (p = 0.41), adjusted HR = 1.17 (95%CI 0.70-1.97)). Three-year RFS and OS differed between patients

who discontinued capecitabine early and patients who completed treatment with capecitabine (RFS: 54% vs. 72%

(p = 0.01), adjusted HR = 2.07 (95%CI 1.11-3.84); OS: 65% vs. 80% (p = 0.01), adjusted HR = 2.00 (95%CI 1.12-3.59)).

Receipt of CAPOX or capecitabine is associated with improved RFS and OS. The advantage does not differ by regimen.

The addition of oxaliplatin might not be justified in elderly stage III colon cancer patients.


PMID: 27634204Evers D, Zwaginga JJ, Tijmensen J, Middelburg RA, de Haas M, de Vooght KM, van de Kerkhof D, Visser O, Péquériaux NC, Hudig F, van der Bom JG. Treatments for hematological malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization. Haematologica. 2016 Sep 15. pii: haematol.2016.152074.

Red cell alloimmunization may induce severe hemolytic side effects. Identification of risk-modifying conditions will

help tailor preventative strategies. This study aims to quantify the associations of hematologic malignancies and solid

cancers with red cell alloimmunization in patients receiving red cell transfusions. We performed a nested multicenter

case-control study in a source population of 24,063 patients receiving their first and subsequent red cell transfusions

during an 8-year follow-up period. Cases (n=505), defined as patients developing a first transfusion-induced red cell

alloantibody, were each compared with 2 non-alloimmunized controls (n=1010) who received a similar number of red

cell units. Using multivariate logistic regression analyses, we evaluated the association of various malignancies and

treatment regimens with alloimmunization during a delineated 5-week risk period. The incidence of alloimmunization

among patients with acute (myeloid or lymphoid) leukemia and mature (B- or T-cell) lymphoma was significantly

reduced compared to patients without these malignancies: adjusted relative risks (RR) with 95% confidence interval

(CI) 0.36 (range 0.19-0.68) and 0.30 (range 0.12-0.81). Associations were primarily explained by immunosuppressive

treatments [RR for (any type of) chemotherapy combined with immunotherapy 0.27 (95%CI: 0.09-0.83)]. Alloimmu-

nization risks were similarly diminished in allogeneic or autologous stem cell transplanted patients (RR 0.34, 95%CI:

0.16-0.74), at least during the six months post transplant. Alloimmunization risks of patients with other hematologic

diseases or solid cancers, and their associated treatment regimens were similar to risks in the general transfused

population. Our findings suggest that, in contrast to malignancies in general, hemato-oncological patients treated with

dose-intensive regimens have strongly diminished risk of red cell alloimmunization.

PMID: 27641921 Mengerink BB, Van Leijsen SA, Vierhout ME, Inthout J, Mol BW, Milani AL, Roovers JP, Van Eijndhoven HW, Van Der Vaart CH, Van Gestel I, Hartog FE, Heesakkers JF, Kluivers KB. The Impact of Midurethral Sling Surgery on Sexual Activity and Function in Women With Stress Urinary Incontinence. J Sex Med. 2016 Oct;13(10):1498-507. doi: 10.1016/j.jsxm.2016.08.005.

INTRODUCTION: Stress urinary incontinence has a negative impact on sexual function. AIM: To assess the effect of mi-

durethral sling surgery on sexual activity and function in women with stress urinary incontinence. METHODS: This is a

secondary analysis of the Value of Urodynamics Prior to Stress Incontinence Surgery (VUSIS-II) study, which assessed

the value of urodynamics in women with (predominantly) stress urinary incontinence. Patients who underwent retro-

pubic or transobturator sling surgery were included in the present study if information was available on sexual activity

before and 12 months after surgery. Data were collected from a self-report validated questionnaire combined with

non-validated questions. The association between midurethral sling surgery and sexual function (coital incontinence,

satisfaction, and dyspareunia) was compared with McNemar κ(2) tests for nominal data and paired t-tests for ordinal

data. Potentially influential factors were analyzed with univariable and multivariable logistic regression analyses. MAIN

OUTCOME MEASURES: Changes in sexual activity and sexual function after midurethral sling surgery. RESULTS:

Information on sexual activity was available in 293 of the 578 women (51%) included in the VUSIS-II study. At baseline,

252 of 293 patients (86%) were sexually active vs 244 of 293 (83%) after 12 months. More patients with cured stress

urinary incontinence were sexually active postoperatively (213 of 247 [86%] vs 31 of 46 [67%], P < .01). There was a

significant decrease in coital incontinence (120 of 236 [51%] preoperatively vs 16 of 236 [7%] postoperatively, P < .01).

De novo dyspareunia was present in 21 of 238 women (9%). There was a greater improvement in coital incontinence


after placement of the retropubic sling compared with the transobturator sling (odds ratio = 2.04, 95% CI = 1.10-3.80,

P = .02). CONCLUSION: These data show that midurethral sling surgery has an overall positive influence on sexual

function in women with stress urinary incontinence. The retropubic sling is more effective than the transobturator sling

for improvement of coital incontinence. De novo dyspareunia was present in 1 of 11 women.

PMID: 27652079Johannesma PC, van de Beek I, van der Wel JW, Paul MA, Houweling AC, Jonker MA, van Waesberghe JH, Reinhard R, Starink TM, van Moorselaar RJ, Menko FH, Postmus PE. Risk of spontaneous pneumothorax due to air travel and diving in patients with Birt-Hogg-Dubé syndrome.Springerplus. 2016 Sep 7;5(1):1506.

BACKGROUND AND OBJECTIVES: Birt-Hogg-Dubé syndrome is an autosomal dominant disorder characterized by skin

fibrofolliculomas, lung cysts, spontaneous pneumothorax and renal cell cancer due to germline folliculin (FLCN) mutati-

ons (Menko et al. in Lancet Oncol 10(12):1199-1206, 2009). The aim of this study was to evaluate the incidence of

spontaneous pneumothorax in patients with BHD during or shortly after air travel and diving. METHODS: A question-

naire was sent to a cohort of 190 BHD patients and the medical files of these patients were evaluated. The diagnosis of

BHD was confirmed by FLCN mutations analysis in all patients. We assessed how many spontaneous pneumothoraces

(SP) occurred within 1 month after air travel or diving. RESULTS: In total 158 (83.2 %) patients returned the completed

questionnaire. A total of 145 patients had a history of air travel. Sixty-one of them had a history of SP (42.1 %), with

a mean of 2.48 episodes (range 1-10). Twenty-four (35.8 %) patients had a history of pneumothorax on both sides.

Thirteen patients developed SP < 1 month after air travel (9.0 %) and two patients developed a SP < 1 month after

diving (3.7 %). We found in this population of BHD patients a pneumothorax risk of 0.63 % per flight and a risk of 0.33

% per episode of diving. Symptoms possible related to SP were perceived in 30 patients (20.7 %) after air travel, res-

pectively in ten patients (18.5 %) after diving. CONCLUSION: Based on the results presented in this retrospective study,

exposure of BHD patients to considerable changes in atmospheric pressure associated with flying and diving may be

related to an increased risk for developing a symptomatic pneumothorax. Symptoms reported during or shortly after

flying and diving might be related to the early phase of pneumothorax. An individualized advice should be given, taking

also into account patients’ preferences and needs.

PMID: 27720180Nijhof WH, Jansen MM, Jager GJ, Slump CH, Rutten MJ. Feasibility of a low concentration test-bolus in CT angiography. Clin Radiol. 2016 Dec;71(12):1313.e1-1313.e4. doi: 10.1016/j.crad.2016.08.008.

AIM: To investigate the feasibility of using a low-concentration test bolus in abdominal aorta computed tomography

(CT) angiography (CTA). MATERIALS AND METHODS: In 10 patients referred for CTA of the abdominal aorta with

a body mass index (BMI) ≤28 kg/m2, a standard test bolus of 10 ml contrast medium (CM; 350 mg iodine/ml) was

compared with a low-concentration test bolus (5 ml CM; 350 mg iodine/ml; 1:1 diluted with saline) in terms of time

to peak enhancement (tPE) and peak enhancement (PE). RESULTS: No significant differences were found between the

standard and low-concentration test bolus in terms of tPE and PE. CONCLUSIONS: A low-concentration test bolus (5

ml, 1:1 diluted with saline) is feasible in patients with a BMI ≤28 kg/m2.


PMID: 27753550Wever PC, Korst MBJM, Otte M. The U.S. Army medical belt for front line first aid: a well-considered design that failed the Medical Department during the First World War. Mil Med 2016;181:1187-1194.

In December 1913, a board of medical officers was appointed to adapt new U.S. Army equipment to the needs of the

Hospital Corps. One of the improvements concerned substitution of the satchel-like Hospital Corps pouch used to

carry first aid equipment. A waist belt with 10 pockets, known as the medical belt, was devised, and supplied with a

tourniquet, adhesive plaster, safety pins, iodine swabs, sublimated gauze, individual dressing packets, gauze bandages,

aromatic spirit of ammonia, and common pins. In addition, an ax carrier accommodating a hand ax, a canteen hanger,

and a pouch to carry diagnosis tags and instruments were attached to the medical belt. In 1916, the medical belt was

incorporated in the field supply tables in the Manual for the Medical Department. The next year, on April 6, 1917, the

U.S. Congress declared war on Germany in reaction to sinking of American ships by German submarines. Although the

medical belt had given satisfaction in preliminary trials, it did not withstand the test of war. In practice, the medical belt

proved a source of dissatisfaction both as to the methods of packing and its contents, which were considered useless in

modern warfare. Subsequently, discontinuance of the medical belt was recommended.

PMID: 27794410Hendriks LE, Brouns AJ, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JS, De Ruysscher DK, Van den Heuvel MM, Dingemans AC. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: does the type of chemotherapy regimen matter? Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008.

OBJECTIVES: Symptomatic brain metastases (BM) occur frequently after chemoradiotherapy (CRT) for stage III NSCLC.

Aim of the current study was to determine whether the specific chemotherapy used in a CRT regimen influences BM

development. MATERIALS AND METHODS: Retrospective multicenter study including all consecutive stage III NSCLC

who completed CRT. Primary endpoints: symptomatic BM development, whether this was the only site of first relapse.

Differences between regimens were assessed with a logistic regression model including known BM risk factors and

the specific chemotherapy: concurrent versus sequential (cCRT/sCRT), within cCRT: daily low dose cisplatin (LDC)-

cyclic dose polychemotherapy; LDC-(non-)taxane cyclic dose; LDC-polychemotherapy subgroups of ≥50 patients.

RESULTS: Between January 2006 and June 2014, 838 patients were eligible (737 cCRT, 101 sCRT). 18.2% developed

symptomatic BM, 8.0% had BM as only site of first relapse. BM patients were significantly younger, female, had more

advanced N-stage and had adenocarcinoma histology. In both cCRT and sCRT BM were found in 18% (p=0.904). In

cyclic dose cCRT (N=346) and LDC (N=391) BM were found in 18.8% and 17.9%, respectively (p=0.757). In 7.2% and

8.7%, respectively, BM were the only site of first relapse (p=0.463). The chemotherapy used (cCRT versus sCRT) had

no influence on BM development, not for all brain relapses nor as only site of first relapse (OR 0.88 (p=0.669), OR

0.93 (p=0.855), respectively). LDC versus cyclic dose cCRT was not significantly different: neither for all brain relapses

nor as only site of first relapse (OR 0.96 (p=0.819), OR 1.21 (p=0.498), respectively). Comparable results were found

for LDC versus cyclic dose non-taxane (N=277) and cyclic dose taxane regimens (N=69) and for cCRT regimens with

≥50 patients (LDC versus cisplatin/etoposide (N=188), cisplatin/vinorelbin (N=65), weekly cisplatin/docetaxel (N=60)).

CONCLUSION: approximately 18% developed symptomatic BM after stage III diagnosis, not dependent on type of

chemotherapy regimen used within a CRT treatment.


PMID: 27894291Huijsmans CJ, Geurts-Giele WR, Leeijen C, Hazenberg HL, van Beek J, de Wild C, van der Linden JC, van den Brule AJ. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows. BMC Cancer. 2016 Nov 28;16(1):922.

BACKGROUND: Primary high risk (hr)HPV screening will be introduced in The Netherlands in January 2017. Our aim

was to determine the hrHPV prevalence in the Dutch cervical cancer screening population (DuSC study). METHODS:

A total of 12,113 residual PreservCyt cervical samples from the Dutch population based cytology screening program

were rendered anonymous, randomized and tested for hrHPV using 3 HPV assays on their respective automated

platforms: QIAGEN’s digene® HC2 HPV DNA Test® (HC2, signal amplification), Roche Cobas® HPV test (DNA ampli-

fication) and Hologic Aptima® HPV Test (RNA amplification). To determine the agreement between results generated

using the different assays, pair wise comparison of the systems was performed by determining kappa coefficients.

RESULTS: The selected samples were representative for the population based screening program with respect to age

distribution and cytology classification. HrHPV prevalences found were: 8.5% for HC2 (n = 959), 8.1% for cobas (n = 919)

and 7.5% for Aptima (n = 849), resulting in a mean hrHPV prevalence of 8.0 ± 0.5%. Although the hrHPV prevalences of

the different assays are in the range of 8%, there was a significant difference in prevalence for the HC2 vs. Aptima assay

(p-value = 0.007). A clear age dependency was found, with an hrHPV prevalence ranging from 18.7 ± 1.2% in women

29-33 years of age to 4.2 ± 0.2% in women 59-63 years of age. Furthermore, a correlation between hrHPV prevalence

and severity of cytology was observed, ranging from 5.5 ± 0.4% in normal cytology to 95.2 ± 1.7% in severe dysplasia.

Indeed, kappa coefficients of 0.77, 0.71 and 0.72 (HC2 vs cobas, cobas vs Aptima and Aptima vs HC2, respectively)

indicated substantial agreement between the results generated by the different systems. However, looking at the

hrHPV positive samples, only 48% of the samples tested positive with all 3 assays. CONCLUSIONS: A hrHPV prevalence

of 8% was found in this unselected population based screening cohort independently of using HC2, Aptima or cobas.

This prevalence is higher than the previously reported 4-5% (POBASCAM and VUSA-Screen trials). Furthermore, the

complete automated hrHPV detection workflow solutions from QIAGEN, Roche, and Hologic were successfully used and

will be valuable for reliably implementing high throughput hrHPV testing in cervical cancer screening.

PMID: 27956438Wever PC. No 10 Stationary Hospital and the chapel ward at Saint-Omer, France, 1914-18. BMJ 2016;355: i6509 (Christmas issue).

PMID: 27981298Nissen LH, Assendorp EL, van der Post RS, Derikx LA, de Jong DJ, Kievit W, Pierik M, van den Heuvel TR, Verhoeven R, Overbeek LI, Hoentjen F, Nagtegaal ID. On behalf of Dutch Initiative on Crohn and Colitis, PALGA group and IBD and gastric cancer group. Impaired gastric cancer survival in inflammatory bowel disease patients. J Gastrointestin Liver Dis. 2016 Dec;25(4):431-440. doi: 10.15403/jgld.2014.1121.254.nis.

BACKGROUND AND AIMS: Both chronic inflammation and reduced immunosurveillance contribute to malignancy

development in inflammatory bowel disease (IBD). Previous literature suggests that especially Crohn’s disease patients

are at an increased risk for developing gastric cancer (GC). This study aimed to identify risk factors for GC development

in IBD and to compare the clinical characteristics of GC in IBD to those in the general population. METHODS: We

retrospectively searched the Dutch Pathology Database to identify all Dutch IBD patients with GC between January

2004 and December 2008. Two case-control studies were performed. I: to identify risk factors for GC in IBD, with


controls from the IBD South Limburg (IBDSL) population-based cohort; and II: to compare GC disease course in IBD

patients with the general population. General population data were obtained from the Eindhoven Cancer Registry

(ECR). RESULTS: We included 59 patients with IBD and GC (cases). Cases were significantly older at IBD diagnosis than

IBDSL controls (median age 61 years versus 40; p<0.01), and ulcerative colitis (UC) was more frequent in the case

group (69.5% versus 51.4%; p<0.01). We found no difference in age at diagnosis, gender, tumor location and tumor

differentiation between IBD GC patients and ECR controls. When corrected for confounders and TNM-stage, IBD pa-

tients showed impaired survival (p=0.035; HR 1.385). CONCLUSIONS: Survival is significantly reduced in IBD patients

compared to the general population in the multivariate analysis of our study, but age at GC diagnosis and TNM-stage

were comparable between IBD cases and controls. Elderly onset IBD emerged as a risk factor for GC development in

IBD patients, particularly in UC.

PMID: 27981302Römkens TE, Gijsbers K, Kievit W, Hoentjen F, Drenth JP. Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice. J Gastrointestin Liver Dis. 2016 Dec;25(4):465-471. doi: 10.15403/jgld.2014.1121.254.ken.

BACKGROUND AND AIMS: Recently, treatment goals in inflammatory bowel disease (IBD) in clinical trials have shifted

from mainly symptom-based to more mucosa-driven. Real world data on treatment priorities are lacking. We aimed

to investigate the current practice and most commonly used definitions of IBD treatment targets among Dutch

gastroenterologists. METHODS: Dutch gastroenterologists were asked to participate in a computer-based nation-wide

survey. We asked questions on demographics, opinion and current practice regarding IBD treatment targets. RESULTS:

Twenty-four percent (134/556) of the respondents completed the survey. For both Crohn’s disease (CD) (47.3%,

61/129) and ulcerative colitis (UC)(45%, 58/129) the main treatment goal was to achieve and maintain deep remission,

defined as clinical, biochemical and endoscopic remission. Seventy-six percent of the participants use mucosal healing

(MH) as a potential treatment target for IBD, whereas 22.6% use histological remission. There is no single definition for

MH in IBD. The majority use Mayo score ≤ 1 in UC (52%) and ‘macroscopic normal mucosa’ in CD (66%). CONCLUSION:

More stringent and mucosa-driven treatment targets as ‘deep remission’ and ‘mucosal healing’ have found traction in

clinical practice. The most commonly used definition for MH in routine practice is endoscopic MAYO score </= 1 in UC

and ‘macroscopic normal mucosa’ in CD.

PMID: 28058028Van de Meeberg MM, Derikx LA, Sinnige HA, Nooijen P, Schipper DL, Nissen LH. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient on thiopurine monotherapy. World J Gastroenterol. 2016 Dec 21;22(47):10465-10470. doi: 10.3748/wjg.v22.i47.10465.

Hepatosplenic T-cell lymphoma (HSTCL) is a rare non-Hodgkin lymphoma with a high mortality rate. Higher incidence

is reported in patients with inflammatory bowel disease, specifically in male patients that are younger than 35 years,

and have been treated with thiopurine and tumor necrosis factor (TNF)-κ inhibitor combination therapy for over 2

years. In this case report we describe a 47-year-old patient with Crohn’s disease (CD) who developed HSTCL after

having been treated with thiopurine monotherapy for 14 years. To our best knowledge, only eleven cases exist of

patients with CD who developed HSTCL while on thiopurine monotherapy. We report the first patient with CD, older

than 35 years, who developed HSTCL while on thiopurine monotherapy. This emphasizes that HSTCL risk is not limited

to young men receiving both thiopurines and TNF-κ inhibitors.


PMID: 28529856Dietvorst M, Roerdink R, Leenders AC, Kiel MA, Bom LP. Acute Mono-Arthritis of the Knee: A Case Report of Infection with Parvimonas Micra and Concomitant Pseudogout. J Bone Jt Infect. 2016 Oct 1;1:65-67.Parvimonas micra is a rare pathogen for septic arthritis and is known for its subacute onset. We report a case of acute arthritis of the knee caused by P. micra and pseudogout. Initially, calcium pyrophosphate crystals were found in the knee, which were successfully treated with a steroid injection. Only anaerobic cultures became positive. A 16S rRNA PCR-analysis was necessary to identify P. micra as causative agent, a method which is never described before in similar cases. The infection was treated with clindamycin for 6 weeks. This is the third case report of a septic arthritis caused by P. micra and the second which also reports concomitant pseudogout.


PUBLI- CATIES - Jeroen Bosch Ziekenhuis...Het werkterrein van de data scientist. En van de...

Documents

Transcript of PUBLI- CATIES - Jeroen Bosch Ziekenhuis...Het werkterrein van de data scientist. En van de...